## BEST AVAILABLE COPY

#### **PCT**

# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



# INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCI)

(51) International Patent Classification 7:			TREATT (PCT)
C12Q 1/68	A2	(11) International Publication Number:	WO 00/40749
		(43) International Publication Date:	13 July 2000 (13.07.00)
(21) International Application Number: PCT/CA(	00/0000	The second states of the second states and the second states are second	T. AU. AZ. BA BR BG
(22) International Filing Date: 5 January 2000 (0	05.01.0		J. CZ. DE. DK. DM. FF.

(30) Priority Data:

60/115,125 09/477,148 6 January 1999 (06.01.99) US 4 January 2000 (04.01.00) US

(71)(72) Applicant and Inventor: LIEW, Choong-Chin [CA/CA]; 81 Millersgrove Drive, Willowdale, Ontario M2R 3S1 (CA).

(74) Agent: DEETH WILLIAMS WALL; National Bank Building, Suite 400, 150 York Street, Toronto, Ontario M5H 3S5 (CA). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


#### **Published**


Without international search report and to be republished upon receipt of that report.

(54) Title: METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF

#### (57) Abstract

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.





BNSDOCID: <WO\_\_\_\_\_0040749A2\_I\_>

#### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	BC	0		_		
		ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	
BY	Belarus	IS	Iceland	MW	Malawi	US	Uganda
CA	Canada	IT	Italy	MX	Mexico	UZ	United States of America
CF	Central African Republic	JP	Japan	NE	Niger	VN	Uzbekistan Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	
CH	Switzerland	KG	Kyrgyzstan	NO	N1		Yugoslavia
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand	zw	Zimbabwe
CM	Cameroon		Republic of Korea	PL			
CN	China	KR	Republic of Korea	PT	Poland		
CU	Cuba	KZ	Kazakstan	RÓ	Portugal		
CZ	Czech Republic	ic	Saint Lucia		Romania		
DE	Germany	u	Liechtenstein	RU	Russian Federation		
DK	Denmark			SD	Sudan		
EE	Estonia	LK	Sri Lanka	SE	Sweden		
EE	ESIONIA	LR	Liberia	SG	Singapore		

BNSDOCID: <WO\_\_\_\_\_0040749A2\_I\_>

## METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF

5

10

15

20

## BACKGROUND OF THE INVENTION

## Cross-Reference to Related Application

This application claims the benefit of priority of provisional patent application U.S. Serial Number 60/115,125, filed January 6, 1999 and of a U.S. application entitled "Method for the Detection of Gene Transcripts in Blood and uses Thereof" filed on January 4, 2000 (application number not yet assigned).

#### Field of the Invention

The present invention relates generally to the molecular biology of human diseases. More specifically, the present invention relates to a process using the genetic information contained in human peripheral whole blood for the diagnosis, prognosis and monitoring of genetic and infectious disease in the human body.

## Description of the Related Art

in the human body at any given time.

The blood is a vital part of the human circulatory system for the human Numerous cell types make up the blood tissue including monocytes, body. leukocytes, lymphocytes and erythrocytes. Although many blood cell types have been described, there are likely many as yet undiscovered cell types in the human blood. Some of these undiscovered cells may exist transiently, such as those derived from tissues and organs that are constantly interacting with the circulating blood in health 25 and disease. Thus, the blood can provide an immediate picture of what is happening

The turnover of cells in the hematopoietic system is enormous. It was reported that over one trillion cells, including 200 billion erythrocytes and 70 billion neutrophilic leukocytes, turn over each day in the human body (Ogawa 1993). As a consequence of continuous interactions between the blood and the body, genetic changes that occur within the cells or tissues of the body will trigger specific changes in gene expression within blood. It is the goal of the present invention that these genetic alterations be harnessed for diagnostic and prognostic purposes, which may lead to the development of therapeutics for ameliorating disease.

The complete profile of gene expression in the circulating blood remains totally unexplored. It is hypothesized that gene expression in the blood is reflective of body state and, as such, the resultant disruption of homeostasis under conditions of disease can be detected through analysis of transcripts differentially expressed in the blood alone. Thus, the identification of several key transcripts or genetic markers in blood will provide information about the genetic state of the cells, tissues, organs and systems of the human body in health and disease.

The prior art is deficient in non-invasive methods of screening for tissue-specific diseases. The present invention fulfills this long-standing need and desire in the art.

#### SUMMARY OF THE INVENTION

This present invention discloses a process of using the genetic information contained in human peripheral whole blood in the diagnosis, prognosis and monitoring of genetic and infectious disease in the human body. The process described herein requires a simple blood sample and is, therefore, non-invasive compared to conventional practices used to detect tissue specific disease, such as biopsies.

5

10

15

20

One object of the present invention is to provide a non-invasive method for the diagnosis, prognosis and monitoring of genetic and infectious disease in humans and animals.

In one embodiment of the present invention, there is provided a method for detecting expression of a gene in blood from a subject, comprising the steps of: a) quantifying RNA from a subject blood sample; and b) detecting expression of the gene in the quantified RNA, wherein the expression of the gene in quantified RNA indicates the expression of the gene in the subject blood.

In another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; and e) detecting expression of the genes in the ESTs, wherein the expression of the genes in the ESTs indicates the expression of the genes in the subject blood. Preferably, the genes are tissue-specific genes.

ţ-

In still another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting DNA fragments from the blood sample; c) amplifying the DNA fragments; and d) detecting expression of the genes in the amplified DNA product, wherein the expression of the genes in the subject blood.

In yet another embodiment of the present invention, there is provided a method for monitoring a course of a therapeutic treatment in an individual, comprising the steps of: a) obtaining a blood sample from the individual; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; e) detecting expression of genes in the ESTs, wherein the expression of the genes is associated with the effect of

5

10

15

20

the therapeutic treatment: and f) repeating steps a)-e), wherein the course of the therapeutic treatment is monitored by detecting the change of expression of the genes in the ESTs. Such a method may also be used for monitoring the onset of overt symptoms of a disease, wherein the expression of the genes is associated with the onset of the symptoms.

In still yet another embodiment of the present invention, there is provided a method for diagnosing a disease in a test subject, comprising the steps of:

a) generating a cDNA library for the disease from a whole blood sample from a normal subject; b) generating expressed sequence tag (EST) profile from the normal subject cDNA library; c) generating a cDNA library for the disease from a whole blood sample from a test subject; d) generating EST profile from the test subject cDNA library; and e) comparing the test subject EST profile to the normal subject EST profile, wherein if the test subject EST profile differs from the normal subject EST profile, the test subject might be diagnosed with the disease.

In still yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) gene-specific primers; wherein the primers are designed in such a way that their sequences contain the opposing ends of two adjacent exons for the specific gene with the intron sequence excluded: and b) a carrier, wherein the carrier immobilizes the primer(s). Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease.

In yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) probes derived from a whole blood sample for a specific disease; and b) a carrier, wherein the carrier immobilizes the probes. Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease.

Furthermore, the present invention provides a cDNA library specific for a disease, wherein the cDNA library is generated from whole blood samples.

5

10

15

20

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention. These embodiments are given for the purpose of disclosure.

5

10

15

20

25

#### BRIEF DESCRIPTION OF THE DRAWINGS

So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.not be considered to limit the scope of the invention.

Figure 1 shows the following RNA samples prepared from human blood; Figure 1A: Lane 1, Molecular weight marker; Lane 2, RT-PCR on APP gene; Lane 3, PCR on APP gene; Lane 4, RT-PCR on APC gene; Lane 5, PCR on APC gene; Figure 1B: Lanes 1 and 2, RT-PCR and PCR of βMyHC, respectively; Lanes 3 and 4, RT-PCR of βMyHC from RNA prepared from human fetal and human adult heart, respectively; Lane 5, Molecular weight marker.

Figure 2 shows quantitative RT-PCR analysis performed on RNA samples extracted from a drop of blood. Forward primer (5'-GCCCTCTGGGGACCTGAC-3', SEQ ID No. 1) of exon 1 and reverse primer (5'-CCCACCTGCAGGTCCTCT-3", SEQ ID No. 2) of exons 1 and 2 of insulin gene. Blood samples of 4 normal subjects were assayed. Lanes 1, 3, 5 and 7 represent overnight "fasting" blood sample and lanes 2, 4, 6 and 8 represent "non-fasting" samples.

Figure 3 shows quantitative RT-PCR analysis performed on RNA samples extracted from a drop of blood. Lanes 1 and 2 represent normal healthy person and lane 3 represents late-onset diabetes (Type II) and lane 4 represents asymptomatic diabetes.

Figure 4 shows multiple RT-PCR assay in a drop of blood. Primers were derived from insulin gene (INS), zinc-finger protein gene (ZFP) and house-keeping gene (GADH). Lane 1 represents normal person. Lane 2 represents late-onset diabetes and lane 3 represents asymptomatic diabetes.

Figure 5 shows standardized levels of insulin gene (Figure 5A) and ZFP gene (Figure 5B) expressed in a drop of blood. The first three subjects were normal, second two subjects showed normal glucose tolerance, and the last subject had late onset diabetes type II. Figure 5C shows standardized levels of insulin gene expressed in each fractionated cell from whole blood.

Figure 6 shows the differential screening of human blood cell cDNA library with different cDNA probes of heart and brain tissue. Figure 6A shows blood cell cDNA probes vs. adult heart cDNA probes. Figure 6B shows blood cell cDNA probes vs. human brain cDNA probes.

Figure 7 graphically shows the 1,800 unique genes in human blood and in the human fetal heart grouped into seven cellular functions.

20

25

5

10

15

#### DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, "Molecular Cloning: A Laboratory Manual (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed. 1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid

Hybridization" [B.D. Hames & S.J. Higgins eds. (1985)]; "Transcription and Translation" [B.D. Hames & S.J. Higgins eds. (1984)]; "Animal Cell Culture" [R.I. Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A Practical Guide To Molecular Cloning" (1984). Therefore, if appearing herein, the following terms shall have the definitions set out below.

A "cDNA" is defined as copy-DNA or complementary-DNA, and is a product of a reverse transcription reaction from an mRNA transcript. "RT-PCR" refers to reverse transcription polymerase chain reaction and results in production of cDNAs that are complementary to the mRNA template(s).

The term "oligonucleotide" is defined as a molecule comprised of two or more deoxyribonucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide. The term "primer" as used herein refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and The primer may be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and the method used. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides. The factors involved in determining the appropriate length of primer are readily known to one of ordinary skill in the art.

As used herein, random sequence primers refer to a composition of primers of random sequence, i.e. not directed towards a specific sequence. These

5

10

15

20

sequences possess sufficient complementary to hybridize with a polynucleotide and the primer sequence need not reflect the exact sequence of the template.

"Restriction fragment length polymorphism" refers to variations in DNA sequence detected by variations in the length of DNA fragments generated by restriction endonuclease digestion.

A standard Northern blot assay can be used to ascertain the relative amounts of mRNA in a cell or tissue obtained from plant or other tissue, in accordance with conventional Northern hybridization techniques known to those persons of ordinary skill in the art. The Northern blot uses a hybridization probe, e.g. radiolabelled cDNA, either containing the full-length, single stranded DNA or a fragment of that DNA sequence at least 20 (preferably at least 30, more preferably at least 50, and most preferably at least 100 consecutive nucleotides in length). The DNA hybridization probe can be labelled by any of the many different methods known to those skilled in this art. The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to untraviolet light, and others. A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is antirabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate. Proteins can also be labeled with a radioactive element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from <sup>3</sup>H, <sup>14</sup>C, <sup>32</sup>P, <sup>35</sup>S, 36Cl, 51Cr, 57Co, 58Co, 59Fe, 90Y, 125I, 131I, and 186Re. Enzyme labels are likewise useful, and can be detected by any of the presently utilized colorimetric, fluorospectrophotometric, amperometric gasometric spectrophotometric, techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known and can be utilized.

5

10

15

20

The preferred are peroxidase,  $\beta$ -glucuronidase,  $\beta$ -D-glucosidase,  $\beta$ -D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Patent Nos. 3,654,090, 3,850,752, and 4,016,043 are referred to by way of example for their disclosure of alternate labeling material and methods.

As used herein, "individual" refers to human subjects as well as non-human subjects. The examples herein are not meant to limit the methodology of the present invention to human subjects only, as the instant methodology is useful in the fields of veterinary medicine, animal sciences and such.

In one embodiment of the present invention, there is provided a method for detecting expression of a gene in blood from a subject, comprising the steps of: a) quantifying RNA from a subject blood sample; and b) detecting expression of the gene in the quantified RNA, wherein the expression of the gene in quantified RNA indicates the expression of the gene in the subject blood. An example of the quantifying method is by mass spectrometry.

In another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; and e) detecting expression of the genes in the ESTs, wherein the expression of the genes in the ESTs indicates the expression of the genes in the subject blood. Preferably, the subject is a fetus, an embryo, a child, an adult or a non-human animal. The genes are non-cancer-associated and tissue-specific genes. Still preferably, the amplification is performed by RT-PCR using random sequence primers or gene-specific primers.

In still another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting DNA fragments from the blood sample; c) amplifying the DNA fragments; and d) detecting

5

10

15

20

expression of the genes in the amplified DNA product, wherein the expression of the genes in the amplified DNA product indicates the expression of the genes in the subject blood.

In yet another embodiment of the present invention, there is provided a method for monitoring a course of a therapeutic treatment in an individual, comprising the steps of: a) obtaining a blood sample from the individual; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; e) detecting expression of genes in the ESTs, wherein the expression of the genes is associated with the effect of the therapeutic treatment; and f) repeating steps a)-e), wherein the course of the therapeutic treatment is monitored by detecting the change of expression of the genes in the ESTs. Such a method may also be used for monitoring the onset of overt symptoms of a disease, wherein the expression of the genes is associated with the onset of the symptoms. Preferably, the amplification is performed by RT-PCR, and the change of the expression of the genes in the ESTs is monitored by sequencing the ESTs and comparing the resulting sequences at various time points; or by performing single nucleotide polymorphism analysis and detecting the variation of a single nucleotide in the ESTs at various time points.

In still yet another embodiment of the present invention, there is provided a method for diagnosing a disease in a test subject, comprising the steps of:

a) generating a cDNA library for the disease from a whole blood sample from a normal subject; b) generating expressed sequence tag (EST) profile from the normal subject cDNA library; c) generating a cDNA library for the disease from a whole blood sample from a test subject; d) generating EST profile from the test subject cDNA library; and e) comparing the test subject EST profile to the normal subject EST profile, wherein if the test subject EST profile differs from the normal subject EST profile, the test subject might be diagnosed with the disease.

5

10

15

20

In still yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) genespecific primers; wherein the primers are designed in such a way that their sequences contain the opposing ends of two adjacent exons for the specific gene with the intron sequence excluded; and b) a carrier, wherein the carrier immobilizes the primer(s). Preferably, the gene-specific primers are selected from the group consisting of insulinspecific primers, atrial natriuretic factor-specific primers, zinc finger protein genespecific primers, beta-myosin heavy chain gene-specific primers, amyloid precurser protein gene-specific primers, and adenomatous polyposis-coli protein gene-specific primers. Further preferably, the gene-specific primers are selected from the group consisting of SEQ ID Nos. 1 and 2; and SEQ ID Nos. 5 and 6. Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease by detecting the quantitative expression levels of specific genes associated with the disease in the test subject and then comparing to the levels of same genes expressed in a normal subject. Such a kit may also be used for monitoring a course of therapeutic treatment or monitoring the onset of overt symptoms of a disease.

In yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) probes derived from a whole blood sample for a specific disease; and b) a carrier, wherein the carrier immobilizes the probes. Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease by detecting the quantitative expression levels of specific genes associated with the disease in the test subject and then comparing to the levels of same genes expressed in a normal subject. Such a kit may also be used for monitoring a course of therapeutic treatment or monitoring the onset of overt symptoms of a disease.

Furthermore, the present invention provides a cDNA library specific for a disease, wherein the cDNA library is generated from whole blood samples.

5

10

15

20

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

5

10

#### **EXAMPLE 1**

#### Construction of a cDNA library

RNA extracted from human tissues (including fetal heart, adult heart, liver, brain, prostate gland and whole blood) were used to construct unidirectional cDNA libraries. The first mammalian heart cDNA library was constructed as early as 1982. Since then, the methodology has been revised and optimal conditions have been developed for construction of human heart and hematopoietic progenitor cDNA libraries (Liew et al., 1984; Liew 1993, Claudio et al., 1998). Most of the novel genes which were identified by sequence annotation can now be obtained as full length transcripts.

#### **EXAMPLE 2**

#### Catalogue of blood cell ESTs

20

15

Random partial sequencing of expressed sequence tags (ESTs) of cDNA clones from the blood cell library was carried out to establish an EST database of blood. The known genes as derived from the ESTs were categorized into seven major cellular functions (Hwang, Dempsey et al., 1997).

5

10

15

20

25

#### **EXAMPLE 3**

#### Differential screening of cDNA library

cDNA probes generated from transcripts of each tissue were used to hybridize the blood cell cDNA clones (Liew et al., 1997). The "positive" signals which were hybridized with <sup>32</sup>P-labelled cDNA probes were defined as genes which shared identity with blood and respective tissues. The "negative" spots which were not exposed to <sup>32</sup>P-labelled cDNA probes were considered to be blood-cell-enriched or low frequency transcripts.

#### **EXAMPLE 4**

#### Reverse transcriptase-polymerase chain reaction (RT-PCR) assay

RNA extracted from samples of human tissue was used for RT-PCR analysis (Jin et al. 1990). Three pairs of forward and reverse primers were designed for human cardiac beta-myosin heavy chain gene (βMyHC), amyloid precurser protein (APP) gene and adenomatous polyposis-coli protein (APC) gene. The PCR products were also subjected to automated DNA sequencing to verify the sequences as derived from the specific transcripts of blood.

#### **EXAMPLE 5**

#### Detection of tissue specific gene expression in human blood using RT-PCR

The beta-myosin heavy chain gene (βMyHC) transcript (mRNA) is known to be highly expressed in ventricles of the human heart. This sarcomeric protein is important for heart muscle contraction and its presence would not be expected in other non-muscle tissues and blood. In 1990, the gene for human cardiac

βMyHC was completely sequenced (Liew et al. 1990) and was comprised of 4 exons and 42 introns.

The method of reverse transcription polymerase chain reaction (RT-PCR) was used to determine whether this cardiac specific mRNA is also present in human blood. A pair of primers was designed; the forward primer (SEQ ID No. 3) was on the boundary of exons 21 and 22, and the reverse primer (SEQ ID No. 4) was on the boundary of exons 24 and 25. This region of mRNA is only present in βMyHC and is not found in the alpha-myosin heavy chain gene (αMyHC).

A blood sample was first treated with lysing buffer and then undergone centrifuge. The resulting pellets were further processed with RT-PCR. RT-PCR was performed using the total blood cell RNA as a template. A nested PCR product was generated and used for sequencing. The sequencing results were subjected to BLAST and the identity of exons 21 to 25 was confirmed to be from βMyHC (Figure 1A).

Using the same method just described, two other tissue specific genes - amyloid precursor protein (APP, forward primer, SEQ ID No. 7; reverse primer, SEQ ID No. 8) found in the brain and associated with Alzheimer's disease, and adenomatous polyposis coli protein (APC) found in the colon and rectum and associated with colorectal cancer (Groden et al. 1991; Santoro and Groden 1997) - were also detected in the RNA extracted from human blood (Figure 1B).

20

25

15

5

10

#### **EXAMPLE 6**

## Multiple RT-PCR analysis on a drop of blood from a normal/diseased individual

A drop of blood was extracted to obtain RNA to carry out quantitative RT-PCR analysis. Specific primers for the insulin gene were designed: forward primer (5'-GCCCTCTGGGGACCTGAC-3', SEQ ID No. 1) of exon 1 and reverse primer (5'-CCCACCTGCAGGTCCTCT-3", SEQ ID No. 2) of exons 1 and 2 of insulin gene. Such reverse primer was obtained by deleting the intron between the

exons 1 and 2. Blood samples of 4 normal subjects were assayed. It was found that the insulin gene is expressed in the blood and the quantitative expression of the insulin gene in a drop of blood is influenced by fasting and non-fasting states of normal healthy subjects (Figure 2). This very low level of expression of the insulin gene reflects the phenotypic status of a person and strongly suggests that there is a physiological and pathological role for its expression, contrary to the basal or illegitimate theory of transcription suggested by Chelly et al. (1989) and Kimoto (1998).

Same quantitative RT-PCR analysis was performed using insulin specific primers on RNA samples extracted from a drop of blood from a normal healthy person, a person having late-onset diabetes (Type II) and a person having asymptomatic diabetes. It was found that the insulin gene is expressed differentially amongst subjects that are healthy, diagnosed as type II diabetic, and also in an asymptomatic preclinical patient (Figure 3).

Similarly, specific primers for the atrial natriuretic factor (ANF) gene were designed (forward primer, SEQ ID No. 5; reverse primer, SEQ ID No. 6) and RT-PCR analysis was performed on a drop of blood. ANF is known to be highly expressed in heart tissue biopsies and in the plasma of heart failure patients. However, atrial natriuretic factor was observed to be expressed in the blood and the expression of the atrial natriuretic factor gene is significantly higher in the blood of patients with heart failure as compared to the blood of a normal control patient.

Specific primers for the zinc finger protein gene (ZFP, forward primer, SEQ ID No. 9; reverse primer, SEQ ID No. 10) were also designed and RT-PCR analysis was performed on a drop of blood. ZFP is known to be high in heart tissue biopsies of cardiac hypertrophy and heart failure patients. In the present study, the expression of ZFP was observed in the blood as well as differential expression levels of ZFP amongst the normal, diabetic and asymptomatic preclinical subjects (Figure 4); although neither of the non-normal subjects has been specifically diagnosed as

5

10

15

20

suffering from cardiac hypertrophy and/or heart failure, the higher expression levels of the ZFP gene in their blood may indicate that these subjects are headed in that general direction.

It was hypothesized that a housekeeping gene such as glyceraldehyde dehydrogenase (GADH) which is required and highly expressed in all cells would not be differentially expressed in the blood of normal vs. disease subjects. This hypothesis was confirmed by RT-PCR using GADH specific primers (Figure 4). Thus, GADH is useful as an internal control.

Standardized levels of insulin gene or ZFP gene expressed in a drop of blood were estimated using a housekeeping gene as an internal control relative to insulin or ZFP expressed (Figures 5A & 5B). The levels of insulin gene expressed in each fractionated cell from whole blood were also standardized and shown in Figure 5C.

EXAMPLE 7

#### Human blood cell cDNA library

In order to further substantiate the present invention, differential screening of the human blood cell cDNA library was conducted. cDNA probes derived from human blood, adult heart or brain were respectively hybridized to the human blood cDNA library clones. As shown in Figure 7, more than 95% of the "positively" identified clones are identical between the blood and other tissue samples.

DNA sequencing of randomly selected clones from the human whole blood cell cDNA library was also performed. This allowed information regarding the cellular function of blood to be obtained concurrently with gene identification. More than 20,000 expressed sequence tags (ESTs) have been generated and characterized to date, 17.6% of which did not result in a statistically significant match to entries in the

5

10

15

20

GenBank databases and thus were designated as "Novel" ESTs. These results are summarized in Figure 7 together with the seven cellular functions related to percent distribution of known genes in blood and in the fetal heart.

From 20,000 ESTs. 1,800 have been identified as known genes which may not all appear in the hemapoietic system. For example, the insulin gene and the atrial natriuretic factor gene have not been detected in these 20,000 ESTs but their transcripts were detected in a drop of blood, strongly suggesting that all transcripts of the human genome can be detected by performing RT-PCR analysis on a drop of blood.

In addition, approximately 400 novel genes have been identified from the 20,000 ESTs characterized to date, and these will be subjected to full length sequencing and open reading frame alignment to reduce the actual number of novel ESTs prior to screening for disease markers.

Analysis of the approximately 6,283 ESTs which have known matches in the GenBank databases revealed that this dataset represents over 1,800 unique genes. These genes have been catalogued into seven cellular functions. Comparisons of this set of unique genes with ESTs derived from human brain, heart, lung and kidney demonstrated a greater than 50% overlap in expression (Table 1).

20

5

TABLE 1

## Overlap of Genes Expressed in Blood \*

_	Tissues	ESTs**	Overlap in Blood	l
	brain	134,000	60%	•
25	heart	65,000	59%	
	lung	60,200	58%	
	kidney 32.	300	54%	

\* Estimated from limited known genes of about 1,800 as derived from the database of 6,297 ESTs from human blood cell library.

\*\* Obtained from the National Centre of Biotechnology Information (NCBI), U.S.A.

5

10

15

20

#### **EXAMPLE 8**

#### Blood cell ESTs

The results from the differential screening clearly indicate that the transcripts expressed in the whole blood are reflective of genes expressed in all cells and tissues of the body. More than 95% of detectable spots were identical from two different tissues. The remaining 5% of spots may represent cell- or tissue-specific transcripts; however, results obtained from partial sequencing to generate ESTs of these clones revealed most of them not to be cell- or tissue-specific transcripts. Therefore, the negative spots are postulated to be reflective of low abundance transcripts in the tissue from which the cDNA probes were derived.

An alternative approach that was employed to identify transcripts expressed at low levels is the large-scale generation of expressed sequence tags (ESTs). There is substantial evidence regarding the efficiency of this technology to detect previously characterized (known) and uncharacterized (unknown or novel) genes expressed in the cardiovascular system (Hwang & Dempsey et al., 1997). In the present invention, 20,000 ESTs have been produced from a human blood cell cDNA library and resulted in the identification of approximately 1,800 unique known genes (Table 2)

25

In the most recent GenBank release, analysis of more than 300,000 ESTs in the database (dbESTs) generated more than 48,000 gene clusters which are thought to represent approximately 50% of the genes in the human genome. Only 4,800 of the dbESTs are blood-derived. In the present invention, 20,000 ESTs have

been obtained to date from a human blood cDNA library, which provides the world's most informative database with respect to blood cell transcripts. From the limited amount of information generated so far (i.e. 1.800 unique genes), it has already been determined that more than 50% of the transcripts are found in other cells or tissues of the human body (Table 2). Thus, it is expected that by increasing the number of ESTs generated, more genes will be identified that have an overlap in expression between the blood and other tissues. Furthermore, the transcripts for several genes which are known to have tissue-restricted patterns of expression (i.e.  $\beta$ MyHC, APP, APC, ANF, ZFP) have also been demonstrated to be present in blood.

5

10

15

20

BNSDOCID: <WO\_\_\_\_\_0040749A2\_I\_>

Most recently, a cDNA library of human hematopoietic progenitor stem cells has also been constructed. From the limited set of 1,000 ESTs, there are at least 200 known genes that are shared with other tissue related genes (Claudio *et al.* 1998).

Table 2 demonstrates the expression of known genes of specific tissues in blood cells. Previously, only the presence of "housekeeping" genes would have been expected. Additionally, the presence of at least 25 of the currently known 500 genes corresponding to molecular drug targets was detected. These molecular drug targets are used in the treatment of a variety of diseases which involve inflammation, renal and cardiovascular function, neoplastic disease, immunomodulation and viral infection (Drews & Ryser, 1997). It is expected that additional novel ESTs will represent future molecular drug targets.

TABLE 2

# Comparison of 1,800 Unique Genes Identified in the Blood Cell cDNA Library to Genes Previously Identified in Specific Tissues

Gene Identification	No. of ESTs	Accession No.		Tissue Distribution								
			В	1 Br	TH.	TK		TLu	<del></del>			
100 kDa coactivator	2	U22055		++	<del>  ''-</del>	1.	<del>                                     </del>	+	-			
10kD protein (BC10)	2	AF053470		<del>                                     </del>	-		+	+				
14-3-3 epsilon	2	U54778		+ +	+		<u> </u>	+				
	11	U28964			<u></u>		L	+				
14-3-3 protein				+	+		+	L				
15 kDa selenoprotein (SEP15)	1	AF051894		+	+			+				
1-phosphatidylinositol-4- phosphate 5-kinase isoform C	1	578798										
23 kD highly basic protein	21	X56932	+	+	+	+	+	+				
2-5A-dependent RNase	1	L10381		<b>†</b>	1	_	$\vdash$	<del>                                     </del>				
2'-5'oligoadenylate synthetase 2 (OAS2)	4	M87284	В									
26S proteasome subunit 11	1	AF086708		<del> </del>		<b></b>	<b></b>	_				
36 kDa phosphothyrosine protein	2	AJ223280	T		+							
3-7 gene product (non- exact 86%aa)	1	D64159										
3-phosphoglycerate dehydrogenase (PGAD)	1	AF006043	T	+	+			+				
3-prime-phosphoadenosine 5-prime-phosphosulfate synthase 1 (PAPSS1)	2	U53447	+	+	+	+		+				
46kd mannose 6- phosphate receptor (MPR46) (low match)	1	X56257										
5-aminoimidazole-4- carboxamide ribonucleotide transformylase	1	D89976										
5'-nucleotidase	3	D38524	T	+			+					
6-phosphofructo-2- kinase/fructose-2,6- biphosphatase 4 (PFKFB4)	1	D49818		+								
6-phosphofructo-2- kinase/fructose-2,6- bisphosphatase (PF2K)	1	AF041829										
71 kd heat shock cognate protein hsc70	23	Y00371										
76 kDa membrane protein (P76)	2	U81006		+	+	+	+	+				
8-oxoguanine DNA glycosylase (OGG1)	1	U96710	В				+	+				
a disintegrin and metalloprotease domain 10 (ADAM10)	1	AF009615					+					
a disintegrin and metalloprotease domain 8 (ADAM8)	1	D26579	В	+								
A kinase anchor protein 95 (AKAP95)	2	Y11997	B, T activated		+			+	······································	-		
A kinase anchor protein, 149kD (AKAP149)	2	X97335		+	+	+		+		· . ·		

A4 differentiation-									PCT/CA00/00005
dependent protein (A4)	1	U93305					T	$\neg \tau$	
Itriple LIM domain protein					- 1	- }	- [		
(LMO6), and synaptophysin (SYP);	J					İ			
calcium channel alpha-1	İ			1		-			
(subunit (CACNA1F)	1		}	1	1		ļ		
ABL and putative M8604 Met protein	1	U07561		┪	+-	+-	+	+	
Absent in melanoma 1 (AIM1)	+	U83115	+	+	+	+	+	-	<u> </u>
accessory proteins	<del>  2</del>	Z31696							
BAP31/BAP29 (DXS1357E)		231090		+	+				
acetyl-Coenzyme A acyltransferase	2	X12966	+	+	+	+	+		
(peroxisomal 3-oxoacyl- Coenzyme A thiolase) (ACAA)									
acetyl-Coenzyme A transporter (ACATN)	1	D88152	Tlymphoma	+	+	+-	+	+	· · · · · · · · · · · · · · · · · · ·
acidic 82 kDa protein	4	U15552	<del>                                     </del>	-	+-	+-	+		
acidic protein rich in leucines (SSP29)	1	Y07969	В	+	+	+	+	++	
Aconitase 2, mitochondrial	+	U80040							
(ACO2)		080040	+	+	+	+		+	
actin binding protein MAYVEN	1	AF059569				+	+-	+-	<del> </del>
actin, beta (ACTB)	158	X04098	1.B	<del></del>	+	┼	+		
actin, beta (ACTB) (non- exact, low match 73%)	1	M10277	.,		<del>  `</del>	+-	<del>                                     </del>	┼	
actin, gamma (low score)	<del> </del>	K00791							-::
actin, gamma 1 (ACTG1)	4	X04098					I	1	
actin-binding LIM protein	4	D31883	+	+	+	+	+	+	high in many libraries
(ABLIM) Actinin, alpha 1 (ACTN1)			1	+	+	+		+	-41
actinin, alpha 4 (ACTN4)	8	M95178		+	+	+	-	+	<del> </del>
activated p21cdc42Hs	1	D89980		+	+	_	+	1	
kinase (ACK)	1 -1 -	L13738	В	+		_		+	
activated RNA polymerase II transcription cofactor 4 (PC4)	1	X79805	+	+	+	+		+	
activating transcription factor 1 (ATF1)	1	X55544		-	+				
activating transcription factor 2 (ATF2)	1	X15875		+	+		+		·
activating transcription	2	M86842							
ractor 4 (tax-responsive enhancer element B67) (ATF4)	_	1000042					+	+	
active BCR-related gene (ABR)	1	U01147	+	+	+	<del>-</del> -		+	
acyl-CoA oxidase (AOX)	1	U03254							
acyl-Coenzyme A	2	M16827		_					
dehydrogenase, C-4 to C- 12 straight chain (ACADM) acyl-Coenzyme A									
dehydrogenase, very long chain (ACADVL)	3	D43682	+	+	+	+	+	+	
acyloxyacyl hydrolase (neutrophil) (AOAH)	3	M62840	T -	$\dashv$	+	+	+	+	
adaptin, delta (ADTD)	2	U91930		++	+	-+	+		
adaptin, delta (ADTD) (non-exact 59%)	1	AC005328		$\dashv$	+	$\dashv$	$\dashv$	-+	
adaptin, gamma (ADTG)		Y12226		++	+	++	+	+	
	' '								
(AP3S3)	2	X99459		+	+	+	$\dashv$	+	
AP3S3) adaptor protein p150	_ '			•		+	1	+	
adaptor complex sigma3B (AP3S3) adaptor protein p150 adducin 1 (alpha) (ADD1)	2	X99459					+	+	

WO 00/40749									
adducin 1 (alpha) (add1)	3	L29296	+	+	+	+		+	
adducin 3 (gamma) (ADD3)	3	U37122	B, W	+	+		+	+	
adenine nucleotide	2	M57424		+	+	$\vdash$	+		
translocator 2 (fibroblast) (ANT2)	-	11107 42 1							
adenine nucleotide translocator 2 (fibroblast)		J02683							
(ANT2) (non-exact 81%) adenine nucleotide		J02683				<b> </b>			
translocator 2 (fibroblast) (ANT2) (non-exact, 79%)	•	302083							
adenine nucleotide translocator 2 (fibroblast) (ANT2) (non-exact, 86%)	1	J02683							
adenine nucleotide translocator 3 (liver)	3	J03592		+	+		+	+	
(ANT3) adenosine deaminase,	6	U18121		+	+		+		
RNA-specific (ADAR) adenylate cyclase 3	2	AF033861		+	+	+	+	+	
(ADCY3)		D25538				ļ			
adenylate cyclase 7 (ADCY7)	1								
adenylate kinase 2 (AK2)	2	U39945		+	+		+	+	
adenylate kinase 3 (AK3) (non-exact, 67%)	1	X60673							
adenylyl cyclase- associated protein (CAP)	28	M98474	· T		+		+		
adipose differentiation- related protein; adipophilin (ADFP)	1	X97324			+		+	+	
ADP-ribosylation factor 1 (ARF1)	13	M84326		+	+		+	+	
ADP-ribosylation factor 3 (ARF3)	2	M33384		+	+		+		
ADP-ribosylation factor 4 (ARF4)	1	M36341	Tlymphoma	+	+			+	
ADP-ribosylation factor 5 (ARF5)	1	M57567			+	+	+	+	
ADP-ribosylation factor domain protein 1, 64kD (ARFD1)	1	L04510		+					
ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase) (ADPRT)	4	M32721	+	+	+	+	+	+	
adrenergic, beta, receptor kinase 1 (ADRBK1)	2	X61157	В	+			+		
adrenoleukodystrophy-like 1 (ALDL1)	1	AJ000327							
AE-binding protein 1 (AEBP1) (non-exact, 62%)	1	D86479							
AF-17	1	U07932							
A-gamma-globin	1	V00514							
A-gamma-globin (chromosome 11 allele)	1	J00176							
agammaglobulinaemia	1	U78027					T		
tyrosine kinase (ATK) AHNAK nudeoprotein	4	M80899	+	+	+	+		+	
(desmoyokin) (AHNAK) alanyi (membrane)	1 1	X13276	+	-	+	$\vdash$	+		
aminopeptidase N, aminopeptidase M, microsomal									
aminopeptidase, CD13, p150) (ANPEP)									
alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5)	1	M29872							
aldehyde dehydrogenase 1, soluble (ALDH1)	1	AF003341		+			+	+	

aldehyde dehydrogenase	1 -							ł	'CT/CA	.00/00005	
10 (fatty aldehyde dehydrogenase) (ALDH10)	2	U75286								<del></del>	
aldehyde reductase 1 (low Km aldose reductase) (ALDR1)	3	J04795	В	+	+	+	+		<del> </del>		_
aldo-keto reductase family 1, member A1 (aldehyde reductase) (AKR1A1)	2	J04794	В	+	+		+				
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II) (AKR1C3)	1	D17793		+	+	+		+			
aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) (AKR7A2)	1	Y16675		+	+		+	+			
aldolase A, fructose- bisphosphate (ALDOA)	7	X12447		+	+	$\vdash$	+			· · · · · · · · · · · · · · · · · · ·	
aldolase C, fructose- bisphosphate (ALDOC)	2	X05196		+	+		+				
alkaline phosphatase, liver/bone/kidney (ALPL) ALL-1 (=L04731;L04284	1	4502062			1.				<del></del> -		
HRX)	4	Z69780									
isozyme alpha thalassemia/mental	1 3	D55649		+			+				
retardation syndrome X- linked (ATRX)	3	U75653	+	+	+	+		+			
alpha-2 macroglobulin	1	Z11711			-					· · · · · ·	
alpha-2-globin	2	V00516				-	$\dashv$	-		· · · · · · · · · · · · · · · · · · ·	
alpha-2-macroglobulin receptor/lipoprotein receptor protein (A2MR/LRP)	1	U06985					1			# .	
alpha-polypeptide of N- acetyl-alpha- glucosaminidase (HEXA)	1	M13520									<u> </u>
alpha-spectrin	1	X86901		+		-	-				
alpha-subunit of Gi2 a (GTP-binding signal transduction protein)	1	X07854	· · · · · · · · · · · · · · · · · · ·		·	7		$\dashv$			
aminin receptor 1 (67kD); Ribosomal protein SA (LAMR1)	2	J03799	T	+	+	+	+	+			
aminolevulinate, delta-, dehydratase (ALAD)	1	X64467		+		_	+	+			
amino-terminal enhancer of split (AES)	2	X73358	+	+	+	+	$\top$	+			_
amino-terminal enhancer of split (AES) AMP deaminase isoform L	3	U04241	В	+	+		+	+	·····		
(AMPD2) amphiphysin (Stiff-Mann	8	M91029		+		1	1	+			
syndrome with breast cancer 128kD autoantigen) (AMPH)	1	U07616	В	+				+			
amphiphysin (Stiff-Mann syndrome with breast cancer 128kD autoantigen) AMPH)(non-exact, 68%)	1	U07616									
amphiphysin (Stiff-Mann syndrome with breast cancer 128kD autoantigen) AMPH)(non-exact, 68%)	1	U07616									1
amphiphysin II	4	U87558		++	+	+	-	+			4
amphiphysin II (67%aa amphiphysin?)	1	AF068915			$\dashv$	-	+	+	·		$\dashv$
amphiphysin II (non-exact 59% aa)	1	AF001383			+	+	+	+			$\dashv$

WO 00/40749		·							
imphiphysin-like (AMPHL)	1	U68485		+	+				
mphiphysin-like (AMPHL)	1 -	AF068918							
MY-1	1	D50692	В, 1				+		
myloid beta (A4) recursor protein-binding, amily B, member 1 (Fe65) APBB1)	1	L77864		+	+	+		+	
myloid beta (A4) recursor-like protein 2 APLP2)	6	L27631	T lymphoma	+	+		+	+	
nkyrin 3, node of Ranvier ankyrin G) (ANK) (non- exact, 50%)	1	U43965							
annexin I (lipocortin I) ANX1)	1	X05908		+	+	+		+	
annexin II		D28364							
annexin II (lipocortin II; calpactin I, heavy polypeptide) (ANX2)	7	D00017	+	+	+	+	+		high in many libranes
annexin IV (placental anticoagulant protein II) (ANX4)	1	M19383		+	+	+	+	+	
annexin V (endonexin II) (ANX5)	2	M21731		+	+	+		+	
annexin V (endonexin II) (ANXV)	1	M19384		+	+	+		+	
annexin VI (p68) (ANX6)	6	Y00097		+	+	+		+	
annexin VII (synexin) (ANX7)	1	J04543		+	+	+		+	
monocional antibodies 12E7, F21 and O13 (MIC2)	2	M16279		+	+	+		+	
antigen identified by monoclonal antibodies 4F2, TRA1.10, TROP4, and T43 (MDU1)	3	J02939		+	+	+	+	+	
antigen TQ1	1				<u> </u>				<u></u>
anti-oxidant protein 2 (non- selenium glutathione peroxidase, acidic calcium- independent phospholipase A2) (KIAA0106)	1	D14662		+	+	+	+	+	
APEX nuclease (multifunctional DNA repair enzyme) (APEX)	5	X66133		+	+		+	+	
Apolipoprotein L (APOL) (59%aa)	1	Z82215				_			
apoptosis inhibitor 1 (API1)	1	L49431		+	+	+	+	+	
apoptosis inhibitor 4 (survivin) (API4)	1	U75285	B, W	+	+		+	$\perp$	
apoptosis inhibitor 5 (API5)	1	U83857	T lymphoma	1			+	1	
apoptosis specific protein (ASP)	1	Y11588	В	+			+	+	
apoptotic protease activating factor (APAF1)	1	AF013263	В	+	+		+		
activating factor (APAFT)	1	AB001325	1		$\top$		+	T	
aquaponn 9 (AQP9)	7	AB008775	T activated	1	1		+	$\top$	
arachidonate 12-	1	M58704	1	1	1	1	+	+	·
lipoxygenase (ALOX12) arachidonate 5- lipoxygenase-activating	3	X52195	+	+	+	+	+	+	
protein (ALOX5AP) ariadne homolog (ARI)	<del>                                     </del>	AJ009771	+	+	+	+	+	+	-
ariadne-2 (D. melanogaster) homolog (all-trans retinoic acid inducible RING finger) (ARI2)	1	AF099149	+	+	+	+		+	

ARP1 (actin-related protein	1	Vone							1 ( 1	/CAU	JU/UU	005
1, yeast) homolog A (centractin alpha) (ACTR1A)		X82206		+							~	
ARP2 (actin-related protein 2. yeast) homolog (ACTR2)	9	AF006082		+	+	+	+	+-	+			
ARP2/3 protein compex subunit 34 (ARC34)	5	AF006085	Tactivated.	+	+	$\dashv$	+	-	+	<del></del>		
Arp2/3 protein compex subunit p41 (ARC41)	6	AF006084	monocyte	+	+	+	+	+	-			
Arp2/3 protein compex subunit p41 (ARC41)) (low	1	AF006084	stimulated		+	+	+	+	+-			
match) Arp2/3 protein complex	20	AF017807		+	+	$\perp$	+	+	_			
subunit p16 (ARC16) Arp2/3 protein complex	2	AF006087		+	+	_	+	+	<u> </u>			
subunit p20 (ARC20) Arp2/3 protein complex	3	AF006086	- w	ļ	<u> </u>	┼	+	+	-			
subunit p21(ARC21) ARP3 (actin-related protein	11	AF006083	W	<u> </u>	+	-	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	+	<u> </u>			
3, yeast) homolog (ACTR3) arrestin, beta 2 (ARRB2)	1	AF106941	5. T. W	-	+	↓_		<u>                                     </u>				
arsA (bacterial) arsenite transporter, ATP-binding,	1	AF047469	B, T	+	+	+	++	-	+			
homolog 1 (ASNA1) aryl hydrocarbon receptor	2	A=0///000										
nuclear translocator-like (ARNTL)	2	AF044288	В	+	+		+					
aryl hydrocarbon receptor- interacting protein (AIP)	1	U31913	+	+	+	+		+	-			
arylsulfatase A (ARSA)	1	X52151	Tactivated	+		-	+	↓			· .	
asialoglycoprotein receptor 2 (ASGR2)	7	M11025				<del> -</del>	+	+			·	
asparaginyl-tRNA synthetase (NARS)	3	D84273		+	+		+	-	-			:
aspartyl-IRNA synthetase (DARS)	1	J05032	В	+	+		+	-				<del></del> -
ataxia telangiectasia mutated (includes complementation groups A, C and D) (ATM)	1	U82828	В, Т		+		+				<u>,</u>	
ataxin-2-like protein A2LP (A2LG)	1	AF034373	B, T activated	+	+			+				
ATF6	1	AF005887	20.1.4.00	+			+					
ATP binding cassette transporter (ABCR) (non-exact 80%)	1	U88667								-	<del></del>	
ATP synthase (F1-ATPase) alpha subunit, mitochondrial	1	X59066										
ATP synthase beta subunit gene	1	M19482	<del></del>					$\dashv$				
ATP synthase, H+ transporting, mitochondrial	1	X60221	+	+	+	+		+				
F0 complex, subunit b, isoform 1 (ATP5F1)												
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 1 (ATP5G1)	1	X69907	Tactivated	+	+		+	+				
ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscle (ATP5A1)	3	D14710							_		<u>.                                      </u>	
ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscle (ATP5A1) (low match)	1	D14710					1			3.		

WO 00/40749									
ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide (ATP5B)	2	M27132							
ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 (ATP5C1)	1	D16563	W	+	+	+	+		
ATP synthase, H+ transporting, mitochondrial F1F0, subunit g (ATP5JG)	1	AF092124	+	+	+	+	+	+	
ATP/GTP-binding protein (HEAB)	2	U73524	+	+	+	+		+	
ATPase, Ca++ transporting, ubiquitous (ATP2A3)	5	Z69881		+					
ATPase, H+ transporting, lysosomal (vacuolar proton pump) 21kD (ATP6F)	2	D89052	+	+	+	+		+	
ATPase, H+ transporting, lysosomal (vacuolar proton pump) 31kD (ATP6E)	1	X76228		+	+	+		+	
ATPase, H+ transporting, lysosomal (vacuolar proton pump) 42kD; Vacuolar proton-ATPase, subunit C; V-ATPase, subunit C (ATP6D)	5	X69151	·	+	+	+		+	
ATPase, H+ transporting, lysosomal (vacuolar proton pump), alpha polypeptide, 70kD, isoform 1 (ATP6A1)	3	L09235		+		+			
ATPase, H+ transporting, lysosomal (vacuolar proton pump), beta polypeptide, 56/58kD, isoform 2 (ATP6B2)	6	X62949	•	+	+	+		+	
ATPase, H+ transporting, lysosomal (vacuolar proton pump), member J (ATP6J)	2	AF038954	+	+	+	+		+	high in testis
ATPase, H+ transporting, lysosomal (vacuolar proton pump), subunit 1 (ATP6S1)	1	D16469		+	+	+		+	
ATP-binding cassette 50 (TNF-alpha stimulated) (ABC50)	.1	AF027302	+	+	+	+		+	
ATP-binding cassette protein M-ABC1 (mitochondnal)	1	AF047690							
ATP-dependent RNA helicase	1	AJ010840	Tlymphoma		+		+		
autoantigen (Hs.75528)	2	L05425	Tactivated		+				
autoantigen (Hs.75528) (non-exact 84%)	1	L05425							
autoantigen (Hs.75682)	1	U17474	В	+				+	
autoantigen La/SS-B	1	Z35127							
axin (AXIN1)	1	AF009674	Т	+			_		
axonemal dynein heavy chain (DNAH17)	1	AJ000522						+	
BAI1-associated protein 3 (BAIAP3) (non-exact 54%)	1	AB017111							
basement membrane- induced gene (ICB1)	1	AF044896				_			
basic leucine zipper nuclear factor 1 (JEM-1) (BLZF1)	2	U79751							
basic transcription factor 3 (BTF3)	5	X74070	+	+	+		+	+	
basigin (BSG)	1	L10240		+			+	_	
BC-2	1	AF042384	В		<u> </u>	+	+	1	<u> </u>

B-cell CLL/lymphoma 6								r	CT/CA00/00005
(zinc finger protein 51) (BCL6)	1	U00115		+	+				
B-cell translocation gene 1 anti-proliferative (BTG)	, 1	X61123			+	+-	$\vdash$	+	
BCL2/adenovirus E1B 19kD-interacting protein 2 (BNIP2)	1	U15173	В	+			+	+	
BCL2/adenovirus E1B 19kD-interacting protein 3- like (BNIP3L)	2	AF067396		+	+	+		+	· .
beclin 1 (coiled-coil, myosin-like BCL2- interacting protein) (BECN1)	1	AF077301	В	+	+		+		·
beta-1,2-N- acetylglucosaminyltransfer ase II (MGAT2)	2	U15128							
beta-2-microglobulin (B2M)	i	S82297	+	+	+	+	+	+	high in invasive prostate tumor
beta-hexosaminidase alpha chain (HEXA)		M16411					•		prostate tumor
beta-tubulin	7	V00599	+	+	+	+	+	+	high in many libraries
beta-tubulin (non-exact, 76%)	1	AF070561	··· <u>·</u>						, and the same of
beta-tubulin, pseudogene	1	J00315		_			$\neg \dashv$		
BING4	1	Z97184	<del></del>	<del>- </del> i				-	
biotinidase (BTD) (non-eact 62%)	1	U03274	<del></del>			_			
biotinidase (BTD) (non- exact 70%)	1	U03274					$\dashv$	_	÷
biotinidase (BTD) (non- exact, 56%)	1	U03274				_	_		
BIOTINIDASE PRECURSOR	1	P43251					$\neg$		ţ.
biphenyl hydrolase-like (serine hydrolase) (BPHL)	1	X81372		+		1	+		
bone marrow stromal cell antigen 1 (BST1)	1	D21878					+		
box-dependent myc- interacting protein isoform BIN1-10 (BIN1)	1	AF043900				1	$\top$		
box-dependent myc- interacting protein isoform BIN1-10 (BIN1) (non-exact, 64%)	1	AF043900							
brain my047 protein	1	AF063605		++	+		+		
branched chain keto acid dehydrogenase E1, alpha polypeptide (maple syrup urine disease) (BCKDHA)	3	214093		+	+		+		
BRCA1 associated protein- 1 (ubiquitin carboxy- terminal hydrolase) (BAP1)		D87462	+	+	+	+		$\top$	
BRCA1, Rho7 and vatl genes, and ipf35	1	L78833				$\dashv$	$\top$	+	
breakpoint cluster region protein, uterine leiomyoma, 1; barrier to autointegration factor (BCRP1)	2	AF044773		+	+	1			
breakpoint cluster region protein, uterine leiomyoma, 2 (BCRP2) breast cancer anti-estrogen	2	AF044774		+	+	1	+	+	
(non-exact 73%)	1	U92715							
promodomain-containing protein, 140kD (peregrin) (BR140)	2	M91585		+			-	$\top$	
Bruton's agammaglobulinemia yrosine kinase (Btk)	1	U13424					$\dagger$	$\top$	
		27							

WO 00/40/49		U78027		<del></del>	<u>-</u>			- т	
Bruton's tyrosine kinase BTK)	1	078027							· · · · · · · · · · · · · · · · · · ·
Intron's tyrosine kinase BTK), alpha-D- alactosidase A (GLA), .44-like ribosomal protein L44L) and FTP3 (FTP3)	1	U78027							
354	1	AF108083							
STG2 (BTG2)	6	Y09943	+	+	+	+		+	
TK region clone ftp	1	U78027	+	+	+	+		+	
TK region clone ftp-3	1	U01923		+	+		+		
BUB3 (budding uninhibited by benzimidazoles 3, reast) homolog (BUB3)	4	AF053304	+	+	+	+		+	
outyrate response factor 1 EGF-response factor 1) BRF1)	4	X79067							
outyrophilin (BTF1)	7	U90543		+	±		+		
outyrophilin like receptor		AB020625.1							
CAG repeat containing (CTG4A)	2	U80744		+	+		+		
CAGH32	2	U80743 M83566		+					
calcium channel, voltage- dependent, L type, alpha 1D subunit (CACNA1D) (low match)	1	M83366							
calcium/calmodulin- dependent protein kinase (CaM kinase) II gamma (CAMK2G)	1	AF069765		+	+	+		+	
calcium/calmodulin- dependent protein kinase kinase (KIAA0787)	1	AF101264	В	+	+		+		
calmodulin (=M19311)	7	D45887			+		+	+	
calmodulin 1 (phosphorylase kinase, delta) (CALM1)	6	M27319	В	+	_				
calnexin (CANX)	3	M94859	T	+			+	+	
calpain, large polypeptide L1 (CAPN1)	5	X04366		+	+		+	+	
calpain, large polypeptide L2 (CANP2)	5	M23254		+	+	↓_	_	+	
calpain, small polypeptide (CAPN4)	1	X04106		+	+		+	Ľ	
calpastatin (CAST)	3	D16217		+-+	<b>_</b>	+	ļ. —	+	
Calponin 2	2	D83735	— <del>Б т</del> —	++	<del> </del>	+-	+	┵	
calponin 2 (CNN2)	1	D83735	В, Т	+-	<del> </del>	+	<del>ļ</del>	+	
calponin 2 (CNN2) (low iscore)	1	003735			<u></u> .				
calumenin (CALU)	3	AF013759	В		+		+	+	
cAMP response element- binding protein CRE-Bpa (H GS165L15.1)	4	L05912							
cAMP-dependent protein kinase type II (Ht31)	1	M90360							
canicular multispecific organic anion transporter (CMOAT2)	1	AF009670				+	+	+	
capping protein (actin filament) muscle Z-line, alpha 1 (CAPZA1)	6	U56637	В, Т		+			+	
capping protein (actin filament) muscle Z-line, alpha 2 (CAPZA2)	2	U03269	В	+	+			1	
capping protein (actin filament) muscle Z-line, beta (CAPZB)	1	U03271	+	+	+	+		+	

capping protein (actin									PCT/CA	00/00005
filament), gelsolin-like (CAPG)	8	M94345	+	+				+		
carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD)	1	D78586	+	+	+	1	F	+		
carbonic anhydrase V, mitochondrial (CA5)	1	L19297	<del></del>	+	+-	$\dashv$	+	+	<del> </del>	
carboxypeptidase D (CPD)	3	U65090	В	+	+	- -	+	-		· · · · · · · · · · · · · · · · · · ·
camitine/acylcamitine translocase (CACT)	1	Y10319	1	+	+	+	++	+	<del> </del>	
Cas-Br-M (murine) ecotropic retroviral transforming sequence (cbl)	2	X57110	·				+			
casein kinase 1, aipha 1 (CSNK1A1)	1	L37042	+	+	+	+	+-	+		
casein kinase 2, alpha 1 polypeptide (CSNK2A1)	2	M55265	В	+		$\dagger$	+	+		
casein kinase I gamma 3L (CSNK1G3L)	1	AF049090.1				+	+	-		<del></del>
casein kinase II alpha subunit(=S72393)	1	X69951			1	+	+-	-		
CASP8 and FADD-like apoptosis regulator (CFLAR)	. 4	AF015450		+	+	+	+	+		
caspase 1, apoptosis- related cysteine protease (interleukin 1, beta, convertase) (CASP1)	7	U13697	. +			+				
caspase 10, apoptosis- related cysteine proteas (CASP10)	1	U60519	B, T aci	ivated, homa	1		+		<del></del>	
caspase 3, apoptosis- related cysteine protease (CASP3)	3	U13737	В, Т	T +	+	+	+			
caspase 4, apoptosis- related cysteine protease (CASP4)	6	U25804	+	+	+	+		+	-	
caspase 5, apoptosis- related cysteine protease (CASP5)	1	U28015			+					
caspase 8, apoptosis- related cysteine protease (CASP8)	2	X98173		+		+		+	···	
caspase 9, apoptosis- related cysteine protease (CASP9)	1	U56390	В			+	+			
catalase (CAT)	5	X04076	В	+ +	<del> </del>		+	$\dashv$	<del></del>	
catechol-O- methyltransferase (COMT)	1	M65213		+	+		+	+		
catenin (cadherin- associated protein), alpha 1 (102kD) (CTNNA1)	6	D14705		+	+			1		<del></del>
cathelicidin antimicrobial peptide (CAMP)	1	X89658	В			+	$\dashv$	-		
cathepsin B (CTSB)	4	L16510		1 - 1	+	$\dashv$	++	+		
cathepsin C (CTSC)	3	U79415		+	+	+		+	· · · · · · · · · · · · · · · · · · ·	
cathepsin D (lysosomal aspartyl protease) (CTSD)	4	M11233		+	+	$\dashv$	+	_		
cathepsin E (CTSE)	1	J05036		<del>                                     </del>	+	$\dashv$	+			
cathepsin G (CTSG)	1 34	M16117 M86553	1, W		+	$\exists$		_		
cathepsin W (lymphopain)			B. Monocyte	e stimu ohoma	iated,	T	+	+		
(CTSW)	4	AF013611					_	+		
corepressor CIR (=U03644 recepin)	1	AF098297				1	+			

WO 00/40749								•	C1/CA00/00003
CCAAT/enhancer binding protein (C/EBP), alpha I(CEBPA)	3	X87248		+	+	+		+	
CCAAT/enhancer binding protein (C/EBP), delta (CEBPB)	1	S63168			+		+	+	
CCAAT-box-binding transcription factor (CBF2)	2	M37197	Tlymphoma			+	+		
CCR5 receptor (CCR5)	1	AF011504							
CD14 antigen (CD14)	11	M86511	+	+	+	+		+	
CD18 (=M95293)	4	X64071							
CD1C antigen, c	2	M28827						+	
CD2 antigen (cytoplasmic tail)-binding protein 2 (CD2BP2)	1	AF104222							
CD2 antigen (p50), sheep red blood cell receptor (CD2)	4	M14362	+		+	+		+	
CD2 cytoplasmic tail- binding protein 1 (CD2BP1)	2	AF038602					+		
CD20 antigen (CD20)	1	X12530							
CD20 receptor (S7)	1	X07203							
CD22 antigen (CD22)	1	U62631	В						
CD24 signal transducer	1	M58664							
CD33 antigen (gp67) (CD33)	1	M23197					+		
CD33 antigen-like 2; OB binding protein-2 (CD33L2) (non-exact, 68%)	1	U71383							
CD33L2 (61% aa)	1	D86359							
CD36 antigen (collagen type I receptor, thrombospondin receptor) (CD36)	7	M98398	Tiymphoma		+		+	+	
CD37 antigen (CD37)	5	X14046	+	+		+		+	
CD38 alt	1 -	D84277							
CD39 antigen (CD39)	1	U87967	В	+			+	+	
CD3D antigen, delta polypeptide (TiT3 complex) (CD3D)	1	X03934			+	+		+	
CD3E antigen, epsilon polypeptide (TIT3 complex) (CD3E)	1	X03884	+			+			
CD3G antigen, gamma polypeptide (TiT3 complex) (CD3G)	2	X06026	W				+		
CD3Z antigen, zeta polypeptide (TiT3 complex) (CD3Z)	2	J04132	+			+			
CD3-zeta (clone pBS NK1)	1	X55510							
CD4 (low match)	1	568043							
CD4 antigen (p55) (CD4)	4	M12807		+	+		+		
CD44 antigen (homing function and Indian blood group system (CD44)	6	X56794	W				+	+	
CD48 antigen (B-cell membrane protein) (CD48)	3	X06341	+	+	+	+		+	
CD53 antigen (CD53)	10	L11670	+	+		+		+	
CD53 antigen (CD53) (low match)	1	M60871							
CD63 antigen (melanoma 1 antigen) (CD63)	3	M59907							
CD68 antigen (CD68)	2	S57235		+	+		+	+	

CD74 antigen (invariant	72	K01144	<del></del>		- ,							
polypeptide of major histocompatibility complex, class II antigen-associated) (CD74)	, 2	701144	+			*	+	+	+	high	n mar	ny librar
CD79A antigen (immunoglobulin- associated alpha) (CD79A)	2	M80462		+	+		$\dashv$	+			·	
CD79B antigen (immunoglobulin-	2	M89957	+	+	+		$\dashv$	$\dashv$				
associated beta) (CD79B) CD8 antigen, alpha	2	M27161	+	$\downarrow$				_				
polypeptide (p32) (CD8A) CD8 antigen, beta	1	X13445		$\perp$			+		+			_
polypeptide 1 (p37) (CD8B1)	•	X13443	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \									
CD81 antigen (target of antiproliferative antibody 1 (CD81)	1	M33680		+	+	+	+		+	<del></del>		
CD83 antigen (activated B lymphocytes, mmunoglobulin superfamily) (CD83)	1	Q01151	В	+	+		+		+			
CD84 antigen (leukocyte antigen) (CD84)	1	U82988		+	+	+	+	+	+			
CD86 antigen	1	L25259	<del> </del>	+	+	+	+-	+	-			
CD9 antigen (p24) (CD9)	2	M38690		+	+	+	+	+-	+ +			
CD97 antigen (CD97)	12	X84700	+	+	+	++			4			
CD97 antigen (CD97) (noin-exact 59%)	1	P48960	<del>                                     </del>	<del>                                     </del>	<del> </del> -	+	+	+	$\dashv$			
CD97 antigen (CD97) (non- exact 62%)	1	X94630	+	+	1	+	+	+	+			
CDC23 (cell division cycle 23, yeast, homolog) CDC23)	1	AF053977		+		1	+	†	+		*3	
CDC37 homolog	1	U63131	В	+	+	+	╁	╁	+			
Cdc42 effector protein 3 CEP3)	2	AF104857	В	+	+	+-	+	+	+		<del></del> .	
DC-like kinase (CLK)	1	L29219	<del>                                     </del>	+	+	╁┿	┿	+	-			
CDC-like kinase 2 (CLK2)	1	AF023268	В	+	+	┼	+	+-	+			
DDW52 antigen CAMPATH-1 antigen) CDW52)	13	X15183	Tactivated	+	+		+	-	$\dagger$			
ell cycle progression estoration 8 protein(CPR8)	1	AF011794				-	<del> -</del>	+	+			
ell division cycle 10 nomologous to CDC10 of . cerevisiae) (CDC10)	4	S72008	+	+	+	+		+	+			
ell division cycle 20, .cerevisiae homolog CDC20)	1	U05340		+	+	+			$\dagger$	-		
ell division cycle 25B CDC25B)	6	Z68092	+	+	+	+		+	+			
ell division cycle 2-like 1 PITSLRE proteins) DDCL1) (non-exact 42%)	1	AF067514										
ell division cycle 42 (GTP- nding protein, 25kD) DC42)	5	M35543	+	+	+	+		+				
ell division protein (non- kact 68%)	1	AF063015							+			
ELL-CYCLE NUCLEAR JTOANTIGEN SG2NA /G2 NUCLEAR NTIGEN)	1	Q13033							-			
entromere protein B 0kD) (CENPB) ep250 centrosome	1	X55039		+			+		T			
sociated protein	3	AF022655	В	+	<del></del>	$\rightarrow$	+		₩-			

WO 00/40749									
ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky	7	AF017456	+	+	+	+	+	+	high in bone
disease) (CLN2) c-fgr (=M63877 nonreceptor protein-	6	X52206							
tyrosine kinase (fgr)) CGI-19 protein	3	AF132953.1							
	1	X74801		+	+			+	
chaperonin containing TCP1, subunit 3 (gamma) (CCT3)							+	+	
chaperonin containing TCP1, subunit 4 (delta) (CCT4)	1	AF026291		+	+		_		
chaperonin containing TCP1, subunit 6A (zeta 1) (CCT6A)	4	L27706	В	+	+				
chaperonin containing TCP1, subunit 7 (eta) (CCT7)	4	AF026292	В	+				+	
Chediak-Higashi syndrome 1 (CHS1)	1	U67615	B, T lymphoma	+	+		+		
Chediak-Higashi syndrome 1 (CHS1) (low score)	1	U67615							
chemokine (C-C motif) receptor 2 (CCR2)	4	U03905							
chemokine (C-C motif) receptor 4 (CCR4) (low match) (may contain repeat)	1	X85740							
chemokine (C-C motif) receptor 7 (CCR7)	6	L31581							
chemokine (C-X3-C) receptor 1 (CX3CR1)	5	U20350		+					
chemokine (C-X-C motif), receptor 4 (fusin) (CXCR4)	5	M99293	+	+	+	+		+	
chitinase 3-like 1 (cartilage glycoprotein-39) (CHI3L1)	2	M80927		+		+		+	
chitinase 3-like 2 (CHI3L2)	2	U49835		+		+		+	
chlonde channel 1 , skeletal muscle (CLCN1)	1	G18280						L	
chloride channel 6 (CLCN6)	1	D28475		+	+	<u> </u>		+	
Chloride intracellular channel 1 (CLIC1)	1	U93205	+	+		+		Ţ	
chondroitin sulfate proteoglycan 2 (versican) (CSPG2)	5	X15998			+				
chondroitin sulfate protein	2	J02814			+			+	
chromatin assembly factor 1 p48 subunit (CAF-1 P48 subunit) (retinoblastoma binding protein p48) (retinoblastoma-binding protein 4) (MSI1 protein homolog)		Q09028							
chromodomain helicase DNA binding protein 1 (CHD1)	2	AF006513							
chromodomain helicase DNA binding protein 1-like (CHD1L)	1	AF054177							
chromodomain helicase DNA binding protein 2 (CHD2)	1	AF006514	В	+	+		+		
chromodomain helicase DNA binding protein 3 (CHD3)	1	AF006515			<u> </u>				
chromodomain helicase DNA binding protein 4 (CHD4)	5	X86691	+	+	+	*			

chromosome 1 open									PC1/C	A00/	00005
reading frame 7 (C10RF7)		AF054176					T		T		
chromosome 1 specific transcript KIAA0493	1	AB007962					T	1	1-		
chromosome 17 open reading frame 18 (C17ORF18)	1	AJ008112	T	+			-	$\dagger$	-		
chromosome 4 open reading frame 1 (C4ORF1)	1	AF006621		+	+	+	+-	+	+-		
chromosome condensation 1-like (CHC1L)	2	AF060219		+	+	+	+-	+	-		-
chromosome X open reading frame 5 (CXORF5)	1	Y15164	В	+	+	+-	+	+-	<del> </del>		
chromosome-associated polypeptide C(CAP-C)	2	AF092564	В	+	+	$\dagger$	+	+	<del>                                     </del>		· ·
cig42	1	AF026944			+	+-	+	+-	<del> </del>		
cig5	3	AF026941			+	+	-	-	+		
citrate synthase (CS)	2	AF047042	В	++	++		+	+	ـــ		
class I major	2	U31372			+	-	<u> </u>	+-	—		
histocompatibility antigen (HLA-Cw3)											
class I major histocompatibility antigen (HLA-Cw3) (low match)	1	U31372									
clathrin assembly protein lymphoid myeloid leukemia (CALM)	3	U45976	В	+	+	$\vdash$		+			
clathrin heavy chain	1	X55878	<del></del>	+	<del> </del>	-			-		
clathrin, heavy polypeptide- like 2 (CLTCL2)	1	D21260									
clathrin, light polypeptide (Lca) (CLTA) (low match)	1	M20472		1							
clathrin- associated/assembly/adapt or protein, medium 1 (CLAPM1)	3	D63475		+	+	+	+	+			\.
cleavage stimulation factor, 3' pre-RNA, subunit 2 64kD (CSTF2) (non-exact 82%)	1	M85085									
cleavage stimulation factor, 3' pre-RNA, subunit 3, 77kD (CSTF3)	1	U15782	В	+	+		+				
clk3	1	L29220	В	╅	+	-					
clone 23815 (Hs.82845)	1	U90916		╅┿┪	+			+			
clone 24592 mRNA sequence	1	D88378	+	+	+	+		+			
Clq/MBL/SPA receptor C1qR(p) ()	1,	U94333		1				$\neg$			
clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed prostate message 2,	1	M64722	+	+	+	+	+	+			
apolipoprotein J) (CLU) CMP-sialic acid transporter (CMPST)	1	D87969	В	+-	+	_	_	-			
CMRF35	3	X66171	<del></del>			$\rightarrow$					
c-myc oncogene containing	1	X54629					-	_			
coagulation factor II (thrombin) receptor (F2R)	1	M62424		+ -	+	-	+	+	·		
(proaccelerin, labile factor) (F5)	1	M14335		+		+	+	$\dashv$			
coagulation factor XIII a subunit	3	M21998			-	$\dashv$	+				
coagulation factor XIII, A1 polypeptide (F13A1)	6	M14354	<del></del> -	+	+	+	$\dashv$	+			
coated vesicle membrane protein (RNP24)	1	X92098	+	+	+	+	+†	+			
				ــــــــــــــــــــــــــــــــــــــ							

WO 00/40749									C1/CA00/00005
coatomer protein complex, subunit alpha (COPA)	5	U24105	T	+			+		
Cofilin 1 (non-muscle) (CFL1)	13	X95404	+	+	+	+	+	+	high in fetal brain
cold inducible RNA-binding protein (CIRBP)	7	D78134		+	+			+	
cold shock domain protein A (CSDA)	3	X95325		+	+				
collagen, type IX, alpha 2 (COL9A2)	3	AF019406	В						
colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog (CSF1R)	3	X03663		+			+	+	
colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) (CSF2RB)	5	M59941							
colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) (CSF2RB) (low match)	1	M59941							
colony stimulating factor 3 receptor (granulocyte) (CSF3R)	16	X55720		+			ē		
complement component 5 receptor 1 (C5a ligand) (C5R1)	1	M62505				+		+	
conserved gene amplified in osteosarcoma (OS4)	2	AF000152		+	+	_			
COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 3 (COPS3)	2	AF031647		+	+		-	+	
COP9 homolog (HCOP9)	2	U51205	В	+	+	+	+	+	
COPII protein, homolog of s. cerevisiae SEC23p (SEC23A)	4	X97064		+	+				
copine I (CPNE1)	2	U83246	В	+	+		+		
copine I (CPNE1) (low score)	1	U83246							
coproporphyrinogen oxidase (coproporphyria, harderoporphyria) (CPO)	1	D16611			+		+	+	
core-binding factor, beta subunit (CBFB)	1	€20298		+					
coronin	22	X89109	T, W	+	+		+		
coronin (low match)	1	U34690		1					
coronin (non-exact, 71%)	1	X89109							
cot (cancer Osaka thyroid) oncogene (COT)	7	D14497	+	+	+			+	
cryptochrome 1 (photolyase-like) (CRY1)	1	D84657		+				+	
CTD (carboxy-terminal domain, RNA polymerase III, polypeptide A) phosphatase, subunit 1 (CTDP1)	1	AF081287		+	+	+		+	
C-terminal binding protein 1 (CTBP1)	1	U37408	В	+	+		+		
C-terminal binding protein 2 (CTBP2)	2	AF016507		+	+		+		
CUG triplet repeat, RNA- binding protein 1 (CUGBP1)	3	U63289		+	+	+		+	
cullin 1 (CUL1)	3	U58087		+	+	+		+	
cullin 3 (CUL3)	2	U58089		+	+	+		+	
cut (Drosophila)-like 1 (CCAAT displacement protein) (CUTL1)	1	M74099	В	+					

cyclin D2 (CCND2)	2	D13639	T	1 +	T +	T +		1 +		
cyclin D3 (CCND3)	5	M92287	В. Т	+-	+	+	++	+		
cyclin G1 (CNNG1)	1	53004	lymphoma							
cyclin I	3	D78341	В	+	+	$\bot \bot =$		+		
cyclin T2 (CNNT2)	1 3	D50310	В	+			+			
		AF048732	B, T lymphoma	В						
cyclin-dependent kinase 2 (CDK2)	1	X62071								
cyclin-dependent kinase inhibitor (p27Kip1)	1	S76986				$\dagger$	-	1	1	
cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A)	2	S67388	+	+	+	+	+	+		
CYP2D7-CYP2D6 intergenic region (partial)	1	X90926	<del> </del>		-	-	$\vdash$	-		
cystatin B (stefin B) (CSTB)	1 -	L03558	<del> </del>	-	+	+	+	+	<del> </del>	
cysteine and glycine-rich protein 3 (cardiac LIM protein) (CSRP3)	5	L54057			+	$\vdash$				
cytidine deaminase (CDA)	2	L27943		-	-	┼	+	-		
cytochrome b	1	AF042500	<del> </del>	<del>                                     </del>	<del> </del>	+-	+	-		
cytochrome b (CYTB) (isolate Aus5)	1	AF042518		<del>                                     </del>		<del>                                     </del>				
cytochrome b(-245) beta chain N-terminal region (X- linked granulomatous disease gene)	2	X05895								<del></del>
cytochrome b-245, beta polypeptide (chronic granulomatous disease) (CYBB)	2	X04011	+			+		+		1
cytochrome C	1	P00001				-				<del></del>
cytochrome c oxidase subunit IV (COX4)	1	U90915		+	+		+	+		-
cytochrome c oxidase subunit Vb (COX5B)	2	M59250					+			
cytochrome c oxidase subunit VII-related protein (COX7RP)	6	AB007618	+	+	+	+		+	-	· · · · ·
cytokine suppressive anti- inflammatory drug binding protein 1 (p38 MAP kinase) (CSBP1)	1	L35263	lymphocyte	+	+		+			
Cytoplasmic antiproteinase=38 kda intracellular serine proteinase inhibitor	1	S69272			+					
cytotoxic granule- associated RNA-binding protein p40-TIA-1	1	S70114								
D123 (D123)	1	D14878	+	+		+		++		
02-2	1	AF019226				-+	-	-		
D38	1	X74802				-	_	$\dashv$		
damage-specific DNA binding protein 1 (127kD) (DDB1)	2	AJ002955	+	+	+	7	+	+		
OCHT (low match)	1	AF017635		-+	$\dashv$	+		-+		
DEAD/H (Asp-Glu-Ala- Asp/His) box binding protein 1 (DDXBP1)	1	U78524		+	+	+	+	+		
DEAD/H (Asp-Glu-Ala- Asp/His) box polypeptide 72KD) (P72)	2	U59321	1	+	+		+.	+		
DEAD/H (Asp-Glu-Ala- Asp/His) box polypeptide 1 (DDX1)	· 1	X70649		+	+			+		

WO 00/40749								1	.1/CA00/00003
DEAD/H (Asp-Glu-Ala- Asp/His) box polypeptide 15 (DDX15)	2	AB001636							
DEAD/H (Asp-Glu-Ala- Asp/His) box polypeptide	2	AB011149	+	+	+	+		+	
16 (DDX16) DEAD/H (Asp-Glu-Ala-	3	U50553	+	+	+	+		+	
Asp/His) box polypeptide 3 (DDX3)									
DEAD/H (Asp-Glu-Ala- Asp/His) box polypeptide 5 (RNA helicase, 68kD) (DDX5)	37	X15729	+	+	+	+		+	
DEAD/H (Asp-Glu-Ala- Asp/His) box polypeptide 5 (RNA helicase, 68kD) (DDX5) (low match)		AF015812							
DEAD/H (Asp-Glu-Ala- Asp/His) box polypeptide 6 (RNA helicase, 54kD) (DDX6)	2	D17532	+	+					
DEAD/H (Asp-Glu-Ala- Asp/His) box polypeptide 8 (RNA helicase, 54kD) (DDX8)	1	D50487		+	+	+		+	
DEAD/H (Asp-Glu-Ala- Asp/His) box polypeptide 9 (RNA helicase A, nuclear DNA helicase II; leukophysin) (DDX9)	3	L13848	+	+	+	+		+	
DEAD/H (Asp-Glu-Ala- Asp/His) box polypeptide, Y chromosome (DBY)	1	AF000985		+	+		+		
Death associated protein 3 (DAP3)	2	X83544	+	+	+	+	+	+	
death effector domain- containing protein (DEDD)	1	AF083236		+	+	+		+	
death-associated protein 6 (DAXX)	2	AF039136		+	+	+		+	
dedicator of cyto-kinesis 2 (DOCK2)	4	D86964	+	+		*	+	+	
defender against cell death 1 (DAD1)	1	D15057			+			+	
Defensin, alpha 1, myeloid- related sequence (DEFA1)	4	L12690			+	+	+	Ľ	
DEK gene (D6S231E)	1 4	X64229 Z50781	B +	+	+	+	ļ. <u> </u>	+	
delta sleep inducing peptide, immunoreactor (DSIPI)									
dendritic cell protein (GA17)	3	AF064603	+	+	+	+		+	
deoxycytidine kinase (DCK)	1.	M60527							
deoxyribonuclease II, iysosomal (DNASE2)	3	AB004574							
DGS-I	2	L77566		+			1_	<u> </u>	
diacylglycerol kinase	3	D16440		+	<u> </u>		<u> </u>	<u> </u>	
diacylglycerol kinase alpha (DAGK1) (clone 24)		AF064771		+		<u> </u>			
diacylglycerol kinase alpha (DAGK1) (clone 24) (low match)	1	AF064771							
diaphanous (Drosophila, homolog) 1 (DIAPH1)	1	AF051782	B, monocyte stimulated		+		+	+	
diaphorase (NADH) (cytochrome b-5 reductase) (DIA1)	1	Y09501	+	+	+	+	+	•	
differentiated Embryo Chondrocyte expressed gene 1 (DEC1)	1	AB004066		+			+	•	

WO 00/40 /49									PCT/CA00/00005
differentiated Embryo Chondrocyte expressed	1	AB004066				$\neg$	1	1	T
igene 1 (DEC1) (low match)					i	ı	ı		
differentiation antigen CD20	1	L23415		+	_	+	+	+	
DiGeorge syndrome critical region gene 2 (DGCR2)	1 1	X84076		+	+	+	+-	+	+
dihydrolipoamide dehydrogenase (E3 component of pyruvate dehydrogenase complex, 2-oxo-glutarate complex, branched chain keto acid dehydrogenase complex) (DLD)	2.	J03620		+				F .	+
dihydrolipoamide S- acetyltransferase (E2 component of pyruvate dehydrogenase complex) (DLAT)	1	Y00978	В	+		+-	+		
dihydropyrimidinase-like 2 (DPYSL2)	1	D78013		+	+	+	+	+	
dinG gene	1	Y10571	<del> </del>	+	+	+	+-	+	
dipthena toxin resistance protein required for diphthamide biosynthesis (Saccharomyces)-like 2 (DPH2L2)	3	AF053003	В	+	+		+	+	
disintegrin-protease (non- exact 72%)		Y13323		<del>                                     </del>		+	+	+	
DJ-1 protein	2	AF021819	+	+	+	+	↓	+	
Dmx-like 1 (DMXL1)	1	AJ005821	+	<u> </u>	+	+	-	<del>                                     </del>	15
DNA (cytosine-5-)- methyltransferase 1 (DNMT1)	3	X63692	Tactivated, lymphoma	+	<u> </u>	+	+	+	
DNA fragmentation factor, 40 kD, beta subunit (DFFB)	1	AF064019			_	╁┈		-	-0.4
DNA fragmentation factor, 45 kD, alpha subunit (DFFA)	2	U91985	1	+	+			+	
DNA mismatch repair protein (hMLH1)	1	U17840					-	-	
DNA segment on chromosome X (unique) 648 expressed seguence	3	M64241	+	+	+	+	+	+	high in many libraries
DNA segment, single copy probe LNS-CAI/LNS-CAII (deleted in polyposis (D5S346)	3	M73547		+	+	+		+	
DNA-damage-inducible transcript 1 (DDIT1) (low match)	1	L24498							
OnaJ protein	1	AJ001309	<del></del>						
OnaJ protein	1	AJ001309						-	
docking protein 2, 56kD DOK2)	1	AF034970		-					
dolichyl- diphosphooligosaccharide- protein glycosyltransferase DDOST)	1	D89060	+	+	+	+	+	+	activated T cell
lolichyl-phosphate nannosyltransferase lolypeptide 1, catalytic lubunit (DPM1)	1	D86198	Tactivated	+	+		+		
own-regulated by ctivation (immunoglobulin uperfamily) (DORA) own-regulated in	1	AJ223183					+		
denoma DRA (low match)	1	P40879							
-type cyclin-interacting rotein 1 (DIP1)	1	AF082569	. В	$\neg +$		_	+	+	

WO 00/40749									.1/CA00/00003
dual specificity phosphatase 1 (DUSP1)	4	X68277	+	+	+	+	+	+	
dual specificity phosphatase 11 (RNA/RNP) complex 1-interacting) (dusp11)	1	AF023917	+	+	+	+		+	
dual specificity phosphatase 3 (vaccinia virus phosphatase VH1- related) (DUSP3)	1	L05147		+	+		+	+	
dual specificity phosphatase 6 (DUSP6)	6	X93920	+	+	+	+	+	+	
dynactin 1 (p150, Glued (Drosophila) homolog) (DYTN1)	3	X98801							
dynactin 1 (p150, Glued (Drosophila) homolog) (DYTN1) (low match)	1	X98801	В	+	+				
dynamin 2 (DNM2)	1	L36983				1			
dynamitin (dynactin complex 50 kD subunit) (DCTN-50) (non-exact 88%)	1	U50733							
dynein, axonemal, heavy polypeptide 17-like (non- exact, 57%aa)	1	X99947							
dynein, cytopiasmic, light intermediate polypeptide 2 (DNCLI2)	1	AF035812	В	+	+			+	
dynein, cytoplasmic, light intermediate polypeptide 2 (DNCLI2) (non-exact, 69%)	1	AF035812							
dyskeratosis congenita 1, dyskerin (DKC1)	1	U59151	В	+			+	+	
dystonia 1, torsion (autosomal dominant) (DYT1)	1	AF007871		+	+	+		+	
dystrobrevin, beta (DTNB)	1	AF022728		+					
dystrophia myotonica- containing WD repeat motif (DMWD)	1	L19267		+	+		+	+	
dystrophia myotonica- protein kinase (DMPK)	1	L08835	+	+	+			+	·
dystrophin (muscular dystrophy, Duchenne and Becker types) (DMD) (low match, 59%aa)	1	X14298							
E1B-55kDa-associated protein	1	AJ007509	W	+	+		+	+	
E2F transcription factor 3 (E2F3)	2	D38550		+	+	+	+	+	
E2F transcription factor 4, p107/p130-binding (E2F4)	1	X86096	В	+			+		
E2F transcription factor 5, p130-binding (E2F5)	2	U15642	+	+		+		+	
E74-like factor 1 (ets domain transcription factor) (ELF1)		M82882	В		+		+	•	
E74-like factor 4 (ets domain transcription factor) (ELF4)	3	U32645		+	+			+	
E74-like factor 4 (ets domain transcription factor) (ELF4) (non-exact, 71%)		U32645							
early development regulator 2 (homolog of polyhomeotic 2) (EDR2)	4	U89278	+	+	+	+		+	
EBV induced G-protein coupled receptor (EBI2)	1	L08177	W						
ecotropic viral integration site 2B (EVI2B)	3	M60830				+			

ectin, galactoside-binding,	1 1		<u> </u>							<b>L</b> UU/UU(	<i>J</i> U5
soluble, 1 (galectin 1)	'	J04456						+			
EGF-like-domain, multiple 4 (EGFL4)	1	AB011541			T	Ť	$\top$	十	+		
elF-2-associated p67 homolog	3	U13261	В	+	1	$\dagger$	+	+	<del>                                     </del>		
elastin (supravalvular aortic stenosis, Williams-Beuren syndrome) (ELN) (low match)	1	M24782		+	+						<u>·                                      </u>
elav-type RNA-binding protein (ETR-3)	3	U69546		1		$\dagger$	1	+			
electron-transfer- flavoprotein, alpha polypeptide (glutaric aciduria II) (ETFA)	2	J04058		+							<del></del>
ELK3, ETS-domain protein (SRF accessory protein 2) (ELK3)	2	Z36715			+			+			···
elongation factor 1-beta	1	L26404		<del> </del>	<del> </del>	+-	+-	+	<del>                                     </del>		
elongation factor Ts (mitochondrial protein)	1	AF110399		+-		<u> </u>	+	1-	<del> </del>	<del></del>	
elongation factor Tu- nuclear encoded mitochondrial	1	X84694							-		
eMDC II protein	1	AJ242015.1		┪──	_	-	┼		<del> </del>		
ems1 sequence (mammary tumor and squamous cell carcinoma-associated (p80/85 src substrate) (EMS1)	1	M98343		+	+		+	+			.:
endogenous retroviral element HC2	1	Z70664		<del> </del>			-	+		. :	
endosulfine alpha (ENSA)	1	X99906	<del></del>	+			<del> </del>		ļ		
endothelial differentiation, sphingolipid G-protein- coupled receptor, 1 (EDG1)	2	M31210	· · · · · · · · · · · · · · · · · · ·	+	+	+		+			
endothelial differentiation, sphingolipid G-protein- coupled receptor, 1 (EDG1) (low match 66%)	1	M31210	· · · · · · · · · · · · · · · · · · ·							-	
endothelial monocyte- activating polypeptide (EMAPII)	1	U10117	+	+	+	+		+			
enolase 1, (alpha) (ENO1)	12	M14328	+	+	+	+	+	+			
enolase 2, (gamma, neuronal) (ENO2)	1	X51956	<del></del>	+							
enolase-alpha	1	D28437		<del>                                     </del>		_		$\vdash$			
enoyl Coenzyme A hydratase 1, peroxisomal (ECH1)	2	U16660									
enoyl Coenzyme A hydratase, short chain, 1, mitochondrial (ECHS1)	1	D13900	+	+	+	+	+	+	<del></del>		
ENOYL-COA HYDRATASE, MITOCHONDRIAL PRECURSOR (SHORT CHAIN ENOYL-COA HYDRATASE) (SCEH) (ENOYL-COA HYDRATASE 1) (low match, non-exact 56%)		P30084									
epidermal growth factor receptor pathway substrate 15 (EPS15)	2	U07707		+	-	+		+			

WO 00/40749									17CA00700005
EPIDIDYMAL SECRETORY PROTEIN E1 PRECURSOR (EPI-1) (HE1) (EPIDIDYMAL SECRETORY PROTEIN 14.6) (ESP14.6)	2	Q15668							
epithelial membrane protein 3 (EM[P3)	1	U87947	+	+	+	+		+	
Epoxide hydrolase 1, microsomal (xenobiotic) (EPHX1)	1	L29766							+ only
ERCC2 (=L47234)	1	X52221							
ERF-2	3	U07802	+	+	+	+			high in gall bladder
ERp28 protein	1	X94910	+	+	+	+		+	
erythrocyte membrane protein	2	M81635							
erythroleukemic cells K562	2	L25343							
EST (Hs.189509)	2	U24166							
estrogen receptor-related protein (hERRa1)	1	L38487			+				
ESTS, Highly similar to ADENYLOSUCCINATE SYNTHETASE	1	X66503	В, Т	+					
ESTs, Moderately similar to cysteine-rich fibroblast growth factor receptor	1	U28811	+	+	+	+		+	
ET binding factor 1 (SBF1)	1	U93181	· +	+				+	
ets domain protein ERF	1	U15655	+	+	+	+		+	
eukaryotic translation elongation factor 1 alpha 1 (EEF1A1)	326	X03558	Т	+	+			+	
eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) (low match)	1	X03558							
eukaryotic translation elongation factor 1 alpha 1 (EEF1A1) (low match)	1	X03558							
eukaryotic translation elongation factor 1 beta 2 (EEF1B2)	5	X60489	+	+	+	+		+	
eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein) (EEF1D)	1	Z21507	+	+	+	+	+	+	
eukaryotic translation elongation factor 1 gamma (EEF1G)	31	Z11531							
eukaryotic translation elongation factor 2 (EEF2)	2	X51466		+		ļ		+	·
eukaryotic translation initiation factor 2, subunit 1 (alpha, 35kD) (EIF2S1)	1	J02645						_	
eukaryotic translation initiation factor 2, subunit 2 (beta, 38kD) (EIF2S2)	1	M29536							
eukaryotic translation initiation factor 2, subunit 3 (gamma, 52kD) (EIF2S3)	3	L19161		+	+				
eukaryotic translation initiation factor 3, subunit 10 (theta, 150/170kD) (EIF3S10)	2	U78311				+			high in white blood
eukaryotic translation initiation factor 3, subunit 2 (beta, 36kD) (EIF3S2)	3	U36764	+	+	+				cells
eukaryotic translation initiation factor 3, subunit 3 (gamma, 40kD) (EIF3S3)		U54559	+	+	+	+			
eukaryotic translation initiation factor 3, subunit 4 (delta, 44kD) (EIF3S4)	9	AF020833		+		+		+	
			40						

## PCT/CA00/00005

								1	PCT/CA00/00005
eukaryotic translation initiation factor 3, subunit 6 (48kD) (EIF3S6)	4	U94175	+	+	+	+	T	+	high in bladder
eukaryotic translation initiation factor 3, subunit 6 (EIF3S6)		U62962		+	+	+		+	Highly represented (1.4833 pct) in librar 36 human gall bladder
eukaryotic translation initiation factor 3, subunit 7 (zeta, 66/67kD) (EIF3S7)	3	U54558	+	+	+	+		+	Diaddel
eukaryotic translation initiation factor 3, subunit 8, 110KD (EIF3S8)	5	U46025	+	+	+	+	+	+	high in testis
eukaryotic translation initiation factor 4 gamma, 1 (EIF4G)	1	AF012088							
eukaryotic translation initiation factor 4 gamma, 1 (EIF4G) (low match)	1	AF012088							
eukaryotic translation initiation factor 4 gamma, 1 (EIF4G1)	2	D12686							
eukaryotic translation initiation factor 4 gamma, 2 (EIF4G2)	6	U73824	+	+	+	+	+	+	
eukaryotic translation initiation factor 4 gamma, 2 (EIFG2)	2	U76111	+	+	+	+	+	+	
eukaryotic translation initiation factor 4A, isoform 1 (EIF4A1)	29	D13748	<del>;</del>						
eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2)	11	D30655	+	+	+	+	+	+	- 14 14.
eukaryotic translation initiation factor 4B (EIF4B)	18	X55733	+	+	+	+		+	
eukaryotic translation initiation factor 4E (EIF4E) Eukaryotic translation	1	P06730							<del></del>
protein 2 (EIF4EBP2)	3	L36056	Т, В	+			+	+	
eukaryotic translation initiation factor 4H (EIF4H)	2	Q15056		1		_	$\dashv$	+	
eukaryotic translation initiation factor 5 (EIF5)	2	U49436	+	+ +	+	+	+	+	
eukaryotic translation termination factor 1 (ETF1)	2	U90176	+	+ +	+	+	$\dashv$	+	
EV12 protein	1	M55266	<del></del>	+++	-		$\dashv$		
Ewing sarcoma breakpoint region 1 (EWSR1)	1	X66899	+	+ +	+	+	-	+	
EWS/FLI1 activated transcript 2 homolog (EAT-2)	2	AF020264				$\dashv$			
EWS-E1A-F chimeric protein	1	U35622		1-1		$\dashv$	$\dashv$	$\dashv$	
excision repair cross- complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence)		M28650	+	+	+	+		+	
(ERCC1) excision repair cross-		Venna							
complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))	•	X69978		+	+	+		+	
(ERCC5) exostoses (multiple)-like 3	1	AF001690							
(EXTL3)	·			+	+	+	1	+	
<u> </u>	1	X77744				+	+	_	

WO 00/40/49									
F1-ATPase beta subunit (F-1 beta)	2	X03559							
Fanconi anaemia group A	2	Z83095							
Fanconi anemia,	1	X99226	+	+	+	+			
complementation group A (FANCA)								+	
far upstream element (FUSE) binding protein 1 (FUBP1)	2	U05040	+		+				
farnesyl diphosphate	1	J05262	+	+	+	+		+	
synthase (farnesyl pyrophosphate synthetase,dimethylallyitra nstransferase, geranyitranstransferase) (FDPS)									
farnesyl-diphosphate farnesyltransferase 1 (FDFT1)	2	X69141	+	+	+	+	+	+	
farnesyltransferase, CAAX box, beta (FNTB)	2	L00635		+	+				
Fas ligand (gene and promoter region)	1	AF044583				1			
Fas-ligand associated factor 1	1	U70667							
fatty-acid-Coenzyme A ligase, long-chain 1 (FACL1)	4	D10040	+	+	+	+	*	+	·
Fc fragment of IgA, receptor for (FCAR)	1	X54150					l		
Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide (FCER1G)	1	M33195	+	+	+	+		+	
Fc fragment of IgE, low affinity II, receptor for (CD23A) (FCER2)	2	X04772	+	+					
Fc tragment of IgG, low affinity Ila, receptor for (CD32)	6	M31932	+	+	+	+	+	+	
Fc fragment of IgG, low affinity Ila, receptor for (CD32) (FCGR2A)	1	X62572	+	+	+	+	+	+	
Fc fragment of IgG, low affinity Illa, receptor for (CD16) (FCGR3A)	34	X07934	+	+	+	+		+	
Fc fragment of IgG, receptor, transporter, alpha (FCGRT)	3	U12255		+	+	+	+	+	high in many libraries
fc-fgr	1	Z13983							
Fc-gamma-receptorIIIB (FCGR3B)	2	M90746							
feline sarcoma (Snyder- Theilen) viral (v- fes)/Fujinami avian sarcoma (PRCII) viral (v- fps) oncogene homolog(FES) c-fes/fps)	3	X06292							
female sterile homeotic- related gene 1 (mouse homolog) (FSRG1)	2	X96670	+	+	+	+		+	
ferritin L-chain	9	Y09188							
ferritin, heavy polypeptide 1 (FTH1)		M11146	+	+	+	+	+	+	
fertilin alpha pseudogene	1	Y09232			1	$\bot$	1_	1_	
fetal Alzheimer antigen (FALZ)	2	U05237		+				1_	
fetal Ig heavy chain variable region	1	M34024							
fibrillarin (FBL)	1	X56597	+	+	+	+	+	+	
fibrinogen-like protein 2 (T49)	3	Z36531				+			
N. 70/	J		42						

fibroblast growth factor	T			- 131					PCT/CA00/00005
receptor 2 (bacteria- expressed kinase, keratinocyte growth factor	'	M35718	+	+	1	4			
receptor, craniofacial dysostosis 1, Crouzon									
syndrome) syndrome, Pfeiffer syndrome, Jackson-Weiss) (FGFR2)									
ficolin (collagen/fibringen domain-containing) 1 (FCN1)	19	D83920			+	+	-	+	-
filamin A, alpha (actin-	2	VESAGE						⊥.	
binding protein-280) (FLNA)	2	X53416							
filamin B, beta (actin- binding protein-278) (FLNB)	1	AF043045		+	+	-	+	$\dagger$	
Finkel-Biskis-Reilly murine	2	X65923	+	+	<del> </del>	٠.	4		
sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived); ribosomal protein S30 (FAU)	_	A3323	*		+	+	+	+	intraepithelial neoplasia and invasive prostate
FK-506 binding protein	1	M80199	+	++	╁	+	╂	+	tumor
FK506-binding protein 1A (12kD) (FKBP1A)	2	M34539				+-	+	+	
FK506-binding protein 18 (12.6 kD) (FKBP1B) FK506-binding protein 5	1	M92423		+		+		+	
(FKBP5) Flightless I (Drosophila)	4	U71321		+	+	+		+	(a)
homolog (FLII) Flightless I (Drosophila)	3	U80184		+					<u>.</u>
homolog (FLII) (low match) FLN29 (FLN29)	1	U80184							
	2	AB007447		+		+		+	
lotillin 2 (FLOT2)	5	M60922	+	+	+	+	+	+	<del></del>
olate receptor 2 (fetal) FOLR2) orkhead (Drosophila)	1	AF000380		+	+	+		+	
nomolog rhabdomyosarcoma) like 1 FKHRL1)	1	AF032886	+	+		+		+	·
ormyl peptide receptor 1 (FPR1)	9	M60627	+	+	+	+		+	
ormyl peptide receptor-like (FPRL1)	1	M84562							Found only in libraries from placenta
ormyl peptide receptor-like (FPRL1) (low score)	1	M84562							piacenta
ragile X mental retardation (FMR1)	1	L29074	+	+		+		+	
ragile X mental etardation, autosomal iomolog 1 (FXR1)	.1	U25165	.+	+	+	+			·
riend leukemia virus ntegration 1 (FLI1)	3	M93255	+	+			$\neg$		
ructose-bisphosphatase 1 FBP1)	1	D26054		1 1		+		+	-1
SHD-associated repeat NA, proximal region	1	U85056					7	$\dashv$	
Jcose-1-phosphate uanylyltransferase FPGT)	1 -	AF017445		+	+	+			·
Ill length insert cDNA lone ZA78A09	1	AF086122				_			
ull length insert cDNA P07G10	1	AF075061			_	+		$\dashv$	
umarate hydratase (FH)	1	U59309		+	+	+	-	+	
US (low match)	1	X99006		<del>                                     </del>	<del>-  </del>	-		∤	
YN-binding protein (FYB- 20/130) (FYB)	16	U93049		+-		+	$\dashv$	-+	

WO 00/40749									
G alpha interacting protein (GAIP) (low score)	1	X91809							
G protein beta subunit-like protein 12.3	2	D28398							
G protein-coupled receptor 64 (HE6) (non-exact 59%)	1	X81892				+			
G protein-coupled receptor kinase 6 (GPRK6)	2	L16862	+	+	+			+	
G1 to S phase transition 1 (GSPT1)	2	X17644		+	+	+	+	+	
GA-binding protein transcription factor, beta subunit 2 (47kD) (GABPB2)	1	D13316		+	+	+	+	+	
galactose-1-phosphate uridylyltransferase (GALT)	2	M60091							
galactosidase, beta 1	3	M27508		+			+	+	
galactosyltransterase (=X13223 N- acetylglucosamide-(beta 1- 4)-galactosyltransferase)	1	M13701							
galectin-9 isoform	1	AB006782	+			+	_	+	
gamma2-adaptin (G2AD)	1	AF068706	+	+		+		+	
gamma-actin	2	M37130							
gamma-aminobutyric acid (GABA) B receptor 1 (GABBR1)	2	AJ012187		+	+			+	
GATA-binding protein 2 (GATA2)	1	M68891				+		+	
GATA-binding protein 3 (GATA3)	1	M69106		,	+	+		+	
GCN5 (general control of amino-acid synthesis, yeast, homolog)-like 1 (GCN5L1)	3	D64007	+	+	+	+		+	
GDP dissociation inhibitor 1 (GDI1)	1	D45021	+	+	+	+		+	high in adult brain
GDP dissociation inhibitor 2 (GCI2)	4	Y13286							
GDS-related protein (HKE1.5)	4	U68142	+	+	+	+		+	
gelsolin (amyloidosis, Finnish type) (GSN)	3	X04412		+	+	+	+	+	
general transcription factor II, I (GTF2I)	4	Y14946	+	+	+	+	+	+	
general transcription factor III, i, pseudogene 1 I(GTF2IP1)	1.	AF038968	+	+	+	+	+	+	high in fetal brain
general transcription factor IIF, polypeptide 1 (74kD subunit) (GTF2F1)	4	X64037	+	+	+	+		+	
general transcription factor IIH, polypeptide 3 (34kD subunit) (GTF2H3)	2	Z30093	В, Т						·
general transcription factor IIH, polypeptide 4 (52kD subunit) (GTF2H4)	3	Y07595		+		+		+	
general transcription factor IIIA (GTF3A)	1	U14134	+	+		+		+	
general transcription factor IIIC, polypeptide 1 (alpha subunit, 220kD) (GTF3C1)		U02619		+		+			
general transcription factor IIIC, polypeptide 2 (beta subunit, 110kD) (GTF3C2)	3	D13636	+	+	+	+	+	+	
germline immunoglobulin heavy chain (IGHV@)	1	L06612			Ŀ				
germline immunoglobulin heavy chain, variabl region	1	X92236							
germline immunoglobulin heavy chain, variable region, (21-2)	1	X92343							
		•	4.4						

GLE1 (yeast homolog)-like, RNA export mediator (GLE1L) glia maturation factor, beta (GMFB) glioma-associated oncogene homolog (zinc finger protein) (GLI) glioma-associated oncogene homolog (zinc finger protein) (GLI) (low score) globin, alpha 2 1 glucocorticoid receptor (=M69104) glucocorticoid receptor (GRL) glucos phosphate 1	AF058922  AB001106  X07384  X07384  V00516  M32284  U80947  L09105	+	+	+	+		+			
glioma-associated 1 oncogene homolog (zinc finger protein) (GLI) glioma-associated 1 oncogene homolog (zinc finger protein) (GLI) (low score) globin, alpha 2 1 glucocorticoid receptor (=M69104) glucocorticoid receptor 2 (GRL) glucos phosphate 1	X07384  X07384  V00516  M32284  U80947  L09105			+	+		+			
oncogene homolog (zinc finger protein) (GLI) glioma-associated 1 oncogene homolog (zinc finger protein) (GLI) (low score) globin, alpha 2 1 glucocorticoid receptor (=M69104) glucocorticoid receptor (GRL) glucos phosphate 1	X07384 V00516 M32284 U80947 L09105	+	+	+						_
oncogene homolog (zinc finger protein) (GLI) (low score) globin, alpha 2 1 glucocorticoid receptor (=M69104) glucocorticoid receptor 2 (GRL) glucos phosphate 1	V00516 M32284 U80947 L09105	+	+	+						
glucocorticoid receptor 1 (=M69104) glucocorticoid receptor 2 (GRL) glucos phosphate 1	M32284 U80947 L09105	+	+	+					 	
glucocorticoid receptor 2 (GRL)	U80947 L09105	+	+	+	-	-	<u> </u>	1		
(GRL)	L09105	+	+	+	- 1	Ĭ	1		 	
glucos phosphate			<del></del>	1	+		+		 <del></del>	
isomerase (CONTAINS LARGE REPEAT)	7477477									
glucosamine (N-acetyl)-6- sulfatase (Sanfilippo disease IIID) (GNS)	212173	+								
glucosamine (N-acetyl)-6- sulfatase (Sanfilippo disease IIID) (GNS) (non- exact 56%)	Z12173									
glucose transporter-like 1 protein-III (GLUT3)	M20681	•	+	+	+	+	+		 	
glucose transporter-like protein-III (GLUT3) (low match)	M20681								 · .	
glucosidase, alpha; acid (Pompe disease, glycogen storage disease type II) (GAA)	Y00839	+	+		+		+		 	
glucosidase, beta; acid 1 (includes glucosylceramidase) (GBA)	K02920	+	+	+	+		+			
glutamate dehydrogenase 1 (GLUD1)	M20867		+	+	+	+	+		 <del></del> ,	_
glutamate-ammonia ligase 12 (glutamine synthase) (GLUL)	X59834	+	+	+	+		+	<del></del>		
glutamate-ammonia ligase (glutamine synthase) (GLUL) (low score)	Y00387									
glutamate-cysteine ligase (gamma-glutamylcysteine synthetase), catalytic (72.8kD) (GLCLC)	M90656				+					
glutamine cyclotransferase 1	X71125		+	+	$\vdash$	$\dashv$			 	$\dashv$
glutamine-fructose-6- 1 phosphate transaminase 1 (GFPT1)	M90516		+		+	1			 	$\dashv$
glutaminyI-tRNA 1 synthetase	X72396				1	$\dashv$	+			$\dashv$
glutaminyl-tRNA 6 synthetase (QARS)	X76013	+	+	+	+	_	+	<del></del>	 	$\dashv$
glutamyl-prolyl-tRNA 1 synthetase (EPRS)	X54326	<del></del>			7	$\dashv$	+	<del></del>	 	$\dashv$
glutathione peroxidase 1 2 (GPX1)	M21304	+	+	+	+	+	+		 	ᅱ
glutathione peroxidase 4 phospholipid hydroperoxidase) (GPX4)	X71973	+	+	+	+		+		 	$\dashv$
glutathione S-transferase pi 1 (GSTP1)	U30897		+	+	+	+	+			$\dashv$
glutathione S-transferase 1 subunit 13 homolog	AF070657				$\dashv$	+	+	<del></del>		$\dashv$
glyceraldehyde-3- phosphate dehydrogenase GAPD)	J02642				1	+				$\dashv$

The state of the s					,		<u> </u>		
glycogenin (GYG)	1	U31525		+	+	+	1	+	
glycophorin C (Gerbich blood group) (GYPC)	1	X12496		+	+	+		+	
glycoprotein M68 (GPM6B)	1	U45955		+	+				
glycyl-tRNA synthetase (GARS)	1	U09587	·	+	+	+		+	
glyoxalase I (lactoyl glutathione lyase) (GLYI)	1	L07837	+	+	+	+		+	
golgi autoantigen, golgin subfamily a, 1 (GOLGA1)	1	U51587		+		+			
golgi autoantigen, golgin subfamily a, 2 (GOLGA2) (non-exact, 70%)	1	L06147							
golgi autoantigen, golgin subfamily a, 4 (GOLGA4)	1	U31906							
golgi autoantigen, golgin subfamily b, macrogolgin (with transmembrane signal), 1 (GOLGB1)	1	X75304		+	+	+		+	
gp25L2 protein	4	X90872							
grancalcin	8	M81637		+	+	+		_	
granulin (GRN)	16	X62320	+	+	+	+		+	
granulin (GRN) (low match)	1	X62320							<del>                                     </del>
Granulysin (NKG5)	5	M85276	+			<del>                                     </del>		+	
granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) (GZMA)	1	M18737	<b>+</b>	+	+	+		+	
GRB2-related adaptor protein (GRAP)	1	U52518	Tonly						
Grb2-related adaptor protein 2 (GRAP2)	1	AF090456	1				+		
GRO1 oncogene (melanoma growth stimulating activity, alpha) (GRO1)	1	X54489				+		+	
growth arrest and DNA- damage-inducible gene (GADD153)	1	S40706							
growth arrest-specific 7 (GAS7)	4	AB007854		+	+				
growth factor receptor- bound protein 2 (GRB2)		X62852	В	+			+	+	
GS1 (protein of unknown function)	1	M86934		+	+	+			
GS3955	4	D87119		+	+	+		+	
GTP binding protein 1	1	U87964		+	+	+			
(GTPBP1) GTP binding protein similar to S. cerevisiae HBS1 (HBS1)	1	U87791		+	+	+		+	
GTPase activating protein- like (GAPL)	1	AB011110		+	+	+		+	high fetal brain
GTP-binding protein (low match)	1	Z49068							
GTP-binding protein G(K), alpha subunit (=G(I) ALPHA-3)(=GTP-binding regulatory protein Gi alpha- 3 chain)	1	P08754							·
Gu protein (GURDB)	2	U41387	+		+	+		+	
guanine nucleotide binding	1			-	<u> </u>	<u> </u>		Ė	
protein guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 (GNAI2)	4	J03004	+	+	+	+		+	

									PCT/CA00/00005
guanine nucleotide binding protein (G protein), alpha	7	M20597	+	+	1	-	<del>F</del> T	$\neg$	+
inhibiting activity	İ	ļ	1	-	-		- 1		
polypeptide 3 (GNAI3)			1				- 1	- 1	į.
guanine nucleotide binding	2	X04409	В, Т	+	+-	<del></del>	+	++	+
protein (G protein), alpha stimulating activity	1			ļ	1	- [			1
polypeptide 1 (GNAS1)					1		-	- 1	1
guanine nucleotide binding	1	740000			L			_ [	
protein (G protein), alpha	'  '	218859	1				$\top$	$\top$	
Itransducing activity	ļ		i	- 1	-	- 1			
polypeptide 2 (GNAT2)	4		ĺ		- 1	-	ĺ	- 1	
guanine nucleotide binding	2	AF017656	<del>                                     </del>	+	+	+		+	+
protein (G protein), beta 5 (GNB5)	1		İ	1					•
guanine nucleotide binding	<del> </del>			_	1				
protein (G protein), beta	5	M36430	+	+	+	+	1	-	+
(polypeptide 1 (GNB1)	ł				1		-		1
guanine nucleotide binding	2	AF011496		+	+	+-	┷	$\bot$	
protein (G protein), a	_	7 511400		+	+	+	-	1	
polypeptide (GNAQ)				- 1	- [			- 1	1
guanine nucleotide binding	1	L25665	+	+	+	+	┿	<del></del> -	+
protein-like 1 (GNL1) guanine nucleotide	1			1		1	J		
exchange factor	1	L13857	+	+	+	+	+	+	
guanine nucleotide	-								
regulatory factor (LFP40)	1	X15610	+	+	+	+	1	7	
guanine nucleotide	<del>                                     </del>	U72206	<del></del>	+			$\perp$		
regulatory factor (LFP40)		0/2200	+	+	+	+		+	•
IGUANINE NUCLEOTIDE	1-1	P25388		+	┼	┼	╀		
IBINDING PROTEIN BETA	1	. 25555		ļ	1			1	***
SUBUNIT-LIKE PROTEIN	ļ	1		1	j		ı	ì	
12.3 (P205) (RECEPTOR		1			1	1	1		1-24 g
OF ACTIVATED PROTEIN KINASE C 1) (RACK1)	ł				l	1	1	1	*
GUANINE-		140000			1		1		
MONOPHOSPHATE	1	U10860			+	T	$\Box$	1	
SYNTHETASE (GMPS)	[			1	İ		1	1	ļ
guanosine monophosphate	7	M24470			├	↓		┼	
reductase (GMPR) (non-				1	j		1		
exact, 72%)					ĺ		l		
guanosine-diphosphatase like protein	1	AF016032		<del>                                     </del>		+	<del>                                     </del>	+	<del></del>
guanylate binding protein					ļ				
1. Interferon-inducible	2	M55542		+	+	+	+	+	<del></del>
67kD (GBP1)		į į	•	1	l		j	1	
guanylate binding protein	6	M55543	+					↓	
2. interferon-inducible		11100040	<b>T</b>	+	+	+		+	
(GBP2)			•	1 1			ĺ		1
H2A histone family,	1	Z83742		<del>  </del>		$\vdash$		┼─	<del> </del>
member C (H2AFC) H2A histone family,								1	
member Y (H2AY)	2	AF041483	+	+	+	+		+	
H2B histone family.		700-0		$\perp$					
member L (H2BFL)	2	Z80783	+	+	+	+	+	+	high in adrenal gland
n2-calponin		D86059		<del>↓</del>					tumor
H-2K binding factor-2					7				
	1	L08904		+	+	+		+	
H3 histone family, member K (H3FK)	1	Z83735				-			
13 histone, family 3A		1				- 1	- 1	1	
(H3F3A)	7	M11353	+	+	+	+	$\neg$	+	high in ovary
13 histone, family 3B	15	Z48950		$\sqcup \bot$					
H3.3B) (H3F3B)	.5	Z-1093U	+	+	+	+1		+	high in endothelial
	1	U68494		+			<u>_</u>		cells
neat shock 27kD protein 1	<del></del>	U12404			+	+	+		
HSPB1)	•	012404		+	+		+.	+	
eat shock 40kD protein 1	4	D85429	+	<b>  </b>	<del></del> l				
HSPF1)		500725	<del>-</del>	+	+	+	+	+	high in testis
eat shock 60kD protein 1	3	M22382	<del></del>	+	+	++	ᆛ		<u> </u>
protein 1			-	/ T	T	T	+	+	
Chaperonin) (HSPD1)		1		1 ]			1	1	1
chaperonin) (HSPD1) leat shock 70kD protein 1 HSPA1A)	7	M59828	+	+	<del></del>	+	+	+	high in activated T

WO 00/40/49								-	CI/CAGG/GGGG
heat shock 70kD protein 5 (glucose-regulated protein, 78kD) (HSPA5)	13	X87949		+	+		+		
heat shock 70kD protein 6 (HSP70B') (HSPA6)	4	X51757	+	+	+				
heat shock 70kD protein 9B (mortalin-2) (HSPA9B)	2	L15189		+	+	+	+	+	
HEAT SHOCK COGNATE 71 KD PROTEIN	1	P11142							
heat shock factor binding protein 1 (HSBP1)	2	AF068754							
heat shock protein 90	13	M27024	7	+	+	+	+	+	high in many libraries
heat shock protein, DNAJ- like 2 (HSJ2)	1	D13388		+	+		+		,
Hect (homologous to the E6-AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 1 (HERC1)	1 "	U50078		+	+	+			
hect domain and RLD 2 (HERC2)	1	AB002391	+	+	+	+		+	
helicase-like protein (HLP)	1	X98378	+	+		+		+	
helix-loop-helix protein HE47 (E2A)	1	M65214				Ŀ		+	
hematopoietic cell-specific Lyn substrate 1 (HCLS1)	18	X16663	+		+	+		+	
heme oxygenase (decycling) 1 (HMOX1)	1	X06985		+		+	+	+	
HEMOGLOBIN ALPHA CHAIN	1	P19015 AF117710							
hemoglobin beta (beta globin) hemoglobin, alpha 1	5 301	V00491			+		+	+	
(HBA1) hemoglobin, alpha 1	301	V00491				<u> </u>	Ľ		
(HBA1) (low match)	•	V00493							
match) hemoglobin, alpha 1 (non-	<u>'</u>	J00153				_			
exact, 76%) hemoglobin, alpha 1 (non-	1	V00493			-				
exact, 82%) hemoglobin, beta (HBB)	129	V00497	+	+	+	+	+	+	high in many libraries
hemoglobin, beta (HBB)	1	V00497		+		├	-		
(low match) hemoglobin, beta (HBB)	1	L48220							
(low match) hemokine (C-X-C motif),	1	D10924	+	+	+	+		+	
receptor 4 (fusin) (CXCR4) hemopoietic cell kinase	5	M16591				+		+	
(HCK) hepatitis C-associated	2	D28908		-		ļ			
microtubular aggregate protein p44									
hepatoma-derived growth factor	1	D16431	+	+	+	+		+	
Hermansky-Pudlak syndrome (HPS)	2	U65676							
HERV-E integrase (non- exact 76%aa)	1	AF026246		<u> </u>		<u> </u>		_	
heterogeneous nuclear protein similar to rat helix destabilizing protein (FBRNP)	2	S63912	-	+	+	+		+	
heterogeneous nuclear ribonucleoprotein (C1/C2) (HNRPC)	4	M16342							
heterogeneous nuclear ribonucleoprotein A/B (HNRPAB)	1	M65028	+	+	+	+	+	+	

## PCT/CA00/00005

Indicated content									P	CT/CA00/00005
inbonucleoprotein AZ/21 (HNRPA) (PR) (PR) (PR) (PR) (PR) (PR) (PR) (PR	(HNRPA1)	20	X12671	+	+	+	+	+	T+	High in alveolar rhabdomyosarcoma
inbonucleoprotein D (mRNP D)    Interrogeneous nuclear inbonucleoprotein P-like   Interrogeneous nuclear inbonucleoprotein F (HNRPF)   Interrogeneous nuclear inbonucleoprotein F (HNRPF)   Interrogeneous nuclear inbonucleoprotein F (HNRPF)   Interrogeneous nuclear inbonucleoprotein F (HNRPF)   Interrogeneous nuclear inbonucleoprotein F (HNRPF)   Interrogeneous nuclear inbonucleoprotein H   Interrogeneous nuclear inbonucleoprotein H   Interrogeneous nuclear inbonucleoprotein H   Interrogeneous nuclear inbonucleoprotein H   Interrogeneous nuclear inbonucleoprotein H   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear inbonucleoprotein K   Interrogeneous nuclear   Interrogeneous	ribonucleoprotein A2/B1 (HNRPA2B1)	3	M29064	+	+	╁Ŧ	+	+	+	High in activated T cell, fetal brain
Indicate protein   Indicate   I	ribonucleoprotein D (hnRNP D)	2	D55673	+	+	+	+	+	+	
Inhonucleoprotein   F	ribonucleoprotein D-like (HNRPDL)	5	D89092	+	+	+	+	+	+	
Inbonucleoprotein   F	ribonucleoprotein F (HNRPF)	1	L28010	+	+	+	+		+	
Inbonucleoprotein G (HNRPG) Reterogeneous nuclear ribonucleoprotein H (HNRPH) (FTP-3) Reterogeneous nuclear ribonucleoprotein H (HNRPH) (IND w match) Reterogeneous nuclear ribonucleoprotein H (HNRPH) (IND w match) Reterogeneous nuclear ribonucleoprotein H (HNRPH) Reterogeneous nuclear ribonucleoprotein K (HNRPH) Reterogeneous nuclear ribonucleoprotein K (HNRPR) Reterogeneous nuclear ribonucleoprotein R (HNRPM) Reterogeneous nuclear ribonucleoprotein R (HNRPM) Reterogeneous nuclear ribonucleoprotein R (HNRPM) Reterogeneous nuclear ribonucleoprotein R (HNRPM) Reterogeneous nuclear ribonucleoprotein R (HNRPM) Reterogeneous nuclear ribonucleoprotein R Reterogeneous nuclear ribonucleoprotein R Reterogeneous R Reterogeneou	ribonucleoprotein F (HNRPF) (83%)	1	L28010							
inbonucleoprotein H (HNRPH) (IOW match) heterogeneous nuclear inbonucleoprotein H (HNRPH) (Iow match) heterogeneous nuclear inbonucleoprotein H1 (H) heterogeneous nuclear inbonucleoprotein H2 (H) heterogeneous nuclear inbonucleoprotein K (HNRPK) heterogeneous nuclear inbonucleoprotein K (HNRPK) heterogeneous nuclear inbonucleoprotein R (HNRPK) heterogeneous nuclear inbonucleoprotein R (HNRPK) heterogeneous nuclear inbonucleoprotein I (HNRPK) heterogeneous nuclear inbonucleoprotein I (Scafiold attachment factor A) (HNRPU) hexokinase 2 (HK2) hexokinase 2 (HK2) hexokinase 2 (HK3)  hexokinase 2 (HK3)  hexokinase 3 (HK3)  hexosaminidase A (alpha polypeptide) (HEXA HGMP071 gene for olfactory receptor High density lipoprotein binding protein (HDLBP) high-mobility group (nonhistone chromosomal) protein 1 (HMG1) (none exact 60%) high-mobility group (nonhistone chromosomal) protein 1 (HMG1) (none exact 60%) high-mobility group (nonhistone chromosomal) protein 1 (HMG1) (none exact 60%) high-mobility group (nonhistone chromosomal) protein (HMG1) (none exact 60%) high-mobility group (nonhistone chromosomal) protein (HMG1) (none exact 60%) high-mobility group (nonhistone chromosomal) protein (HMG1) (none exact 60%) high-mobility group (nonhistone chromosomal) protein (HMG1) (none exact 60%) high-mobility group (nonhistone chromosomal) protein (HMG1) (none exact 60%) high-mobility group (nonhistone chromosomal) protein (HMG1) (none exact 60%) high-mobility group (nonhistone chromosomal) protein (HMG1) (none exact 60%) high-mobility group (nonhistone chromosomal) protein (HMG1) (none exact 60%) high-mobility group (nonhistone chromosomal) protein (HMG1) (none exact 60%) high-mobility group (nonhistone chromosomal) protein (HMG1) (none exact 60%) high-mobility group (none exact 60%) high-mobility group (none exact 60%) high-mobility group (none exact 60%) high-mobility group (none exact 60%) high-mobility group (none exact 60%) high-mobility group (none exact 60%)	(HNRPG)	2	Z23064		+	+	+		+	
Inbonucleoprotein H (HNRPH) (Ilow match)  Ineterogeneous nuclear arbonucleoprotein H1 (H)  (HNRPH) Ineterogeneous nuclear arbonucleoprotein K (HNRPK)  Ineterogeneous nuclear arbonucleoprotein K (HNRPK)  Ineterogeneous nuclear arbonucleoprotein K (HNRPK)  Ineterogeneous nuclear arbonucleoprotein G (HNRPK)  Ineterogeneous nuclear arbonucleoprotein U (scaffold attachment factor A) (HNRPL)  Ineterogeneous nuclear arbonucleoprotein U (scaffold attachment factor A) (HNRPL)  Inexokinase 1 (HK1)	ribonucleoprotein H (HNRPH) (FTP-3)	3	P55795							
Inbonucleoprotein H1 (H) (HNRPH) Ineterogeneous nuclear ribonucleoprotein K (HNRPK) Ineterogeneous nuclear ribonucleoprotein R (HNRPK) Ineterogeneous nuclear ribonucleoprotein R (HNRPK) Ineterogeneous nuclear ribonucleoprotein R (HNRPK) Ineterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A) (HNRPL) Inexokinase 1 (HK1) Inexokinase 1 (HK1) Inexokinase 1 (HK1) Inexokinase 2 (HK2) Inexokinase 3 (HK3) Inexokinase 4 (HK3) Inexoki	ribonucleoprotein H (HNRPH) (low match)	1	P31943							
inbonucleoprotein K (HNRPK) heterogeneous nuclear inbonucleoprotein R (HNRPR) heterogeneous nuclear inbonucleoprotein U (scaffold attachment factor A) (HNRPU) hexokinase 1 (HK1) hexokinase 2 (HK2) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK2) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 3 (HK3) hexokinase 1 (HK3) hexokinase 3 (HK3) hexokinase 4 (HK2) hexoki	nbonucleoprotein H1 (H) (HNRPH1)	2	L22009	+	+	+	+		+	
Inbonucleoprotein R (HNRPR) Inelerogeneous nuclear ribonucleoprotein U (scaffold attachment factor A) (HNRPU) Inexerogeneous 1 (HK1) Inexerogeneous 1 (HK1) Inexerogeneous 1 (HK1) Inexerogeneous 1 (HK1) Inexerogeneous 2 (HK2) Inexerogeneous 3 (HK3) Inexerogeneous 3 (HK3) Inexerogeneous 3 (HK3) Inexerogeneous 3 (HK3) Inexerogeneous 3 (HK3) Inexerogeneous 3 (HK3) Inexerogeneous 3 (HK3) Inexerogeneous 3 (HK3) Inexerogeneous 4 (Inexerogeneous 4 Inexerogeneous 4 Inexercise 5 Inexerogeneous 4 Inexercise 5 Inexerogeneous 4 Inexercise 5 Inexerogeneous 5 Inexerogeneous 5 Inexerogeneous 5 Inexerogeneous 6 Inexerogeneous 6 Inexerogeneous 6 Inexercise 6 Inexercise 6 Inexercise 6 Inexerogeneous 6 Inexercise 6 Inexerogeneous 6 Inexercise 6	ribonucleoprotein K (HNRPK)	21	S74678	+	+	+	+	+	+	, .
Inbonucleoprotein U   (scaffold attachment factor A) (HNRPU)	ribonucleoprotein R (HNRPR)				+	+	+	+	+	
hexokinase 2 (HK2)	ribonucleoprotein U (scaffold attachment factor A) (HNRPU)	3	X65488	+	+	+	+	+	+	
hexokinase 2 (HK2)		2	X66957		++-	<del>-</del> -	+		┰┼	
Nexokinase 3 (HK3)		3	Z46376	+	++	+				
Dolypeptide) (HEXA   HGMP071 gene for olfactory receptor		2	U51333		+				-+	
olfactory receptor High density lipoprotein binding protein (HDLBP) high-mobility group (nonhistone chromosomal) protein 1 (HMG1) high-mobility group (nonhistone chromosomal) protein 1 (HMG1) (non- exact 60%) High-mobility group (nonhistone chromosomal) protein 17 (HMG17) high-mobility group (nonhistone chromosomal) protein 2 (HMG2) high-mobility group (nonhistone chromosomal) protein 2 (HMG2) high-mobility group (nonhistone chromosomal) protein 2 (HMG2) high-mobility group (nonhistone chromosomal) protein isoforms I and Y high-risk humanpapilloma viruses E6 oncoproteins targeted protein E6TP1 beta (=AB007900 KIAS0440) histidine ammonia-lyase	(POlypeptide) (HEXA						$\dashv$	+	$\dashv$	
Dinding protein (HDLBP)   Dinding protein (HDLBP)   Dinding protein (HDLBP)   Dinding protein (HMG1)   Dinding protein (HMG1)   Dinding protein (HMG1)   Dinding protein (HMG1)   Dinding protein (HMG1)   Dinding protein (HMG1)   Dinding protein (HMG1)   Dinding protein (HMG17)   Dinding protein (HMG17)   Dinding protein (HMG17)   Dinding protein (HMG2)   Dinding prote	Olfactory receptor	. 2	U76377							
(nonhistone chromosomal) protein 1 (HMG1) high-mobility group (nonhistone chromosomal) protein 1 (HMG1) (non- exact 60%) High-mobility group (nonhistone chromosomal) protein 17 (HMG17) high-mobility group (nonhistone chromosomal) protein 2 (HMG2) high-mobility group (nonhistone chromosomal) protein 2 (HMG2) high-mobility group (nonhistone chromosomal) protein isoforms I and Y high-risk humanpapilloma viruses E6 oncoproteins targeted protein E6TP1 beta (=AB007900 KIAA0440) histidine ammonia-lyase	Dinding protein (HDI RP)			+	+	+	+	+	+	
(nonhistone chromosomal) protein 1 (HMG1) (non-exact 60%) High-mobility group (nonhistone chromosomal) protein 17 (HMG17) high-mobility group (nonhistone chromosomal) protein 2 (HMG2) high-mobility group 2 M83665 + + + + + + + + + + + + + + + + + +	(nonhistone chromosomal)	5	X12597	+	+	+	+	+	Ť.	
(nonhistone chromosomal) protein 17 (HMG17) high-mobility group (nonhistone chromosomal) protein 2 (HMG2) high-mobility group (nonhistone chromosomal) protein isoforms I and Y high-risk humanpapilloma viruses E6 oncoproteins targeted protein E6TP1 beta (=AB007900 KIAA0440) histidine ammonia-lyase	(nonhistone chromosomal) protein 1 (HMG1) (non- exact 60%)		D63874							
(nonhistone chromosomal) protein 2 (HMG2) high-mobility group (nonhistone chromosomal) protein isoforms I and Y high-risk humanpapilloma viruses E6 oncoproteins targeted protein E6TP1 beta (=AB007900 KIAA0440) histidine ammonia-lyase	(nonhistone chromosomal) protein 17 (HMG17)	2	M12623	+	+	+	+		+	
(nonhistone chromosomal) protein isoforms I and Y high-risk humanpapilloma viruses E6 oncoproteins targeted protein E6TP1 beta (=AB007900 KIAA0440) histidine ammonia-lyase	(nonhistone chromosomal)	2	M83665	+	+	+	+	+	+	
Viruses E6 oncoproteins targeted protein E6TP1 beta (=AB007900 KIAA0440) histidine ammonia-lyase 1 D16626	(nonhistone chromosomal) protein isoforms I and Y	2	L17131	+	+	+		+	+	
institutine ammonia-lyase 1 D16626 + CONV	viruses E6 oncoproteins targeted protein E6TP1 beta (=AB007900 KIAA0440)	1	AF090990.1							
(MAL)	nistidine ammonia-lyase (HAL)	1	D16626			+.,	only	$\dashv$	+	

WO 00/40749									
histidyl-IRNA synthetase (HARS)	2	Z11518	+	+	+	+	+	+	
histocompatibility antigen (HLA-Cw3), class I	1	U31372							
histone deacetylase 1 (HDAC)	4	U50079	+	+	+	+		+ .	
histone deacetylase 1 (HDAC1)	2	D50405	+	+	+	+		+	
histone deacetylase 5 (NY- CO-9)	1	AF039691		+	+				
HK2 gene for hexokinase II	1	Z46362							
HL9 monocyte inhibitory receptor precursor	2	U91928				+			
HLA class I heavy chain (HLA-Cw*1701)	1								
HLA class Hocus C heavy chain	1	X58536							
HLA class II SB 4-beta chain	1	X03022							
HLA class III region	1	U89335	+	+	+	+		+	
containing NOTCH4 gene	<del>1</del>	Z72423		<del> </del>					
HLA-A		AJ006020		+	-				
HLA-A*7402		AJ223060		+					
HLA-A11	<del></del>	U02934		+				-	
HLA-B	2	X75953		1		_			
HLA-B	<del></del> -	X83401	<del></del>						
HLA-B	<u>_</u>	X78426		-					
HLA-B associated transcript-1 (D6S81E)	<del>i</del>	Z37166	+	+	+	+	+	+	
HLA-B associated transcript-2 (D6S51E)	2	M33509	+	+	+	+			
HLA-B*1529	4	D44501							
HLA-Bw72 antigen	119	L09736	+	+	+	+	+	+	high in many libraries
HLA-C gene (HLA- Cw*0701 allele)	1	D83957					·		
HLA-CW*0701	9	Z46810							·
HLA-Cw*0801	1	D64151							
HLA-Cw*1203	1	D64146							
HLA-DC classII histocompatibility antigens	2	X00370						}	
lalpha-chain (=K01160)	_	700370							
alpha-chain (=K01160) HLA-DR alpha-chain	17	M60333	+	+	+	+	+	+	high in spleen
alpha-chain (=K01160) HLA-DR alpha-chain HLA-F (leukocyte antigen F)	_	M60333 X17093	+	+	+	+ +	+	+	high in spleen
alpha-chain (=K01160) HLA-DR alpha-chain HLA-F (leukocyte antigen F) HMG box containing protein 1	17	M60333 X17093 AF019214	+	+			+		high in spleen
alpha-chain (=K01160) HLA-DR alpha-chain HLA-F (leukocyte antigen F) HMG box containing	17 3 3	M60333 X17093 AF019214 AB017806.1	+	+			+		high in spleen
alpha-chain (=K01160) HLA-DR alpha-chain HLA-F (leukocyte antigen F) HMG box containing protein 1 hMLH1 (=U83845) Hmob33	17 3 3 1 3	M60333 X17093 AF019214 AB017806.1 Y14155	+		+	+	+	+	high in spleen
alpha-chain (=K01160) HLA-DR alpha-chain HLA-F (leukocyte antigen F) HMG box containing protein 1 hMLH1 (=U83845)	17 3 3	M60333 X17093 AF019214 AB017806.1	+	+			+		high in spieen
alpha-chain (=K01160) HLA-DR alpha-chain HLA-F (leukocyte antigen F) HMG box containing protein 1 hMLH1 (=U83845) Hmob33 HMT1 (hnRNP methyltransferase, S. cerevisiae)-like 1	17 3 3 1 3	M60333 X17093 AF019214 AB017806.1 Y14155			+	+	+	+	high in spieen
alpha-chain (=K01160) HLA-DR alpha-chain HLA-F (leukocyte antigen F) HMG box containing protein 1 hMLH1 (=U83845) Hmob33 HMT1 (hnRNP methyltransferase, S. cerevisiae)-like 1 (HRMT1L1) hnRNP C1/C2 homeobox (=X58250 Mouse homeo box protein, put. transcription factor involved in embryogenesis and hematopoiesis)	17 3 3 1 3 2	M60333 X17093 AF019214 AB017806.1 Y14155 U80213 D28382 M60721			+	+	+	+	high in spleen
alpha-chain (=K01160) HLA-DR alpha-chain HLA-F (leukocyte antigen F) HMG box containing protein 1 hMLH1 (=U83845) Hmob33 HMT1 (hnRNP methyltransferase, S. cerevisiae)-like 1 (HRMT1L1) hnRNP C1/C2 homeobox (=X58250 Mouse homeo box protein, put. transcription factor involved in embryogenesis and hematopoiesis) homeobox protein (HLX1) (=M60721)	17 3 3 1 3 2	M60333 X17093 AF019214 AB017806.1 Y14155 U80213 D28382 M60721	+		+	+	+	+	high in spleen
alpha-chain (=KŌ116Ō) HLA-DR alpha-chain HLA-F (leukocyte antigen F) HMG box containing protein 1 hMLH1 (=U83845) Hmob33 HMT1 (hnRNP methyltransferase, S. cerevisiae)-like 1 (HRMT1L1) hnRNP C1/C2 homeobox (=X58250 Mouse homeo box protein, put. transcription factor involved in embryogenesis and hematopoiesis) homeobox protein (HLX1) (=M60721) homeodomain-interacting protein kinase 3 (HIPK3)	17 3 3 1 3 2 2	M60333 X17093 AF019214 AB017806.1 Y14155 U80213 D28382 M60721 U14326 AF004849			+	+	+	+	high in spleen
alpha-chain (=K01160) HLA-DR alpha-chain HLA-F (leukocyte antigen F) HMG box containing protein 1 hMLH1 (=U83845) Hmob33 HMT1 (hnRNP methyltransferase, S. cerevisiae)-like 1 (HRMT1L1) hnRNP C1/C2 homeobox (=X58250 Mouse homeo box protein, put. transcription factor involved in embryogenesis and hematopoiesis) homeobox protein (HLX1) (=M60721) homeodomain-interacting protein kinase 3 (HIPK3) homolog of Drosophila past (PAST)	17 3 3 1 3 2 2 1	M60333 X17093 AF019214 AB017806.1 Y14155 U80213 D28382 M60721 U14326 AF004849	+	+	+ + + +	+	+	+	high in spleen
alpha-chain (=K01160) HLA-DR alpha-chain HLA-F (leukocyte antigen F) HMG box containing protein 1 hMLH1 (=U83845) Hmob33 HMT1 (hnRNP methyltransferase, S. cerevisiae)-like 1 (HRMT1L1) hnRNP C1/C2 homeobox (=X58250 Mouse homeo box protein, put. transcription factor involved in embryogenesis and hematopoiesis) homeobox protein (HLX1) (=M60721) homeodomain-interacting protein kinase 3 (HiPK3) homolog of Drosophila past	17 3 3 1 3 2 2	M60333 X17093 AF019214 AB017806.1 Y14155 U80213 D28382 M60721 U14326 AF004849 AF001434 D50916	+	+	+	+	+	+	high in spleen

PCT/CA00/00005

HPV16 E1 protein binding								P	CT/CA00/00005
protein		U96131		+	+		T	1 +	
HRIHFB2157	1	AB015344		+	+	+-	+-	+	
HRX-like protein (=AF010403 ALR)	1	Y08836	<del></del>			╁	+-	+	<del></del>
hsc70 gene for 71 kd heat	3	Y00371	<del></del>			$\perp$			
shock cognate protein						1			
HSPC021	1	AF077036.1	1		+-	+	+-	+-	<del> </del>
L	1	AF077207.1			+	<del> </del>	+	+	
HsPex13p htra2-beta-2	1	U71374			+	_	+-	+-	
HU-K4	1	U87836	+	+	+	+	<del>                                     </del>	+	
hunc18b2	1	U60644					-	+	<del> </del>
HUNKI	1	U63533	T	+	+	+	1-	+	<del></del>
huntingtin-interacting	1	Y12059	+	+		+	+	+	<del></del>
protein HYPA/FBP11  (HYPA)	1	AF049528							
hVps41p (HVPS41)	1	U87309	<del> </del>		<del> </del> -	├			
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-	1	U04627	<del>                                     </del>	+	+	-	+	<b>-</b>	
Coenzyme A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), alpha subunit (HADHA)	1								*
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-	1	D16481	+	+	+	+		+	
Coenzyme A	1						ł		27
thiolase/enoyl-Coenzyme A hydratase (trifunctional			1			- 1			÷.
Drotein), beta subunit						- 1		l	* .
(HADHB) hydroxysteroid (17-beta)							- 1	- 1	tu⁻
<b>den</b> vdrogenase 1	1	U34879		+	-	$\overline{}$	+	+	
(HSD17B1)	L					1	- 1	ı	
hypothetical protein	1			+	-+	$\dashv$	-	-+	
nypothetical protein (AL008729) (dJ257A7.2)	1			1					
Avpothetical protein	1	U96629		+					
CIT987SK_2A8_1 chromosome 8)									
hypothetical protein (clone 24640)	1	AF055004				+	$\dashv$	+	·
nypothetical protein (clone	1	Z70222		+		_ -	$\perp$		
CRFp507G2490).		1		1 1			İ		
dJ1042K10.4) (non-exact /6%)	1	AL022238				+	1		,
ypothetical protein dJ465N24.1 similar to	2	AL031432		++				$\dashv$	·····
predicted yeast and worm proteins)									
ypothetical protein dJ487J7.1.1)	2	AL008730		+-+		+	+		
ypothetical protein 1J753P9.2)	2	AL023653	<del></del>			+	+	+	
ypothetical protein DKFZp586I111)	1	AL050131.1		<del>                                     </del>	_	+	+		
ypothetical protein 1257A7.2)	1	AL008729		<del>                                     </del>	+	+	+	+	
ypothetical protein (IAA0440) (=AF026504 .norvegicus SPA-1 like rotein)	1	AB007900			+	1.		+	3)
pothetical protein (L1H 3"	1			<del>                                     </del>		+	_		
gion) pothetical protein (S164)		1				-	1		
p. 5(6) (5 (04))	1	P49756				$\top$	$\neg$	1	

Insportmental protein (similar to thrombospondin) (non-exact 56%)   Insportmental protein 3   Insportmental protein 5   Insportmental protein 6   Insportmental protein 7   Insportmental protein 6   Insportmental protein 7   Insportmental protein 6	WO 00/40749								10	
Inpontentical protein 3	to thrombospondin) (non-	1	AF109907							
Importmetical protein B	hypothetical protein 3	<del></del>								
Inspire   Insp	hypothetical protein B (HSU47926) (non-exact,	1	U47926						·	
Inypoxida-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) (HIF1A)   Il-sessociated invariant gamma-chain (clones lambda-y (1.2.3))   Iduronale 2-sulfatase   2   M58342   +	hypothetical protein from	3	U50532	+	+	+	+		+	
Ia-associated invariant   gamma-chain (clones lambda-y (1,2,3))	hypoxia-inducible factor 1, alpha subunit (basic helix- loop-helix transcription	1	AF050115							
Iduronate 2-sulfatase	la-associated invariant gamma-chain (clones	1	M13555							
Ig heavy chain V region   1	iduronate 2-sulfatase	2	M58342	+	+	+				
Ig heavy chain variable   region   To the property of the pr	ig heavy chain V region	1	L20779							
Ig heavy chain variable   1   275378	lg heavy chain variable	2	M34024							
Ig heavy Chain variable region (VH4DJ) (clone T22.18)   Ig J chain	Ig heavy chain variable region (VH4DJ) (clone	1	Z75378							
Ig J chain	Ig heavy chain variable region (VH4DJ) (clone	1	Z75392							
		1	M12378							
Nampal   Indian   I	lg kappa	1	S49007				$\perp$			
Ig kappa light chain, V- and J-region (=X59315)		1		_						
Ig lambda light chain   1   285052	lig kappa light chain, V- and	1						_	_	
Ig mu-chain VDJ4-region	variable region (26-	1	Z85052							
Nappa-chain (V-J4-region, hybridoma AE6-5)   Ig rearranged H-chain mRNA V-region		1								
Ig rearranged H-chain   2   M97920	kappa-chain (V-J4-region,	1	M29469							
Ig rearranged light-chain V region (=D90158)  IGF-II mRNA-binding 1 U97188 + + + + + + + + + + + + + + + + + +	Ig rearranged H-chain	2	M97920							
TGF-II mRNA-binding	Ig rearranged light-chain V	1	M74020							
IgG Fc binding protein (FC(GAMMA)BP) IgG heavy chain variable region (vH26) IgM heavy chain (C mu, 1 X14939 Imembrane exons) IKB kinase-beta (IKK-beta) 1 AF029684 IL-1 receptor type II 1 U14177	IGF-II mRNA-binding protein 3 (KOC1) (non-	1	U97188	+	+	+				
region (vH26) IgM heavy chain (C mu, 1 X14939 membrane exons) IkB kinase-beta (IKK-beta) 1 AF029684 IL-1 receptor type II 1 U14177	IgG Fc binding protein	1		+	+		+			
membrane exons) IKB kinase-beta (IKK-beta) 1 AF029684 IL-1 receptor type II 1 U14177	region (vH26)	1								
IL-1 receptor type II 1 U14177	IgM heavy chain (C mu, membrane exons)									
ite-i receptor type ii	IKB kinase-beta (IKK-beta)									
IL2-inducible T-cell kinase 2 S65186		,								
(ITK)	(ITK)					<u> </u>			_	
immediate early protein 1 M62831 + + + + + + + + + + + + + + + + + + +	(ETR101)			+		+	+		<u> </u>	
immunogloblin light chain 1 D87018 (lambda)	(lambda)							_	_	
Immunoglobulin (CD79A) 1 Y08915 B, T + + + binding protein 1 (IGBP1)	binding protein 1 (IGBP1)			В, Т	+	+		+		
immunoglobulin C (mu) and 2 X57331 C (delta) heavy chain (=K02878)	immunoglobulin C (mu) an C (delta) heavy chain									
immunoglobulin G Fc 1 Z46223 receptor IIIB	immunoglobulin G Fc receptor IIIB						_		<u> </u>	high in many libraries
immunoglobulin gamma 3 3 Y14737 + + high in many librari (Gm marker) (IGHG3)	immunoglobulin gamma 3	3								high in many libraries

WO 00/40/49								P	C1/C	.AUU	/0000	5
immunoglobulin gamma heavy chain variable region (=X61011)	1	Z66542										
immunoglobulin heavy chain (VI-3B)	1 .	X62109		_	<b>-</b>	$\top$	+-	$\dagger$	<del>                                     </del>			
immunoglobulin heavy chain J region	1	X86356			-	+		+	+			
immunoglobulin heavy chain J region, B1	2	X86355				-	+		<del>                                     </del>	_		
haplotype immunoglobulin heavy chain variable region (IGH)	1	AF062126		-	+-	+	-	-	1			
(clone 21u-48) immunoglobulin heavy	<del>- 1</del>	AF062212			-		1_	-				
chain variable region (IGH) (clone 23u-1)												
immunoglobulin heavy chain variable region V1-18 (IGHV@) (=X60503)	2	M99641							·		¥ .	
immunoglobulin heavy chain variable region V3-43 (IGHV@)	2	M99672										_
immunoglobulin heavy chain variable region V3-7 (IGHV@)	3	M99649										
immunoglobulin IgH heavy chain Fd fragment	1	U07986		1				<del>                                     </del>	-	_		
immunoglobulin kappa light chain	1	X58081	·			1	$\vdash$					
immunoglobulin kappa light chain V-segment A27	1	X12686									* :	
immunoglobulin light chain	- 1	D86990					]					
immunoglobulin light chain (low match)	1	D86996					<u> </u>			· · · · · · ·		
immunoglobulin light chain variable region (lambda IIIb subgroup) from IgM rheumatoid factor	1	L29157										- "
immunoglobulin M heavy chain V region=anti-lipid A antibody	1	S50735										•
immunoglobulin mu (IGHM)	9	X57086	+	++	<del>                                     </del>	+	-	+				
immunoglobulin mu binding protein 2 (IGHMBP2)	1	L24544		++			+					
immunoglobulin superfamily, member 2 (IGSF2)	1	Z33642										
Immunoglobulin VH mRNA (487 bp) (=M99652 immunoglobulin heavy chain variable region V3-11 (IGHV@))	1	X61013										
imogen 38 (IMOGEN38)	1	Z68747		+	+	+		+				
IMP (inosine monophosphate) dehydrogenase 1 (IMPDH1)	1	J05272	+	+	+	+						
IMP (inosine monophosphate) dehydrogenase 2 (IMPDH2)	2	L39210	+	+	+	+		+				
inc finger protein 151 (pHZ-67) (ZNF151)	1	Y09723 .	+	+	+	+		+				
inc finger protein, C2H2, rapidly turned over (ZNF20)	1	AF011573		+	+							
inducible poly(A)-binding protein (IPABP)	1	U33818	+	+	+	+		+				$\dashv$
inducible poly(Á)-binding protein (IPABP) (low match)	1	U33818			-							

WO 00/40749									1/CA00/00003
inducible protein (Hs.80313)	2	L47738	+	+	+	+		*	
inhibitor of DNA binding 2, dominant negative helix-	4	М97796	. +	+	+	+	+	+	
loop-helix protein (ID2) Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex- associated protein ((KBKAP)	2	AF044195							
inositol 1,3,4-trisphosphate 5/6-kinase	1	U51336	+	+	+	+	+	+	
inositol 1,4,5 trisphosphate receptor type 1 (ITPR1)	1	U23850		+	+	+	+	$\perp$	
inositol 1,4,5-trisphosphate 3-kinase B (ITPKB)	2	X57206	В	+	+			_	
inositol monophosphatase	1	538980						<del>  </del>	
inositol polyphosphate-5- phosphatase, 145kD (INPP5D)	2	U84400	+	+	+	+		+	
ins(1,3,4,5)P4-binding protein	1	X89399		+				+	
insulin-like growth factor 2 receptor (IGF2R)	5	Y00285	+	+	+	+ +		+	
integral membrane protein 1 (ITM1)	1	L38961			+	•	+	+	
integral membrane protein 2C (ITM2C)	1	AF038953						+	
integral membrane protein Tmp21-I (p23)	3	U61734	+	+	+	+	+	+	
integrin beta 4 binding protein (ITGB4BP)	2	AF047433			+			<u> </u>	
integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41B) (ITGA2B)	3	M34480		+			+		
integrin, alpha 5 (fibronectin receptor, alpha polypeptide) (ITGA5)	4	X06256	+	+	+		+	+	·
integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) (ITGAL)	6	Y00796							
integrin, alpha M (complement componentreceptor 3, alpha; also known as CD11b (p170), macrophage antigen alpha polypeptide) (ITGAM)	1	M18044							
integrin, alpha X (antigen CD11C (p150), alpha polypeptide) (ITGAX)	1	M81695	+	+				+	
integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2 MSK12) (ITGB1)	2	X07979							
integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 (mac-1) beta subunit) (ITGB2)	32	M15395	+	+		+		+	
integrin, beta 7 (ITGB7)	1	M68892	+					ļ.	
Integrin-linked kinase (ILK)		U40282	+	+	+	1+	_	+	
intercellular adhesion molecule 1 (CD54), human rhinovirus receptor (ICAM1)	1	J03132	+			+	+	+	
intercellular adhesion molecule 2 (ICAM2)	1	X15606	+	+		+		+	

		55	5				$\bot$	- 1	cells, bone and pancreatic islets
nterleukin 8 (IL8)	8	Y00787	+		+	-	+		High in activated T
nterleukin 7 receptor IL7R) (low match)	1	AF043123					$\dashv$		
nterleukin 7 receptor IL7R)	14	M29696	+ .		$\dashv$		$\dashv$	+	
ransducer (gp130, pncostatin M receptor) IL6ST)		·							
nterleukin 6 signal	1	M57230							
nterleukin 6 receptor IL6R)	5	X12830		+		$\dashv$	-+	+	
nterleukin 4 receptor IL4R)	3	X52425	+	+		+		+	
gamma (severe combined mmunodeficiency) (IL2RG)					•		1	Ť	
IL2RB) nterleukin 2 receptor,	6	D11086	+		+			+	
IL18R1) nterleukin 2 receptor, beta	9	M26062					_		
(IL16) nterleukin 18 receptor 1	1	U43672					_		
nterleukin 16 (lymphocyte chemoattractant factor)	6	U82972		+					
nterleukin 13 receptor, alpha 1 (IL13RA1)	2	Y09328	-	+	+	+	+	+	
interleukin 12 receptor, beta 1 (IL12RB1)	2	U03187	+						only found in T cell
Interleukin 10 receptor, beta (I.10RB)	1	U08988	Tactivate	ed	+			+	
II (IL1R2)	1	U64094				+			
gamma (48kD) (ISGF3G) interleukin 1 receptor, type									
interferon-stimulated transcription factor 3.	2	M87503		+		+		+	
developmental regulator 1 (IFRD1)	5	Y10313		+	+			+	
interferon-related	5	X57352			+		+	+	
interferon-inducible (1-8D) interferon-inducible (1-8U)	5	X57351			+		+.	+	
54 (IFI54)	5	M14660							
17 (IFI17) interferon-induced protein				+	+	+		+	
PROTEIN 1 (GUANINE NUCLEOTIDE-BINDING PROTEIN 1) (non-exact 62%) Interferon-induced protein	3	X84958							·
inducible protein 30 (IFI30) INTERFERON-INDUCED GUANYLATE-BINDING	1	P32455	-	+	+-	+	-	-	-
inducible protein 16 (IFI16) interferon, gamma-	9	J03909	+	+	-	+	┼	+	
factor5 (IRF5) interferon, gamma-	2	M63838	+	+	++	+		+	
factor1 (IRF1) interferon regulatory	1	U51127	+	+	+	+	-	<u> </u>	
2 (IRF2) interferon regulatory	4	L05072	+	+	+	+	┦	+	
sequence binding protein 1 (ICSBP1) (low match) interferon regulatory factor	4	X15949	+	+	+	+		_	
sequence binding protein 1 (ICSBP1) Interferon consensus	<del>                                     </del>	M91196 M91196	W.	. T lym	phon	na			
Wiener blood group (ICAM4) Interferon consensus									
intercellular adhesion molecule 4, Landsteiner-	1	L27670	1	1	- 1		- 1	i -	•

BNSDOCID: <WO\_\_\_\_\_0040749A2\_I\_>

WO 00/40749									
interleukin 8 receptor alpha (IL8RA)	11	L19591							
interleukin 8 receptor, beta (IL8RB)	14	M94582							
interieukin enhancer binding factor 2, 45kD (ILF2)	3	U10323	+	+	+	+	+	+	high in uterus
interleukin enhancer binding factor 3, 90kD (ILF3)	2	U10324							
interleukin-1 receptor- associated kinase 1	2	L76191		+	+	+		+	
(IRAK1) interleukin-1 receptor- associated kinase 1 (low	1	U52112							
match) interleukin-10 receptor,	5	U00672	+	+	+	+			
laipha (IL10RA) interleukin-11 receptor, laipha (IL11RA)	7	Z38102		+	+				
INTERLEUKIN-14 PRECURSOR (IL-14) (HIGH MOLECULAR WEIGHT B-CELL GROWTH FACTOR) (HMW-BCGF) (non-exact 46%)	1	P40222							
intestinal carboxylesterase; liver carboxylesterase-2 (ICE)	1	U60553		+			+		
inversin protein (non-exact 52%)	1	AF084367							
TQ motif containing GTPase activating protein 1 (IQGAP1)	6	L33075							
IQ motif containing GTPase activating protein 2 (IQGAP2)	1	U51903		+		+			·
isocitrate dehydrogenase 1 (NADP+), soluble (IDH1)	1	AF020038	+	+	+	+	+	+	
isocitrate dehydrogenase 2 (NADP+), mitochondrial (IDH2)	2	X69433	+	+	+	+	+	+	·
isocitrate dehydrogenase 3 (NAD+) alpha (IDH3A)	_	U07681			+				
isocitrate dehydrogenase 3 (NAD+) gamma (IDH3G)	1	Z68907	+	+	+	+		+	
isolate Aus3 cytochrome b (CYTB)	1	AF042516							
isolate TzCCR5-179 CCR5 receptor (CCR5)	1	AF011524							
isopentenyl-diphosphate delta isomerase (IDI1)	5	X17025	+	+	+	+		+	
Janus kinase 1 (a protein tyrosine kinase) (JAK1)	4	M64174	+		+	+		+	
Janus kinase 2 (a protein tyrosine kinase) (JAK2)	1	AF005216							
Jk-recombination signal binding protein (RBPJK)	2	L07876							
JM1 protein	1	AJ005890 U57592		+	+	++		+	
jumonji (mouse) homolog (JMJ)		X51346	+	+	+	+	_	+	
jun D proto-oncogene (JUND)	1		ļ , ,	<del>  </del>	<u>                                     </u>	<u>                                     </u>	_		only found in germ
jun dimerization protein junction plakoglobin (JUP)	1	AF111167 M23410	<del>                                     </del>	+	+	+	+	+	
P=====================================	<u> </u>	1			٠	—	<u>-</u>		<del></del>

Color   Colo	WO 00/40 /49									PCT/CA00/00005
Imponectional and antibody   Italy) (KAIT)   Italy) (KAIT)   Italy) (KAIT)   Italy) (KAIT)   Italy) (KAIT)   Italy) (KAIT)   Italy)   Italy	CD82 antigen (R2 leukocyte antigen, antigen detected by		U20770	+	+	+				
Karyophem (importin) beta	monocional and antibody									
Raryopherin (importin) beta   1	karyopherin (importin) beta	2	L39793	+	+	+	+	+-	-	-
Karyophenn alpha 1	karyopherin (importin) beta	1	U72395	+	+	+	+	+		
Karyophenn alpha 2 (RAG control 1	karyopherin alpha 1	1	S75295	+	+	+	+	┿	+	
Control 1, Importin alpha 1   (ICPNA2)	karyopherin alpha 2 (RAG	1	U09559	<del> </del>	+-		+-	+	+-	
((Importin alpha 4) (KPNA3)	(DPNA2)	ļ			1					
Karyophenn alpha 4	karyopherin alpha 3 (importin alpha 4) (KPNA3)	1	D89618	<del> </del>	+		+	+	+-	
Katanin (80 KDa) (KAT)	karyopherin alpha 4	1	M17887	<del>                                     </del>	+	+	+	+-	+-	
RE03 protein		1	AF052432	<del> </del>	+_	1	4	4	٠,	
Reich-like ECH-associated protein 1 (KIAA0132)	,	1			+-	+-	+		<b>↓</b> ▼	
Drotein 1 (KIAA0132)   (66%aa)   (66%aa)   (66%aa)   (66%aa)   (66%aa)   (66%aa)   (66%aa)   (66%aa)   (74%ab)   (74%ab)   (75%ab)   (75%ab)   (75%ab)   (75%ab)   (75%ab)   (75%ab)   (75%ab)   (76%ab)   (	•	<u> </u>	1		4	-	_		4_	
KEIDNEXCKINASE	protein 1 (KIAA0132) (66%aa)		550522							
(Iffuctokinase) (KHK) KIAA0001 (KIAA0001) (172% ae) KIAA0001 (KIAA0001) (176% ee) KIAA0001 (KIAA0001) (100-exact 72%) KIAA0002 (KIAA0002) 5 D13627 KIAA0001 (KIAA0001) (1 D13835	, ,	1	X74929		++	+	++	+	+	
KIAA0001 (KIAA0001)		1	X78678		+	+	+	+	+	
(72% aa) KIAA0001 (KIAA0001) (76% aa) KIAA0002 (KIAA0002) 5 D13627 KIAA0002 (KIAA0005) 4 D13630 + + + + + + + + + + + + + + + + + + +	KIAA0001 (KIAA0001)	1	015301				↓_	1_		
(76% aa) KIAA0001 (KIAA0001) (non-exact 72%) KIAA0002 (KIAA0002) 5 D13627 KIAA0005 (KIAA0005) 4 D13630 + + + + + + + + + + + + + + + + + + +	(72% aa)		215551							
(Indnewact 72%) KIAA0005 (KIAA0005) KIAA0005 (KIAA0005) KIAA0010 (KIAA0010) I D13635 KIAA0016 (KIAA0016) I D13635 KIAA0016 (KIAA0016) I D13631 KIAA0017 (KIAA0017) D13635 KIAA0017 (KIAA0017) D13636 KIAA0017 (KIAA0017) D13636  KIAA0022 (KIAA0022) D14668 KIAA0022 (KIAA0022) D146689 KIAA0023 (KIAA0023) I D14689 KIAA0024 (KIAA0024) I D14689 KIAA0025 (KIAA0025) I D14695 KIAA0026 (KIAA00025) I D14695 KIAA0026 (KIAA00026) D14812 H + + + + + + + + + + + + + + + + + + +	(76% aa)							<u> </u>	†	
KIAA0002 (KIAA0002)	(non-exact 72%)	1	Q15391						1	
KIAA0005 (KIAA0005)	KIAA0002 (KIAA0002)	5	D13627		++	+	+	├	╅	.,
KIAA0016 (KIAA0016)		4	D13630		+	+		+-		<del>                                     </del>
KIAA0017 (KIAA0017)   2		1	D13635	<del></del>	+		<del>                                     </del>	+	+	
RIAA0022 (KIAA0023)		1	D13641	+	+	+	+	┼	+	<del> </del>
KIAA0023 (KIAA0023)		2	D87686		+		-	$\vdash$	+	
KIAA0024 (KIAA0024)		2	D14664		+	+	+	<del>                                     </del>	-	
KIAA0025 (KIAA0025)		1	D14689		+	<del> </del>	-	-	+	
KIAA0026 (KIAA0026)   2		1	D14694	+	+	+	+	├-	+	
KIAA0027		1		·	+	+	+	+	+	
KIAA0032 (KIAA0032)   2   D25215   + + + + +   +   +   +   +   +   +		_		·	+	+	+	$\vdash$	+	<del></del>
KIAA0040 (KIAA0040)		1			+		<u> </u>		<del>                                     </del>	
KIAA0050 (KIAA0050)       4       D26069         KIAA0053 (KIAA0053)       17       D29642       +			D25215		+	+	+		<del>                                     </del>	
KIAA0053 (KIAA0053) 17 D29642 + + + + + high in fetal lung KIAA0057 (KIAA0057) 1 D31762 + + + + + + high in fetal lung KIAA0058 (KIAA0058) 11 D31767 + + + + + + + + + + + + + + + + + +		1		+	+	+	+		+	
KIAA0057 (KIAA0057)  1			4				<del>                                     </del>		_	
KIAA0058 (KIAA0058)  11				+		+	+		1	
KIAA0063 (KIAA0063)  KIAA0064 (KIAA0064)  1				+	+	+	+	+	+	high in fetal lung
KIAA0064 (KIAA0064)  1		- 1		+		+	+		+	
KIAA0066 1 D31886 + + + + + + + + + + + + + + + + + +				+	+	+	+		+	
KIAA0068					+	+	+		+	
KIAA0073 3 D38552 + + + + + + + + + + + + + + + + + +				+	+	+	+		+	
KIAA0081 2 D42039 + + + + + + + + + + + + + + + + + + +		i					+	+	+	
KIAA0084 2 D42043 + + + + + + + + + + + + + + + + + + +					+	+	+		+	
KIAA0085 26 U30498 + + + + + + + + + + + + + + + + + + +							+		+	
KIAA0088 3 D42041 + + + + + + + + + + + + + + + + + + +							+			
KIAA0090 2 D42044 + + + + + + + + + + + + + + + + + +							+	+	+	
KIAA0092 (KIAA0092) 1 D42054 + + + + +							+	+	+	
				+				+		
	(1.0002)				+	+	+		+	

IAA0094	3	D42084			+	+			
IAA0095 (KIAA0095)		D42085							
IAA0096	- 1	D43636	+	+	+	+		+	
(AA0097 (KIAA0097)	1	X92474	T	+	+		+		
IAA0099 (KIAA0099)	3	D43951	+	+	+	+	+	+	
TAA0102 (KIAA0102)	2	D14658		+		+	+	+	
TAA0105	1	D14661	В	+			+	+	
(AA0120	2	P37802							
(AA0120 (non-exact,	<del></del>	M83106							
55%)					+	+		++	
(IAA0121 (KIAA0121)	1	D50911	+	+		+		+	
(IAA0123	7	D21064		+	+				
(IAA0128	1	D50918	+	+	+	+		+	
(IAA0129 (KIAA0129)	1	D50919	+	+	+	+		$\sqcup$	
(IAA0130 (KIAA0130)	1	AF055995		+	+	+		11	
CIAA0136	2	D50926							
(IAA0137 (KIAA0137)	1	AB004885		+	+	+		+	
(IAA0140 (KIAA0140)	1	D50930	+	+		+		+	
KIAA0141 (KIAA0141)	3	D50931							
KIAA0144 (KIAA0144)	3	D63478	+	+	+	+		+	
KIAA0144 (KIAA0144) (low	1	D63478							
match)		Q14157				-	-	┼╾╾╏	
KIAA0144 (non-exact 61%)	1			<u> </u>		├	├	-	
KIAA0144 (non-exact 65%)	1	Q14157		+	+	+	-	+	
KIAA0146	2	D63480		+	<u> </u>	<u> </u>	<del> </del>	+	
KIAA0148 (KIAA0148)	1	D63482	+	++	+	+	├	+	
KIAA0154	2	D63876		++	+	+	┞—	++	
KIAA0156	1	D63879		<u> </u>	<u> </u>	<del>↓</del>	┷	<del>                                     </del>	
KIAA0160	2	D63881	+	+ +	ļ	+	├		
KIAA0161 (KIAA0161)	1	D79983		ļ <u> </u>	<u> </u>	<del>  '</del> -	↓_	-	
KIAA0164 (KIAA0164)	3	D79986		+		╀	<del> </del>	<b>↓</b>	
KIAA0167 (KIAA0167)	1	D79989			+	+	↓	+	
KIAA0168 (KIAA0168)	3	D79990		+	ļ <u> </u>	<u>                                     </u>	1_	1	
KIAA0169	3	D79991	-		<u> </u>	+-	╄	+	
KIAA0171 (KIAA0171)	3	D79993		+	+	+	<del> </del>	+	
KIAA0174 (KIAA0174)	7	D79996	+	+	+	1+			
KIAA0179	2	D80001		+	+	+		+	
KIAA0181	1	D80003		+	+	+	_	+	
KIAA0183	4	D80005	+	+	+	+	+	+	
KIAA0184	1	D80006	+	+	+	+		+	
KIAA0191 (72% aa)	1	D83776							
KIAA0191 (non-exact 77%)	1								
KIAA0193 (KIAA0193)	1	D83777	+	+	+	+	1_	+	
KIAA0200 (KIAA0200)	1	D83785		+	+	+		+	
KIAA0210 (KIAA0210)	3	D86965					•		
KIAA0217	2	D86971	+	+	+	+		+	
KIAA0219	2	U77700		+	+	+	$\prod$	+	
KIAA0222 (KIAA0222)	1	D86975				$\prod$	$oxed{\Box}$		
KIAA0223	2	D86976						$oldsymbol{oldsymbol{oldsymbol{\Box}}}$	
KIAA0229	1 1	D86982	+	+					
KIAA0232 (KIAA0232)	1	D86985		+	+	7		+	
KIAA0233 (KIAA0233)	1	D87071		$\top$		$\top$	1		
KIAA0235	2	D87078	+	+	+	17	-		
KIAA0239	1	D87076	+	+	_	1	$\top$	$\neg \vdash$	

KIAA0239 (non-exact 80%	0) 1	D87076	T	1					<del>,                                    </del>	CT/CA		
KIAA0240	1 7	D87077	<del> </del>			-	-			<del> </del>		
KIAA0242	4	D87684	+	+		++	┿┤	+	+			
KIAA0248	2	D87435		-		+	┿┼		+			
KIAA0249 (KIAA0249)	3	D87436	+		L_		+					
KIAA0253	5	D87442	<del>                                     </del>	+			+		+			
KIAA0254 (KIAA0254)	1	D87443	<u> </u>	+	!_			+	+			
KIAA0255(KIAA0255)	4	D87444	<u> </u>		L_		+			,		
KIAA0262 (KIAA0262)	3	D87451		+			+		+			
KIAA0263 (KIAA0263)	+ - 1	D87452	<u></u>	+		!	+		+			
KIAA0264	3	D87453	+	+			+		+			
KIAA0268	+ 1	D87742		+		L	+		+			
KIAA0269	+	Q92558	+	+		'	٢		+			
KIAA0275 (KIAA0275)	13	D87465										
KIAA0304 (KIAA0304)	13		+	+					+			
KIAA0308	2	AB002302	+	+	1		$\Box$	+	+			
KIAA0310 (KIAA0310)		AB002306		+	+				+			
KIAA0314 (=U96635	1 3	AB002308		+	+	7			+			
M.musculus ubiquitin Protein ligase Nedd-4)	3	AB002312										
KIAA0315 (KIAA0315)	4	AB002313		7	+	++	+-	∓+	+		_	
(IAA0325 (=L08505 R.norvegicus cytoplasmic dynein heavy chain (MAP IC))	2	AB002323						1			<del></del> -	
(IAA0329 (KIAA0329)	1	AB002327	<del></del>	+	+	+	+	4				
(IAA0330	1 -1	AB002328	+	+	+÷	<del>                                     </del>	4_	4	+			• 4.
(IAA0332	1	AB002330		+	+	┿	4	_	+			•
(IAA0333	2	AB002331		+	+	+	4	4	+			-
(IAA0336 (KIAA0336)	3	AB002334	+	+ +		+		1	+			
(IAA0336 (KIAA0336) (low		AB002334		+-	+	+	$\perp$	$\perp$	+			
natch) (IAA0342 (KIAA0342)					]	1						
1AA0342 (KIAA0342)	1	AB002340		+	+	+	+-	+	++			
IAA0344 (KIAA0344)	2	AB002342		1	_	+	+-	╁	+			
IAA0354 (KIAA0354)	1	AB002352	+	+	+	+	+	┿	+ +			
IAA0365 (KIAA0365)	3	AB002363	+	+	+	+	+	+	+ +			
IAA0370	6	AB002368		+	+	++	+	+	+ +			
IAA0372 (KIAA0372)	1	AB002370		<del>                                     </del>	<del>                                     </del>	+	+-	╁				
IAA0373 (KIAA0373)	1	AB002371		+		+	╁	+				
IAA0375 (KIAA0375)	1	AB002373		+		++	├	+-				
IAA0377 (KIAA0377)	1	AB002375	<del> </del>	+		++	+	+-	+			
IAA0379	1	AB002377				+	Ë	+				
AA0379 (non-exact,	1	AB002377				<u> </u>		4-				
5%) IAA0380 (KIAA0380)		1				1			- 1			
AA0380 (KIAA0380)		AB002378	+	+		+		13	F			
0%aa)	1	AB002378						丅	1			
AA0382 (KIAA0382)	2	AB002380		+	+.	+.		+-	_			
AA0383	1	AB002381				<u>  ' '</u>		╀.				
AA0386 (KIAA0386)	5	AB002384		<b></b>		<u> </u>		1_				
AA0392	1	AB002390		<b> </b> -		<u> </u>		1_				
AA0397 (KIAA0397)	4	AB007857				<u> </u>		$\perp$				
AA0403	3	AB007863		+	+	+	+	+				
AA0404	1	AB007864										
AA0409	<del></del>	AB007869		+		+						
AA0421	<del>- i</del>	AB007881		+		+						
AA0424 (non-exact 82%)	•	UP001001	+	+	+			+				

0214 10200 2021 15 15 0									
KIAA0428 (KIAA0428)	9	Y13829							
KIAA0429 (KIAA0429)	2	AB007889	+	+	+	+		+	
KIAA0430 (KIAA0430)	2	AB007890							only in ovary
KIAA0432 (KIAA0432)	2	U86753	1	+	+			-	
KIAA0435 (KIAA0435)	1	AB007895				T			
KIAA0438 (KIAA0438)	1	AB007898		+	+	+		+	
KIAA0447 (KIAA0447)	3	AB007916	+	+	+	+	$\top$	+	
KIAA0449	1	AB007918		+	†	$\dagger$	†	+	
KIAA0456	1 1	AB007925		+	+	+	1	+	
KIAA0458 (KIAA0458)	7	AB007927		+		-	-	<del>                                     </del>	
KIAA0462	1	AB007931	+	+	+	+	┼	+	
KIAA0465	1	AB007934	<del></del>	+	+	+	+	+	
KIAA0476 (KIAA0476)	1	AB007945		++	+	+	-	├─	
KIAA0489	1	AB007958		┼	-	├	├	-	
KIAA0494 (KIAA0494)	1 1	AB007963	+	+	+	+		+	
KIAA0515	1-1-	AB011087	<u> </u>	+	+	+	<del> </del>	+	
KIAA0521	3	AB011093	<del></del>	+ +	<u> </u>	<u> </u>	<del> </del>	+	
KIAA0525	1	AB011097		+		+	1	<b>*</b>	
KIAA0530	1	AB011097			<u> </u>	1	<u> </u>		
KIAA0532	<del>                                     </del>	AB011102		+	+	+		_	
		1	+	+	+	+		+	
KIAA0537 (KIAA0537)	1	AB011109	• 5	<u> </u>					
	1	AB011112	+	+	+	+		+	
KIAA0543	1	AB011115			+	+		+	
KIAA0544	1	AB011116		+	+	+		+	
KIAA0549	2	AB011121		+	+	+		+	
KIAA0551	2	AB011123		+				+	
KIAA0554	8	AB011126		+	+	+		+	
KIAA0561	1	AB011133		+		+			
KIAA0562 (KIAA0562)	1	AB011134							
KIAA0563 (KIAA0563)	1	AB011135							
KIAA0569 (KIAA0569)	2	AB011141		+	+	+	_	+	
KIAA0571 (KIAA0571)	2	AB011143		+	+	+			
KIAA0573	1	AB011145		+		+		+	
KIAA0576	1	AB011148						$\dashv$	
KIAA0580	1	AB011152					_	-	
KIAA0584	1	AB011156		+					
KIAA0592	3	AB011164	+	+	+	+		+	<del></del>
KIAA0596	1	AB011168		+	+				
KIAA0598 (KIAA0598)	1	AB011170		+	+	+			
KIAA0608	1	AB011180			+	+			
KIAA0614	2	AB014514	+	+	+	+		+	
KIAA0615 (KIAA0615)	1	AB014515	т	<u> </u>		<del>-</del>		<u> </u>	
KIAA0621	1	AB014521		+	<del>-</del>				
KIAA0648	<del></del>	AB014548						+	
KIAA0652 (KIAA0652)	<del></del>			+	+	+		+	
KIAA0668		AB014552	+	+	+	+		+	
KIAA0669	1	AB014568							
KIAA0671 (KIAA0671)	1	AB014569							
1	1	AB014571			+	+		+	
KIAA0675 (KIAA0675)	1	AB014575		+		+	+		
KIAA0676	1	AB014576		+	+	+		+	
KIAA0677 (KIAA0677)	2	AB014577		+	+	+	+	+	
KIAA0678	1	AB014578	+	+	+	+		+	
KIAA0679	. 6	AB014579		+	+	+		+	

KIAA0680 (KIAA0680)			_						PCT/CA00/00005
KIAA0692	1	AB014580				1	T	T	
KIAA0697	1	AB014592	+	+	7	7	-	$\neg$	+
KIAA0699	1	AB014597						$\neg$	
KIAA0700	1	AB014599	+	+	+	7	-	$\neg$	+
KIAA0737 (KIAA0737)	1	AB014600		+	+	7	-	$\neg$	+
KIAA0748 (KIAA0748)	3	AF014837	+	+	+	7 4	-	$\neg$	+
KIAA0763 (KIAA0763)	2	AB018291		+	$\neg$		+	$\neg$	
KIAA0769 (KIAA0769)	2	AB018306	+	1 +	+	+	-		+
KIAA0782	2	AB018312		+	+	+	+	_	+
	1	AB018325	+	+		+	+	$\dashv$	high in BPH stroi
KIAA0796	1	AB018339		+	+	+	+	+-	+
KIAA0798 (KIAA0798)	1	AB018341			+	+-	+-	+-	
KIAA0823	1	AB020630		<del></del>	+-	+-	+-	+	
KIAA0854	1	AB020661	+	+	+	+	+	+-	
KIAA0856	1	AB020663	<del> </del>	+	+	+	+-		
KIAA0860	1	AB020667		<del>-   +</del>	+	+	+-	-	
KIAA0862	1	AF054828	<del> </del>	+	++	+	+-		
KIAA0871 (non-exact 88%)	1	AB020678		<del>- -</del>	+-	+-	+		
KIAA0873	1	AB020680		+	+	+.	1	$\bot$	
KIAA0892	1	AB020699	+	+	++	+	$\bot$	+	
KIAA0906	1	AB020713	+			+	$\downarrow$	+	
KIAA0991	1	AB023208.1	**	+	+	+		+	
killer cell lectin-like	1	U11276			<u> </u>	1			
receptor subfamily B, member 1 (KLRR1)	·	011270			+	+		+	
ciller cell lectin-like eceptor subfamily C nember 4 (KLRC4)		U96846					<u> </u>	1	1.
kinectin 1 (kinesin receptor) KTN1)	1	D13629		+	<del> </del>	-		+	
kinesin family member 5B KIF5B)	2	X65873		+	+	+	$\vdash$	+-	
inesin-like DNA binding rotein rueppel-related DNA-	1	AB017430	+	+	+	+		+	
anding protein (TF6) (low latch)	1	M61869							
ruppel related gene clone pHKR1RS)	1	M20675	· · · · · · · · · · · · · · · · · · ·	†					
ruppel-like zinc finger rotein Zf9	3	U51869	+	+	+	+	+	+	<del> </del>
ruppel-like zinc finger	1	U44975						Ĺ	<u> </u>
rotein Zf9 (non-exact 6%)	_	0449/5		+	+		+ .	+	
uppel-type zinc finger rotein, ZK1 apoferntin	1	AB011414.1			-			<u> </u>	
ctate dehydrogenase A	3	X03742			一十			$\vdash$	
DHA) ctate dehydrogenase A	3	X02152		+	+	+	+	+	
DHA) (non-exact, 81%)	6	X02152							
DHB) ctotransferrin (LTF)		X13794	+	+	+	+	+	+	high in fetal lung fibrablast
	1	U07643	+		$\neg \uparrow$	+		+	high in bone marro
minin binding protein (low core) minin receptor 1 (67kD);	1	D28372				7			
Dosomal protein SA AMR1)	20	X15005	+	+	+	+	+	+	high in many librari
minin receptor homolog 'region}	1	S35960			_	$\dashv$	$\dashv$		
minin, gamma 1 (formerly MB2) (LAMC1)	2	J03202	+	++	+	-+	$\dashv$	+	

WO 00/40749									.1/CA00/00003
latent transforming growth	2	M34057		+	+	+		+	
1 (LTBP1) LAZ3/BCL6 (=Z79582:D28522/4)	1	Z79581							
LDLC	- 2	Z34975	+	+	+	+		+	
lecithin-cholesterol acyltransferase (LCAT)	1	М17959							
(non-exact, 66%) lectin, galactoside-binding,	1	M87842				+			
soluble, 2 (galectin 2) (LGALS2)	- 1	L13210	+	+	<del>-</del>	+		+	
lectin, galactoside-binding, soluble, 3 binding protein (galectin 6 binding protein) (LGALS3BP)	ŕ							+	
leucine rich repeat (in FLII) interacting protein 1 (LRRFIP1)	5	AJ223075	+	†		+	+		
leucocyte immunoglobulin- like receptor-5 (LIR-5)	2	AF072099				+			
leucocyte immunoglobulin- like receptor-6a (LIR-6)	7	AF025530 U82275							only found in CNS
leucocyte immunoglobulin- like receptor-7 (LIR-7)	2	L20859	+	'	+	+		+	
leukemia virus receptor 1 (GLVR1)	1	M29484	<u> </u>						
leukocyte adhesion protein p150,95 alpha subunit leukocyte antigen, HLA-A2	3	Y13267							
leukocyte immunoglobulin-	3	AF025528		+					·
like receptor (MIR-10) leukocyte tyrosine kinase	1	X60702	+						found only in blood
(LTK) leukocyte-associated lg- like receptor 1 (LIAR1)	3.	AF013249				+			
leukotnene A4 hydrolase (LTA4H)	6	J03459	+	+	+	+	+	+	
leupaxin (LDPL)	2	AF062075	+			+		+	
ligase I, DNA, ATP- dependent (LIG1)	1	M36067	В, Т	+	+		+	+	
LIM and SH3 protein 1 (LASP1)	2	X82456	+	+	+	+	+		
LIM domain kinase 2 (LIMK2)	2	AC002073	+	+	+	+		+	
line-1 protein	1				<u></u>	<u> </u>	+	+	
Line-1 repeat mRNA with 2 open reading frames		U93566	+	++	+	+	+		high in gastric tumor
Line-1 repeat with 2 open reading frames	1	M22332	Ť	<u> </u>		ļ.,	<u> </u>	Ļ	ing. in geometric
LINE-1 REVERSE TRANSCRIPTASE HOMOLOG		P08547							
lipase A, lysosomal acid, cholesterol esterase (Wolman disease) (LIPA)	4	X76488	+	+	+	+			
lipase, hormone-sensitive (LIPE)	1	L11706	+	+				+	
LMP7	1	L11045			<u> </u>				
Lon protease-like protein (LONP)	2	X74215	+	+	+	+		+	only in liver
low density lipoprotein- related protein 1 (alpha-2- macroglobulin receptor) (LRP1)	2	AF058414					+		
low density lipoprotein- related protein-associated protein 1 (alpha-2- macroglobulin receptor- associated protein 1) (LRPAP1)	1	M63959		+	*		+	+	

llow donethy lines								]	PCT/CA	00/00005
low density lipoprotein- related protein-associated protein 1 (alpha-2- macroglobulin receptor- associated protein 1) (LRPAP1) (non-exact,	1	M63959								
75%)  low-affinity Fc-gamma  receptor IIA	1	L08107					$\downarrow$		<del> </del>	<u>.</u>
LPS-induced TNF-alpha factor (PIG7)	9	AF010312	+			+	-	+ +	ļ	
Lst-1	1	U00921	<u> </u>			$\perp$	$\bot$			
L-type amino acid	1	AF104032	<del>                                     </del>	-   +	- 1	-   -	_	+		
transporter subunit LAT1 lung resistance-related	1			_				İ		
protein (LRP) Lymphocyte antigen 75	 	X79882	+	+	+	+		+		
(LY75)		AF011333	В		T					
lymphocyte antigen 9 (LY9)		L42621		$\dashv$	+-		╁	+	<del> </del>	
lymphocyte antigen HLA- B*4402 and HLA-B*5101	2	L42345			$\top$	+	╁		<del> </del>	
lymphocyte cytosolic protein 1 (L-plastin) (LCP1)	42	J02923			1	-	+	+-		
lymphocyte cytosolic protein 2 (SH2 domain- containing leukocyte protein of 76kD) (LCP2)	4	U20158			Tiyn	phor	na,	activ	/ated	
lymphocyte glycoprotein T1/Leu-1	2	X04391	• +	T	+	$\top$	Τ	1		
lymphocyte-specific protein 1 (LSP1)	16	M33552	+	+	+	+	+	+		400
lymphocyte-specific protein tyrosine kinase (LCK)	7	M36881		+	+	+	┼-	+		•
lymphoid phosphatase LyP1	1	AF001847		+	-	+-	┼─			· · · · · · · · · · · · · · · · · · ·
ymphoid-restricted membrane protein (LRMP)	4	U10485	+		+	+	-	$\left  \cdot \cdot \right $		
ymphoid-specific SP100 nomolog (LYSP100-A)	1	U36500		+-	-	+-	-	+		
ymphoma proprotein convertase (LPC)	2	U33849	+	+	+	+	-	+		<del></del>
PROTECTIVE PROTEIN PRECURSOR CATHEPSIN A) CARBOXYPEPTIDASE C)		P10619					·			
ysosomal-associated nembrane protein 1 LAMP1)	1	J04182	+	+	+	+	+	+		
ysosomal-associated nembrane protein 2 LAMP2)	1	J04183		+	+	+	+	+		
vsozyme (renal myloidosis) (LYZ)	39	M19045	+	+	+	+		+		
vsyl-tRNA synthetase KARS)	2	D32053	+	+	+	+		+		
1 phase phosphoprotein 0 (U3 small nucleolar bonucleoprotein) (MPP- 0)	1	X98494							•	
11-type and M2-type yruvate kinase	2	X56494						-+		
6A methyltransferase MT-A70)	7.	AF014837	+	+		+	$\dashv$	+		
ab-21 (C. elegans)-like 1 AAB21L1)	1	U38810		+	+	+	-	+		
acMarcks	1	X70326	+	+	+	+	+	+		
acrophage-associated htigen (MM130)	1	Z22968		+	+	+	-	+	<u> </u>	

MADS box transcription enhancer factor 2, polypeptide A (myocyte enhancer factor 2A) (MEF2A) MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2C) (MEF2C)	1	U49020		+	+	+		+	
(MEF2A) MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2C) (MEF2C)	1						1		
enhancer factor 2, polypeptide C (myocyte enhancer factor 2C) (MEF2C)	1			1 + 1		+		+	
(MEF2C)	•	L08895			•				
major cytoplasmic tRNA-	<u> </u>	X17516							
Val(IAC) (=M33940)				$\perp$					
major histocompatibility complex class I beta chain (HLA-B)	1	M95531							
major histocompatibility complex, class I, A (HLA-A)	41	Z93949	+	+	+	+		+	high in villous adenoma
major histocompatibility complex, class I, A (HLA-A) (low match)	1	272422							
major histocompatibility complex, class I, C (HAL- C)	82	M24097	+	+	+	+	+	+	
major histocompatibility complex, class I, E (HLA-E)	77	M20022	+	+	+	+		+	
major histocompatibility complex, class II, DM BETA (HLA-DMB)	2	U15085	+	+	+	+		+	
major histocompatibility complex, class II, DP beta 1 (HLA-DPB1)	10	M57466	+	+	+	+		+	
major histocompatibility complex, class II, DR beta 1 (HLA-DRB1)	9	√00522	+	+	+	+		+	
Major histocompatibility complex, class II, Y boxbinding protein I; DNA-binding protein B (YB1)	2	M24070		+	+		+	+	
malate dehydrogenase 1, INAD (soluble) (mdh1)	1	D55654	+	+	+	+	+	+	
malate dehydrogenase 1,	3	D55654		+	+		+	+	
NAD (soluble) (MDH1) malonyl-CoA	2	AF097832		-		-			
decarboxylase precursor maltase-glucoamylase	1	AF016833				+			
(mg) manic fringe (Drosophila)	1	U94352	+	+-	+	+		+	
homolog (MFNG) mannose phosphate	1	X76057	<del></del>	+	+	+		+	
isomerase (MPI) mannose phosphate	2	X76057		+-	+	+		+	
isomerase (mpi) mannose-6-phosphate	3	X56253	<del></del>	+	+	-	+	+	
receptor (cation dependent) (M6PR)					_			+	
mannose-P-dolichol utilitzation defect 1 (MPDU1)	1	AF038961		+	_	+			
mannosidase, alpha B, lysosomal (MANB)	1	U60885		+		+	+	+	
mannosyl (alpha-1,3-)- glycoprotein beta-1,2-N- acetylglucosaminyltransfer ase (MGAT1)	1	M55621	+	+	+	+	+	+	
map 4q35 repeat region	1	AF064849							
MAP kinase-interacting serine/threonine kinase 1 (MKNK1)	2	AB000409		+	+	+	_	+	
MAP/ERK kinase kinase 3 (MEKK3)	5	U78876		+					
MAP/ERK kinase kinase 5 (MEKK5)	1	D84476		+	+		+		

17 1001									PCT/C	CA00/00	005
MAP/microtubule affinity- regulating kinase 3 (MARK3)	4	M80359		•				Τ.	•		
Marenostrin protein	1	Y14441			-	-				·	
MASL1	+	AB016816	+								
MAX dimenzation protein	3				$\bot$	$\bot \Box$					
(MAD) MaxiK potassium channel	1 3	L06895					1	7			
beta subunit MBP-2 for MHC binding		AF035046				T					
protein 2	1	X65644		+	+	7	-	+	+		
Meis (mouse) homolog 3 (MEIS3)	1	U68385		+	+	7	+	+			
melanoma-associated antigen p97 (melanotransferrin)	1	M12154				$\dagger$	-	+	-		
membrane cofactor protein (CD46, trophoblast- lymphocyte cross-reactive antigen) (MCP)	4	X59405		+	+	+		+			
membrane component, chromosome 17, surface marker 2 (ovarian carcinoma antigen CA125) (M17S2)	4	D14696		+	+	+	+	+			
membrane metallo- endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10) (MME)	2	J03779			+	+	+	+			
membrane protein, palmitoylated 1 (55kD) (MPP1)	2	M64925		+	+	+	+	+		V	*#F.
meningioma expressed antigen (MGEA)	1	U94780			-	+	<del>                                     </del>	+		<u> </u>	
meningioma-expressed antigen 11 (MEA11)	1	U73682	+	+	<del> </del>	+	+	†-			
Menkes Disease (ATP7A) putative Cu++-transporting P-type ATPase	1	L06133		+							
netallothionein 2A (MT2A)	1	V00594		+	+	+	+	+		·	
netaxin 1 (MTX1)	1	U46920		+		<u></u>	, T	ł			
nethionine	2	X68836	+			+	<u> </u>	+			
denosyltransferase II, lpha (MAT2A)	~	700030	*	+	+	+		+			
nethyl-CpG binding lomain protein 1 (MBD1) non-exact 59%aa)	1	Y10746									
nethylene tetrahydrofolate ehydrogenase (NAD+ ependent), nethenyltetrahydrofolate yclohydrolase (MTHFD2)	. 2	X16396	+	+	+	+		+	<del></del>	····	
nethylenetetrahydrofolate ehydrogenase (NADP+ ependent), ethenyltetrahydrofolate yclohydrolase, myltetrahydrofolate	1	J04031		+	+	+	+	+			
Inthetase (MTHFD1) ethyltransferase, putative	<del></del>	1000					İ				
HC antigen (HLA-B)	2	AJ224442						1			
L42024)	1	U14943						$\dashv$			
HC class 1 region	2	AF055066		+		- +		$-\!\!\!\!+$			
HC class I antigen (HLA- 2)	1	U70863	<del></del>			$\dashv$	-	+			
HC class I antigen (HLA- 33)	1	U19736		+-+	+	$\dashv$	-				
HC class I antigen (HLA-	1	U38975	-	+	-+	-	-			<u> </u>	
				1 1	- 1	- 1	- 1	- 1			

AHC class I antigen	1	U52813						
3*5801 (HLA-B)		0.000000	 1					
MHC class I antigen HLA-A	2	AF015930						
MHC class I antigen HLA-A	1	U36687						
HLA-A-2402 allele)		X13112	 +				-	
MHC class I antigen HLA-	2	1 13/12						
MHC class I antigen HLA-B	1	U67331						
B*0801 variant) = AF028596)		1						
MHC class I antigen HLA-B	1	U67330						
B*0801 variant) (=U88254) MHC class I antigen HLA-B	1	AF017328	 				<del> </del> —	
B*48 allele)	•	71017320						
MHC class I antigen HLA-B HLA-B*1502 allele)	1	AF014770					_	
WHC class I antigen HLA-B (HLA-B*40MD)	1	U58643						
MHC class I antigen HLA-B	1	AF028596				ł	Ì	
(HLA-B*4103 allele) MHC class I antigen HLA-B		AF035648	 +	-	-		<del>                                     </del>	
gene (HLA-B*4402 variant	•							
allele) MHC class I antigen HLA-B	1	U52175	 +	<del>                                     </del>	-	-	1	
GN00110-B*3910			 			<u> </u>	_	
MHC class I antigen HLA- Cw*04011	1	D83030						
MHC class I antigen		U56434						
R69772 HLA-A (A*0302)	- 1	U58469	 -				┼	
MHC class I antigen SHCHA (HLA-B*4403 variant)	'	000400						
MHC class I	1	U06697	1					
histocompatibility antigen (HLA-B) (clone C21/14)								
MHC class THLA B71	2	L07950						
MHC class I HLA-A	1	Flp	 1					
(Aw33.1) MHC class I HLA-B	1	U18660	 +-	├	╀	├	╁	
MHC class I HLA-B (HLA-	- 1	U18661	 	-	+-	-	+	
B-07ZEL allele) (=X86704)	•		 		_			
MHC class I HLA-B (HLA-	1	U28759			İ		1	
B-08NR allele) MHC class I HLA-B*3512	1	L76094	 +				+	
MHC class I HLA-B41	3	U17572		† 💳			T	
variant (=U17572)	1	M24038	 		┼	┼	+	
MHC class I HLA-B44.2 chain	'	14124036			<u> </u>			
MHC class I HLA-B51- cd3.3	1	L41086						
MHC class I HLA-C allele	2	Z33459						
MHC class I HLA-Cw*0304 (=M84172; M99389)	1	D64150						
MHC class I HLA-Cw*0803	3	Z15144						
MHC class I HLA-Cw6	1	M28206					$\bot$	
MHC class I HLA-J antigen	1	L56139				_		
MHC class I lymphocyte antigen A2 (A2.1) variant DK1	1	M19670						
MHC class I mic-B antigen	1	X91625		$L^-$				
MHC class I polypeptide-	1	L14848			+			
related sequence A (MICA) MHC class I protein HLA-C heavy chain (C*0701new allele) (=AF017331)	1	U61274		-		<b>†</b>		
MHC class II DNA Sequence (clone A37G7-	1.	L18885		1	$\top$	+		
1C11)						丄		<u></u> _

MHC class II DQ-alpha									PC1/C	A00/00	005
associated with DRw6, DQw1 protein	1	M16995	+		7		+	T	+		
MHC class II DQ-beta associated with DR2, DQw1 protein	2	M17564				+	+	+			
MHC class II HAL-DQ- LTR5 (DQ.w8) DNA fragment, long terminal repeat region	1	M33842	<del></del>			-		-	-		
MHC class II hla-dr alpha- chain (=J00197;M60334;K01117	1	J00195			_	+	+	-	+		
1;J00194;M60334;K01117 1;J00194;M60333;X00274) MHC class II HLA-DRB1	1 1	AF007883									
MHC class II HLA-DRw11-					_1			T			
MHC class II lymphocyte	-	M21966 M23907							1		
antigen (DPw4-beta-1)  MHC CLASS II	<u> </u>	P33076								-	
TRANSACTIVATOR CIITA (non-exact 57%) MHC HLA-E2.1 (=X87679)											
MHC 1154-522.1 (=X87679)	1	M32507			$\top$	_	+		<del> </del>		
MHC HLA-E2.1 (alpha-2 domain) (low match) Mi-2 autoantigen 240 kDa	1	M32507			1	+	1	$\top$	<del>                                     </del>		
protein (non-exact 84%) microsomal stress 70	1	U08379					$\dagger$	+			
protein ATPase core (stch) microtubule-associated	-	U04735 U19727									
protein 4 (MAP4) microtubule-associated	· 	X73882	+	+	+	+		+		···	,
protein 7 (MAP7) mineralocorticoid recentor	2	M16801									
(aldosterone receptor)	_	14110801		+		+		+		7.	
minichromosome maintenance deficient (S. cerevisiae) 3 (MCM31)	1	X62153		+	+	+		+			
minichromosome maintenance deficient (S. perevisiae) 3-associated protein (MCM3AP)	1	AB011144	÷	+	+	+		+			
ninichromosome naintenance deficient (S. perevisiae) 5 (cell division cycle 46) (MCM5)	2	X74795	+	+	+	+	+	+			
nitochondiral cytochrome b CYTB) nitochondrial 16S rRNA	1	AF042517					_				
nitochondnal ATP	11	Z70759						$\dashv$			
ynthase (F1-ATPase) Ipha subunit	2 -	X59066	· · · · · · · · · · · · · · · · · · ·					+			
nitochondrial ATP ynthase c subunit (P1 prm)	1	X69907			-	1					
nitochondrial cytochrome b	6	AF042508	<u> </u>	+	_	$\dashv$	_	-+			
itochondrial cytochrome b mall subunit of complex II	1	AB006202		1 1		+	+	+			
YTOCHROME C XIDASE POLYPEPTIDE I	1	P00395					1	1			
itochondrial YTOCHROME C XIDASE POLYPEPTIDE	1	P00403						+	·		
itochondrial cytochrome oxidase subunit II	2	P00403		++	-	+	+	+			

WO 00/40749									 		_
mitochondrial cytochrome oxidase subunit II (COII) (=U12692 Hsa4 mitochondrion cytochrome	5	U12691								-	
oxidase subunit II)									 		
mitochondnal DNA loop attachment sequences (clone LAS34)	1	X89763									
mitochondrial DNA polymerase accessory subunit precursor (MtPolB) nuclear gene encoding mitochondrial protein.	1	U94703		+					 		
mitochondrial DNA, complete genome	1	X93334							 		↲
mitochondrial genes for several tRNAs (Phe, Val, Leu) and 12S and 16S ribosomal RNAs.	8	∨00710							 		
mitochondrial genes for tRNA (Phe) and 12S rRNA (fragment)	3	V00660									
mitochondrial inner membrane preprotein translocase Tim17a	1	AF106622							 		
mitochondrial isolate Afr7 cytochrome b(CYTB)	1	AF042503									
mitochondrial loop attachment sequence (clone LAS88)	1	X89843									
mitochondrial NADH dehydrogenase subunit 2 (ND2)	14	AF014893									
mitochondrial translational initiation factor 2 (MTIF2)	1	L34600		+	+	+		+			
mitochondrion cytochrome	1	U09500									
mitogen inducible gene mig-2	1	Z24725		+	+	+		+			┙
mitogen inducible gene mig-2 (non-exact, 71%)	1	Z24725									╛
mitogen-activated protein kinase-activated protein kinase 3 (MAPKAPK3)	2	U43784		+	+	+		+			
MLN51	2	X80199		+	+	+	+	+			
MLN64 (=D38255 CAB1)	1	X80198	+	+	+	+			<del></del>		٦
moesin (MSN)	14	M69066	+	+	+	+		+			٦
monocytic leukaemia zinc finger protein (MOZ)	2	U47742		+	+	+		+			
MOP1 ()	2	U29165	i								٦
motor protein (Hs.78504)	2	D21094	+	+	+	+		+			ceil
mouse double minute 2, human homolog of; p53- binding protein (MDM2)	1	U39736			+	+					
M-phase phosphoprotein 6 (MPP-6)	1	X98263		+	+	+		+			
M-phase phosphoprotein, mpp11	1	X98260									
MPS1	1	L20314						Π			
Mr 110,000 antigen	2	D64154	1	+		+	+	+			
MRC OX-2, V-like region (=M17227)	1	X05324		$\top$			Π				
mu-adaptin-related protein- 2; mu subunit of AP-4 (MU- ARP2)	1	Y08387									
multifunctional polypeptide similar to SAICAR synthetase and AIR carboxylase (ADE2H1)	1	X53793	+	+	+	+		+			

									 	0003	
murine leukemia viral (bmi- 1) oncogene homolog (BMI1)	1	L13689	·	+		+		+			
mutant (Daudi) beta2 - microglobulin	44	X07621		<del>                                     </del>				<del>                                     </del>			
mutated in colorectal cancers (MCC)	1	M62397		+	+	1		+			
myeloid cell leukemia sequence 1 (BCL2-related) (MCL1)	9	L08246	+	+	+	+	+	-			
myeloid cell nuclear differentiation antigeN (MNDA)	11	M81750	+					+	• .	<del></del>	
myeloid differentiation primary response gene (88) (MYD88)	4	U70451		+	+	+		+			
myeloid leukemia factor 2 (MLF2)	3	U57342		+		+		+			
myeloid/lymphoid or mixed- lineage leukemia (trithorax (Drosophila) homolog); translocated to, 7 (MLLT7)	8	U89867		+	+	+		+			
MYH9 (cellular myosin heavy chain)	1	M81105									
myomesin (M-protein) 2 (165kD) (MYOM2)	7	X69089							 		
myosin IE (MYO1E)	11	X98411		+		+					
myosin light chain kinase (MLCK)	1	U48959	+		+	+		+	 		
myosin phosphatase, target subunit 1 (MYPT1)	2	D87930		+	+	+		+		414	
myosin regulatory light chain (=U26162)	2	D50372				·				•	;
myosin VIIa (low match 71)		U55208									
myosin, heavy polypeptide 9, non-muscle (MYH9)	3	M81105	+	+	+	+		+	 		
myosin, light polypeptide, regulatory, non-sarcomeric (20kD) (MLCB)	6	X54304	+	+	+	+	+	+			
myosin-I beta	1	X98507	+	+	+	+		+	 •		-
mynstoylated alanine-rich protein kinase C substrate (MARCKS, 80K-L) (MACS)	1	D10522		+	+					·	
myxovirus (influenza) resistance 1, homolog of murine (interferon-inducible protein p78) (MX1)		M30817	+	+	+	+		+			
myxovirus (influenza) resistance 2, homolog of murine (MX2)	3	M30818		-	+						
N-acetylgalactosaminidase, alpha- (NAGA)	2	M62783		+	+	7	+	+			$\dashv$
N-acetylglucosamine receptor 1 (thyroid) (NAGR1)	1	L03532		+	+	+		+			
NACP/alpha-synuclein	2	U46896		<del>                                     </del>		_	-	-	 		
N-acylaminoacyl-peptide hydrolase (APEH)	1	D38441		+	+		+	+	<del></del>		$\dashv$
N-acylsphingosine amidohydrolase (acid ceramidase) (ASAH)	11	U47674	+	+	+	+		+			
NAD+-specific isocitrate dehydrogenase beta subunit precursor (encoding mitochondrial protein)	1	U49283	+	+	+	+	+	+			
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5 (13kD, B13) (NDUFA5)	1	U53468.1	+	+	+	+	+	+		<del></del>	

WO 00/40749								10	.1/CA00/00003
NADH dehydrogenase (ubiquinone) 1 beta	1	AF047181		+	+	+	+	+	
subcomplex, 5 (16kD, SGDH) (NDUFB5)									
NADH dehydrogenase (ubiquinone) Fe-S protein 2 (49kD) (NADH-coenzyme Q eductase) (NDUFS2)	1	AF050640		*	+	+	+	+	
NADH dehydrogenase (ubiquinone) flavoprotein 2 (24kD) (NDUFV2)	1	M22538			+	+	+	+	
NADH:ubiquinone dehydrogenase 51 kDa	2	AF053070	+	+	+	+	+	+	
subunit (NDUFV1) NADH-CYTOCHROME B5 REDUCTASE (B5R)	1	P00387							
(50%aa) NADH-UBIQUINONE OXIDOREDUCTASE	1	P03886							
CHAIN 1 Nardilysin (N-arginine dibasic convertase) (NRD1)	2	U64898	+	+	+	+		+	
nascent-polypeptide- associated complex alpha polypeptide (NACA)	5	X80909		+	+		+	+	
natural killer cell group 7 sequence (NKG7)	8	S69115				+ 10		+	
natural killer cell transcript 4 (NK4)	19	M32011	+						blood only
natural killer-associated transcript 3 (NKAT3)	1	U30274	+						blood only
natural killer-associated transcript 5 (NKAT5)	1	AF022045	+ В		+	<u> </u>	+	+	blood only
natural killer-tumor recognition sequence (NKTR)	1	L04288							
N-deacetylase/N- sulfotransferase (heparan glucosaminyl) 2 (NDST2)	2	AF042084	+	+		+		+	
Ndr protein kinase	3	Z35102		+			<u> </u>		
Nedd-4-like ubiquitin- protein ligase WWP1	1	U96113						_	
nel (chicken)-like 2 (NELL2)	3	D83018		+	+	<u> </u>	+	_	
N-ethylmaleimide-sensitive factor attachment protein, alpha (NAPA)	*	U39412		+					
N-ethylmaleimide-sensitive factor attachment protein, gamma (NAPG)	1	U78107		+	+	+			
neural precursor cell expressed, developmentally down- regulated 5 (NEDD5)	3	X92544	+	+	+	+		+	high in testis
neural precursor cell expressed, developmentally down- regulated 8 (NEDD8)		D23662	+	+	+	+	+	+	,
neuregulin 1 (NRG1)	1	U02330		+		+	+	<u> </u>	
neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS)		AB020692	+	+	+	+		+	·
Neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) (low match)		X68286	·						
Neurofibromin 2 (bilateral acoustic neuroma) (NF2)	1	S73853		+	<u>                                     </u>	$\perp$	_	+	
neuronal apoptosis inhibitory protein (NAIP)	2	U19251	+	+	+	1	$\perp$	1	
neuronal cell adhesion molecule (NRCAM)	1	AB002341		+	+	+			

neuropathy target esterase	1	i AJ004832					<del>.</del>		C17CA00700003
(NTE)		A3004832		+	+	+		+	
neuropeptide Y3 receptor, 5'UTR (low score)	1	D28433			Ť –	†	T	T	
neurotrophic tyrosine	14	X03541	+	+	++	+	+	+	
kinase, receptor, type 1 (NTRK1)							`	,	
neutrophil cytosolic factor 4 (40kD)	2	U50720				$\vdash$	<del>                                     </del>	$\vdash$	
NG31	1	AF129756	<del> </del>		-	-	├	+	
NGAL (=X83006)	1	X99133				┼	├	┼	
nibrin (NBS)	1	AF051334	<del> </del>	<del></del>		╁	-	-	
NIK	1	AB014587	<del> </del> -	+	+	+	-	+	<del> </del>
Ninjurin 1; nerve injury- induced protein-1	1	U72661		+	+	+		+	
nitrilase 1 (NIT1) (=AF069984)	1	AF069987							
NKG2-D (low match) (non- exact, 58%)	1	X54870							
Nmi	1	U32849		+					
N-myristoyltransferase 1 (NMT1)	1	AF043324		+	+	+	+	+	
No arches-like (zebratish)	1	U79569		+	+	+		+	
non-histone chromosome	1	D50420	+	++	+	+	+	+	
protein 2 (S. cerevisiae)- like 1 (NHP2L1) non-muscle (fibroblast)									
tropomyosin	1								
non-muscle alpha-actinin	1	U48734		+					14
non-muscle myosin alkali light chain (Hs.77385)	3	M22918	+	+	+	+	+	+	High in fetal adrenal gland and BPH
non-neuronal enolase (EC 4.2.1.11)	1	X16289				$\dashv$	-		stroma
non-receptor tyrosine phosphatase 1	1	M33689					$\dashv$		
normal keratinocyte substraction library mRNA, clone H22a	3	X53778	+	+	+	+	+	+	high in many libranes
notch group protein (N)	3	M99437		+-+	$\dashv$			-	
novel protein	1	X99961		+	+		$\dashv$		
novel T-cell activation protein	1	X94232		++	+	+	$\dashv$	+	
N-ras protein NRU	1	A60196		<del>                                     </del>		-	$\dashv$	$\dashv$	
N-sulfoglucosamine sulfohydrolase	1	U60111	<del></del>	1+1		$\dagger$	$\dashv$	+	
(sulfamidase) (SGSH) nsulin induced gene 1 (INSIG1)	7	U96876	+	+	+	+	+	+	
ntegrin, alpha 4 (antigen	3	L12002	<del></del>						
CD49D, alpha 4 subunit of VLA-4 receptor) (ITGA14)		2.2002	•			+			
nterferon, gamma-inducible protein 16 (IFI16)	1	M63838	+	+	+	+	$\dashv$	+	
nterleukin 1, beta (IL1RB)	1	M15330		++		-	-		
nuclear antigen H731-like	2	U83908		++-	++	++	+	+	
protein nuclear antigen Sp100	4	U36501	+	-	-	+	+	+	
(SP100) Nuclear antigen Sp100	1	P23497		$\vdash \vdash$		_	_	_	
(SP100) (85%aa) Nuclear antigen Sp100									
(SP100) (89%aa) nuclear autoantigenic		P23497							
sperm protein (histone- binding) (NASP)	1	M97856	+		+		T		

nuclear corepressor KAP-1 (KAP-1) (=U95040; X97548 TIF1beta zinc finger protein) Nuclear domain 10 protein (NDP52) Nuclear factor (erythroid-	4	U78773							
Nuclear domain 10 protein (NDP52)	·	1122807							
		022037	+	+	+	+	+	+	
derived 2)-like 2 (NFE2L2)		574017		+	+	+	+	+	
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105) (NFKB1)	2	M58603		+	+		+	+	
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA)	3	M69043		+	+	+		+	
nuclear factor related to kappa B binding protein (NFRKB)	1	U08191		+	+	+		+	
nuclear mitotic apparatus protein 1 (NUMA1)	3	Z11583	+	+	+	+	+	+	
nuclear receptor coactivator 2 (GRIP1)	1	X97674							
nuclear receptor coactivator 3 (AIB3)	2	AF010227	+	+	+			+	
nuclear receptor coactivator 4 (ELE1)	22	X77548		+	+	+	+	+	
nuclear receptor interacting protein 1 (NRIP1)	1	X84373		+		+		+	
nuclear respiratory factor 1 (NRF1)	1	U02683	В	+	+				
nuclear RNA helicase, DECD variant of DEAD box family (DDXL)	4	U90426	+	+	+	+		+	
nuclear transcription factor Y, alpha (NFYA)	1	X59711	В						
nuclear transcription factor, X-box binding 1 (NFX1)	3	U15306		+	+		+		
nuclear transport factor 2 (placental protein 15) (PP15)	1	X07315	+	+	+	+		+	
nucleobindin (=M96824)	1	U31336							
nucleobindin 1 (NUCB1)	2	M96824	+	+	+	+		+	
nucleolar phosphoprotein p130 (P130)	1	Z34289		+	+				
nucleolar protein (KKE/D repeat) (NOP56)	1	Y12065	+	+	+	+		+	
nucleolar protein (MSP58)		AF015308		1					
nucleolar protein 1 (120kD) (NOL1)	1	M32110	+	+					
nucleolar protein p40	1	U86602	+	+	+	+		+	
nucleolin (NCL)	2	M60858	+	+	+	+		+	
nucleophosmin (nucleolar phosphoprotein B23, numatrin) (NPM1)	14	M28699	+	+	+	+		+	
nucleophosmin-retinoic acid receptor alpha fusion protein NPM-RAR long form	1	U41742							
nucleoporin (NUP358) (=D42063 RanBP2 (Ran- binding protein 2))	2	L41840							
nucleoporin 153kD (NUP153)	1	Z25535							
nucleoporin 98kD (NUP98)	1	U41815							
nucleosome assembly protein	1	D28430							
nucleosome assembly protein 1-like 1 (NAP1L1)	1	M86667		+	+			+	
nucleosome assembly protein 1-like 4 (NAP1L4)	2	U77456	+	+	+	+		+	

									PCT/CA00/00005
nucleosome assembly protein, 5'UTR	1	D28430			$\top$		T	$\top$	
olfactory receptor (OR7- 141)	1	U86281		-	+	+	-	+	
OLFACTORY RECEPTOR	- 1	P34982					_		
(OR17-4) (non-exact 65%)	:	34302							
oligodendrocyte myelin glycoprotein (OMG)	7	L05367		+	+	+-	+	+	
O-linked N-	1	U77413	+	+					
acetylglucosamine (GlcNAc) transferase (UDP-N-									
acetylglucosamine:polypep tide-N-acetylglucosaminyl transferase) (OGT)									
oncofetal trophoblast glycoprotein 5T4 precursor (non-exact 55%)	1	A53531					+		
Oncogene TIM (TIM) (non- exact 84%)	+	U02082			-	+-	+-	+	
ORF (Hs.77868)	+ -	M68864	<del>                                     </del>				$\bot$	⊥.	
ORF1; MER37; putative	1 -	U49973	+		+	+	+	+	
transposase similar to pogo element Length = 454									
origin recognition complex, subunit 2 (yeast homolog)- like (ORC2L)	2	U27459				+		1	
ongin recognition complex, subunit 4 (yeast homolog)- like (ORC4L) (low match)	1	AF022108							
ornithine aminotransferase (gyrate atrophy) (OAT)	2	M23204		+	+	+	-	+-	
ornithine decarboxylase (ODC)	1	M20372				+		+	,:
omithine decarboxylase antizyme, ORF 1 and ORF 2	11	D78361	+	+	+	+	+	+	High in pancreas, and activated T cells
orphan receptor (Hs.100221)	2	U07132	+	+	+	+	├─	+	
OS-9 precurosor	6	AB002806	+	$+$ $\leftarrow$	+	+	+	+	
osteonectin (=X82259 BM- 40)	1	D28381		+-	H	+-	+	-	
ovel centrosomal protein RanBPM (RANBPM)	1	AB008515		+	+	+		+	
over-expressed breast tumor protein	1	L34839				-			
oviductal glycoprotein 1, 120kD (OVGP1)	1	U09550			+	+	+		
oxidase (cytochrome c) assembly 1-like (OXAIL)	1	X80695		+	+	+	+	+	
oxoglutarate dehydrogenase (lipoamide) (OGDH)	4	D10523	T	+	+		+	+	
oxysterol binding protein (OSBP)	1	M86917	+	+			+		
ÖZF	1	X70394		╀┯┦	+	+			
OZF (non-exact zinc finger)	1	X70394		+		-		+	
p21/Cdc42/Rac1-activated kinase 1 (yeast Ste20- related) (PAK1)	2	U51120	+	+		+			
P35-related protein (= S80990 ficolin)	1	D63392		+			$\dashv$		
040	1	U93569		<del>  </del>					
040phox (=U50720)	1	X77094		1					
247 LBC oncogene	4	U03634		<del> </del>				$\dashv$	
53-induced protein PIG11)	1	AF010315	+	++	+	+			
54nrb (low match)	1	Y11287	<del></del>	+				$\dashv$	
	····								

p62 nucleoporin	1	X58521							
p63 mRNA for	1	X69910	+	+	+	+		+	
transmembrane protein									
PAC clone DJ0701016 from 7q33-q36 (non-exact 54%)	1	Q07108							
palmitoyl-protein thioesterase (ceroid- lipofuscinosis, neuronal 1, infantile: Haltia-Santavuori disease) (PPT)	10	U44772		+	+	+		+	
papillary renal cell carcinoma (translocation- associated) (PRCC)	1	X99720	+	+	+	+	+	+	
PAR protein	1	AF115850		1 +		+			
partial EST (clone c-1gh04)	1	Z43627							
PAX3/forkhead transcription factor gene fusion	<del>- 1</del>	U02368							
paxillin (PXN)	4	D86862		+	+	+		+	
PBK1 protein	2	AJ007398	+	+	+	+		+	
PBS-EST (nz92e01.s1 NCI_CGAP_GCB1 clone IMAGE:1302936) (low score)	1	AA732534							
PDZ domain protein (Drosophila inaD-like) (INALD)	1	AJ224747	+			+		+	
PEBP2aC Runt domain	1	Z38108							
encoding gene (=Z35728) peptidase D (PEPD)	1	J04605		+		$\vdash$		<del>                                     </del>	
peptidylprolyl isomerase A	3	Y00052		+	+	+	+	+	high in many libraries
(cyclophilin A) (PPIA)	- 2	L11667	<del></del>	+	+		+	+	
peptidylprolyl isomerase D (cyclophilin D) (PPID)					+	_	+	+	
peptidylprolyl isomerase E (cyclophilin E) (PPIE)	1	AF042386		+			Ľ	Ľ	
PERB11.1 (=U56942 MHC class I chain-related protein A)	1	U69630							
perform 1 (preforming protein) (PRF1)	14	M28393							
peroxisomal acyl-CoA thioesterase (PTE1)	2	X86032							
Peroxisomal acyl- coenzyme A oxidase	1	X71440		+	+	+	+	+	
peroxisomal farnesylated protein (PXF)	1	X75535		+	+	+	+	+	
phorbol-12-myristate-13- acetate-induced protein (PMAIP1)	1	D90070	B, W						
phosphate carrier (mitochondrial gene?)	1	X77337							
Phosphate carrier, mitochondrial (PHC)	3	X60036	+	+	+	+		+	
phosphate cytidylytransferase 1, choline, alpha isoform (PCYT1A)	1	L28957	<b>T</b>		+		+		
PHOSPHATIDATE CYTIDYLYLTRANSFERAS E (CDP-DIGLYCERIDE)	1	Q92903							
phosphatidylinositol 3- kinase delta catalytic subunit	2	U57843							
phosphatidylinositol 4- kinase, catalytic, beta polypeptide (PIK4CB)	3	AB005910	+	+	+	+		+	
phosphatidylinositol glycan, class H (PIGH)	1	L19783		+	+	+	+	+	

labora boti di Vianni di									PCT/	CA00	0/00005
phosphatidylinositol transfer protein (PI-TPbeta)	2	D30037		T	T		Т	T			
phosphatidylinositol	2	X98654		++	+-	-					
transfer protein, membrane-associated (PITPNM)			lymphoma			Ì					
phosphatidylinositol transfer protein, membrane-associated	1	X98654			+		+				
(PITPNM) (non-exact 64%) phosphatidylinositol-4-	1	U14957		-	++	$\perp$	$\perp$	+			
phosphate 5-kinase, type II, alpha (PIP5K2A)											
phosphatidylinositol-4- phosphate 5-kinase, type II, beta (PIP5K2B)	1	U85245		+	+	1		7			
phosphodiesterase 7A (PDE7A)	1	L12052	B, W	+	+		+	-			
phosphodiesterase IB (PDES1B)	1	U56976		OI	4LY	+-	+	+	<del> </del>		
phosphoglucomutase 1 (PGM1)	2	M83088		+	+	+	+	+	+		
phosphogluconate dehydrogenase (PGD)	1	U30255			+	$\dagger$	+	+-	<del> </del>		
phosphoglycerate kinase 1 (PGK1)	12	V00572				†	1	+	+		
phosphoglycerate mutase 1 (brain) (PGAM1) phosphoglycerate mutase	3	J04173	+	+	+	+	+	+	<del>                                     </del>		
2 (muscle) (PGAM2)  phosphoinositide-3-kinase,	1	M55673		+	+	1		+			
catalytic, alpha polypeptide (PIK3CA)	1	229090		+	+	+		T		_	;
phosphoinositide-3-kinase, catalytic, delta polypeptide (PIK3CD)	4	U86453		+	+	+	$\vdash$	+			
phosphoinositide-3-kinase, catalytic, gamma polypeptide (PIK3CG)	1	X83368				-	-	$\vdash$			
phospholipase C	1	X14034					<u> </u>	↓			
phospholipase C, delta 1 (PLCD1)	2	U09117		+	+	+	-	+			
phospholipase C, gamma 1 (formerly subtype 148) (PLCG1)	7	M34667	+	+	+	+		+			
phospholipid scramblase	1	AF008445						<b>_</b>			
phosphoribosyl pyrophosphate synthetase- associated protein 1 PRPSAP1)	1	D61391		+	+			+			
hosphoribosylglycinamide omyltransferase, hosphoribosylglycinamide ynthetase, hosphoribosylaminoimida ole synthetase (GART)	3	X54199		+	+	+	+	+			
hosphorylase kinase, lpha 2 (liver), glycogen torage disease IX PHKA2)	3	D38616		+	+	+	+	+			<del></del> -
hosphorylase, glycogen; rain (PYGB) hosphorylase, glycogen;	1	U47025	+	+	+	$\dashv$	$\dashv$	+			
on-exact, 75%)	1	U47025		$\top$	$\dashv$	+		+			
nosphorylase, glycogen; ver (Hers disease, cogen storage disease pe VI) (PYGL)	1	Y15233		+	+	+		+	·····		
hosphorylation regulatory rotein HP-10	2			+	+	$\dashv$	$\dashv$	-		<del></del>	
hosphotidylinositol ansfer protein (PITPN)	1	D30036	<del></del>	+-	+	+		+			

pigment epithelium-derived factor (PEDF)	1	U29953	+	+	+	+	+	+	
pim-1 oncogene (PIM1)	1	M24779	+	+	+			+	
pinin, desmosome associated protein (PNN)	1	U77718		В.	mon	ocyt	e, T	lymp	homa
placenta (Diff33)	5	U49188		1+	+	+	Ι	+	
placenta (Diff33) (non- exact, 69%)	1	U49188							İ
placenta (Diff48)	18	U49187	+			$\vdash$	<del>                                     </del>	╁	-
placenta (Diff48) (low match)	1	U49187							
placenta(Diff48) (low match)	1	U49187							
plasminogen activator, urokinase receptor (PLAUR)	1	X74039		+		+		+	
platelet factor 4 (PF4)	1	M25897			+		-	+	
platelet/endothelial cell adhesion molecule (CD31 ntigen) (PECAM1)	8	M37780		+	+	+	+	+	
platelet-activating factor acetylhydrolase 2 (40kD) (PAFAH2)	4	U89386		+	+	+			
platelet-activating factor acetylhydrolase, isoform lb, alpha subunit (45kD) (PAFAH1B1)	1	U72342	+	+	+	+	+	+	
platelet-activating factor receptor (PTAFR)	1	D10202		+	-			+	
pleckstrin (PLEK)	10	X07743			+	+		+	
pleckstrin (PLEK) (low match)	1	X07743					·		
pleckstrin homology, Sec7 and coiled/coil domains 1(cytohesin 1) (PSCD1)	4	M85169	+	+		+		+	
pleckstrin homology, Sec7 and coiled/coil domains, binding protein (PSCDBP)	4	L06633	+			+			
pM5 protein	1	X57398	+	+	+	+		+	
PMP69	2	Y14322							
poly (ADP-ribose) polymerase (NAD (+) ADP- ribosyltransferase) (=X16674)	1	X56140							
poly(A) polymerase (PAP)	1	X76770	+	+	+	+		+	
poly(A)-binding protein-like 1 (PABPL1)	19	Y00345	+	+	+	+	+	+	
poly(rC)-binding protein 1 (PCBP1)	3	X78137	+	+	+	+	+	+	
polyadenylate binding protein	1	U75686							
polycystic kidney disease 1 (autosomal dominant) (PKD1)	5	U24498							
polymerase (DNA directed), beta (POLB)	1	D29013		+			+	+	
polymerase (DNA directed), gamma (POLG)	6	D84103							
polymerase (RNA) II (DNA directed) polypeptide A (220kD) (POLR2A)	1	X63564	+	+	+	+	+	+	
polymyositis/scleroderma autoantigen 2 (100kD) (PMSCL2)	1	L01457	+	+	+	+	+.	+	
polypyrimidine tract binding protein (heterogeneous nuclear ribonucleoprotein I) (PTB)	1	X65372	+	+	+	+	+	+	

			•					r	C1/CA00/00005	
positive regulator of programmed cell death ICH-1L (Ich-1)	3	U13021			+					<del></del>
postmeiotic segregation increased 2-like 12 (PMS2L12)	1	M16514	+	+	+	+	_	+		
postmeiotic segregation increased 2-like 8 (PMS2L8)	1	U38964	+	+	+	+		+		
potassium inwardly- rectifying channel, subfamily J, member 15 (KCNJ15)	1	D87291				+		+		
potassium voltage-gated channel, KQT-like subfamily, member 1 (KCNQ1)	1	AF051426		+	+	+		+		
POU domain, class 2, associating factor 1 (POU2AF1)	1	Z49194				+				
POU domain, class 2, transcription factor 1 (POU2F1)	2	X13403		+		+				
PPAR binding protein (PPARBP)	1	Y13467	+	+	+	+		+		
PPAR gamma2	1	D83233				$\neg \neg$	$\neg$			
pre-B-cell colony- enhancing factor (PBEF)	8	U02020		1						
prefoldin 1 (PFDN1)	1	Y17392	+	+	+	++	+	+		
prefoldin 5 (PRFLD5)	3	D89667	В	+++	+-	-+	+			
prefoldin subunit 3 (=U96759 von Hippel- Lindau binding protein (VBP-1))	1	Y17394				1				
pregnancy-associated plasma protein A (PAPPA)	1	U28727		+ +		+	+	$\dashv$	high in placenta	—
pre-mRNA splicing factor SF3a (60kD), similar to S. cerevisiae PRP9 (spliceosome-associated protein 61) (SF3A60)	1	U08815	+	+	+	+	·	+		
pre-mRNA splicing factor SF3a (60kD), similar to S. cerevisiae PRP9 (spliceosome-associated protein 61) (SF3A60) (low score)	1	U08815								
pre-mRNA splicing factor SRp20, 5'UTR	2	D28423			$\neg$	$\dashv$	$\dashv$	$\dashv$		
preprotein translocase (TIM17)	3	X97544	+	+	+	+	+	+		$\dashv$
prion protein	1	X82545		<del>                                     </del>	$\dashv$	-	$\dashv$	-+		
prion protein (p27-30) (Creutzfeld-Jakob disease, Gerstmann-Strausler- Scheinker syndrome, fatal familial insomnia) (PRNP)	1	M13899		+	+	+		+		
pristanoyl-CoA oxidase (low match)	1	Y11411				+	+	-		$\dashv$
pristanoyl-CoA oxidase (low score)	1	Y11411			<del></del>	+	+	+		-
procollagen-lysine, 2- oxoglutarate 5- dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome type VI) (PLOD)	1	M98252		+	+	+	-	+		
procollagen-proline, 2- oxoglutarate 4- dioxygenase (proline 4- hydroxylase), alpha polypeptide 1 (P4HA1)	1	M24486	•	+	+   -	+   -		+		1

WO 00/40749								PC	[/CA00/00005
procollagen-proline, 2- oxoglutarate 4- dioxygenase (proline 4- hydroxylase), beta polypeptide (protein disulfide isomerase; thyroid hormone binding protein p55) (P4HB)	-4	X05130	+	+	+	+	+	+	
profilin 1 (PFN1)	1	J03191	+	+	+	+	+	+	
progesterone receptor- associated p48 protein (P48)	2	U28918		+					
prohibitin (PHB)	1	S85655		+ 1	+	+	+	+	
proliferating cell nuclear antigen (PCNA)	3	J04718	+	+	+	+		+	
proliferation-associated gene A (natural iller- enhancing factor A) (PAGA)	4	L19184	+ ""	+	+	+	+	+	
proline-rich protein BstNI subfamily 2 (PRB2) (non- exact, 43%aa)	1	S62936							
proline-serine-threonine phosphatase interacting protein 1 (PSTPIP1)		U94778							
prolyl endopeptidase (PREP)	2	X74496		+		+		+	
prolylcarboxypeptidase (angiotensinase C) (PRCP)	5	L13977	·	+	+	+	+	+	
promyelocytic leukemia (PML)	1	M80185	+	+	+	+		+	
properdin P factor, complement (PFC)	4	X57748	+				-		
pro-platelet basic protein (includes platelet basic protein, beta-thromboglobulin, connective tissue-activating peptide III, neutrophil-activating peptide-2) (PPBP)	1	M54995			+	+		+	
pro-platelet basic protein (includes platelet basic protein, beta-thromboglobulin, connective tissue-activating peptide III, neutrophil-activating peptide-2) (PPBP)	7	M54995	+		+		+		
proprotein convertase subtilisin/kexin type 7 (PCSK7)	4	U40623							
prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy) (PSAP)	89	D00422	+	+	+	+	+	+	
prostaglandin- endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) (PTGS1)	1	U63846	В	+			+	+	
prostaglandin- endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (PTGS2)	2	L15326							
prostaglandin- endoperoxide synthase-1 (=L08404; U84208) (all promoters)	1	D64068							
prostate carcinoma tumor antigen (pcta-1)	2	L78132							

W O 00/40/49								Г	L1/CA00/00005
protease inhibitor 1 (anti- elastase), alpha-1- antitrypsin (PI)	. 17	K02212		+	+	+	+	+	high in many libraries
protease inhibitor 2 (anti- lelastase), monocyte/neutrophil	1	M93056				+		+	
(ELANH2) (low match) proteasome (prosome,	3	L02426	В	+-	+	-	<u> </u>	+	
macropain) 26S subunit, ATPase, 1 (PSMC1)		202420	J						
proteasome (prosome, macropain) 26S subunit, ATPase, 3 (PSMC3)		M34079	+	+	+	+		+	
proteasome (prosome, macropain) 26S subunit, ATPase, 4 (PSMC4)	2	AF020736							
proteasome (prosome, macropain) 26S subunit, ATPase, 5 (PSMC5)	5	L38810	+	+	+	+	+	+	
proteasome (prosome, macropain) 26S subunit, ATPase, 6 (PMSC6)	- 2	D78275	+	+	+	+		+	
proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 (PSMD11)	1	AF001212	T	+			+		
proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 (PSMD2)	2	D78151		+	+			+	
proteasome (prosome, macropain) 26S subunit, non-ATPase, 5 (PSMD5)	1	S79862		+	+		+		
proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 (Mov34 homolog) (PMSD7)	1	D50063		+	+	+		+	high in many libraries
proteasome (prosome, macropain) 26S subunit, on-ATPase, 12 (PMSD12)	1	AB003103		+	+	+		+	
proteasome (prosome, macropain) activator subunit 1 (PA28 alpha) (PSME1)		L07633	+	+	+	+	-	+	
proteasome (prosome, macropain) subunit, alpha type, 3 (PSMA3)	2	D00762		+	+	+		+	
proteasome (prosome, macropain) subunit, alpha type, 5 (PSMA5)	3	X61970	+	+	+	+	1	+	
proteasome (prosome, macropain) subunit, alpha type, 7 (PSMA7)	3	AF054185		+	+	+	+	+	
proteasome (prosome, macropain) subunit, alpha type, 7 (PSMA7) (low match)	1	AF022815							
proteasome (prosome, macropain) subunit, beta type, 1 (PSMB1)	1	D00761	+	+	+	+	+	+	
proteasome (prosome, macropain) subunit, beta type, 10 (PSMB10)	1	X71874	+	+		+	+	+	
proteasome (prosome, macropain) subunit, beta type, 6 (PMSB6)	1	D29012		+	+	+		+	
proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional protease 7) (PSMB8)	1	U17497	+	+	+	+		+	
proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional protease 2) (PSMB9)	3	Z14977	+			+		+	· .

<b>WO 00/40749</b>									.1/CA00/00003
proteasome (prosome, macropain) subunit, beta ype, 7 (PSMB7)	1	D38048	+	+	+	+	+	+	
protective protein for beta- galactosidase	3	M22960	+	+	+	+	+	+	
(galactosialidosis) (PPGB) protein A alternatively	1	U47925		+					
spliced form 2 (A-2) protein activator of the interferon-induced protein	1	AF072860		+	+	+		+	high in testis
kinase (PACT) protein disulfide isomerase- related protein (P5)	2	D49489	+	+	+	+	+	+	
protein geranylgeranyltransferase type I, beta subunit	1	L25441	+	+	+				
(PGGT1B) protein homologous to chicken B complex protein, guanine nucleotide binding (H12.3)	20	M24194	+	+	+	+	+	+	high in many libraries
protein kinase A anchoring protein	1	AF037439		+					
protein kinase C substrate 80K-H (PRKCSH)	2	U50317	+	+	+	+		+	
protein kinase C, beta 1 (PRKCB1)	6	X06318	+	+	+	+		+	
protein kinase C, delta (PRKCD)	1	D10495	. +	+	+	+		+	
protein kinase C, eta (PRKCH)	1	M55284			+			+	
protein kinase C, mu (PRKCM) (non-exact 78%)	1	X75756							
Protein kinase C-like 1 (PRKCL1)	2	D26181	+	+	+	+		+	
protein kinase, AMP- activated, gamma 1 non- catalytic subunit (PRKAG1)	1	U42412	B, T lymphoma	+	+				
protein kinase, cAMP- dependent, regulatory, type I, alpha (tissue specific	4	M18468		+	+	+	+	+	
extinguisher 1) (PRKAR1A) protein kinase, DNA- activated, catalytic polypeptide (PRKDC)	1	U47077		+	+		+	+	
protein kinase, mitogen- activated 1 (MAP kinase 1; p40, p41) (PRKM1)	1	Z11695	В	+			+		
protein kinase, mitogen- activated 6 (extracellular signal-regulated kinase,	1	L77964		+		+	+	+	
protein kinase, mitogen- activated, kinase 3 (MAP kinase kinase 3) (PRKMK3)	1	U66839	+	+	+	+	+		
protein phosphatase 1, catalytic subunit, alpha isoform (PPP1CA)	5	M63960	+	+	+	+	+	+	
protein phosphatase 1, regulatory subunit 10 (PPPR10)	3	Y13247		+	+	+		+	
protein phosphatase 1, regulatory subunit 7 (PPP1R7)	2	Z50749	+	+	+	+	+	+	
protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform (PPP2CB)	1	X12656	+	+	+	+	+	+	
protein phosphatase 2 (formerly 2A), regulatory subunit B" (PR 72), alpha isoform and (PR 130), beta isoform (PPP2R3)	1	L07590			+	+		+	

BNSDOCID: <WO\_\_\_\_0040749A2\_I\_>

									FCIA	-A00/0000	<b>J</b> 5
protein phosphatase 2. regulatory subunit B (B56), alpha isoform (PPP2R5A)	2	L42373	+	1	T	+	+		+		
protein phosphatase 2, regulatory subunit B (B56), delta isoform (PPP2R5D)	3	D78360		+	+	+	+		+	<del></del> -	
protein phosphatase 2, regulatory subunit B (B56), gamma isoform (PPP2R5C)	1	D26445	+	+		+	+		+	<del></del>	
protein phosphatase 2A regulatory subunit alpha- isotype (alpha-PR65)	5	J02902	+	+	+-	•	+	-	•		
protein phosphatase 4 (formerly X), catalytic subunit (PPP4C)	2	AF097996	+	+	+	-	+	+	-	<u> </u>	
protein tyrosine kinase 2 beta (PTK2B)	4	L49207		+	+	+	+	+	-		
protein tyrosine phosphatase epsilon	1	X54134			+	$\top$		+	+-		
protein tyrosine phosphatase type IVA, member 2 (PTP4A2)	2	L48723	+	+	1	-	+	+			
protein tyrosine phosphatase, non-receptor type 1 (PTPN1)	1	M31724	+	+	+	+		+	+		
protein tyrosine phosphatase, non-receptor type 12 (PTPN12)	1	M93425		+	+	+-	+	+	high	in testis	
protein tyrosine phosphatase, non-receptor type 12 (PTPN12) (non- exact, 70%)	1	M93425						$\dagger$		• स्वर्धन 	
protein tyrosine phosphatase, non-receptor ype 2 (PTPN2)	2	M25393		+	+	+	+-	+	-		
orotein tyrosine ohosphatase, non-receptor ype 4 (megakaryocyte) PTPN4)	1	M68941			+	+		+		4	
protein tyrosine phosphatase, non-receptor type 6 (PTPN6)	7	M74903	+	+	+	+	+	+	-	<del></del>	
rotein tyrosine hosphatase, non-receptor ype 7 (PTPN7)	1	D11327	+			+		+		<del></del>	
rotein tyrosiné hosphatase, receptor /pe, alpha polypeptide PTPRA)	1	M34668	+	+	+	+		+			
rotein tyrosine hosphatase, receptor /pe, c polypeptide PTPRC)	44	Y00638	+	+		+		+			
rotein tyrosine hosphatase, receptor rpe, M (PTPRM)	1	X58288		+	+	+	$\vdash$	+			
rotein tyrosine hosphatase, receptor pe, N polypeptide 2 PTPRN2)	2	U81561		+		+	-	+			
otein with polyglutamine peat (ERPROT213-21)	1	U94836	+	+	+	+	_	+			
otein-kinase, interferon- ducible double stranded NA dependent inhibitor RKRI)	1	U28424		+	+	+	+	+			
otein-L-isoaspartate (D- spartate) O- ethyltransferase (PCMT1)	4	D13892		+	+	-					
oteoglycan 1, secretory anule (PRG1)	7	J03223		+		+		+		<del></del> -	_
othymosin, alpha (gene equence 28) (PTMA)	12	M14483	+	+	+	+	+	+			_

WO 00/40749									
orp28, U5 snRNP 100 kd protein (U5-100K)	7	AF026402	+	+	+	+		+	
PRP4/STK/WD splicing factor (HPRP4P)	1	AF001687		+	+	+		+	
PTK7 protein tyrosine kinase 7 (PTK7)	1	U40271		+	+	+		+	
punnergic receptor P2X, ligand-gated ion channel, 4 (P2RX4)	3	AF000234		+	+	+		+	
purinergic receptor P2X, ligand-gated ion channel, 7 (P2RX7)	1	Y12851	+						macrophage only
puromycin-sensitive aminopeptidase (PSA)	1	Y07701		+	+			+	
putative ATP(GTP)-binding protein	2	AJ010842		+				+	
putative brain nuclearly- targeted protein (KIAA0765)	1	AB018308	+	+	+	+		+	
putative chemokine receptor; GTP-binding protein (HM74)	1	D10923	+						
putative dienoyl-CoA isomerase (ECH1)	1	AF030249							
putative G-binding protein	1	AF065393							
Putative human HLA class II associated protein I (PHAP1)	1	U73477	В	+			+		
Putative L-type neutral amino acid transporter (KIAA0436)	1	AB007896							
putative mitochondrial space protein 32.1	1	AF050198							
PUTATIVE MUCIN CORE PROTEIN PRECURSOR 24 (MULTI- GLYCOSYLATED CORE PROTEIN 24) (MGC-24) (MUC-24)	1	Q04900							
putative nucleic acid binding protein	2	X76302	+	+	+	+		+	
putative outer mitochondrial membrane 34 kDa translocase Htom34	1	U58970		+	+	+		+	
putative p150 (non-exact 88%)	1	U93568							
putative translation initiation factor (SUI1)	1	L26247	+	+	+	+	+	+	High in moderately differentiated colon adenocarcinoma
putative tumor suppressor protein (123F2)	1	AF061836		+	+	+		+	
pyrroline 5-carboxylate reductase	1	M77836	+	+	+	+		+	
pyruvate dehydrogenase (lipoamide) alpha 1 (PDHA1)	1	D90084		+	+	+	+	+	
pyruvate dehydrogenase (lipoamide) beta (PDHB)	2	J03576	+	+	+	+		+	
Pyruvate dehydrogenase complex, lipoyl-containing component X; E3-binding protein (PDX1)	. 3	Y13145		+	+				
pyruvate kinase, muscle (PKM2)	11	M23725							
RAB, member of RAS oncogene family-like (RABL)	1	U18420		+	+	+		+	
RAB1, member RAS oncogene family (RAB1)	3	M28209		+	+	+		+	
RAB11A, member RAS oncogene family (RAB11A)	2	X56740	+	+	+	+		+	high in spleen

RAB11B, member RAS	<del>- 1</del>							· F	C1/CA00/00005
oncogene family (Rab11B)		D45418		+				7	
RAB27A, member RAS oncogene family (RAB27A)	3	U38654				+		$\top$	
RAB5B, member RAS oncogene family (RAB5B)	1	X54871		+	++	+	╁╌	+	
RAB6, member RAS oncogene family (RAB6)	1	M28212	<del>                                     </del>	+	+	+	+	+	<del></del>
RAB7, member RAS	1	X93499	+		+	+	↓_	+	
oncogene family (RAB7) RAB7, member RAS	2	D84488			↓	<u> </u>	L		
oncogene family-like 1 (RAB7L1)	_	204488		+	+	+		+	
RAB9, member RAS oncogene family (RAB9)	1	U44103					<del>                                     </del>	+-	<del> </del>
RAD50 (S. cerevisiae) homolog (RAD50)	2	U63139		+	+	+	$\vdash$	+	
RAD51 (S. cerevisiae) homolog C (RAD51C)	1	AF029669		++	+	+	-	+	
Radin blood group (RD)	2	L03411		+	+	+		+	
RAE1 (RNA export 1, S.pombe) homolog (RAE1)	3	U84720	+	+	+	+	_	+	
ralA-binding protein (RLIP76)	2	L42542	+	+	+	+		┼	
RAN binding protein 2-like 1 (RANBP2L1)	2	AF012086						-	
Ran GTPase activating	3	X82260	+	++	+	+		+	
protein 1 (RANGAP1) RAN, member RAS	1	M31469						L	
oncogene family (RAN) (low match)					ļ				- Janes -
RanBP2 (Ran-binding protein 2) (=U19248;	1	D42063							
L41840 sapiens nucleoporin (NUP358))						Í			
ransforming growth factor, beta receptor II (70-80kD) (TGFBR2)	4	D50683	+	+	+	+		+	
RAP1A, member of RAS oncogene family (RAP1A)	10	M22995	+	+	+	+	+	+	·
RAR-related orphan receptor C (RORC)	1	U16997		+		$\dashv$		+	
RAS guanyi releasing protein 2 (calcium and DAG-regulated)	1	Y12336	+	+		$\dashv$			
ras homolog gene family	12	X05026	+	+	+	$\downarrow$	_		Mak :
ras homolog gene family	1	X61587	+				+	+	high in ovary
member G (rho G) (ARHG) ras homolog gene family,	- 2			+	+	+	-	•	
member H (ARHH) ras inhibitor (RIN1)		Z35227	+	+	+			+	
Ras-GTPase activating	2	M37191 AF053535		+					
protein SH3 domain- binding protein 2 (KIAA0660)	_	AF053535	+	+	+	+		+	
Ras-GTPase-activating protein SH3-domain-binding protein (G3BP)	3	U32519	+	+	+	+	+	+	
ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2) (RAC2)	11	M29871			+		+	+	
RAS-RELATED PROTEIN RAP-1B (GTP-BINDING PROTEIN SMG P21B)	1	P09526				$\dagger$	+		
RBQ-1	1	X85133		+ .	+   .	+	$\dashv$	$\dashv$	
rearranged T cell receptor beta variable region (TCRB) (=X58810)	1	L06891			_	+	$\dagger$		,
regulator of Fas-induced apoptosis (TOSO)	1	AF057557	В		+		+-	$\dashv$	
	<u></u>								

WO 00/40749									1/CA00/0000	
regulator of G protein signalling 6 (RGS6)	1	AF073920		+ 1						
regulator of G-protein Isignalling 14 (RGS14)	2	AF037195	+	+	+	+			<del></del>	
regulator of G-protein	6	L13391	+	+	+	+		+		
signalling 2, 24kD (RGS2) regulator of G-protein		O15539		1			1			
signalling 5 (RGS5) (49% aa)		W60307			+	+				
regulatory factor X, 4 (influences HLA class II	1	M69297			•					
expression) (RFX4) regulatory factor X, 5	2	X85786	T	+	+		一	7		
(influences HLA class II expression (RFX5)							$\perp$	+		
replication protein A1 (RPA1)		M63488	+	+	+	+				
replication protein A3 (14kD) (RPA3) (low match)	1	L07493								
reproduction 8 (D8S2298E)	1	D83767		+	+	+				
requiem, apoptosis response zinc finger gene (REQ)	2	U94585	+	+	+	+		+		
requiem, apoptosis response zinc finger gene (REQ) (=AF001433) (low match)	1	U94585					*			
restin (Reed-Steinberg cell- expressed intermediate	1	M97501	• В, Т	+	+					
filament-associated										
retinoblastoma 1 (including osteosarcoma) (RB1)	3	L11910	+	+	+	+				
retinoblastoma binding protein 2 homolog 1 (RBBP2H1)	1	AF087481								
retinoblastoma-binding protein 1 (RBBP1)	1	S66427	+	+						
retinoblastoma-binding protein 2 (RBBP2)	5	S66431	+	+	+	+		+		
retinoblastoma-binding protein 4 (RBBP4)	1	X71810		+	+	+		+		
retinoblastoma-binding protein 4 (RBBP4)	1	X74262	-	+	+	+		+		
retinoblastoma-binding protein 7 (RBBP7)	1	U35143								
retinoblastoma-like 2 (p130) (RBL2)	1	X76061		+	+	+		+		
retinoic acid receptor responder (tazarotene induced) 3 (RARRES3)	1	AF060228		+		+	+	+		
retinoic acid receptor, alpha (RARA)	1	X06538	+	+		+				
retinoic acid responsive (NN8-4AG)	.1	U50383		+		+		+		
retinoid X receptor beta (RXR-beta)	2	X66424		+	+	+		+		
REV3 (yeast homolog)-like, catalytic subunit of DNA polymerase zeta (REV3L)	1	AF035537								
Rho GDP dissociation inhibitor (GDI) beta (ARHGDIB)	23	L07916	+	+	+	+	+	+		
Rho GTPase activating protein 4 (ARHGAP4)	2	X78817	+	+						
Rho GTPase activating protein 4 (ARHGAP4) (low match)	1	P98171								
Rho-associated, coiled-coil containing protein kinase 2 (ROCK2)		AB014519								
ribonuclease 6 precursor (RNASE6PL)	2	U85625	+	+	+	+	+	+		
			21							

ribonuclease 6 precursor	1 1	Blotzalata							PCT/CA00/0	0005
(KNASE6PL) (low match)		U85625								
ribonuclease, RNase A family, 2 (liver, eosinophil-	1	X55988					-	+	_	
(RNASE2)										
ribonuclease/angiogenin inhibitor (RNH)	3	M36717	+	<del>-   -</del>		+	+		+	
ribonucleoside diphosphate reductase M1 subunit		X65708			$\top$	_				
ribonucleotide reductase M2 polypeptide (non-exact 91%)	1	P31350		+		$\uparrow$		$\dashv$		
nbophorin I (RPN1)	1	Y00281	+	+	+	-	+	-	+	
ribophorin II (RPN2)	1	Y00282	+	<del>-   -</del>				+	+	
ribosomal 18S rRNA	3	M10098	<del> </del>			+	+	+	<del>-</del>	
ribosomal 28S RNA	1	M11167		_	+-	-		-		
nbosomal phosphoprotein P0. 5'UTR (low match) Ribosomal protein	1	D28418			$\dagger$	+	+	+	<del></del>	<del></del>
nbosomal protein L10	1				1	1	_	+		
(RPL10) RIBOSOMAL PROTEIN	30	L25899	+	+	7	•	-	+	+ high in mar	y librane
L10A (CSA-19)	2	P53025				_	+	+		
ribosomal protein L11 (RPL11)	4	X79234	+	+	+	+-	+ -	-	Alveolar	
ribosomal protein L12 (RPL19)	2	L06505	+	+	+	+	+-	-   -	rhabdomyo	sarcoma
nbosomal protein L13 (PRL13)	1	P26373	+	+	+	+	+-	+:	high in man	y libraries
ribosomal protein L14 (RPL14)	4	D87735	+	+	+	+	++	+	high in man	y libranes
ribosomal protein L17 (RPL17)	4	X53777	+	+-	-	-	+	+	blood only	<del></del> -
ribosomai protein L18 (RPL18)	10	L11566	+	+	+	++	+	╁		
ribosomal protein L18a (RPL18A)	5	L05093		+	+	+	+	++		adrenal
ribosomal protein L18a homologue	2	X80821		+	-	+	+	+	gland and si	<u>cin</u>
ribosomal protein L19 (RPL19)	15	X63527	+	+	+	+	+	╅	<del> </del>	
ribosomal protein L21 (RPL21)	6	U14967	+	++	+	+	+	+		
ribosomal protein L22 (RPL22)	3	D17652	+	+	+	+	-	+	<del> </del>	
ribosomal protein L23 (RPL23)	2	X55954	+	+	+	+	+	+	high in many	libraries
ribosomal protein L23a (RPL23A)	5	U37230	+	+	+	+	+	+	high in many	
ribosomal protein L26 (RPL26)	8	X69392	+	+	+	+	+	+	-	
ribosomal protein L27 (RPL27)	6	L05094	+	+	+	+	-	+		
nbosomal protein L27a (RPL27A)	10	U14968	+	+	+	+	+	+		
ribosomal protein L28 (RPL28)	6	U14969	+	+-	+	+		+		
ribosomal protein L29 (RPL29)	6	U10248	+	+	+	+	+	+		
ribosomal protein L3 (RPL3)	81		+	+-	+	+	+	+	high in many	beenes
nbosomal protein L3	81	X06323								
nbosomal protein L30 (RPL30)	6	X79238	+	+	+	+		+	high in lymphi	)ma
ibosomal protein L30 (RPL30) (low score)	1	X79238	·				-		gympni	7/11d
ibosomal protein L31 RPL31)	10	X15940	+		+	+	+	+	High in object	
2017									High in alveolation in the high in alveolation in the high in alveolation in the high in the high in the high in alveolation i	Coma

WO 00/40749								PC	T/CA00/00005
osomal protein L32	3 1	X03342	+	+	+	+	+	+	
PI 32)		AF047440		+	+	+		+	
osomal protein L33-like PL33L)	5	L38941		+	+	+	+	+	
posomal protein L34 (PL34)									
posomal protein L34 RPL34) (low match)	1	L38941					+	+	high in barstead
posomal protein L37	5	D23661	+	+	+	+		. 1	prostate
RPL37) posomal protein L37a	4	X66699	+	+	+	+	+		high in many libraries high in many libraries
posomal protein L38 PRL38)	1	Z26876	+	+	+				high in many libranes
posomal protein L4	27	D23660	+	+	+	+	+		
RPL4) bosomal protein L41	4	AF026844	+	+	+	+	+	+	high in many libraries
RPL41) bosomal protein L5	14	U14966	+	+	+	+	+	+	High in alveolar rhabdomyosarcoma
RPI 5)	- 1	U14966		1-1					masac, co
bosomal protein L5 RPL5) (low match)		X69391	+	++-	<del></del>	+	+	+	high in many libranes
bosomal protein L6 RPL6)	7		<del></del>	+-	+	+	+	+	high in conorm
bosomal protein L7	14	X52967						١	High in uterus, and
bosomal protein L7a	15	M36072	+	+	+	+	+	+	seminoma
RPL7A) ibosomal protein L8	5	Z28407	· +	+	+	+	+	+	high in ovary
RPL8) ibosomal protein L9	10	U09953		+	+	+	+	+	
RPL9) ibosomal protein S10	- 5	U14972	+	++	+	+	+	+	high in many libranes
(RPS10)	4	X06617	+	++	+	+	+	+	high in many libranes
ribosomal protein S11 (RPS11)	·	AB007152				+	-	+-	
ribosomal protein S11 (RPS11) (low match)	-11			+	+	+	+	+	high in many librarie
nbosomal protein S12 (RPS12)	3	X53505	+					1	,
ribosomal protein S13	2	L01124		+	+	+	+		
(RPS13) nbosomal protein S14	12	M13934	+	+	+	+	T+	+	
(RPS14) ribosomal protein S15	2	M32405	+	+	+	+	+	+	
(RPS15) ribosomal protein S16		M60854	+	+	+	+	+	+	High in prostate invasive tumor
(RPS16)		M13932	+	+	+	+	╁	++	
(RPS17)		X69150			┼-	╀	+	╁	
ribosomal protein S18	8	M81757	+	+	+	+	+	+	high in many librane
(RPS19)	4	X17206	<del></del>	+	+	+	+-	. +	high in many librarie
ribosomal protein S2 (RPS2)				_	_	_	+	- -	
RIBOSOMAL PROTEIN S2 (RPS4)	2	P15880				۰	.   .		high in many librarie
ribosomal protein S20 (RPS20)	7	L06498	+	+	+				
ribosomal protein S21 (RPS21)	3	L04483	+	+	+	1		-	hematopoietic cells and skin tumor
ribosomal protein S23	3	D14530	1	+	1			1	+
(RPS23) ribosomal protein S24	7	M31520	+	+	+-	-   -	+	+	+ high in uterus
(RPS24) ribosomal protein S25	3	M64716	+	+	+-	-	+	+	+ high in barstead
(RPS25)	2	X69654	+	<del>-   -</del>		+	+	+ -	+ prostate
ribosomal protein S26 (RPS26)			+			+	+	++	+
ribosomal protein S27 ((metallopanstimulin 1) (RPS27)	5	U57847							

## PCT/CA00/00005

ribosomai protein S28	7 - 7								P	C1/CA00/00005
(RPS28)	3	U58682	+		+	+	+		+	
ribosomal protein S29 (RPS29)	2	U14973	+		+ †	+	+	+	+	
nbosomal protein S3 (RPS3)	9	X55715	+	7	+	+	+	+	+	high in many librani
ribosomal protein S3 (RPS3) (low match)		U14990		一				-	+-	
nbosomai protein S3A (RPS3A)	21	Z83334			+	+	+	+	+	high in many librarie
ribosomal protein S3A (RPS3A) (low score)	1	M77234		$\dashv$	+	_			-	
ribosomal protein S4, X- linked (RPS4X)	9	M58458	+	<del>- -</del>	- +	<del>+                                    </del>	+		+	high in ovary and
ribosomal protein S4, Y- linked (RPS4Y)	2	M58459	+-+	<del>-   -</del>	-	+ +	+	+	+	Synovial sarcoma
ribosomal protein S5 (RPS5)	4	U14970	+ +	+	+	+-	+	+	+	high in lymphoma
RIBOSOMAL PROTEIN SE (PHOSPHOPROTEIN NP33)	1	P10660	<del>                                     </del>	+	+	+				,,,,,
ribosomal protein S6 (RPS6)	22	M20020	+	+	+	-	+	+	+	
ribosomal protein S6 (RPS6) (non-exact 86%)	1	M77232		+	+	-	+	$\dashv$	$\dashv$	
ribosomal protein S6 kinase, 90kD, polypeptide 1 (RPS6KA1)	3	L07597	+	+	-	+	+	-	+	
ribosomal protein S6-kinase, 90kD, polypeptide 2 (RPS6KA2)	1	X85106			$\dagger$	+	$\dagger$	_		
ribosomal protein S7 (RPS7)	4	Z25749		+	+	╅	+	+	+	# 14·1
ribosomal protein S8 (RPS8)	6	X67247		+	++	+-	+	+	+	<u> </u>
ribosomal protein S9 (RPS9)	8	U14971			+	+-	+			colon tumor
nbosomal protein, large, P0 (RPLP0)	18	M17885	T	-	+	+-	+	$\dashv$	+	
ribosomal protein, large, P1 (RPLP1)	12	M17886	<del></del>	+	+	+	+-	+	_	
ibosomal RNA 18S =M10098; K03432) =polyadenylating sequence)	11	X03205		-			-	-		
ibosomal RNA 28S	2	M11167		+	-	+	+	+		
ibosomal RNA, 16S	1	U25123		+	<del>                                     </del>		┿	+	-	·
ing finger protein (non- exact 58%)	1	AJ001019		-	-	+	+	+	+	
ng finger protein 3 (RNF3)	1	AJ001019		-		┼-	╄-	+		
ng finger protein 4 (RNF4)	3	AB000468		+	+	+	╄	+-	+	
ng zinc-tinger protein ZNF127-Xp)	3	U41315		+	+	+	-	+-		
NA (guanine-7-) nethyltransferase (RNMT)	1	AB007858	<del></del>	+	+	+	$\vdash$	+-		
NA binding motif protein 5 RBM5)	4	U23946	+	+	+	+	-	╅	+	
NA binding motif, single tranded interacting protein (RBMS2)	1	D28483		+		+		+	+	
NA helicase (putative), Myc-regulated DEAD box otein) (MRD8)	1	X98743	+	+	+	+	_	+	+-	
NA helicase-related otein	1	AF083255		++	+	+		+	+	
NA pol II largest subunit	2	X74872		<del>                                     </del>				╀	+-	
NA polymerase I subunit PA40)	1	AF008442		+	+			+	+-	
VP-1 protein	2	X91911	+	+	+	+		+	4	

M81457	WO 00/40749									
X80201	rotein A10 (annexin II gand, calpactin I, light	2	M81457			+		+	+	
X80201	signature (p11))	İ								
M80563   B	100 calcium-binding protein A11 (calgizzarin)	7	X80201		+	+	+		+	
M21005	5100 calcium-binding protein A4 (calcium protein, calvasculin, metastasin, murine placental	3	M80563	В		+		+		
S100A8    S100 Calcum-binding   14	5100 calcium-binding	7	M21005			+	+		+	high in bone marrow
ST64 gene	S100 calcium-binding	14	X06233	<del></del>		+	+			high in invasive larynx squamous cell
ST64 gene	(S100A9)									carcinoma
S-adenosylmethionine decarboxylase 1 (AMD1) SB classil histocompatibility antigen alpha-chain SC35-interacting protein 1 (SRRP129) Scaffold attachment factor B (SAFB) (SC3F) (non-exact 78%) Scaffold attachment factor B (SAFB) (non-exact 78%) ScRNA molecule, transcribed from Alu repeat SEC14 (S. Cerevisiae)-like C (SEC14L) SEC23-like protein B 2 X97065 + + + + + + + + + + + + + + + + + + +	S164 gene	•								
histompatibility antigen alphacchain is approachain is approachain is C2S-interacting protein 1 (GRRP129)	decarboxylase 1 (AMD1)									
SC35-interacting protein 1 (SCARP129)   5	histocompatibility antigen	5	M2/48/	<b>.</b>						
1	SC35-interacting protein 1	5	AF030234	+		+	+	+		
scartola attachment factor B (SAFB) (non-exact 78%) scRNA molecule, 1 transcribed from Alu repeat SEC14 (S. cerevisiae)-like (SEC14(S. cerevisiae)-like (SEC14(S. cerevisiae)-like (SEC14(S. cerevisiae)-like (SEC23-like protein B (SEC23-like protein B (SEC23B)	scaffold attachment factor	1		. +	+	+	+		+	
ScRNA molecule, transcribed from Alu repeat SEC14 (S. cerevisiae)-like (SEC14 (S. cerevisiae)-like (SEC14L) SEC23-like protein B (SEC23-like protein B (SEC23-like protein B (SEC23B)	scaffold attachment factor	1								
SEC14 (S. cerevisiae)-like (SEC14L)	scRNA molecule,	1								
SEC23-like protein B   2   X97065   +	SEC14 (S. cerevisiae)-like	4	D67029							-
SEC63 (SEC63)   1	SEC23-like protein B	2		+			+			
Secreted protein, acidic, cysteine-rich (osteonectin) (SPARC)   Secretory carner membrane protein 1	SEC63 (SEC63)	1	1					<u> </u>		high in hono marrow
Secretory carrier membrane protein 1	cysteine-rich (osteonectin)	7				+		_	_	
Secretory carmer membrane protein 2 (SCAMP2)   Secretory carmer membrane protein 3 (SCAMP3)   Secretory granule proteoglycan core (clones lambda-PG[6,7,8])   Selectin L (lymphocyte adhesion molecule 1) (SELL)   Selectin P ligand (SELPLG)   13   U02297   + +   +   +   +   +   +   +   +   +	secretory carner membrane protein 1	1								
secretory carrier membrane protein 3 (SCAMP3) secretory granule proteoglycan core (clones lambda-PG[6,7,8]) selectin L (lymphocyte adhesion molecule 1) (SELL) selectin P ligand (SELPLG) selectin P ligand (SELPLG) sema domain, (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D (SEMA4D) Ser/Arg-related nuclear matrix protein (plenty of prolines 101-like) (SRM160) serine palimitoyltransferase subunit I (SPTI) senine palimitoyltransferase, 1 AB011098 + + + + + +	secretory carner membrane protein 2	1	AF005038	+	+	+	+	_		
secretory granule proteoglycan core (clones lambda-PG[6,7,8]) selectin L (lymphocyte adhesion molecule 1) (SELL) selectin P ligand (SELPLG) 13 U02297 + +	secretory carrier membrane protein 3	1	AF005039							
selectin L (lymphocyte adhesion molecule 1) (SELL) selectin P ligand (SELPLG) 13 U02297 + + + + + + + + + + + + + + + + + + +	secretory granule proteoglycan core (ciones	1	M33649							
selectin P ligand (SELPLG) 13 U02297 + + + + + + + + + + + + + + + + + + +	selectin L (lymphocyte adhesion molecule 1)	43	X17519	+			+		+	
sema domain, immunoglobulin domain (lg), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D (SEMA4D)  Ser/Arg-related nuclear domain (plenty of prolines 101-like) (SRM160)  serine palmitoyltransferase 1 y08685 + + + + + + + + + + + + + + + + + + +		13	U02297	+	+					
Ser/Arg-related nuclear 4 AF048977 + + + + + + + + + + + + + + + + + +	immunoglobulin domain (lg), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D	2	U60800		+		+		+	
(SRM160)	Ser/Arg-related nuclear matrix protein (plenty of	4	AF048977		+	+	+	+	1	
subunit I (SPTI) senne palmitoyltransferase, 1 AB011098 + + + + + +	(SRM160) serine palmitoyltransferase	1	Y08685	<del>                                     </del>	+	+	+	+	+	
subunit II (LCB2)	subunit I (SPTI) senne palmitoyltransferase,	1	AB011098	+	+	+	+	+	+	-

## PCT/CA00/00005

senne protease	1	J02907			_	-	—	1				
serine protease inhibitor,	1	U78095	+	-	_	+	+		<del>-</del>			
Kunitz type, 2 (SPINT2) senne/threonine kinase 10	+	AB015718	<del>                                     </del>									
(STK10) serine/threonine kinase 19	-			_   *		+	+	-	+			
(STK19)		L26260	+	7	T	+	+					
serine/threonine kinase 4 (STK4)	1	U18297		+	+	$\dashv$	$\exists$	$\dashv$	+			
senne/threonine protein kinase KKIALRE (KKIALRE)	1	X66358		+	$\dagger$	+	+		+			
serine/threonine protein- kinase (NIK)	1	Y10256		+	+-	+	++	-+				
SERINE/THREONINE- PROTEIN KINASE RECEPTOR R3 PRECURSOR (SKR3)	1	P37023			-							<del></del> .
serologically defined colon cancer antigen 16 (NY-CO-16)	2	AF039694			-	+	+	$\dashv$	+	<del></del>		
serologically defined colon cancer antigen 33 (SDCCAG33)	1	AF039698	В, Т	+	+		$\dagger$	+	+			
serologically defined colon cancer antigen 33 (SDCCAG33) (low score)	1	AF039698			$\dagger$		$\dagger$		+			
serologically defined colon cancer antigen 33 (SDCCAG33) (low score) serum deprivation	1	AF039698	•				+		+			
esponse phosphatidylserine-binding protein) (SDPR) (≐S67386)		AF085481.1							+			-:-
serum/glucocorticoid regulated kinase (SGK)	2	Y10032	+	+	+	+	+	+	+		<del></del>	
SET domain, bifurcated 1 (SETDB1)	2	D31891	+	+	+	+	+	┿	+			<u> </u>
SH2 domain protein 1A, Duncan's disease ymphoproliferative yndrome) (SH2D1A)	1	AF073019	1			-	+	+				
H3 binding protein (SAB)	2	AB005047	+	+-+-	+	++	+-	++	- -			
H3 domain protein 1B SH3D1B)	4	U61167	+	+		+	+-	+				
H3BGR PROTEIN (=21- GLUTAMIC ACID-RICH ROTEIN;21-GARP) (non- xact 82%aa)	1	P55822										
H3-binding domain lutamic acid-rich protein ke (SH3BGRL)	1	AF042081	+	+	+	+		+	+			
H3-domain GRB2-like 1 SH3GL1)	1	U65999	+	+	+	+	$\vdash$	+	╁╴			<del></del>
HC (Src homology 2 omain-containing) ansforming protein 1 HC1)	2	X68148		+	+	+		+			<del> </del>	
ah binding protein 1 SiahBP1)	2	U51586		+	+	+	_	+	-			
ah binding protein 1 iahBP1) (non-exact, %)	1	U51586						-	-			
alomucin CD164 D164)	9	D14043		<del>                                     </del>				-	├-			
alophorin (gpL115, ukosialin, CD43) (SNP)	2	J04536		}				-	<u> </u>			
alyltransferase (STHM)	1	U14550	·						L			
alyltransferase 1 (beta- lactoside alpha-2,6- alytransferase) (SIAT1)	2	X17247	+ .	+	+	+	+	++				

WO 00/40/49									
sialyltransferase 4A (beta- galactosidase alpha-2,3- sialytransferase) (SIAT4A)	1	AF059321	В	+	+		+	+	
sialyltransferase 8 (alpha- 2, 8-polysialytransferase) D	1	L41680		+					
(SIAT8D) signal peptidase 25kDa subunit	1	L38950							
signal recognition particle 14kD (homologous Alu RNA-binding protein) (SRP14)	1	X73459	+	+	+	+	+	+	
signal recognition particle 54kD (SRP54)	1	U51920			+	+		+,	
signal recognition particle 9kD (SRP9)	2	U20998		+	+	+	+	+	
signal recognition particle receptor ('docking protein') SRPR	5	X06272							
signal regulatory protein, beta, 1 (SIRP-BETA-1)	5	Y10376		+				+	
signal sequence receptor, alpha (translocon- associated protein alpha) (SSR1)	2	Z12830				+		+	
signal sequence receptor, beta (translocon- associated protein beta) (SSR2)	2	X74104	+	+	+	+		+	
signal transducer and activator of transcription (STAT5A)	4	L41142	+	+	+	+	+	+	
signal transducer and activator of transcription 2, 113KD (STAT2)	1	U18671						+	
signal transducer and activator of transcription 3 (acute-phase response factor) (STAT3)	3	L29277							·
signal transducer and activator of transcription 5A (STAT5A)	2	U48730	+	+	+	+	+	+	
signal transducing adaptor molecule (SH3 domain and ITAM motif) 1 (STAM)	1	U43899					)		·
silencing mediator of retinoid and thyroid hormone action (SMRT)	1	U37146							
similar to beta-transducin superfamily proteins (SAZD)	1	U02609	+	+	+			+	
similar to S. cerevisiae SSM4 (TEB4)	1	AB011169		+	+	+		+	
similar to yeast pre-mRNA splicing factors, Prp1/Zer1 and Prp6	1	AF026031	+	+	+	+		+	
SIT protein	1	AJ010059.1							
Sjogren syndrome antigen A1 (52kD, ribonucleoprotein	2	M62800					+		
autoantigen SS-A/Ro) (SSA1)									
Sjogren syndrome antigen A1 (52kD, ribonucleoprotein autoantigen SS-A/Ro) (SSA1) (non-exact 63%) (match to zinc finger)	1	M62800		-					
SKAP55 homologue (SKAP-HOM)	1	AJ004886		+	+	+		+	
skb1 (S. pombe) homolog (SKB1)	2	AF015913	+	+	+	+		+	

## PCT/CA00/00005

skeletal muscle abundant	1	X87613	<del></del>		- 1					CT/CA00/00005
protein SMA3 (SMA3)	<del> </del>				+	+	+		+	
small acidic protein	1	X83300	<del>-</del>		+		+	+-	+	<del></del>
small EDRK-rich factor 2	3	U51678	+		+ +	+	+	<del> </del>	+	<del> </del>
(SERF2) small inducible cytokine A5	2	Y10351	_		+	+	+	+	+	high in fetal lung
I(RANTES) (SCYA5)		M21121	+		+	+	+	+	+	high in many librar
small inducible cytokine subfamily C, member 2 (SCYC2)		D63789				$\neg$				
small nuclear ribonucleoprotein polypeptide B" (SNRPB2)	2	M15841	<del>                                     </del>	-	+	+	+		+	
small nuclear ribonucleoprotein polypeptide N (SNRPN)	4	J04615	+	+-		+	+	+	+	
small nuclear ribonucleoprotein polypeptides B and B1 (SNRPB)	2	J04564	+	+	-	+	+		+	
small nuclear RNA activating complex, polypeptide 5, 19kD (SNAPC5)	1	AF093593	+	+	-		+		+	
smallest subunit of ubiquinol-cytochrome c eductase	1	D55636	+	+	+	+	+	+	+	high in fetal lung
SMC (mouse) homolog, X chromosome (SMCX)	1	L25270	+	+	+	+	-	$\dashv$	+	
SMT3B protein (2)	2	X99585	+	+	┵		+	++	+	
SNARE protein (YKT6) low match)	1	U95735		+	+	+	+		-+	· · · · · · · · · · · · · · · · · · ·
SNC19	1	U20428	<del> </del>	+	+-			4		
NC73 protein (SNC73)	2	J00220	<del>                                     </del>	┿	┼	+,	-	+		-
olute carrier family 1 neutral amino acid ansporter), member 5 SLC1A5)	2	U53347		+	-	1	L_	+	+	nigh in many libraries
olute carner family 11 proton-coupled divalent netal ion transporters), nember 1 (SLC11A1)	7	D50403	+		ļ		-	$\dagger$		
plute carner family 17 codium phosphate), ember 3 (SLC17A3)	1	U90545				+	+	+	+	
Diute carrier family 19 plate transporter), ember 1 (SLC19A1)	1 .	U17566	B. lymphoma	+		$\dagger$	+	+	$\dashv$	
plute carrier family 2 acilitated glucose ansporter), member 1 LC2A1)	1	K03195	+	+	+	+	+	+-	+	
olute carrier family 23 ucleobase transporters), ember 2 (SLC23A2)	3	D87075		+	+	+	+	+	+	
lute carner family 25 intochondrial carner; oglutarate carner), ember 11 (SLC25A11)	1	AF070548	В, Т	+	+		+		+	
pper transporters), ember 2 (SLC31A2) ute carrier family 4,	3	U83461		+		+		+	+	
erythrocyte membrane otein band 3-like 1)	1	X62137		+	+			+		
_C4A2) ute carrier family 4.		j .								

91

WO 00/40749								- 1	C1/CA00/00005
solute carrier family 7 (cationic amino acid	2	M80244	T, <b>VV</b>	+	+		+		·
transporter, y+ system), member 5 (SLC7A5)							L		
solute carrier family 7 (cationic amino acid transporter, y+ system),	3	D87432	+	+	+			+	
member 6 (SLC7A6)								L.,	
solute carner family 7 (cationic amino acid	1	D87432							
transporter, y+ system), member 6 (SLC7A6) (non- exact 77%)									
solute carrier family 9 (sodium/hydrogen exchanger), isoform 6	1	AF030409		+	+	+		+	-
(SLC9A6) somatic cytochrome c		M22877		-					
(HCS)	2	M228//							
SON DNA binding protein (SON)	2	X63753		+	+	+		+	
son of sevenless (Drosophila) homolog 1 (SOS1)	1	L13858	+	+		+			
sorcin (SRI)	1	M32886							
sortilin 1 (SORT1)	2	X98248		+		+		+	
sortilin-related receptor, L(DLR class) A repeats- containing (SORL1)		Y08110							·
sorting nexin 1 (SNX1)	3	U53225	+	+	+	+		+	
sorting nexin 2 (SNX2)	2	AF043453							
sorting nexin 6 (SNX6) (=U83194.1 TRAF4- associated factor 2)	1	AF121856.1							
Sp3 transcription factor (SP3)	1	X68560	+	+	+	+		+	
Sp3 transcription factor (SP3)	4	M97191	+	+	+	+		+	
special AT-rich sequence binding protein 1 (binds to nuclear matrix/scaffold- associating DNA's) (SATB1)	1	M97287							
speckle-type POZ protein (SPOP)	4	AJ000644							
speckle-type POZ protein (SPOP) (non-exact)	1	AJ000644							
spectrin SH3 domain binding protein 1 (SSH3BP1)	6	U87166	+	+	+	+			
Spectrin, alpha, non- erythrocytic 1 (alpha-fodrin) (SPTAN1)	2	J05243		+	+			+	
spermidine/spermine N1- acetyltransferase (SAT)	11	M55580							
spermidine/spermine N1- acetyltransferase (SAT) (non-exact, 84%)	1	U40369							
spermine synthase (SMS)	1	AD001528	+	+	+	+		+	
SPF31 (SPF31)	1	AF083190	+	+	+	+		+	
sphingomyelin phosphodiesterase 1, acid lysosomal (acid sphingomyelinase) (SMPD1)	1	X52679		+	+		+		
SPINDLÍN HOMOLOG (PROTEIN DXF34)	1	Q99865			·				
spinocerebellar ataxia 1 (olivopontocerebellar ataxia 1, autosomal dominant, ataxin 1) (SCA1)	3	X79204	В	+			+		1 ¥ 1

									CI/CA	00/000	103
spinocerebellar ataxia 2 (olivopontocerebellar ataxia 2, autosomal dominant,	1	U70323	В				+				
ataxin 2) (SCA2) spinocerebellar ataxia 7	2	A 1000E47		<u> </u>		<u> </u>	$oldsymbol{ol}}}}}}}}}}}}}}}}}}$		<u> </u>		
(olivopontocerebellar atrophy with retinal degeneration) (SCA7)	2	AJ000517		+							
spliceosome associated protein (SAP 145)	3	U41371		+	+	+	+	+			<u>-</u>
splicing factor (CC1.3) (CC1.3)	2	L10910	+	+	+	+	+	+			<del></del>
splicing factor SRp40-1 (SRp40)	7	U30826	+	+	+	+	+	+			
splicing factor, arginine/serine-rich 11 (SFRS11)	3	M74002	В	+	+		+	+			
splicing factor, arginine/serine-rich 7 (35kD) (SFRS7)	4	L41887		+	+	+		+			
Src-like adapter protein (non-exact, 76%aa)	1	U30473									
Src-like-adapter (SLA)	6	D89077		+	+	+		+			
Src-like-adapter (SLA) (low match)	1	D89077									
Src-like-adapter (SLA) (low score)	1	U44403									
stannin (SNN)	2	AF030196	. +	+	+	+		+			
STAT induced STAT inhibitor 3 (SSI-3)	1	AB004904				+					
STE20-like kinase 3 (MST-3)	2	AF024636	+	+	+	+		+			·
step II splicing factor SLU7 (SLU7)	1	AF101074		+		+	+	+		· · ·	•
steroid sulfatase	1	M17591		<del> </del>		-				<del></del>	<del></del>
steroid suffatase (microsomal), arylsulfatase C, isozyme S (STS)	1	J04964		+	+	+					
sterol carrier protein 2 (SCP2)	1	M55421		+	+	+	+	+			
sterol O-acyltransferase (acyl-Coenzyme A: cholesterol acyltransferase) 1 (SOAT1)	1	AF059202					+		··· <u>·</u>	-	
stimulated trans-acting factor (50 kDa) (STAF50)	6	X82200	+	+		+					
Stnatin, calmodulin-binding protein (STRN) (low match, 71%aa)	1	U17989							·		
Stromal antigen 2 (STAG2)	2	Z75331		1	+	+	++	+			
stromal interaction molecule 1 (STIM1)	3	U52426	+	+	+	+	$\neg \dagger$	+			
structure specific recognition protein 1 (SSRP1)	1	M86737	-	+	+	+	+	+			
succinate dehydrogenase complex, subunit A, flavoprotein (Fp) (SDHA)	5	L21936			+			$\dashv$			
succinate dehydrogenase complex, subunit B, iron sulfur (lp) (SDHB)	1	U17248	+	+	+	+	-	+			
succinate dehydrogenase complex, subunit C, integral membrane protein, 15kD (SDHC)	1	U57877	+	+	+	+		+			
succinate dehydrogenase complex, subunit D, Integral membrane protein (SDHD)	3	AB006202		+	+		+				
succinate-CoA ligase, GDP-forming, beta subunit (SUCLG2)	1	AF058954		+	+	+	+	+			
		03									

<b>WO 00/40749</b>								PC	T/CA00/00005
succinyl CoA synthetase	1	Z68204				1			
sudD (suppressor of bimD6, Aspergillus nidulans) homolog (SUDD)	2	AF013591		+			+	+	
sulfotransferase family 1A, phenol-preferring, member 1 (SULT1A1)	1	L19999		+			+	+	
sulfotransferase family 1A, phenol-preferring, member 3 (SULT1A3) (non-exact 67%)	1	U37686	<del> </del>						
superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) (SOD1)	4	X02317		+	+		+	+	
superoxide dismutase 2, mitochondrial (SOD2)	5	Y00985		+	+	+	+	+	
supervillin (SVIL)	2	AF051851			+	+		+	
suppression of tumorigenicity 5 (ST5)	2	U15131		+		+		+	
suppression of tumorigenicity 5 (ST5) (non-exact 82%)	1	U15779							
suppressor of K+ transport defect 1 (SKD1)	1	AF038960			+	+			
suppressor of Ty (S.cerevisiae) 3 homolog (SUPT3H)	1	AF064804	+	+	+	+		+	
suppressor of Ty (S.cerevisiae) 4 homolog 1 (SUPT4H1)	2	U38817	- +	+	+	+		+	
suppressor of Ty (S.cerevisiae) 5 homolog (SUPT5H)	2	U56402		+				+	
suppressor of Ty (S.cerevisiae) 6 homolog (SUPT6H)	2	U46691	+	+	+	+	+	+	
suppressor of variegation 3-9 (Drosophila) homolog 1 (SUV39H1)	1	AF019968		+	+	+			
survival of motor neuron 1, telomeric (SMN1)	1	U18423							
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 (SMARCA1) (non-exact, 75%)	1	M88163			+	+		+	
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2)	2	D26155		+					
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (SMARCA4)	1	D26156	+	+	+	+	+	+	
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, member 2 (SMARCC2)	4	U66616	+	+	+	+	+	+	
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1 (SMARCE1)	2	AF035262	B, W	+	+		+	+	
synaptobrevin-like 1 (SYBL1)	1	X95803		Ŧ	+	+		+	
synaptosomal-associated protein, 23kD (SNAP23)	2	AJ011915	·	+	+	+		+	
syndecan binding protein (syntenin) (SDCBP)	15	AF006636	+	+	+	+		+	

WO 00/40/49								P	PCT/CA	100/00	005
synovial sarcoma, translocated to X chromosome (SSXT)	2	X79201		+	T		T				
syntaxin 16	<del>                                     </del>	AF038897	<del></del>		┷						
syntaxin 3A (STX3A)	2	U32315					$\perp$				
syntaxin 6 (STX6)	1 1			+		+		+	1.		
SYNTAXIN BINDING		AJ002078.1			T	$\neg \vdash$					
PROTEIN 3 (UNC-18 HOMOLOG 3) (UNC-18C)	1	000186	1		T		$\top$	1			
syntaxin-16C	1	AF008937	<del></del>		—		—				
SY1 interacting protein		AF080561	<del></del>		↓_				<b>⊥</b>		
(SIP) T cell activation, increased	4	M88282		+.	+			+			
late expression (TACTILE)  T cell receptor V alpha	2	X58744			_	+					
gene segment V-alpha-7 (clone IGRa11)	_	7,00744									
T cell receptor V alpha gene segment V-alpha-w27	1	X58740	†	+-	<del> </del>	+-	+-	+-	<del> </del>		
13 receptor-associating	5	583390	+	+	+	+-	╀-	+	<u> </u>		
cofactor-1				7	•	+	+	+	1		-
tafazzin (cardiomyopathy, dilated 3A (X-linked); endocardial fibroelastosis 2; Barth syndrome) (TAZ)		X92763	+	+		+		+			
TAFII100 protein (non- exact 53%)	1	U80191	<del> </del>		-	+	+-	+			
tankyrase, TRF1-	1	AF082556	<del> </del>		<u> </u>	<del> </del>	<del></del>				
interacting ankyrin-related ADP-ribose polymerase (TNKS)		7 11 332333		+	+	+		+			-£
TAP1, TAP2, LMP2, LMP7 and DOB	1	X66401				+	<del>                                     </del>	+			
TAR DNA-binding protein- 43	6	U23731	+	+	+	+	$\vdash$	+			
Tat interactive protein (60kD) (TIP60)	2	U40989	+	+	+	+	_	+			a\$t_
TATA box binding protein (TBP)-associated factor, RNA polymerase II, C1, 130kD (TAF2C1) (non- exact, 55%)	1	000268									
TATA box binding protein (TBP)-associated factor, RNA polymerase II, F, 55kD (TAF2F)	4	X97999		+	+	+	+	+			
TATA box binding protein (TBP)-associated factor, RNA polymerase II, G, 32kD (TAF2G)	2	U21858		+	+	+	+	+			
TATA box binding protein (TBP)-associated factor, RNA polymerase II, I, 28kD (TAF2I)	1 -	D63705	+	+	+	+		+			
Tax1 (human T-cell eukemia virus type I) pinding protein 1 TAX1BP1)	1	U33821		+	+	+	+	+			
I-box 2 (TBX2) (non-exact 77%)	1	U28049		1 1	+	+		+	<del></del>		
BP-associated factor 172 TAF-172)	1	AJ001017		+	$\dashv$	+	-	+			
-cell death-associated gene 8 (TDAG8)	1	U95218		+		+	-	-			
-cell leukemia/lymphoma A (TCL1A)	1	X82240	+	1	$\dashv$	-+	-+	+	<del></del>		
-cell leukemia/lymphoma A (TCL1A) (low match)	1	X82240		<del>                                      </del>	-	_	$\dashv$	+			
-cell receptor (delta D2-											

***************************************								•	CITCAOOTOOOGS
T-cell receptor (V beta 5.1,	1	M97705		T	T	T	T	T	
J beta 1.5, C beta 1) (low match)				İ					
T-cell receptor alpha delta	2	AE000662		+-	┼	+	┿	╄	<del> </del>
(=M94081)	_	ALUUUUUZ							
T-cell receptor alpha	1	B39625				$\top$			
enhancer-binding protein, short form (=X58636				}			1	1	
Mouse LEF1 lymphoid				1			1	l	
enhancer binding factor 1				1		1			
(=D16503))				İ		1	1	ì	Į.
T-cell receptor delta gene	1	M22197		+	$\vdash$	+	1	1	
D2-J1-region, clone K3B				1					
T-cell receptor germline	1	M11955						1	
beta chain gene V-region				1	i	1		ŀ	
(V) V-beta-MT1-1 T-cell receptor germline		M14159		<del></del>		↓	-	<b> </b>	
beta-chain gene J2.1 exon	1	M14159	+		1		•		only in blood
1-cell receptor germline	2	M22152		+		┿	+	├	
delta-chain D-J region	_						I	l	
T-cell receptor interacting	2	AJ224878		<b>—</b>		1	1	+	
molecule (TRIM) protein						1	<u>L</u>		
T-cell receptor rearranged	1	M21784							
delta-chain, V-region (V- delta 3-J)					1	İ			
T-cell receptor, alpha	3	AE000660	+	+	+	+	<del> </del>	+	<del> </del>
(V.D.J.C) (TCRA)		AL000000	·	'	, ·	1	1	1	
T-cell receptor, beta cluster	3	L34740	+	+	+	+	+	+	high in pancreas
(TCRB)				_					
T-cell receptor, delta	2	X73617			+	+		+	
(V,D,J,C) (TCRD)		114500		<u> </u>					
T-cell, immune regulator 1 (TCIRG1)	3	U45285			1	1		1	only found in tumor
TCF-1 mRNA for T cell	1	X59870		<del></del>	<u> </u>	┼—	<u> </u>	├	
factor 1		733010				1			Ì
TCF-1 mRNA for T cell	1	X59870							
factor 1 (splice form B) (low				1		1		ļ	
match)									
T-COMPLEX PROTEIN 1, ETA SUBUNIT (TCP-1-	1	Q99832							
ETA) (CCT-ETA) (HIV-1						1			i i
NEF INTERACTING						l	1		1
PROTEIN)									· .
T-COMPLEX PROTEIN 1,	1	P50990					<u> </u>		
THETA SUBUNIT (TCP-1-		1							
THETA) (CCT-THETA)		1							
TCR eta =1 cell		594421	<del></del>	-		<del> </del>			
receptor(eta-exon)	•	337721							]
TCR V Beta 13.2	1	X75419		1		<del> </del> -	<del>  -</del>	_	
TERA	1	AC004472							
testis enhanced gene				<b>_</b>		<u> </u>			
transcript (TEGT)	33	X75861	+	+	+	+	+	+	
tetracycline transporter-like	2	L11669		+	+	+	-	+	
protein (TETRAN)				1					
tetratricopeptide repeat	1	U46570	+	+	+	+		+	
domain 1 (TTC1)						L			
tetratricopeptide repeat domain 2 (TTC2)	1	U46571		+		+		+	
tetratricopeptide repeat		D84296	+	+	+	+		+	
domain 3 (TTC3)	•	557230	•		•		j	_	
TGFB1-induced anti-	1	D86970	+	+	+	+		+	
apoptotic factor 1 (TIAF1)				Ш І					2
thioredoxin reductase 1	3	S79851		+	+	+		+	
(TXNRD1) THIOREDOXIN-	<del>1</del>	120045		$\perp$		<u> </u>			
DEPENDENT PEROXIDE	ı	P30048							
REDUCTASE				1 1					1
PRECURSOR.									
mitochondrial (ANTI-		.		1 1					
OXIDANT PROTEIN 1) (AOP-1)		]		1 1					
(AOI-I)									

threonyl-tRNA synthetase	<del></del>	Violetava							PCT/CA00/00005
I(IARS)		M63180		7	+	+	T	T.	+
thrombin inhibitor	1	Z22658	<del>                                     </del>		+	+-	╁	+	
thrombospondin 1 (THBS1	) 2	X04665		+	+	+	+	+-	+
thromboxane A synthase 1 (platelet, cytochrome P450 subfamily V) (TBXAZ1)		M80647		+		+	+	†	
thymidine kinase 2, mitochondrial (TK2)	2	X76104		+	+		+	$\dagger$	
thymidylate kinase (CDC8)	1	L16991		+	+	+	+	++	
thymine-DNA glycosylase (TDG)	2	U51166	+	+	+	+		+	
Thymosin, beta 10 (TMSB10)	2	M20259	+	1+	+	+	+	+	
thymosin, beta 4, X chromosome (TMSB4X)	29	M17733		+	+	+	<del>                                     </del>	+	
thyroid autoantigen 70kD (Ku antigen) (G22P1)	7	J04611			+	+			
thyroid hormone receptor coactivating protein (SMAP)	1	AF016270		+		+		+	,
thyroid hormone receptor interactor 7 (TRIP7)	2	L40357		+	+	+		+	
thyroid hormone receptor interactor 8r (TRIP8)	4	L40411		+	†				
thyroid hormone receptor- associated protein, 230 kDa subunit (TRAP230)	1	D83783		1					
thyroid receptor interacting protein 15 (TRIP15)	2	L40388	+	+	+	+			
11-227H	1	D50525							
TIA1 cytotoxic granule- associated RNA-binding protein (TIA1)	1	M77142		+	+	+	$\dashv$	+	
tissue inhibitor of	1	X02598	+		<u> </u>				Tr.
metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) (TIMP1)			Ť	+	+	+	+	+	
issue inhibitor of metalloproteinase 2 (TIMP2)	7	M32304	+	+	+	+	+	+	high in placenta
issue specific ransplantation antigen 235B (TSTA3)	1	U58766	+	+	+	+	-	+	
itin (TTN)		X64697	+	++	+	++	-+	+	high in muscle
NF receptor-associated actor 2 (TRAF2)	1	U12597		+	+	+	$\dashv$	+	
NF receptor-associated actor 3 (TRAF3)	1	AF110908.1		+		-+	$\dashv$		
NF receptor-associated actor 6 (TRAF6) (low natch)	1	U78798				$\dashv$	$\dagger$		
oll-liké receptor 1 (TLR1)	1	U88540	<del></del>	1		++	-	-	
oll-like receptor 2 (TLR2)	1	U88878	+	╀┯╂	-+	<del>-</del>  -		++	
oll-like receptor 4 (TLR4)	1	U88880		+++			+	4	
oll-like receptor 5 (TILR5)	1	AF051151		+	$\dashv$	+-	-		
ppoisomerase (DNA) I (OP1)	1	J03250	<del></del>	+	+	++	+	+	
poisomerase (DNA) II eta (180kD) (TOP2B)	2	X68060	+	+	+	+   -	+.	+	
poisomerase (DNA) III eta (TOP3B)	3	D87012	+		+	+	+	+	
R3beta	1	D85245		+ +	$\dashv$	<del>- -</del>	+	+	
RAF family member- ssociated NF-kB activator ANK)	3	U63830	+	+	+	+ +	+-	+	·
RANSALDOLASE	1	P37837						4	
insaldolase 1 (TALDO1)	4	L19437			_				
		97		+	+	+ +	1		

WO 00/40749									1/CA00/00005
transaldolase-related protein	1	AF010398							
transcobalamin II (TCII)	1	AF047576		Τ"					
transcription elongation factor B (SIII), polypeptide 1-like (TCEB1L)	2	Z47087	+	+	+	+		+	
transcription elongation factor B (SIII), polypeptide 3 (110kD, elongin A) (TCEB3)	1	L47345	+	+	+	+	+	+	
transcription factor 12 (HTF4, helix-loop-helix transcription factors 4) (TCF12)	1	M83233	· <b>+</b>	+	+	+		+	
transcription factor 17 (TCF17)	2	D89928		+		+			
transcription factor 4 (TCR4)	2	X52079		+	+	+		+	
transcription factor 6-like 1 (mitochondrial transcription factor 1-like) (TCF6L1)	2	M62810	+	+	+	+			
transcription factor 7-like 2 (T-cell specific, HMG-box) (TCF7L2)	1	Y11306		+	+	+		+	
transcription factor binding to IGHM enhancer 3 (TFE3	1	X96717	+	+	+	+		+	
transcription factor IL-4 Stat	7	AF067575	+	+	+	+	+	+	
transcription factor IL-4 Stat (low match)	1	U16031							
transcription factor ISGF-3 (=M97936)	4	M97935							
transcription factor REST	1	A56138		1		<u></u>			
transcription factor TFIID	1	Z22828							
transcriptional adaptor 2 (ADA2, yeast, homolog)- like (TADA2L)		AF064094							
transcriptional intermediary factor 1 (TIF1) (non-exact 72%)	. 1	AF009353							
transducin (beta)-like 1 (TBL1)	1	Y12781	+	+	+	+		+	
transducin-like enhancer of split 3, homolog of Drosophila E(sp1) (TLE3)	1	M99438	+	+					
Transformation/transcription domain-associated protein (TRRAP)	1	AF076974	+	+	+	+		+	
transformation-sensitive, similar to Saccharomyces cerevisiae STI1 (STI1L)	2	M86752		+	+	+		+	
transforming growth factor beta-activated kinase 1 (TAK1) (non-exact 78%)	1	AB009356							
transforming growth factor beta-stimulated protein TSC-22 (TSC22)	3	AJ222700	+	+	+	+		+	
transforming growth factor, beta receptor III (betaglycan, 300kD) (TGFBR3)	1	L07594		+	+	+		+	
transforming growth factor, beta-induced, 68kD (TGFBI)	2	4507466	+	+	+	+	+	+	
TRANSFORMING GROWTH FACTOR-BETA INDUCED PROTEIN IG-H3 PRECURSOR (BETA IG- H3)	2	Q15582							
transforming, acidic coiled- coil containing protein 1 (TACC1) (non-exact 70%)	1	AF049910							

transgelin 2 (TAGLN2)	14	T Barbor							C1/CA00/00005
transgelin 2 (TAGLN2)	14	D21261	+	+	+	+	+	+	
(non-exact) trans-Golgi network protein		D21261							
(46, 48, 51kD isoforms) (TGN51)	2	AF029316		+		+			
transient receptor potential channel 1 (TRPC1)	1	X89066		+	+	+		+	
transketolase (Wernicke- Korsakoff syndrome) (TKT)	7	L12711		+	+	+		+	
translation factor sui1 homolog (GC20)	1	AF064607	<del></del>	+	+	+	+	+	
translin (TSN)	3	X78627	+	+	+	+	-	+	
translin-associated factor X (TSNAX)	1	X95073	<del></del>	+	+	+	-	+	
transmembrane glycoprotein (A33)	1	U79725		+		-	<u></u>		
transmembrane protein (63kD), endoplasmic reticulum/Golgi intermediate compartment	1	X69910	+	+	+	+		+	
(P63) transmembrane protein 1 (TMEM2)	1	AB001523		+		+		+	
TRANSMEMBRANE	1	P51805	·	-					
PROTEIN SEX PRECURSOR (non-exact 65%)									
transmembrane trafficking protein (TMP21)	2	X97442	+	+	+	+	+	-+	
transporter 1, ABC (ATP binding cassette) (TAP1)	3	L21208	+	+	+	+		+	~
Treacher Collins- Franceschetti syndrome 1 (TCOF1)	2	U40847	+	+	+	+		+	high in many libraries
triosephosphate isomerase 1 (TPI1)	2	X69723	+	+	+	+	+	+	
tropomyosin	2	X04201		1 + 1	+	++	-	+	
tropomyosin 4 (TPM4)	2	X05276	+	+ +	+	+	-+	+	
TRPM-2 protein	2	M63376		<del>                                     </del>	$\dashv$	-	$\rightarrow$		
fryptase I precursor (non- exact 64%)(=P20231)	1	A35863				-+	+	$\dashv$	
tryptophan rich basic protein (WRB)	1	Y12478			$\dashv$		-	-	
tryptophanyl-tRNA synthetase (WARS)	1	X59892	+	+	+ -	+	+	+	
Ts translation elongation factor, mitochondrial (TSFM)	1	L37936	+	+		+	+	+	
topoisomerase (DNA) II beta (180kD)	1	Z15115	<del></del>	+	+	-	$\dashv$	+	
lu translation elongation actor, mitochondrial (TUFM)	4	L38995				_	1		
uberous scierosis 1 TSC1)	1	AF013168		+	+	+	十	+	
uberous scierosis 2 TSC2)	1	X75621		+	+	+	+	+	
ubulin, alpha 1 (testis specific) (TUBA1) ubulin, alpha, ubiquitous	1	X06956	<del></del>	+	$\dashv$	$\dashv$	+	$\dashv$	
K-ALPHA-1) (	11	K00558	+	+	+	+	+	+	high in many libraries
ubulin, alpha, ubiquitous K-ALPHA-1) (low match)	1	K00558		_	-	$\dashv$	-	$\dashv$	
ubulin-specific chaperone (TBCC)	1	U61234		+	+	+  -	+	+	
umor necrosis factor ligand) superfamily, nember 10 (TNFSF10)	7	U37518		+	+	+	+	+	

WO 00/40749									
tumor necrosis factor (ligand) superfamily,	1	AF046888	+	+		+		+	
member 13 (TNFSF13) tumor necrosis factor (ligand) superfamily,	1	AF036581							
member 14 (TNFSF14) tumor necrosis factor	1	D38122	+			_	-		Found only in library 386: T-cell lymphoma
(ligand) superfamily, member 6 (TNFSF6) tumor necrosis factor	1	L09753	B only						
(ligand) superfamily, member 8 (TNFSF8)		A5054024			+	4		+	
tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains (FIP2)	1	AF061034						·	
Tumor necrosis factor receptor superfamily member 7 (TNFRSF7)	2	M63928		+			+		
tumor necrosis factor receptor superfamily, member 10b (TNFRSF10B)	1	AF016266		+	+	+	+	+	
tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain (TNFRSF10C)	3	AF012629		a.			+		
tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain (TNFRSF10D) (non-exact 84%)	1	AF023849							found only in prostate
tumor necrosis factor receptor superfamily, member 12 (translocating chain-association membrane protein) (TNFRSF12)		U94508	+	+	+	+		+	
tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator) (TNFRSF14)	1	U70321	+	+	+	+		+	
tumor necrosis factor receptor superfamily, member 1B (TNFRSF1B)	5	U52165	+	+	+	+		+	
tumor necrosis factor receptor superfamily, member 6 (TNFRSF6)	1	X63717	B, W					+	
tumor necrosis factor receptor superfamily, member 7 (TNFRSF7)	1	M63928	+	+					
tumor necrosis factor, alpha-induced protein 2 (TNFAIP2)	8	M92357		+	+		+		
tumor necrosis factor, alpha-induced protein 3 (TNFAIP3)	2	M59465							
tumor protein 53-binding protein, 1 (TP53BP1)	1	AF078776		+	+	+		+	
tumor protein p53 (Li- Fraumeni syndrome) (TP53)	1	M14695	+	+				+	
Tumor protein p53-binding protein (TP53BPL)	1	U82939	+			+		+	
tumor protein, translationally-controlled 1 (TPT1)	35	X16064							
tumor protein, translationally-controlled 1 (TPT1) (low score)	1	X16064							
tumor rejection antigen (gp96) 1 (TRA1)	9	X15187	+	+	+	+	+		1

tumorous imaginal discs (Drosophila) homolog (TID1) TXK tyrosine kinase (TXK) type II integral membrane protein (NKG2-E) TYRO protein tyrosine kinase binding protein (TYROBP) tyrosine 3-monooxygenase/tryptopha n 5-monooxygenase activation protein, beta polypeptide (YWHAB) tyrosine 3-monooxygenase/tryptopha n 5-monooxygenase/tryptopha n 5-monooxygenase	2 1 3 1	L27071 AJ001685 AF019562			•			+	found only in	_
type II integral membrane protein (NKG2-E) TYRO protein tyrosine kinase binding protein (TYROBP) tyrosine 3- monooxygenase/tryptopha n 5-monooxygenase activation protein, beta polypeptide (YWHAB) tyrosine 3- monooxygenase/tryptopha	3	AJ001685 AF019562			十			+	found only in	
protein (NKG2-E) TYRO protein fyrosine kinase binding protein (TYROBP) tyrosine 3- monooxygenase/tryptopha n 5-monooxygenase activation protein, beta polypeptide (YWHAB) tyrosine 3- monooxygenase/tryptopha	3	AF019562			$\dagger$	$\dashv$		+	found only in	
kinase binding protein (TYROBP) tyrosine 3- monooxygenase/tryptopha n 5-monooxygenase activation protein, beta polypeptide (YWHAB) tyrosine 3- monooxygenase/tryptopha					- 1					n
monooxygenase/tryptopha n 5-monooxygenase activation protein, beta polypeptide (YWHAB) tyrosine 3- monooxygenase/tryptopha	1	X57346			$\top$	+			liver/spleen	
tyrosine 3- monooxygenase/tryptopha	1		+	+		+	+		+ high in ecnorm	
activation protein, zeta polypeptide ( YWHAZ)		M86400								
tyrosine 3-	1	Macros								
monooxygenase/tryptopha n 5-monooxygenase activation protein, zeta polypeptide (YWHAZ)	·	M86400								
Tyrosine kinase 2 (TYK2)	3	X54637		+	++	-		+	+	
TYROSINE-PROTEIN KINASE ZAP-70 (70 KD. ZETA-ASSOCIATED PROTEIN) (SYK-RELATED TYROSINE KINASE)	2	P43403			+		-			
yrosyl-tRNA synthetase YARS)	1	U89436	+	+	+	+	+	+	+	
I1 small nuclear RNA	1	M14387			┼		- -			
119H snoRNA (=M63485	1	AJ224166		<del></del>	╄		4_			
R.norvegicus matrin 3) U2(RNU2) small nuclear				ı	1					
RNA auxillary factor 1 non-standard symbol) U2AF1)	1	M96982		+	+	+		†	-	
J22 snoRNA host gene UHG)	2	U40580		_	├-	╁	+	+	<del></del>	
4/U6-associated RNA plicing factor (HPRP3P)	4	AF016370		+	+	+	+	+-		
49 small nuclear RNA	1	X96649			<b>├</b>	-	╀			
5 snRNP-specific protein 220 kD), ortholog of S. erevisiae Prp8p (PRP8)	1	AB007510	+	+	+	+	-	+		
5 snRNP-specific protein, 16 kD (U5-116KD)	4	D21163	+	+	+	+	+	+		
5 snRNP-specific protein, 00 kDa (DEXH RNA elicase family) (U5-200- D)	3	Z70200								_
pa80 mRNA for ubiquitin	4	S79522	+	++	+	+	+	+_	biob is see	
oiquinol-cytochrome c ductase (6.4kD) subunit QCR)	1	D55636	+	+	+	+	+	++	high in ovary high in fetal lung	
BIQUINOL-	<del>-1</del>	P47985		4						
TOCHROME C EDUCTASE IRON- JLFUR SUBUNIT RECURSOR (RIESKE ON-SULFUR PROTEIN) ISP) (low match)	·								-	
quitin A-52 residue osomal protein fusion oduct 1 (UBA52)	. 2	X56999			-		-			
Courties a selection of				<del></del>						
quitin activating enzyme -like protein (GSA7) quitin C (UBC)	1	AF094516		+	+			+		

WO 00/40/49								•	CITCAUGICUUS
ubiquitin carboxyl-terminal esterase L3 (ubiquitin	1	M30496	+	+	+	+		+	
thiolesterase) (UCHL3)	1	U64444	+	++	+	+		+	
1-like (UFD1L)									
ubiquitin protein ligase E3A (human papilloma virus E6- associated protein, Angelman syndrome) (UBE3A)	<b>1</b>	U84404	В	+	+			+	
ubiquitin specific protease 10 (USP10)	4	D80012	+	+	+	+		+	
ubiquitin specific protease	1	U44839	+	+	+	+	+	+	
ubiquitin specific protease 15 (USP15)	3	AB011101	+	+	+	+		+	
ubiquitin specific protease 19 (USP19)	1	AB020698		+					
ubiquitin specific protease 4 (proto-oncogene) (USP4)	1	AF017305	В	+	+		+	+	
ubiquitin specific protease 4 (proto-oncogene) (USP4) (non-exact, 66%)	1	AF017306							
ubiquitin specific protease 7 (herpes virus-associated) (USP7)	1	Z72499		+	+	+		+	
ubiquitin specific protease 8 (USP8)	5	D29956		+	+	+		+	
UBIQUITIN-ACTIVATING ENZYME E1 (A1S9 PROTEIN) (56%)	1	P22314							
ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing) (UBE1)	. <b>1</b>	M58028	+	+	+	+.		+	
ubiquitin-activating enzyme E1, like (UBE1L)	1	L34170	+	+		+		+	
UBIQUITIN-BINDING PROTEIN P62; phosphotyrosine independent ligand for the Lck SH2 domain p62 (P62)		U41806			+		+		
ubiquitin-conjugating enzyme E2 variant 1 (UBE2V1)	2	U49278	+	+	+	+	+	+	
ubiquitin-conjugating enzyme E2 variant 2 (UBE2V2)	1	X98091							
UBIQUITIN- CONJUGATING ENZYME	1	Q16781		1-1					
E2-17 KD (UBIQUITIN- PROTEIN LIGASE)									
ubiquitin-conjugating enzyme E2B (RAD6 homolog) (UBE2B)	1	M74525	+	+	+	+		+	
ubiquitin-conjugating enzyme E2G 2 (homologous to yeast UBC7) (UBE2G2)	1	AF032456	+	+	+	+		+	
ubiquitin-conjugating enzyme E2H (homologous to yeast UBC8) (UBE2H)	. ,	Z29328	+	+	+	+		+	
ubiquitin-conjugating enzyme E2L 1 (UBE2L1)	1	X92962		+	+			+	·
ubiquitin-conjugating enzyme E2L 3 (UBE2L3)	3	AJ000519		+	+	+		+	
ubiquitin-conjugating enzyme E2L 6 (UBE2L6)	4	AF031141		+	+	+	+	+	
ubiquitin-like 1 (sentrin) (UBL1)	2	U61397	+	+	+	+		+	

UDP-N-acetyl-alpha-D-									PCT/CA00/00005
galactosamine:polypeptide	2	X85019						T	
acetylgalactosaminyltransf erase 2 (GalNAc-T2) (GALNT2)									
UDP-N-acetyl-alpha-D- galactosamine:polypeptide N-	1	X92689				$\top$	7	+	
acetylgalactosaminyltransf erase 3									
(GalNAc-T3) (GALNT3) (non-exact 65%)		*					İ		
unactive progesterone receptor, 23 Kd (P23)	2	L24804		+	+		+	+	
unconventional myosin-ID (MYO1F)	3	U57053			+		+	+	<del>-</del>
uncoupling protein homolog (UCPH)	1	U94592		_	+	+	+	+	
uncoupling protein homolog (UCPH) (low match 67%)	1	U94592					-	$\top$	
Unknown gene product	1	AC002310	+					- -	
unknown mRNA (clone 24514)	1	AF070542			+	+	+	╬	+
unknown protein (clone ICRFp507L0677)	2	Z70223	<del> </del>	<del>                                     </del>	+-		╁	+	
unknown protein (Hs.93832)	1	AF070626	. +	+	+	+	+	+	
unknown protein IT14	1	AF040966	<del> </del>		┪—	+-	-	+	ļ <u>-</u>
uppressor of Ty (S.cerevisiae) 6 homolog	1	D79984	+	+	+	+	+	+	· rese
upregulated by 1,25- dihydroxyvitamin D-3 (VDUP1)	74	573591	+	+	+	+	-	+	high in heart
upregulated by 1,25- dihydroxyvitamin D-3 (VDUP1) (low match)	1	573591						+	
upregulated by 1,25- dihydroxyvitamin D-3 VDUP1) (low match)	1	S73591				<u> </u>			
upregulated by 1,25- dihydroxyvitamin D-3 VDUP1) (low score)	1	S73591							
ipstream binding factor (hUBF)	1	X53461	+	+	-	+	<del>                                     </del>	+	
UV radiation resistance associated gene (UVRAG)	2	X99050		+	+	+	-	+	
acuolar proton-ATPase, subunit D; V-ATPase, subunit D (ATP6DV)	4	X71490		+	+	+	+	+	
r-akt murine thymoma viral encogene homolog 1 AKT1)	1	M63167	+	+	+	+		+	
anin 2 (VNN2)	3	AJ132100		+		-			
asodilator-stimulated hosphoprotein (VASP)	3	Z46389	+	+ -	+	+		+	
av 1 oncogene (VAV1)	1	M59834		<del>  </del>		-		+	•
av 2 oncogene (VAV2)	1	S76992	+	+	_				
-crk avian sarcoma virus T10 oncogene homolog CRK)	1	D10656	w .	+	+		+		
erb-b2 avian rythroblastic leukemia iral oncogene homolog 3 ERBB3)	1	M29366			<del>-</del>			+	
ERSICAN CORE ROTEIN PRECURSOR esicle-associated	1	P13611							
esicle-associated tembrane protein 1 synaptobrevin 1) (VAMP1)	1	M36196		+	+	+		+	

vesicle-associated		I III I I I I I I I I I I I I I I I I			,				
membrane protein 3 (cellubrevin) (VAMP3)	1	U64520	<u> </u>						
v-fos FBJ munne osteosarcoma viral oncogene homolog (FOS)	26	K00650		+	+	+	+	+	high in aorta
v-fos FBJ munne	1	K00650			<del></del>	ļ	-	<del> </del>	
osteosarcoma viral oncogene homolog (FOS) (low match)	1	K00650							
villin 2 (ezrin) (VIL2)	1	X51521	+	+	+	+		+	
villin-like protein	1-1-	D88154			<del> </del>	-	<del>                                     </del>	-	
vimentin (VIM)	12	X56134		++	+	+	+	+	high in many libraries
vinculin (VCL)	4	M33308		+	+	+	H	+	ingit in many indianes
vitamin A responsive; cytoskeleton related (JWA)	6	AF070523		+	+	+		+	
v-jun avian sarcoma virus 17 oncogene homolog (JUN)	2	U65928	+	+	+	+		+	
v-myb avian myeloblastosis viral oncogene homolog (MYB)	1	M15024			+		+		
voltage-dependent anion channel 1 (VDAC1)	1	L06132	+	+	+	+		+	
voltage-dependent anion channel 3 (VDAC3)	4	U90943		+	+	+		+	
von Hippel-Lindau syndrome (VHL)	1	L15409		+	+	+		+	
von Willebrand factor (vWF) (low matched)	1	X06828		Ť					
v-raf murine sarcoma 3611	2	L24038	+	+	+	+	-	-	
viral oncogene homolog 1 (ARAF1)									
v-raf-1 murine leukemia viral oncogene homolog 1 (RAF1)	1	X03484	+	+	+	+		+	
v-ral simian leukemia viral oncogene homolog B (ras	3	M35416							· · · · · · · · · · · · · · · · · · ·
related; GTP binding protein) (RALB)									
V-rel avian	1	L19067		+	+	+		+	
reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 (p65)) (RELA)								·	
v-yes-1 Yamaguchi sarcoma viral related oncogene homolog (LYN)	2	M16038	+	+		+		+	
WD repeat domain 1 (WDR1)	1	AB010427	+	+	+	+	+	+	
WDR1 (=AF020260)	1	AF020056							
WD-repeat protein (HAN11)	2	U94747		1+1	+			+	
Williams-Beuren syndrome chromosome region 1 (WBSCR1)	12	AF045555	+	+	+	+	+	+	
Wiskott-Aldrich syndrome protein interacting protein (WASPIP)	4	X86019	+	+	+			+	
X (inactive)-specific transcript (XIST)	2	M97168		+ +				$\dashv$	
xeroderma pigmentosum, complementation group C	3	D21089	+	+	+	+			
XIAP associated factor-1		X99699		+		+			
XIB	<del>-</del>	X90392		+	+		+		
X-linked anhidroitic							7	+	
ectodermal dysplasia	1	AF003528			Į		ł	I	
, -F		L							

7									PCT/CA00/00005
X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining; Ku autoantigen, 80kD) (XRCC5)		M30938	+	+		•	+		+ high in spleen
XRP2 protein	1	AJ007590	<del>                                     </del>	<del>-  </del>	+-			-	
yeloid differentiation primary response gene (88) (MYD88)	1	U84408		+	+	+	+	+	+
zeta-chain (TCR) associated protein kinase (70kD) (ZAP70)	1	L05148	+			-		+	
zeta-chain (TCR) associated protein kinase (70kD) (ZAP70) (low match)		L05148							
zinc finger protein (Hs.47371)	2	U69274	+	+	+	+	+	+,	
zinc finger protein (Hs.78765)	1	U69645	+	+	+	1	+	†•	-
zinc finger protein 10 (KOX 1) (ZNF10)	1 -1 -	X78933				$\top$		十	+ only
ZÍNC FINGER PROTEIN 124 (HZF-16) (non-exact 51%)	1	Q15973			<del> </del>	+	+	$\dagger$	
zinc finger protein 124 (HZF-16) (ZNF124) (non- exact, 78%)	1	S54641					1	1.	
ZINC FINGER PROTEIN 133	1	P52736				+	$\dagger$	+	mar e e
zinc finger protein 136 (clone pHZ-20) (ZNF136)	1	U09367			+	+	+	+	
zinc finger protein 140 (clone pHZ-39) (ZNF140)	1	U09368		+-		+	+	+	<del></del>
zinc finger protein 140 (clone pHZ-39) (ZNF140) (non-exact 59%)	1	AF060865						1	71
zinc finger protein 140 (clone pHZ-39) (ZNF140) (non-exact 73%)	1	U09368						-	
zinc finger protein 140 (clone pHZ-39) (ZNF140) (non-exact 73%aa)	1	S66508						<del>                                     </del>	
zinc finger protein 140 (clone pHZ-39) (ZNF140) (non-exact, 80%)	1	U09368							
zinc finger protein 143 (clone pHZ-1) (ZNF143) zinc finger protein 143	2	U09850	+	+	+	+	+	+	
(clone pHZ-1) (ZNF143) (low match)	1	U09850							
zinc finger protein 148 (pHZ-52) (ZNF148)	1	AF039019	+					<del>                                     </del>	
ZINC FINGER PROTEIN 151 (MIZ-1 PROTEIN) (low match)	1	Q13105							
zinc finger protein 173 (ZNF173)	1	U09825	В, Т	+	+		+	-	
zinc finger protein 192 (ZNF192) (non-exact, 66%)	1	U57796						-	
zinc finger protein 198 (ZNF198)	1	AJ224901		+	+	+		_	2
zinc finger protein 2 (ZNF2) low match)	1	X60152				$\vdash$		-	
zinc finger protein 200 ZNF200)	1	AF060866		+		+	<u> </u>		
zinc finger protein 207 ZNF207)	6	AF046001	+	+	+	+	+	+	high in prostate
inc finger protein 216 ZNF216)	2	AF062072	+	+	+	+		+	

WO 00/40/49								•	C1/CA00/00003
zinc finger protein 217 (ZNF217)	1	AF041259	Tacti	vated				+	
ZINC FINGER PROTEIN 22 (ZINC FINGER PROTEIN KOX15) (non-	1	P17026							
exact 58%) zinc finger protein 230 (ZNF230)	1	U95044		+	-	$\vdash$			
Zinc finger protein 239 (ANF239)	1	L26914		+		+			
zinc finger protein 261 (ZNF261)	1	AB002383		+	+	+		+	
zinc tinger protein 262 (ANF262)	1	AB007885		+	+	+		+	
zinc finger protein 263 (ZNF263)	1	D88827							
zinc finger protein 264 (ZNF264)	1	AB007872		+	+	+			
ZINC FINGER PROTEIN 33A (ZINC FINGER PROTEIN KOX31) (KIAA0065) (HA0946)	1	Q06730							_
zinc finger protein 42 (myeloid-specific retinoic cid- responsive) (ZNF42)	1	M58297	+	+	+	+		+	
zinc finger protein 43 (HTF6) (ZNF43) (low match)	1	X59244							
zinc finger protein 43 (HTF6) (ZNF43) (non- exact, 54%)	1	X59244							
zinc finger protein 43 (HTF6) (ZNF43) (non- exact, 71%)	7	X59244						•	
ZINC FINGER PROTEIN 43 (ZINC PROTEIN HTF6) (non-exact 67%)	1	P28160							
zinc finger protein 45 (a Kruppel-associated box (KRAB) domain polypeptide) (ZNF45)	1	L75847							only found in testis
ZINC FINGER PROTEIN 46 (ZINC FINGER PROTEIN KUP) (non-exact 62%)	1	P24278							
zinc finger protein 6 (CMPX1) (ZNF6)	1	X56465		+	+	+		+	
zinc finger protein 74 (Cos52) (ZNF74) (non- exact, 67%)	1	X71623							
zinc finger protein 76 (expressed in testis) (ZNF76)	1	M91592		+	+	+		+	
ZINC FINGER PROTEIN 83 (ZINC FINGER PROTEIN HPF1) (non- exact 65%)	1	P51522	·						
zinc finger protein 84 (HPF2) (ZNF84)	1	M27878	Tactivated	+	+			+	
zinc finger protein 85 (ZNF85))	2	U35376		+	+	+			
zinc finger protein 9 (ZNF9)	5	M28372		+	+	+	+	+	
ZINC FINGER PROTEIN 93 (=ZINC FINGER PROTEIN HTF34) (non- exact 70%)	1	P35789							
zinc finger protein C2H2-25 (ZNF25)	3	U38904		+	+	+		,	
zinc finger protein clone L3-4	1	AF024706							
zinc finger protein homologous to Zfp-36 in mouse (ZFP36)	4	M92843	+						blood only

ZINC FINGER PROTEIN HRX (ALL-1) (71%a.a.)	1	Q03164		T	T	T	Т	Т	
zinc finger protein HZF4	1	X78927			+	+	┼	-	
zinc finger protein RIZ	1	D45132	+	+	++	+	<del> </del>	+	
zinc finger protein, subfamily 1A, 1 (Ikaros) (LYF1)	1	U40462	+			+	-		
zinc finger protein, subfamily 1A, 1 (Ikaros) (LYF1) (low match)	1	U40462		-					
zinc finger transcriptional regulator (GOS24)	1	M92844				-			
zinc-finger helicase (hZFH)	2	U91543	+	+	+	+	$\vdash$	+	
Zn-15 related zinc finger protein (rtf)	1	U22377		+	+	+		-	
Zn-15 related zinc finger protein (rif) (non-exact 56%)	1	U22377							
ZNF80-linked ERV9 long terminal repeat	1	X83497	······						·
ZW10 (Drosophila) homolog, centromere/kinetochore protein (ZW10)	2	U54996		+					
zyxin (ZYX)	4	X95735		+				-	

Column 1: List of unique genes derived from 6,283 known ESTs from blood cells. Column 2: Number of genes found in randomly sequenced ESTs from blood cells. Column 3: Accession number. Column 4: "+" indicates the presence of the unique gene in publicly available cDNA libraries of blood (Bl), brain (Br), heart (H), kidney (K), liver (Li) and lung (Lu). \*\*Comparison to previously identified tissue-specific genes was determined using the GenBank of the National Centre of Biotechnology Information (NCBI) Database.

10

15

5

#### Discussion

Every cell and tissue comprising the human body share the necessary genetic information required to maintain cellular homeostasis. These "housekeeping" genes function in basic cellular maintenance, including energy metabolism and cellular structure in all cell types. However, in certain situations, even the housekeeping genes show altered expression. Thus, it is necessary to define the use of these genes as internal controls from one investigation to another. Current results from the human blood cell EST database indicate that over 50% of the transcripts are

widely expressed throughout the human body. Most of the cell or tissue specific genes are also detectable in blood cells by RT-PCR analysis.

For example, isoformic myosin heavy chain genes are known to be generally expressed in cardiac muscle tissue. In the rodent, the βMyHC gene is only highly expressed in the fetus and in diseased states such as overt cardiac hypertrophy, heart failure and diabetes; the αMyHC gene is highly expressed shortly after birth and continues to be expressed in the adult heart. In the human, however, βMyHC is highly expressed in the ventricles from the fetal stage through adulthood. This highly expressed βMyHC, which harbours several mutations, has been demonstrated to be involved in familial hypertrophic cardiomyopathy (Geisterfer-Lowrance *et al.* 1990). It was reported that mutations of βMyHC can be detected by PCR using blood lymphocyte DNA (Ferrie et al., 1992). Most recently, it was also demonstrated that mutations of the myosin-binding protein C in familial hypertrophic cardiomyopathy can be detected in the DNA extracted from lymphocytes (Niimura *et al.*, 1998).

Similarly, APP and APC, which are known to be tissue specific and predominantly expressed in the brain and intestinal tract, are also detectable in the transcripts of blood. These cell- or tissue-specific transcripts are not detectable by Northern blot analysis. However, the low number of transcript copies can be detected by RT-PCR analysis. These findings strongly demonstrate that genes preferentially expressed in specific tissues can be detected by a highly sensitive RT-PCR assay. In recent years, evidence has been obtained to indicate that expression of cell or tissue-restricted genes can be detected in the peripheral blood of patients with metastatic transitional cell carcinoma (Yuasa et al. 1998) and patients with prostate cancer (Gala et al. 1998).

Atrial natriuretic factor (ANF) and zinc finger protein (ZFP), which are known to be highly expressed in heart tissue biopsies and in the plasma of heart failure patients, are also detectable in the transcripts of blood. Differential expression of zinc finger protein among the normal, diabetic and asymptomatic preclinical

5

10

15

20

subjects may have additional value as a prophylactic "early warning system". On a related note, there is now more attention/discussion in the cardiovascular disease field being focused on Syndrome X, loosely defined as a continuum of hypertension, increasing sugar levels, diabetes, kidney failure, culminating in heart failure, with the possibility of stroke and heart attack at any time in the continuum. The early identification of patients at risk of organ failure has been a challenge to the medical community for some time and the present method has the potential of resolving or, at least, ameliorating this challenge.

5

10

15

20

25

BNSDOCID: <WO

\_0040749A2\_I\_>

The present invention demonstrates that a simple drop of blood may be used to determine the quantitative expression of various mRNAs that reflect the health/disease state of the subject through the use of RT-PCR analysis. This entire process takes about three hours or less. The single drop of blood may also be used for multiple RT-PCR analyses. There is no need for large samples and/or costly and time-consuming separation of cell types within the blood for this method as compared to the methods described by Kimoto (1998) and Chelly et al. (1989; 1988). It is believed that the present finding can potentially revolutionize the way that diseases are detected, diagnosed and monitored because it provides a non-invasive, simple, highly sensitive and quick screening for tissue-specific transcripts. The transcripts detected in whole blood have potential as prognostic or diagnostic markers of disease, as they reflect disturbances in homeostasis in the human body. Delineation of the sequences and/or quantitation of the expression levels of these marker genes by RT-PCR will allow for an immediate and accurate diagnostic/prognostic test for disease or to assess the efficacy and monitor a particular therapeutic.

In addition to RT-PCR, other methods of amplifying may also be used for the purpose of measuring/quantitating tissue-specific transcripts in human blood. For example, mass spectrometry may be used to quantify the transcripts (Koster et al., 1996; Fu et al., 1998). The application of presently disclosed method for detecting tissue-specific transcripts in blood does not restrict to subjects undergoing course of

... : 1.21 Delik :

therapy or treatment, it may also be used for monitoring a patient for the onset of overt symptoms of a disease. Furthermore, the present method may be used for detecting any gene transcripts in blood. A kit for diagnosing, prognosing or even predicting a disease may be designed using gene-specific primers or probes derived from a whole blood sample for a specific disease and applied directly to a drop of blood. A cDNA library specific for a disease may be generated from whole blood samples and used for diagnosis, prognosis or even predicting a disease.

The following references were cited herein:

Claudio JO et al. (1998). Genomics 50:44-52.

5

10 Chelly J et al. (1989). Proc. Nat. Acad. Sci. USA. 86:2617-2621.

Chelly J et al. (1988). Nature 333:858-860.

Drews J & Ryser S (1997). Nature Biotech. 15:1318-9.

Ferrie RM et al. (1992). Am. J. Hum. Genet. 51:251-62.

Fu D-J et al. (1998). Nat. Biotech 16: 381-4.

15 Gala JL et al. (1998). Clin. Chem. 44(3):472-81.

Geisterfer-Lowrance AAT et al. (1990). Cell 62:999-1006.

Groden J et al. (1991). Cell 66:589-600.

Hwang DM et al. (1997). Circulation 96:4146-4203.

Jandreski MA & Liew CC (1987). Hum. Genet. 76:47-53.

20 Jin O et al. (1990). Circulation 82:8-16

Kimoto Y (1998). Mol. Gen. Genet 258:233-239.

Koster M et al. (1996). Nat. Biotech 14: 1123-8.

Liew & Jandreski (1986). Proc. Nat. Acad. Sci. USA. 83:3175-3179

Liew CC et al. (1990). Nucleic Acids Res. 18:3647-3651.

25 Liew CC (1993). J Mol. Cell. Cardiol. 25:891-894

Liew CC et al. (1994). Proc. Natl. Acad. Sci. USA. 91:10645-10649.

Liew et al. (1997). Mol. and Cell. Biochem. 172:81-87.

Niimura H et al. (1998). New Eng. J. Med. 338:1248-1257.

Ogawa M (1993). Blood 81:2844-2853.

Santoro IM & Groden J (1997). Cancer Res. 57:488-494.

Yuasa T et al. (1998). Japanese J. Cancer Res. 89:879-882.

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. Further, these patents and publications are incorporated by reference herein in their entirety to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. The present examples, along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

5

10

# WO 00/40749 WHAT IS CLAIMED IS:

5

- 1. A method for detecting expression of a gene in blood from a subject, comprising the steps of:
  - a) quantifying RNA from a subject blood sample; and
- b) detecting expression of said gene in the quantified RNA, wherein the expression of said gene in said quantified RNA indicates expression of said gene in the subject blood.
- 10 2. The method of claim 1, wherein the quantification is performed by mass spectrometry.
  - 3. A method for detecting expression of one or more genes in blood from a subject, comprising the steps of:
    - a) obtaining a subject blood sample;
    - b) extracting RNA from said blood sample;
    - c) amplifying said RNA;
  - d) generating expressed sequence tags from the amplified RNA product; and
- e) detecting expression of said genes in the expressed sequence tags, wherein the expression of said genes in said expressed sequence tags indicates expression of said genes in the subject blood.
- 4. The method of claim 3, wherein said genes are non-cancer-25 associated genes.
  - 5. The method of claim 3, wherein said genes are tissue-specific genes.

- 6. The method of claim 3, wherein said subject is a fetus, an embryo, a child, an adult or a non-human animal.
- 5 7. The method of claim 3, wherein the amplification is performed by RT-PCR.
- 8. The method of claim 7, wherein said RT-PCR utilizes primers selected from the group consisting of random sequence primers and gene-specific primers.
  - 9. A method for detecting expression of one or more genes in blood from a subject, comprising the steps of:
    - a) obtaining a subject blood sample;
    - b) extracting DNA fragment(s) from said blood sample;
    - c) amplifying said DNA fragment(s); and
  - d) detecting expression of said genes in the amplified DNA product, wherein the expression of said genes in said amplified DNA product indicates expression of said genes in the subject blood.

20

- 10. A method for monitoring a course of therapeutic treatment in an individual, comprising the steps of:
  - a) obtaining a blood sample from said individual;
  - b) extracting RNA from said blood sample;
- c) amplifying said RNA;
  - d) generating expressed sequence tags from the amplified RNA product; and

e) detecting expression of genes in said expressed sequence tags, wherein the expression of said genes is associated with the effect of said therapeutic treatment; and

- f) repeating steps a)-e), wherein the course of said therapeutic treatment is monitored by detecting the change of expression of said genes in the expressed sequence tags.
  - 11. The method of claim 10, wherein the amplification is performed by RT-PCR.

- 12. The method of claim 11, wherein the change of expression of said genes in the expressed sequence tags is monitored by sequencing the expressed sequence tags and comparing the resulting sequences at various time points.
- 13. The method of claim 11, wherein the change of expression of said genes in the expressed sequence tags is monitored by performing single nucleotide polymorphism analysis and detecting the variation of a single nucleotide in the expressed sequence tags at various time points.
- 20 14. The method of claim 10, wherein said individual is monitored for the onset of overt symptoms of a disease, and wherein the expression of said genes is associated with the onset of said symptoms.
- 15. A method for diagnosing a disease in a test subject, comprising the steps of:
  - a) generating a cDNA library for said disease from a whole blood sample from a normal subject;

b) generating expressed sequence tag (EST) profile from the normal subject cDNA library;

- c) generating a cDNA library for said disease from a whole blood sample from a test subject;
  - d) generating EST profile from the test subject cDNA library; and
- e) comparing the test subject EST profile to the normal subject EST profile, wherein if said test subject EST profile differs from said normal subject EST profile, said test subject might be diagnosed with said disease.
- 16. A kit for diagnosing, prognosing or predicting a disease, comprising:
  - a) gene-specific primers; wherein said primers are designed in such a way that the sequences of said primers contain the opposing ends of two adjacent exons for the specific gene with the intron sequence excluded; and
    - b) a carrier, wherein said carrier immobilizes said primer(s).
  - 17. The kit of claim 16, wherein said gene-specific primer(s) are selected from the group consisting of insulin-specific primers, atrial natriuretic factor-specific primers, zinc finger protein gene-specific primers, beta-myosin heavy chain gene-specific primers, amyloid precurser protein gene-specific primers, and adenomatous polyposis-coli protein gene-specific primers.
  - 18. The kit of claim 17, wherein the sequences of said gene-specific primers are selected from the group consisting of SEQ ID Nos. 1 and 2, and SEQ ID Nos. 5 and 6.
  - 19. A method for diagnosing, prognosing or predicting a disease in a test subject, comprising the step of:

Service Committee of the Service

5

15

20

applying the kit of claim 16 to a test subject whole blood sample, wherein quantitative expression levels of specific genes associated with said disease are detected and compared to the levels of said specific genes expressed in a normal subject, therefore, said disease may be diagnosed, prognosed or predicted.

5

20. The method of claim 19, wherein said method is used for monitoring a course of therapeutic treatment or monitoring the onset of overt symptoms of said disease.

10

- 21. A kit for diagnosing, prognosing or predicting a disease, comprising:
- a) probes derived from a whole blood sample for a specific disease; and
  - b) a carrier, wherein said carrier immobilizes said probes.

15


20

25

22. A method for diagnosing, prognosing or predicting a disease in a test subject, comprising the step of:

applying the kit of claim 21 to a test subject whole blood sample, wherein quantitative expression levels of specific genes associated with said disease are detected and compared to the levels of said specific genes expressed in a normal subject, therefore, said disease may be diagnosed, prognosed or predicted.

- 23. The method of claim 22, wherein said method is used for monitoring a course of therapeutic treatment or monitoring the onset of overt symptoms of said disease.
- 24. A cDNA library specific for a disease, wherein said cDNA library is generated from whole blood samples.






FIGURE 1





FIGURE 2





FIGURE 3



FIGURE 4

Diabetic




Subjects


Asymptomatic

Standardized levels of ZFP gene expressed in a drop of blood.

Normal



Standardized levels of insulin gene expressed in each fractionated cell from whole blood.



Fractionated Cell Type

FIGURE 5

CC siew Sept 1999

6/7





FIGURE 6





#### SEQUENCE LISTING

<110> Liew, Choong-Chin <120> Method for the Detection of Gene Transcripts in Blood and Uses Thereof 2173/0003 <130> <150> US Number not yet assigned <151> 2000-01-04 <150> US 60/115,125 <151> 1999-01-06 <160> 10 <210> 1 <211> 18 <212> DNA <213> artificial sequence <220> <221> primer bind <223> forward primer of exon 1 of insulin gene used for quantitative RT-PCR analysis <400> 1 gccctctggg gacctgac 18 <210> 2 <211> 18 <212> DNA <213> artificial sequence <220> <221> primer\_bind <223> reverse primer of exons 1 and 2 of insulin
gene used for quantitative RT-PCR analysis <400> 2 cccacctgca ggtcctct

1/4

WO 00/40749				PCT/C	A00/00005
<210>	3				
<211>	24				
<212>	DNA				
<213>	artificial sequence				
<220>					
<221>	primer_bind				
<223> quantitative	forward primer of RT-PCR analysis	§ Вмунс	gene	used	for
<400>	3				
gctggaacgt ag	gagactece tget		•	24	
				•	
<210>	4				•
<211>	24				
<212>	DNA				
<213>	artificial sequence				
<220>					
<221>	primer_bind				
<223> quantitative	reverse primer of RT-PCR analysis	βмунс	gene	used	for
<400>	4				
ggatccttcc ag	atcatcca cttg		:	24	
<210>	5				
<211>	20				
<212>	DNA				
<213>	artificial sequence				
<220>					
<221>	primer_bind				
<223> RT-PCR	forward primer of AM	NF used	for qua	ntitat	ive
	analysis				
<400>	5	•			
ggatttcaag aat	ttgctgg		20		

```
PCT/CA00/00005
  WO 00/40749
    <210>
               6
               20
    <211>
    <212>
               DNA
              artificial sequence
    <213>
    <220>
               primer_bind
     <221>
               reverse primer of ANF used for quantitative
     <223>
RT-PCR analysis
     <400>
                                                 20
gcagatcgat cagaggagtc
               7
     <210>
     <211>
               20
               DNA
     <212>
               artificial sequence
     <213>
     <220>
               primer_bind
     <221>
               forward primer of APP used for quantitative
     <223>
RT-PCR
               analysis
     <400>
                                                20
ggatgcttca tgtgaacgtg
     <210>
               8
     <211>
               19
     <212>
               artificial sequence
     <213>
     <220>
               primer_bind
     <221>
               reverse primer of APP used for quantitative
     <223>
RT-PCR
                analysis
     <400>
                                                19
tcattcacac cagcacatg
```

WO 00/40749		PCT/CA00/00005
<210>	9	
<211>	21	
<212>	DNA	
<213>	artificial sequence	·
<220>		
<221>	primer_bind	
<223> RT-PCR analys	forward primer of ZFP used for	quantitative
<400>	9	
cacargagrc ar	ggtcaacg a	21
<210>	10	
<211>	22	
<212>	DNA	
<213>	artificial sequence	
<220>		
<221>	<pre>primer_bind</pre>	
<223> RT-PCR analys:	reverse primer of ZFP used for is	quantitative
<400>	10	
ggattaaaat gaa	agcaccca ga	22

# THIS PAGE BLANK (USPTO)

#### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

## (19) World Intellectual Property Organization International Bureau



## . 1 Mart | 18 Mart | 18 Mart | 18 Mart | 18 Mart | 18 Mart | 18 Mart | 18 Mart | 18 Mart | 18 Mart | 18 Mart |

#### (43) International Publication Date 13 July 2000 (13.07.2000)

PCT

# (10) International Publication Number WO 00/40749 A3

(51) International Patent Classification7:

\_\_\_\_

C12Q 1/68

- (21) International Application Number: PCT/CA00/00005
- (22) International Filing Date: 5 January 2000 (05.01.2000)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/115,125 09/477,148 6 January 1999 (06.01.1999) US •4 January 2000 (04.01.2000) US

- (71) Applicant (for all designated States except US): GENE-NEWS INC. [CA/CA]; 45 Bevdale Road, Toronto, Ontario, M2R 1L8 (CA).
- (72) Inventor: and
- (75) Inventor/Applicant (for US only): LIEW, Choong-Chin [CA/CA]; 81 Millersgrove Drive, Willowdale, Ontario M2R 3S1 (CA).


- (74) Agent: DEETH WILLIAMS WALL; National Bank Building, Suite 400, 150 York Street, Toronto, Ontario M5H 3S5 (CA).
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


#### Published:

- with international search report
- (88) Date of publication of the international search report:
  19 July 2001

[Continued on next page]

(54) Title: METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF





(57) Abstract: The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Inter Inal Application No PCT/CA 00/0005

		PCT/CA	00/00005
	FICATION OF SUBJECT MATTER C12Q1/68		
According to	o International Patent Classification (IPC) or to both national class	ification and IPC	
B. FIELDS	SEARCHED		
Minimum do	ocumentation searched (classification system followed by classific	ation symbols)	
Documentar	tion searched other than minimum documentation to the extent the	it such documents are included in the he	eas searched
	ata base consulted during the international search (name of data		
EPO-In	ternal, WPI Data, PAJ, MEDLINE, CH	EM ABS Data, BIOSIS,	EMBASE, EMBL
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the	elevant passages	Relevant to claim No.
х	WO 98 49342 A (COCKBAIN JULIAN ); FORSKNINGSPARKEN I AAS AS (NO) LOENNEBORG AN)		1-15, 21-24
Y	5 November 1998 (1998-11-05) the whole document 		19,20
X	WO 98 24935 A (AN GANG ; HARA MAR RALPH DAVID (US); VELTRI ROBERT 11 June 1998 (1998-06-11)	RK O (US); (US); U)	1-15, 21-24
Υ	the whole document		19,20
X	EP 0 534 640 A (PFIZER) 31 March 1993 (1993-03-31)		16
Υ	the whole document		17-20
ļ		-/ <del></del>	
İ			
X Furth	er documents are listed in the continuation of box C.	Patent family members are li	sted in annex.
<ul> <li>Special cate</li> </ul>	egories of cited documents :	"T" later document published after the	international filing data
conside	nt defining the general state of the art which is not red to be of particular relevance ocument but published on or after the international	or priority date and not in conflict cited to understand the principle of invention	with the application but
filing da	te	"X" document of particular relevance; is cannot be considered novel or ca	nnot be considered to
which is	It which may throw doubts on priority claim(s) or cited to establish the publication date of another	involve an inventive step when the "Y" document of particular relevance;	
"O" documer	or other special reason (as specified) nt referring to an oral disclosure, use, exhibition or	cannot be considered to involve a document is combined with one of	in inventive step when the
other m	eans It published prior to the international filing date but	ments, such combination being of in the art.	ovious to a person skilled
later tha	in the phonty date claimed	*& * document member of the same pa	tent family
	ctual completion of the international search	_ate of mailing of the international	i search report
	June 2000	12/07/2000	
ivame and ma	aling address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,	Authorized officer	
	Fax: (+31-70) 340-3016	Hagenmaier, S	(

Form PCT ISA/210 (second sheeti (July 1992)

Inter mai Application No
PCT/CA 00/00005

	PATENT ABSTRACTS OF JAPAN vol. 1997, no. 11, 28 November 1997 (1997-11-28) & JP 09 187299 A (NIPPON BIO SERAPII KK), 22 July 1997 (1997-07-22) abstract & DATABASE GCG_GENESEQ 'Online! AC:V00198, March 1998 (1998-03) NIPPON BIOTHERAPY: "HUMAN INSULIN SENSE PRIMER INS-7" abstract	17,18
,	DATABASE GENBANK 'Online! AC:V00565, March 1995 (1995-03) BELL ET AL: "HUMAN GENE FOR PREPROINSULIN" XP002141055 abstract	17,18
1	DATABASE GENBANK 'Online! AC:M54947, April 1993 (1993-04) SEIDMAN ET AL.: "HUMAN ATRIAL NATRIURETIC FACTOR GENE" XP002141054 abstract	17,18
Y	DATABASE GENBANK 'Online! AC:X52889, September 1993 (1993-09) LIEW: "HUMAN GENE FOR CARDIAC BETA MYOSIN HEAVY CHAIN" XP002141056 abstract	17
Y	DATABASE GENBANK 'Online! AC:2808656, December 1998 (1998-12) BERNOT ET AL.: "A TRANSCRIPTIONAL MAP OF THE FMF REGION/ZINC FINGER PROTEIN" XP002141057 abstract	17
Y	YOSHIKAI ET AL.: "GENOMIC ORGANIZATION OF THE HUMAN AMYLOID BETA-PROTEIN PRECURSOR GENE" GENE, vol. 87, 1990, pages 257-263, XP002141053 the whole document	17
Y	DATABASE GENBANK 'Online! AC:M73548, January 1995 (1995-01) JOSLYN ET AL: "HUMAN POLYPOSIS LOCUS mRNA" XP002141058 abstract	17

Inter shall Application No PCT/CA 00/00005

		PCI/CA O	7/00005
C.(Continu	citation of document, with indication, where appropriate, of the relevant passages		Reevant to claim No.
	onation of december 4 miles appropriate, of the recent in passages		Helevant to daim No.
A	WO 98 18906 A (CLAYCOMB WILLIAM CREIGHTON; PROCTER & GAMBLE (US)) 7 May 1998 (1998-05-07) the whole document		
4	US 5 352 775 A (MARKHAM ALEXANDER F ET AL) 4 October 1994 (1994-10-04) the whole document		
<b>\</b>	DE 44 35 919 C (DEUTSCHES KREBSFORSCH) 7 December 1995 (1995-12-07) the whole document		
1	US 5 837 449 A (ECKER DAVID J ET AL) 17 November 1998 (1998-11-17) the whole document		V.
<b>A</b> .	WO 98 33942 A (NAKAO KOICHI ;BRISTOW MICHAEL R (US); LEINWAND LESLIE A (US); MINO) 6 August 1998 (1998-08-06) the whole document		;
		*	
	~		
			ý.
		¥ .	
		- 91	
1			
	•		
į			

2

Form PCT/ISA210 (continuation of second sheet) (July 1992)

information on patent family members

Inter onal Application No PCT/CA 00/00005

Patent document ited in search report		Publication date	Patent family member(s)	Publication date
WO 9849342	A	05-11-1998	AU 7222698 A EP 0979308 A NO 995296 A	24-11-1998 16-02-2000 14-12-1999
 WO 9824935	Α	11-06-1998	AU 5515198 A EP 0960214 A	29-06-1998 01-12-1999
EP 0534640	A	31-03-1993	AT 143700 T CA 2078703 A DE 69214243 D DE 69214243 T DK 534640 T ES 2092056 T FI 924242 A GR 3021721 T JP 2703156 B JP 5192199 A	15-10-1996 24-03-1993 07-11-1996 06-02-1997 17-03-1997 16-11-1996 24-03-1993 28-02-1997 26-01-1998 03-08-1993
 JP 09187299		 22-07-1997	US 5643730 A NONE	01-07-1997 
WO 9818906	Α	07-05-1998	AU 5149998 A EP 0956341 A NO 991894 A	22-05-1998 17-11-1999 24-06-1999
US 5352775	A	04-10-1994	US 5648212 A US 5691454 A US 5783666 A US RE36713 E AU 1366992 A EP 0569527 A WO 9213103 A	15-07-1997 25-11-1997 21-07-1998 23-05-2000 27-08-1992 18-11-1993 06-08-1992
DE 4435919	C	07-12-1995	WO 9611267 A EP 0784680 A JP 10506789 T	18-04-1996 23-07-1997 07-07-1998
US 5837449	Α	17-11-1998	AU 3249793 A CA 2126451 A EP 0644889 A JP 6511387 T WO 9313114 A	28-07-1993 08-07-1993 29-03-1995 22-12-1994 08-07-1993
WO 9833942	Α	06-08-1998	AU 6141098 A	25-08-1998

Form PCT/ISA/210 (patent tamily annex) (July 1992)

## CORRECTED VERSION

#### (19) World Intellectual Property Organization International Bureau



## 

(43) International Publication Date 13 July 2000 (13.07.2000)

#### PCT

#### (10) International Publication Number WO 00/40749 A3

- (51) International Patent Classification7:
- (21) International Application Number: PCT/CA00/00005
- (22) International Filing Date: 5 January 2000 (05.01.2000)
- (25) Filing Language:

English

C12Q 1/68

(26) Publication Language:

English

(30) Priority Data: 60/115.125 09/477,148


6 January 1999 (06.01.1999) US 4 January 2000 (04.01.2000)

(71) Applicant (for all designated States except US): GENE-NEWS INC. [CA/CA]; 45 Bevdale Road, Toronto, Ontario, M2R 1L8 (CA).

- (72) Inventor; and
- (75) Inventor/Applicant (for US only): LIEW, Choong-Chin [CA/CA]: 81 Millersgrove Drive, Willowdale, Ontario M2R 3S1 (CA).
- (74) Agent: DEETH WILLIAMS WALL; National Bank Building, Suite 400, 150 York Street, Toronto, Ontario M5H 3S5 (CA).
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


[Continued on next page]

(54) Title: METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF



(57) Abstract: The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.







(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- (88) Date of publication of the international search report:
  19 July 2001

- (48) Date of publication of this corrected version: 23 August 2001
- (15) Information about Correction:
  see PCT Gazette No. 34/2001 of 23 August 2001, Section
  II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

# METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF

5

10

15

#### BACKGROUND OF THE INVENTION

#### Cross-Reference to Related Application

This application claims the benefit of priority of provisional patent application U.S. Serial Number 60/115,125, filed January 6, 1999 and of a U.S. application entitled "Method for the Detection of Gene Transcripts in Blood and uses Thereof" filed on January 4, 2000 (application number not yet assigned).

#### Field of the Invention

The present invention relates generally to the molecular biology of human diseases. More specifically, the present invention relates to a process using the genetic information contained in human peripheral whole blood for the diagnosis, prognosis and monitoring of genetic and infectious disease in the human body.

#### Description of the Related Art

20

25

The blood is a vital part of the human circulatory system for the human body. Numerous cell types make up the blood tissue including monocytes, leukocytes, lymphocytes and erythrocytes. Although many blood cell types have been described, there are likely many as yet undiscovered cell types in the human blood. Some of these undiscovered cells may exist transiently, such as those derived from tissues and organs that are constantly interacting with the circulating blood in health and disease. Thus, the blood can provide an immediate picture of what is happening in the human body at any given time.

The turnover of cells in the hematopoietic system is enormous. It was reported that over one trillion cells, including 200 billion erythrocytes and 70 billion neutrophilic leukocytes, turn over each day in the human body (Ogawa 1993). As a consequence of continuous interactions between the blood and the body, genetic changes that occur within the cells or tissues of the body will trigger specific changes in gene expression within blood. It is the goal of the present invention that these genetic alterations be harnessed for diagnostic and prognostic purposes, which may lead to the development of therapeutics for ameliorating disease.

The complete profile of gene expression in the circulating blood remains totally unexplored. It is hypothesized that gene expression in the blood is reflective of body state and, as such, the resultant disruption of homeostasis under conditions of disease can be detected through analysis of transcripts differentially expressed in the blood alone. Thus, the identification of several key transcripts or genetic markers in blood will provide information about the genetic state of the cells, tissues, organs and systems of the human body in health and disease.

The prior art is deficient in non-invasive methods of screening for tissue-specific diseases. The present invention fulfills this long-standing need and desire in the art.

#### SUMMARY OF THE INVENTION

This present invention discloses a process of using the genetic information contained in human peripheral whole blood in the diagnosis, prognosis and monitoring of genetic and infectious disease in the human body. The process described herein requires a simple blood sample and is, therefore, non-invasive compared to conventional practices used to detect tissue specific disease, such as biopsies.

5

10

15

20

One object of the present invention is to provide a non-invasive method for the diagnosis, prognosis and monitoring of genetic and infectious disease in humans and animals.

In one embodiment of the present invention, there is provided a method for detecting expression of a gene in blood from a subject, comprising the steps of: a) quantifying RNA from a subject blood sample: and b) detecting expression of the gene in the quantified RNA, wherein the expression of the gene in quantified RNA indicates the expression of the gene in the subject blood.

5

10

15

20

25

BNSDOCID: <WO\_\_\_\_

0040749A3 IA>

In another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample: b) extracting RNA from the blood sample; c) amplifying the RNA: d) generating expressed sequence tags (ESTs) from the amplified RNA product: and e) detecting expression of the genes in the ESTs, wherein the expression of the genes in the ESTs indicates the expression of the genes in the subject blood. Preferably, the genes are tissue-specific genes.

...

In still another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample: b) extracting DNA fragments from the blood sample: c) amplifying the DNA fragments; and d) detecting expression of the genes in the amplified DNA product, wherein the expression of the genes in the subject blood.

In yet another embodiment of the present invention, there is provided a method for monitoring a course of a therapeutic treatment in an individual, comprising the steps of: a) obtaining a blood sample from the individual; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; e) detecting expression of genes in the ESTs, wherein the expression of the genes is associated with the effect of

the therapeutic treatment: and f) repeating steps a)-e), wherein the course of the therapeutic treatment is monitored by detecting the change of expression of the genes in the ESTs. Such a method may also be used for monitoring the onset of overt symptoms of a disease, wherein the expression of the genes is associated with the onset of the symptoms.

In still yet another embodiment of the present invention, there is provided a method for diagnosing a disease in a test subject, comprising the steps of:

a) generating a cDNA library for the disease from a whole blood sample from a normal subject; b) generating expressed sequence tag (EST) profile from the normal subject cDNA library; c) generating a cDNA library for the disease from a whole blood sample from a test subject; d) generating EST profile from the test subject cDNA library; and e) comparing the test subject EST profile to the normal subject EST profile, wherein if the test subject EST profile differs from the normal subject EST profile, the test subject might be diagnosed with the disease.

In still yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) gene-specific primers; wherein the primers are designed in such a way that their sequences contain the opposing ends of two adjacent exons for the specific gene with the intron sequence excluded; and b) a carrier, wherein the carrier immobilizes the primer(s). Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease.

In yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) probes derived from a whole blood sample for a specific disease; and b) a carrier, wherein the carrier immobilizes the probes. Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease.

Furthermore, the present invention provides a cDNA library specific for a disease, wherein the cDNA library is generated from whole blood samples.

5

10

15

20

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention. These embodiments are given for the purpose of disclosure.

5

10

15

20

25

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope not be considered to limit the scope of the invention.

Figure 1 shows the following RNA samples prepared from human blood; Figure 1A: Lane 1, Molecular weight marker; Lane 2, RT-PCR on APP gene; Lane 3, PCR on APP gene: Lane 4, RT-PCR on APC gene; Lane 5, PCR on APC gene; Figure 1B: Lanes 1 and 2, RT-PCR and PCR of βMyHC, respectively; Lanes 3 and 4, RT-PCR of βMyHC from RNA prepared from human fetal and human adult heart, respectively; Lane 5, Molecular weight marker.

Figure 2 shows quantitative RT-PCR analysis performed on RNA samples extracted from a drop of blood. Forward primer (5'-GCCCTCTGGGGACCTGAC-3', SEQ ID No. 1) of exon 1 and reverse primer (5'-CCCACCTGCAGGTCCTCT-3", SEQ ID No. 2) of exons 1 and 2 of insulin gene. Blood samples of 4 normal subjects were assayed. Lanes 1, 3, 5 and 7 represent overnight "fasting" blood sample and lanes 2, 4, 6 and 8 represent "non-fasting" samples.

Figure 3 shows quantitative RT-PCR analysis performed on RNA samples extracted from a drop of blood. Lanes 1 and 2 represent normal healthy person and lane 3 represents late-onset diabetes (Type II) and lane 4 represents asymptomatic diabetes.

Figure 4 shows multiple RT-PCR assay in a drop of blood. Primers were derived from insulin gene (INS), zinc-finger protein gene (ZFP) and house-keeping gene (GADH). Lane 1 represents normal person. Lane 2 represents late-onset diabetes and lane 3 represents asymptomatic diabetes.

Figure 5 shows standardized levels of insulin gene (Figure 5A) and ZFP gene (Figure 5B) expressed in a drop of blood. The first three subjects were normal, second two subjects showed normal glucose tolerance, and the last subject had late onset diabetes type II. Figure 5C shows standardized levels of insulin gene expressed in each fractionated cell from whole blood.

Figure 6 shows the differential screening of human blood cell cDNA library with different cDNA probes of heart and brain tissue. Figure 6A shows blood cell cDNA probes vs. adult heart cDNA probes. Figure 6B shows blood cell cDNA probes vs. human brain cDNA probes.

Figure 7 graphically shows the 1,800 unique genes in human blood and in the human fetal heart grouped into seven cellular functions.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, "Molecular Cloning: A Laboratory Manual (1982); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed.

1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid

5

10

15

20

Hybridization" [B.D. Hames & S.J. Higgins eds. (1985)]; "Transcription and Translation" [B.D. Hames & S.J. Higgins eds. (1984)]; "Animal Cell Culture" [R.I. Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A Practical Guide To Molecular Cloning" (1984). Therefore, if appearing herein, the following terms shall have the definitions set out below.

A "cDNA" is defined as copy-DNA or complementary-DNA, and is a product of a reverse transcription reaction from an mRNA transcript. "RT-PCR" refers to reverse transcription polymerase chain reaction and results in production of cDNAs that are complementary to the mRNA template(s).

\*\*\*

The term "oligonucleotide" is defined as a molecule comprised of two or more deoxyribonucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide. The term "primer" as used herein refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and The primer may be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and the method used. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides. The factors involved in determining the appropriate length of primer are readily known to one of ordinary skill in the art.

As used herein, random sequence primers refer to a composition of primers of random sequence, i.e. not directed towards a specific sequence. These

5

10

15

20

sequences possess sufficient complementary to hybridize with a polynucleotide and the primer sequence need not reflect the exact sequence of the template.

"Restriction fragment length polymorphism" refers to variations in DNA sequence detected by variations in the length of DNA fragments generated by restriction endonuclease digestion.

A standard Northern blot assay can be used to ascertain the relative amounts of mRNA in a cell or tissue obtained from plant or other tissue, in accordance with conventional Northern hybridization techniques known to those persons of ordinary skill in the art. The Northern blot uses a hybridization probe, e.g. radiolabelled cDNA, either containing the full-length, single stranded DNA or a fragment of that DNA sequence at least 20 (preferably at least 30, more preferably at least 50, and most preferably at least 100 consecutive nucleotides in length). The DNA hybridization probe can be labelled by any of the many different methods known to those skilled in this art. The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to untraviolet light, and others. A number of fluorescent materials are known and can be utilized as labels. These include, for example, fluorescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is antirabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate. Proteins can also be labeled with a radioactive element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from <sup>3</sup>H, <sup>14</sup>C, <sup>32</sup>P, <sup>35</sup>S, 36Cl, 51Cr, 57Co, 58Co, 59Fe, 90Y, 125I, 131I, and 186Re. Enzyme labels are likewise useful, and can be detected by any of the presently utilized colorimetric, fluorospectrophotometric, amperometric or gasometric spectrophotometric, techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known and can be utilized.

5

10

15

20

The preferred are peroxidase,  $\beta$ -glucuronidase,  $\beta$ -D-glucosidase,  $\beta$ -D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Patent Nos. 3,654,090, 3.850,752, and 4,016,043 are referred to by way of example for their disclosure of alternate labeling material and methods.

As used herein, "individual" refers to human subjects as well as non-human subjects. The examples herein are not meant to limit the methodology of the present invention to human subjects only, as the instant methodology is useful in the fields of veterinary medicine, animal sciences and such.

In one embodiment of the present invention, there is provided a method for detecting expression of a gene in blood from a subject, comprising the steps of: a) quantifying RNA from a subject blood sample; and b) detecting expression of the gene in the quantified RNA, wherein the expression of the gene in quantified RNA indicates the expression of the gene in the subject blood. An example of the quantifying method is by mass spectrometry.

In another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; and e) detecting expression of the genes in the ESTs, wherein the expression of the genes in the ESTs indicates the expression of the genes in the subject blood. Preferably, the subject is a fetus, an embryo, a child, an adult or a non-human animal. The genes are non-cancer-associated and tissue-specific genes. Still preferably, the amplification is performed by RT-PCR using random sequence primers or gene-specific primers.

In still another embodiment of the present invention, there is provided a method for detecting expression of one or more genes in blood from a subject, comprising the steps of: a) obtaining a subject blood sample; b) extracting DNA fragments from the blood sample; c) amplifying the DNA fragments; and d) detecting

5

10

15

20

expression of the genes in the amplified DNA product, wherein the expression of the genes in the amplified DNA product indicates the expression of the genes in the subject blood.

In yet another embodiment of the present invention, there is provided a method for monitoring a course of a therapeutic treatment in an individual, comprising the steps of: a) obtaining a blood sample from the individual; b) extracting RNA from the blood sample; c) amplifying the RNA; d) generating expressed sequence tags (ESTs) from the amplified RNA product; e) detecting expression of genes in the ESTs, wherein the expression of the genes is associated with the effect of the therapeutic treatment; and f) repeating steps a)-e), wherein the course of the therapeutic treatment is monitored by detecting the change of expression of the genes in the ESTs. Such a method may also be used for monitoring the onset of overt symptoms of a disease, wherein the expression of the genes is associated with the onset of the symptoms. Preferably, the amplification is performed by RT-PCR, and the change of the expression of the genes in the ESTs is monitored by sequencing the ESTs and comparing the resulting sequences at various time points; or by performing single nucleotide polymorphism analysis and detecting the variation of a single nucleotide in the ESTs at various time points.

In still yet another embodiment of the present invention, there is provided a method for diagnosing a disease in a test subject, comprising the steps of:

a) generating a cDNA library for the disease from a whole blood sample from a normal subject; b) generating expressed sequence tag (EST) profile from the normal subject cDNA library; c) generating a cDNA library for the disease from a whole blood sample from a test subject; d) generating EST profile from the test subject cDNA library; and e) comparing the test subject EST profile to the normal subject EST profile, wherein if the test subject EST profile differs from the normal subject EST profile, the test subject might be diagnosed with the disease.

5

10

15

20

In still yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) genespecific primers; wherein the primers are designed in such a way that their sequences contain the opposing ends of two adjacent exons for the specific gene with the intron sequence excluded; and b) a carrier, wherein the carrier immobilizes the primer(s). Preferably, the gene-specific primers are selected from the group consisting of insulinspecific primers, atrial natriuretic factor-specific primers, zinc finger protein genespecific primers, beta-myosin heavy chain gene-specific primers, amyloid precurser protein gene-specific primers, and adenomatous polyposis-coli protein gene-specific primers. Further preferably, the gene-specific primers are selected from the group consisting of SEQ ID Nos. 1 and 2; and SEQ ID Nos. 5 and 6. Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease by detecting the quantitative expression levels of specific genes associated with the disease in the test subject and then comparing to the levels of same genes expressed in a normal subject. Such a kit may also be used for monitoring a course of therapeutic treatment or monitoring the onset of overt symptoms of a disease.

5

10

15

20

25

BNSDCCID: <WO\_\_\_\_\_0040749A3\_IA>

In yet another embodiment of the present invention, there is provided a kit for diagnosing, prognosing or predicting a disease, comprising: a) probes derived from a whole blood sample for a specific disease; and b) a carrier, wherein the carrier immobilizes the probes. Such a kit may be applied to a test subject whole blood sample to diagnose, prognose or predict a disease by detecting the quantitative expression levels of specific genes associated with the disease in the test subject and then comparing to the levels of same genes expressed in a normal subject. Such a kit may also be used for monitoring a course of therapeutic treatment or monitoring the onset of overt symptoms of a disease.

Furthermore, the present invention provides a cDNA library specific for a disease, wherein the cDNA library is generated from whole blood samples.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

5

10

15

#### **EXAMPLE 1**

#### Construction of a cDNA library

RNA extracted from human tissues (including fetal heart, adult heart, liver, brain, prostate gland and whole blood) were used to construct unidirectional cDNA libraries. The first mammalian heart cDNA library was constructed as early as 1982. Since then, the methodology has been revised and optimal conditions have been developed for construction of human heart and hematopoietic progenitor cDNA libraries (Liew et al., 1984; Liew 1993, Claudio et al., 1998). Most of the novel genes which were identified by sequence annotation can now be obtained as full length transcripts.

#### EXAMPLE 2

#### Catalogue of blood cell ESTs

20

Random partial sequencing of expressed sequence tags (ESTs) of cDNA clones from the blood cell library was carried out to establish an EST database of blood. The known genes as derived from the ESTs were categorized into seven major cellular functions (Hwang, Dempsey et al., 1997).

5

10

15

20

25

770

#### **EXAMPLE 3**

#### Differential screening of cDNA library

cDNA probes generated from transcripts of each tissue were used to hybridize the blood cell cDNA clones (Liew *et al.*, 1997). The "positive" signals which were hybridized with <sup>32</sup>P-labelled cDNA probes were defined as genes which shared identity with blood and respective tissues. The "negative" spots which were not exposed to <sup>32</sup>P-labelled cDNA probes were considered to be blood-cell-enriched or low frequency transcripts.

#### **EXAMPLE 4**

#### Reverse transcriptase-polymerase chain reaction (RT-PCR) assay

RNA extracted from samples of human tissue was used for RT-PCR analysis (Jin et al. 1990). Three pairs of forward and reverse primers were designed for human cardiac beta-myosin heavy chain gene (βMyHC), amyloid precurser protein (APP) gene and adenomatous polyposis-coli protein (APC) gene. The PCR products were also subjected to automated DNA sequencing to verify the sequences as derived from the specific transcripts of blood.

#### **EXAMPLE 5**

#### Detection of tissue specific gene expression in human blood using RT-PCR

The beta-myosin heavy chain gene (βMyHC) transcript (mRNA) is known to be highly expressed in ventricles of the human heart. This sarcomeric protein is important for heart muscle contraction and its presence would not be expected in other non-muscle tissues and blood. In 1990, the gene for human cardiac

βMyHC was completely sequenced (Liew et al. 1990) and was comprised of - exons and 42 introns.

The method of reverse transcription polymerase chain reaction (RT-PCR) was used to determine whether this cardiac specific mRNA is also present in human blood. A pair of primers was designed; the forward primer (SEQ ID No. 3) was on the boundary of exons 21 and 22, and the reverse primer (SEQ ID No. 4) was on the boundary of exons 24 and 25. This region of mRNA is only present in  $\beta$ MyHC and is not found in the alpha-myosin heavy chain gene ( $\alpha$ MyHC).

A blood sample was first treated with lysing buffer and then undergone centrifuge. The resulting pellets were further processed with RT-PCR. RT-PCR was performed using the total blood cell RNA as a template. A nested PCR product was generated and used for sequencing. The sequencing results were subjected to BLAST and the identity of exons 21 to 25 was confirmed to be from βMyHC (Figure 1A).

Using the same method just described, two other tissue specific genes - amyloid precursor protein (APP, forward primer, SEQ ID No. 7; reverse primer, SEQ ID No. 8) found in the brain and associated with Alzheimer's disease, and adenomatous polyposis coli protein (APC) found in the colon and rectum and associated with colorectal cancer (Groden *et al.* 1991; Santoro and Groden 1997) - were also detected in the RNA extracted from human blood (Figure 1B).

20

25

5

10

15

#### EXAMPLE 6

#### Multiple RT-PCR analysis on a drop of blood from a normal/diseased individual

A drop of blood was extracted to obtain RNA to carry out quantitative RT-PCR analysis. Specific primers for the insulin gene were designed: forward primer (5'-GCCCTCTGGGGACCTGAC-3', SEQ ID No. 1) of exon 1 and reverse primer (5'-CCCACCTGCAGGTCCTCT-3", SEQ ID No. 2) of exons 1 and 2 of insulin gene. Such reverse primer was obtained by deleting the intron between the

exons 1 and 2. Blood samples of 4 normal subjects were assayed. It was found that the insulin gene is expressed in the blood and the quantitative expression of the insulin gene in a drop of blood is influenced by fasting and non-fasting states of normal healthy subjects (Figure 2). This very low level of expression of the insulin gene reflects the phenotypic status of a person and strongly suggests that there is a physiological and pathological role for its expression, contrary to the basal or illegitimate theory of transcription suggested by Chelly *et al.* (1989) and Kimoto (1998).

Same quantitative RT-PCR analysis was performed using insulin specific primers on RNA samples extracted from a drop of blood from a normal healthy person, a person having late-onset diabetes (Type II) and a person having asymptomatic diabetes. It was found that the insulin gene is expressed differentially amongst subjects that are healthy, diagnosed as type II diabetic, and also in an asymptomatic preclinical patient (Figure 3).

Similarly, specific primers for the atrial natriuretic factor (ANF) gene were designed (forward primer, SEQ ID No. 5; reverse primer, SEQ ID No. 6) and RT-PCR analysis was performed on a drop of blood. ANF is known to be highly expressed in heart tissue biopsies and in the plasma of heart failure patients. However, atrial natriuretic factor was observed to be expressed in the blood and the expression of the atrial natriuretic factor gene is significantly higher in the blood of patients with heart failure as compared to the blood of a normal control patient.

Specific primers for the zinc finger protein gene (ZFP, forward primer, SEQ ID No. 9; reverse primer, SEQ ID No. 10) were also designed and RT-PCR analysis was performed on a drop of blood. ZFP is known to be high in heart tissue biopsies of cardiac hypertrophy and heart failure patients. In the present study, the expression of ZFP was observed in the blood as well as differential expression levels of ZFP amongst the normal, diabetic and asymptomatic preclinical subjects (Figure 4); although neither of the non-normal subjects has been specifically diagnosed as

5

10

15

20

suffering from cardiac hypertrophy and/or heart failure, the higher expression levels of the ZFP gene in their blood may indicate that these subjects are headed in that general direction.

It was hypothesized that a housekeeping gene such as glyceraldehyde dehydrogenase (GADH) which is required and highly expressed in all cells would not be differentially expressed in the blood of normal vs. disease subjects. This hypothesis was confirmed by RT-PCR using GADH specific primers (Figure 4). Thus, GADH is useful as an internal control.

Standardized levels of insulin gene or ZFP gene expressed in a drop of blood were estimated using a housekeeping gene as an internal control relative to insulin or ZFP expressed (Figures 5A & 5B). The levels of insulin gene expressed in each fractionated cell from whole blood were also standardized and shown in Figure 5C.

EXAMPLE 7

### Human blood cell cDNA library

In order to further substantiate the present invention, differential screening of the human blood cell cDNA library was conducted. cDNA probes derived from human blood, adult heart or brain were respectively hybridized to the human blood cDNA library clones. As shown in Figure 7, more than 95% of the "positively" identified clones are identical between the blood and other tissue samples.

DNA sequencing of randomly selected clones from the human whole blood cell cDNA library was also performed. This allowed information regarding the cellular function of blood to be obtained concurrently with gene identification. More than 20,000 expressed sequence tags (ESTs) have been generated and characterized to date, 17.6% of which did not result in a statistically significant match to entries in the

5

10

15

20

GenBank databases and thus were designated as "Novel" ESTs. These results are summarized in Figure 7 together with the seven cellular functions related to percent distribution of known genes in blood and in the fetal heart.

From 20,000 ESTs. 1,800 have been identified as known genes which may not all appear in the hemapoietic system. For example, the insulin gene and the atrial natriuretic factor gene have not been detected in these 20,000 ESTs but their transcripts were detected in a drop of blood, strongly suggesting that all transcripts of the human genome can be detected by performing RT-PCR analysis on a drop of blood.

In addition, approximately 400 novel genes have been identified from the 20,000 ESTs characterized to date, and these will be subjected to full length sequencing and open reading frame alignment to reduce the actual number of novel ESTs prior to screening for disease markers.

Analysis of the approximately 6,283 ESTs which have known matches in the GenBank databases revealed that this dataset represents over 1,800 unique genes. These genes have been catalogued into seven cellular functions. Comparisons of this set of unique genes with ESTs derived from human brain, heart, lung and kidney demonstrated a greater than 50% overlap in expression (Table 1).

20

25

5

10

15

TABLE 1

#### Overlap of Genes Expressed in Blood \*

Tissues	ESTs**	Overlap in Blood	i
brain	134,000	60%	
heart	65,000	59%	
lung	60,200	58%	
kidney	32,300	54%	

\* Estimated from limited known genes of about 1,800 as derived from the database of 6,297 ESTs from human blood cell library.

\*\* Obtained from the National Centre of Biotechnology Information (NCBI), U.S.A.

5

10

15

20

25

#### **EXAMPLE 8**

#### Blood cell ESTs

The results from the differential screening clearly indicate that the transcripts expressed in the whole blood are reflective of genes expressed in all cells and tissues of the body. More than 95% of detectable spots were identical from two different tissues. The remaining 5% of spots may represent cell- or tissue-specific transcripts; however, results obtained from partial sequencing to generate ESTs of these clones revealed most of them not to be cell- or tissue-specific transcripts. Therefore, the negative spots are postulated to be reflective of low abundance transcripts in the tissue from which the cDNA probes were derived.

An alternative approach that was employed to identify transcripts expressed at low levels is the large-scale generation of expressed sequence tags (ESTs). There is substantial evidence regarding the efficiency of this technology to detect previously characterized (known) and uncharacterized (unknown or novel) genes expressed in the cardiovascular system (Hwang & Dempsey et al., 1997). In the present invention, 20,000 ESTs have been produced from a human blood cell cDNA library and resulted in the identification of approximately 1,800 unique known genes (Table 2)

In the most recent GenBank release, analysis of more than 300,000 ESTs in the database (dbESTs) generated more than 48,000 gene clusters which are thought to represent approximately 50% of the genes in the human genome. Only 4,800 of the dbESTs are blood-derived. In the present invention, 20,000 ESTs have

been obtained to date from a human blood cDNA library, which provides the world's most informative database with respect to blood cell transcripts. From the limited amount of information generated so far (i.e. 1,800 unique genes), it has already been determined that more than 50% of the transcripts are found in other cells or tissues of the human body (Table 2). Thus, it is expected that by increasing the number of ESTs generated, more genes will be identified that have an overlap in expression between the blood and other tissues. Furthermore, the transcripts for several genes which are known to have tissue-restricted patterns of expression (i.e. βMyHC, APP, APC, ANF, ZFP) have also been demonstrated to be present in blood.

5

10

15

20

BNSDOCID: <WO

0040749A3 IA>

Most recently, a cDNA library of human hematopoietic progenitor stem cells has also been constructed. From the limited set of 1,000 ESTs, there are at least 200 known genes that are shared with other tissue related genes (Claudio *et al.* 1998).

12

Table 2 demonstrates the expression of known genes of specific tissues in blood cells. Previously, only the presence of "housekeeping" genes would have been expected. Additionally, the presence of at least 25 of the currently known 500 genes corresponding to molecular drug targets was detected. These molecular drug targets are used in the treatment of a variety of diseases which involve inflammation, renal and cardiovascular function. neoplastic disease, immunomodulation and viral infection (Drews & Ryser, 1997). It is expected that additional novel ESTs will represent future molecular drug targets.

TABLE 2

# Comparison of 1.800 Unique Genes Identified in the Blood Cell cDNA Library to Genes Previously Identified in Specific Tissues

Gene Identification	No. of ESTs		Tissue Distribution								
			В	Br	н	K	Li	Lu			
100 kDa coactivator	2	U22055		+				+			
10kD protein (BC10)	2	AF053470		+	+		+	+			
14-3-3 epsilon	2	U54778		+	+			+			
14-3-3 protein	- 11	U28964		+	+		+	-			
15 kDa selenoprotein (SEP15)	<del>1</del>	AF051894		+	+			+			
1-phosphatidylinositol-4- phosphate 5-kinase isoform C	1	S78798									
23 kD highly basic protein	21	X56932	+	+	+	+	+	+			
2-5A-dependent RNase	7	L10381									
2'-5'oligoadenylate synthetase 2 (OAS2)	4	M87284	В								
26S proteasome subunit 11	1	AF086708									
36 kDa phosphothyrosine protein	2	AJ223280			+						
3-7 gene product (non- exact 86%aa)	1	D64159									
3-phosphoglycerate dehydrogenase (PGAD)	1	AF006043	Т	+	+			+			
3-prime-phosphoadenosine 5-prime-phosphosulfate synthase 1 (PAPSS1)	2	U53447	+	+	•	+		+			
46kd mannose 6- phosphate receptor (MPR46) (low match)	1	X56257									
5-aminoimidazole-4- carboxamide ribonucleotide transformylase	1	D89976									
5'-nucleotidase	3	D38524	T	+		$\Box$	+				
6-phosphofructo-2- kinase/fructose-2,6- biphosphatase 4 (PFKFB4)	1	D49818		+							
6-phosphofructo-2- kinase/fructose-2,6- bisphosphatase (PF2K)	1	AF041829									
71 kd heat shock cognate protein hsc70	23	Y00371									
76 kDa membrane protein (P76)	2	U81006		+	+	+	+	+			
8-oxoguanine DNA glycosylase (OGG1)	1	U96710	В				+	+			
a disintegrin and metalloprotease domain 10 (ADAM10)	1	AF009615	1				+				
a disintegrin and metalloprotease domain 8 (ADAM8)	1	D26579	В	+							
A kinase anchor protein 95 (AKAP95)	2	Y11997	B, T activated		+			+			
A kinase anchor protein, 149kD (AKAP149)	2	X97335		+	+	+		+			

A4 differentiation-									1 C 1/CA00/00005
dependent protein (A4), triple LIM domain protein (LMO6), and synaptophysin (SYP); calcium channel alpha-1		U93305							
Subunit (CACNA1F) ABL and putative M8604	1	U07561		+-	-	+	- -	-	
Met protein Absent in melanoma 1	1 1	U83115	<del>                                     </del>	+	<u> </u>	$\bot$	4	+	
(AIM1) accessory proteins	1 2	Z31696	<del> </del>	<u> </u>					
BAP31/BAP29 (DXS1357E)				+	+				
acetyl-Coenzyme A acyltransferase (peroxisomal 3-oxoacyl- Coenzyme A thiolase) (ACAA)	2	X12966	+	+	+	+	+	+	
acetyl-Coenzyme A transporter (ACATN)	1	D88152	Tlymphoma	+	+	+	+-	+-	
acidic 82 kDa protein	4	U15552			<del> </del>	+-	+	+	
acidic protein rich in leucines (SSP29)	1	Y07969	В	+	+		+	+	
Aconitase 2, mitochondrial (ACO2)	1	U80040	+	+	+	+	+	+	
actin binding protein MAYVEN	1	AF059569			1	+-	+	+	
actin, beta (ACTB)	158	X04098	Т, В	+	+	+-	+	+-	<del>                                     </del>
actin, beta (ACTB) (non- exact, low match 73%)	1	M10277				1			
actin, gamma (low score)	1	K00791				1		+	o .
actin, gamma 1 (ACTG1)	4	X04098	+	+	+	+	+	+	high in many librar
actin-binding LIM protein (ABLIM) Actinin, alpha 1 (ACTN1)	4	D31883		+	+	+		+	
actinin, alpha 4 (ACTN4)	8	M95178		+	+	+		+	
activated p21cdc42Hs	1	D89980		+	+		+		
kinase (ACK) activated RNA polymerase		L13738	В	+				+	
I transcription cofactor 4 PC4)	1	X79805	+	+	+	+		+	
activating transcription actor 1 (ATF1)		X55544			+				
actor 2 (ATF2)	1	X15875		+	+		+		
activating transcription actor 4 (tax-responsive enhancer element B67) ATF4)	2	M86842					+	+	
ctive BCR-related gene ABR)	1	U01147	+	+	+	+		+	
cyl-CoA oxidase (AOX)	1	U03254		<del>-  </del>			_		<del></del>
cyl-Coenzyme A ehydrogenase, C-4 to C- 2 straight chain (ACADM)	2	M16827				$\dashv$			
cyl-Coenzyme A ehydrogenase, very long hain (ACADVL)	3	D43682	+	+	+	+	+	+	
cyloxyacyl hydrolase neutrophil) (AOAH)	3	M62840	1	_	+	+	+	+	
daptin, delta (ADTD)	2	U91930		+	+	$\dashv$	+	$\dashv$	
daptin, delta (ADTD) ion-exact 59%)	1	AC005328		$\dashv$	$\dashv$	+			
daptin, gamma (ADTG)	1	Y12226	<del></del>	+	+	+	4	+	
aptor complex sigma3B	2	X99459		+		+		+	
AP3S3)	-	1.00	J	· 1				•	
P3S3) Idaptor protein p150 Iducin 1 (alpha) (ADD1)	<del>-</del> 1	Y08991		-			-		

WO 00/40749									
adducin 1 (alpha) (add1)	3	L29296	+	+	+	+		+	
adducin 3 (gamma) (ADD3)	3	U37122	B. W	+	+		+	+	
adenine nucleotide		M57424		+	+		+		
translocator 2 (fibroblast)	-	11.07.424							
(ANT2)									
adenine nucleotide	1	J02683							
translocator 2 (fibroblast)									ł
(ANT2) (non-exact 81%)		J02683						-	
adenine nucleotide translocator 2 (fibroblast)	1	102003							
(ANT2) (non-exact, 79%)						1			
adenine nucleotide	1	J02683							
translocator 2 (fibroblast)									ļ
(ANT2) (non-exact, 86%)		100500		+	+		+	+	
adenine nucleotide	3	J03592		_	_		-	•	<b>.</b>
translocator 3 (liver) (ANT3)									
adenosine deaminase,	6	U18121		+	+		+		
RNA-specific (ADAR)									
adenylate cyclase 3	2	AF033861		+	+	+	+	+	
(ADCY3)						<del> </del>			
adenylate cyclase 7	1	D25538	į į			1			
(ADCY7)	2	U39945		+	+	<del>                                     </del>	+	+	
adenylate kinase 2 (AK2)		X60673			-	-	-		
adenylate kinase 3 (AK3)	. 1	V00012		1	1	1			
(non-exact, 67%) adenylyl cyclase-	28	M98474	1 . 1	<del>                                     </del>	+		+		
associated protein (CAP)			l						
adipose differentiation-	1	X97324			+		+	+	
related protein; adipophilin			İ	1			İ		
(ADFP)	42	M84326	ļ	+	+	<del>-</del>	+	+	
ADP-ribosylation factor 1	13	10104320		, ,	'		l .		
(ARF1) ADP-nbosylation factor 3	2	M33384		+	+	1	+		
(ARF3)	_					1		<u> </u>	
ADP-ribosylation factor 4	1	M36341	T lymphoma	+	+			+	
(ARF4)					+	++	+	+	
ADP-ribosylation factor 5	1	M57567	1	ļ	-		+	*	
(ARF5)	1	L04510		+	-	+	<del>                                     </del>	$\vdash$	
ADP-ribosylation factor domain protein 1, 64kD	1	204310		`			l	l	
(ARFD1)	1			İ	<u> </u>		<u> </u>		
ADP-ribosyltransferase	4	M32721	+	+	+	+	+	+	
(NAD+; poly (ADP-ribose)	i				1	1	ļ	1	i
polymerase) (ADPRT)	ļ	X61157	В	+	-	+	+	<del> </del>	
adrenergic, beta, receptor	2	701137		'		1			
kinase 1 (ADRBK1) adrenoleukodystrophy-like	-	AJ000327		<del>                                     </del>	†	T		1	
11 (ALDL1)	1								
AE-binding protein 1	1	D86479			1 _		]	1	
(AEBP1) (non-exact, 62%)	<del> </del> _	1107023		-	+	┼—		+-	
AF-17	1	U07932		<del>                  _       _  </del>	<del>            _     _  </del>	1_	<u> </u>	<del> </del>	
A-gamma-globin	1	V00514	<u> </u>				<u> </u>		ļ. <u></u>
A-gamma-globin	1	J00176					_	1	
(chromosome 11 allele)	<u> </u>	I HORAN		-	+	+		₩	
agammaglobulinaemia		U78027					1		1
tyrosine kinase (ATK) AHNAK nucleoprotein	4	M80899	+	+	+	+	1	+	
(desmoyokin) (AHNAK)	-		i				L	1_	
(alanyl (membrane)	1	X13276			+		+		
aminopeptidase	1		1			1	1		1
(aminopeptidase N,		1	ĺ		[		[		
aminopeptidase M, microsomal	1	1	1		1			,	
microsomai aminopeptidase, CD13,	1		1	1	1		1		
p150) (ANPEP)					<u>l</u> .			1	
alcohol dehydrogenase 5	1 1	M29872		T		T			
(class III), chi polypeptide	1			1	ì	1	1		
(ADH5)	<del> </del>	AF003341	+	+	+-	+	+	+	
aldehyde dehydrogenase  1. soluble (ALDH1)	1	AF003341					'	'	
I, SUIUDIE (ALDITI)			1						·

										400/00	
laldehyde dehydrogenase 10 (fatty aldehyde dehydrogenase) (ALDH10)	2	U75286									
aldehyde reductase 1 (low Km aldose reductase) (ALDR1)	3	J04795	В	+	+	+	+				
aldo-keto reductase family 1, member A1 (aldehyde reductase) (AKR1A1)	2	J04794	В	+	+		+				
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II)	1	D17793		+	+	+		+		<del></del> -	
(AKR1C3) aldo-keto reductase family	1	Y16675	1	+	+	-	+	+			
7, member A2 (aflatoxin aldehyde reductase) (AKR7A2)											
aldolase A, fructose- bisphosphate (ALDOA)	7	X12447		+	+		+				
aldolase C, fructose- bisphosphate (ALDOC)	2	X05196		+	+		+				
alkaline phosphatase, liver/bone/kidney (ALPL) ALL-1 (=L04731;L04284	4	4502062 Z69780									
HRX)	1	D55649		+			+				
isozyme alpha thalassemia/mental	3	U75653					_				
retardation syndrome X- linked (ATRX)			+	+	+	+		+		•	
alpha-2 macroglobulin	1	211711									
alpha-2-globin	2	∨00516					·				
alpha-2-macroglobulin receptor/lipoprotein receptor protein (A2MR/LRP)		U06985							당		
alpha-polypeptide of N- acetyl-alpha- glucosaminidase (HEXA)	1	M13520									
alpha-spectrin	1	X86901		+				+			
alpha-subunit of Gi2 a (GTP-binding signal transduction protein)	1	X07854						-			
aminin receptor 1 (67kD); Ribosomal protein SA (LAMR1)	2	J03799	T	+	+		+	+	-		
aminolevulinate, delta-, dehydratase (ALAD)	1	X64467		+							
amino-terminal enhancer of split (AES)	2	X73358	+	1+	+	+	7	+			
amino-terminal enhancer of split (AES)	3	U04241	В	+	+		+	+			
AMP deaminase isoform L (AMPD2)	8	M91029		+			$\neg$	7			
amphiphysin (Stiff-Mann syndrome with breast cancer 128kD autoantigen) (AMPH)	1	U07616	В	+				+			
amphiphysin (Stiff-Mann syndrome with breast cancer 128kD autoantigen) (AMPH)(non-exact, 68%)	1	U07616									
amphiphysin (Stiff-Mann syndrome with breast cancer 128kD autoantigen) (AMPH)(non-exact, 68%)		U07616									
amphiphysin II	4	U87558		1 +	+	$\neg$	+				$\overline{}$
amphiphysin II (67%aa amphiphysin?)	1	AF068915					$\neg \uparrow$	$\top$		····	
amphiphysin II (non-exact 69% aa)	1	AF001383									

#### WO 00/40749

WO 00/40/49									
amphiphysin-like (AMPHL)	1	U68485		+	+				
amphiphysin-like (AMPHL) (low match)	1	AF068918							
AMY-1	1	D50692	В, Т				+		
amyloid beta (A4) precursor protein-binding, family B, member 1 (Fe65) (APBB1)	1	L77864		+	+	+		+	
amyloid beta (A4) precursor-like protein 2 (APLP2)	6	L27631	Tlymphoma	+	+		+	+	
ankyrin 3, node of Ranvier (ankyrin G) (ANK) (non- exact, 50%)	1	U43965							
annexin I (lipocortin I) (ANX1)	1	X05908		+	+	+		+	
annexin II	1	D28364							1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
annexin II (lipocortin II; calpactin I, heavy polypeptide) (ANX2)	7	D00017	*	+	+	+	+		high in many libranes
annexin IV (placental anticoagulant protein II) (ANX4)	1	M19383		+	+	+	+	+	
annexin V (endonexin II) (ANX5)	2	M21731		+	+	+		+	
annexin V (endonexin II) (ANXV)	1	M19384		+	+	+		+	
annexin VI (p68) (ANX6)	6	Y00097		+	+	+		+	
annexin VII (synexin) (ANX7)	1	J04543		+	+	+		*	
antigen identified by monoclonal antibodies 12E7, F21 and O13 (MIC2)	2	M16279		+	+	+		+	
antigen identified by monoclonal antibodies 4F2, TRA1.10, TROP4, and T43 (MDU1)	3	J02939		+	+	+	+	+	
antigen TQ1	1					<u>L</u> _	<u></u>	<u> </u>	<u> </u>
anti-oxidant protein 2 (non- selenium glutathione peroxidase, acidic calcium- independent phospholipase A2) (KIAA0106)	1	D14662		+	+	+	+	+	
APEX nuclease (multifunctional DNA repair enzyme) (APEX)	5	X66133		+	+		+	+	
Apolipoprotein L (APOL) (59%aa)	1	Z82215						<u> </u>	
apoptosis inhibitor 1 (API1)	1	L49431	<u> </u>	+	+	+	+	+	
apoptosis inhibitor 4 (survivin) (API4)	1	U75285	B, W	+	+		+		
apoptosis inhibitor 5 (API5)	1	U83857	T lymphoma	<u> </u>		↓	+	<del>↓</del>	ļ
apoptosis specific protein (ASP)	1	Y11588	В	+		_	+	+	
apoptotic protease activating factor (APAF1)	1	AF013263	В	†	+		+		
aquaporin 3 (AQP3)	1	AB001325					+		
aquaponn 9 (AQP9)	7	AB008775	Tactivated				+		
arachidonate 12- lipoxygenase (ALOX12)	1	M58704					+	+	
arachidonate 5- lipoxygenase-activating protein (ALOX5AP)	3	X52195	+	+		+		+	
anadne homolog (ARI)	1	AJ009771	+	+	+	+	_	+	
ariadne-2 (D. melanogaster) homolog (all-trans retinoic acid inducible RING finger ) (ARI2)	1	AF099149	+	+	+	+		+	

ARP1 (actin-related protein		Vanna									00005
1, yeast) homolog A (centractin alpha)	1	X82206		+			+				
ARP2 (actin-related protein 2, yeast) homolog (ACTR2)	9	AF006082	<del> </del>	+	+	+	+	+			
ARP2/3 protein compex subunit 34 (ARC34)	5	AF006085	Tactivated,	+	+	$\dagger$	+	+			
Arp2/3 protein compex subunit p41 (ARC41)	6	AF006084	monocyte stimulated	+	+		1=	1			<del></del> .
Arp2/3 protein compex subunit p41 (ARC41)) (low match)	1	AF006084									
Arp2/3 protein complex subunit p16 (ARC16)	20	AF017807		+	+		+	+	<u> </u>		·
Arp2/3 protein complex subunit p20 (ARC20)	2	AF006087		+	+		+	+			
Arp2/3 protein complex subunit p21(ARC21)	3	AF006086	W				+	+			
ARP3 (actin-related protein 3, yeast) homolog (ACTR3)	1	AF006083	W		+		+	+			_
arrestin, beta 2 (ARRB2)	7	AF106941	B, T, W	+	+		+				
arsA (bacterial) arsenite transporter, ATP-binding, homolog 1 (ASNA1)	1	AF047469	B, T	+			+				•
aryl hydrocarbon receptor nuclear translocator-like (ARNTL)	2	AF044288	В	+	+		+				<del></del>
aryl hydrocarbon receptor- interacting protein (AIP)	1	U31913	+	+	+	+		+			
arylsulfatase A (ARSA)	1	X52151	Tactivated	+		-	+				
asialoglycoprotein receptor 2 (ASGR2)	1	M11025					+	+		9	nath.
asparaginyl-tRNA synthetase (NARS)	3	D84273		+	+		+				
aspartyl-tRNA synthetase (DARS)	1	J05032	В	+	+		+		• • • • • • • • • • • • • • • • • • • •		
ataxia telangiectasia mutated (includes	1	U82828	В, Т		+		+				
complementation groups A, C and D) (ATM)											****
ataxin-2-like protein A2LP (A2LG)	1	AF034373	B, T activated	+	+			+			
ATF6	1	AF005887	activated	+-			+				
ATP binding cassette	1	U88667									
transporter (ABCR) (non- exact 80%)											
ATP synthase (F1-ATPase) alpha subunit, mitochondrial	1	X59066									
ATP synthase beta subunit gene	1	M19482					$\neg$	_			
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b, isoform 1 (ATP5F1)	1	X60221	+	+	+	+		+	_		
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c (subunit 9), isoform 1 (ATP5G1)	1	X69907	Tactivated	+	+		+	+	-		
ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscle (ATP5A1)	3	D14710									- <u> </u>
ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit, isoform 1, cardiac muscle (ATP5A1) (low match)	1	D14710			·						

WO 00/40749								PC	T/CA00/00005
ATP synthase, H+ transporting, mitochondrial F1 complex, beta	2	M27132							
polypeptide (ATP5B) ATP synthase, H+ transporting, mitochondrial F1 complex, gamma	1	D16563	w	+	+	+	+		
polypeptide 1 (ATP5C1) ATP synthase, H+ transporting, mitochondrial F1F0, subunit g (ATP5JG)	1	AF092124	+	+	+	+	+	+	·
ATP/GTP-binding protein (HEAB)	2	U73524	+	+	+	+		+	
ATPase, Ca++ transporting, ubiquitous (ATP2A3)	5	Z69881		+					
ATPase, H+ transporting, lysosomal (vacuolar proton pump) 21kD (ATP6F)	2	D89052	+	+	+	+		+	
ATPase, H+ transporting, lysosomal (vacuolar proton pump) 31kD (ATP6E)	1	X76228		+	+	+		+	
ATPase, H+ transporting, lysosomal (vacuolar proton pump) 42kD; Vacuolar proton-ATPase, subunit C; V-ATPase, subunit C (ATP6D)	5	X69151		+	+	+		+	
ATPase, H+ transporting, lysosomal (vacuolar proton pump), alpha polypeptide, 70kD, isoform 1 (ATP6A1)	3	L09235		+		+			
ATPase, H+ transporting, iysosomal (vacuolar proton pump), beta polypeptide, 56/58kD, isoform 2 (ATP6B2)	6	X62949	+	+	+	+		+	
ATPase, H+ transporting, lysosomal (vacuolar proton pump), member J (ATP6J)	2	AF038954	+	+	+	+	·		high in testis
ATPase, H+ transporting, lysosomal (vacuolar proton pump), subunit 1 (ATP6S1)	1	D16469		+	+	+		+	
ATP-binding cassette 50 (TNF-alpha stimulated) (ABC50)	1	AF027302	+	+	+	+		+	
ATP-binding cassette protein M-ABC1 (mitochondrial)	1	AF047690							
ATP-dependent RNA	1	AJ010840	Tlymphoma		+		+		
autoantigen (Hs.75528)	2	L05425	Tactivated		+	<del>                                     </del>		<u> </u>	
autoantigen (Hs.75528) (non-exact 84%)	1	L05425		L				<u> </u>	
autoantigen (Hs.75682)	1	U17474	В	+		<u> </u>	-	+	
autoantigen La/SS-B	1	Z35127	ļ	+	<u> </u>	-	<u> </u>		
axin (AXIN1)	1	AF009674 AJ000522		<del>                                     </del>		$\vdash$	-	+	
axonemal dynein heavy chain (DNAH17)	1					<u> </u>	<u> </u>	Ĺ	
BAI1-associated protein 3 (BAIAP3) (non-exact 54%)	1	AB017111			<u> </u>	_			
basement membrane- induced gene (ICB1)	1	AF044896				<u> </u>		_	
basic leucine zipper nuclear factor 1 (JEM-1) (BLZF1)	2	U79751						_	
basic transcription factor 3 (BTF3)	5	X74070	+	+	+	+	+	+	
basigin (BSG)	1	L10240		+	<del> </del>	<del> </del>	+	╄	
BC-2	1	AF042384	В	<u> </u>	+	+	+		<u> </u>

P coll CU /lymphome 5		1 110044							C1/CA00/00005
B-cell CLL/lymphoma 6 (zinc finger protein 51) (BCL6)		U00115		+	+				
B-cell translocation gene 1, anti-proliferative (BTG)		X61123			+			+	·
BCL2/adenovirus E1B 19kD-interacting protein 2 (BNIP2)	1	U15173	В	+			+	+	
BCL2/adenovirus E1B 19kD-interacting protein 3- like (BNIP3L)	2	AF067396		+	+	+		+	
beclin 1 (coiled-coil, myosin-like BCL2- interacting protein) (BECN1)	1	AF077301	В	+	+		+		
beta-1,2-N- acetylglucosaminyltransfer ase II (MGAT2)	2	U15128							
beta-2-microglobulin (B2M)	63	S82297	+	+	+	+	+	+	high in invasive prostate tumor
beta-hexosaminidase alpha chain (HEXA)	1	M16411							prostate tamor
beta-tubulin	7	V00599	+	+ +	+	+	+	+	high in many libraries
beta-tubulin (non-exact, 76%)	1	AF070561	-						
beta-tubulin, pseudogene	1	J00315		+		$\dashv$			
BING4	1	Z97184	<del></del>	1					· · · · · · · · · · · · · · · · · · ·
biotinidase (BTD) (non-eact 62%)	1	U03274				$\dashv$			
biotinidase (BTD) (non- exact 70%)	1	U03274			_		_	$\dashv$	
biotinidase (BTD) (non- exact, 56%)	1	U03274				_		+	
BIOTINIDASE PRECURSOR	1	P43251				_	$\dashv$		
biphenyl hydrolase-like (serine hydrolase) (BPHL)	1	X81372	<del></del>	+		$\dashv$	+		•
bone marrow stromal cell antigen 1 (BST1)	1	D21878				_	+	$\dashv$	
box-dependent myc- interacting protein isoform BIN1-10 (BIN1)	1	AF043900					$\top$		
box-dependent myc- interacting protein isoform BIN1-10 (BIN1) (non-exact, 64%)	1	AF043900							
brain my047 protein	1	AF063605	T	+ 1	+	_	+	_	
branched chain keto acid dehydrogenase E1, alpha polypeptide (maple syrup urine disease) (BCKDHA)	3	Z14093	. 1	+	+	1	+		
BRCA1 associated protein- 1 (ubiquitin carboxy-	1	D87462	+	+ +	+	+	+	$\dashv$	
terminal hydrolase) (BAP1) BRCA1, Rho7 and vati	1	L78833			_		_	-	
genes, and ipf35 breakpoint cluster region								[	
protein, uterine leiomyoma, 1; barrier to autointegration factor (BCRP1)	2	AF044773		+	+				
breakpoint cluster region protein, uterine leiomyoma, 2 (BCRP2)	2	AF044774	·	+	+		+	+	
breast cancer anti-estrogen resistance 3 (BCAR3) (non-exact 73%)	1	U92715							
bromodomain-containing protein, 140kD (peregrin) (BR140)	2	M91585		+					
Bruton's agammaglobulinemia tyrosine kinase (Btk)	1	U13424				-	+		

WO 00/40/49									
Bruton's tyrosine kinase (BTK)	1	U78027							
Bruton's tyrosine kinase (BTK), alpha-D- galactosidase A (GLA), L44-like ribosomal protein (L44L) and FTP3 (FTP3)	1	U78027							
BS4	1	AF108083						]	
BTG2 (BTG2)	6	Y09943	+	+	+	+		+	
BTK region clone ftp	1	U78027	+	+	+	+		+	
BTK region clone ftp-3	1	U01923		1 + 1	+		+		
BUB3 (budding uninhibited by benzimidazoles 3, yeast) homolog (BUB3)	4	AF053304	+	+	+	+		+	
butyrate response factor 1 (EGF-response factor 1) (BRF1)	4	X79067	+	+	+	+		+	
butyrophilin (BTF1)	7	U90543		+	+		+		
butyrophilin like receptor	1	AB020625.1							
CAG repeat containing (CTG4A)	2	U80744		+	+				
CAGH32	2	U80743		+	+		+		
calcium channel, voltage- dependent, L type, alpha 1D subunit (CACNA1D) (low match)	1	M83566							
calcium/caimodulin- dependent protein kinase (CaM kinase) Il gamma (CAMK2G)	1	AF069765		+	+	+		+	
calcium/calmodulin- dependent protein kinase kinase (KIAA0787)	1	AF101264	В	+	+		+		
calmodulin (=M19311)	7	D45887							
calmodulin 1 (phosphorylase kinase, delta) (CALM1)	6	M27319	В	+	+		+	+	
calnexin (CANX)	3	M94859	T	+			+	+	
calpain, large polypeptide L1 (CAPN1)	5	X04366		+	+		+	+	
calpain, large polypeptide L2 (CANP2)	5	M23254		+	+				
calpain, small polypeptide (CAPN4)	1	X04106		+	+		+	+	
calpastatin (CAST)	3	D16217			L		<u> </u>	L.,	
Calponin 2	2	D83735		+	<u> </u>	+	<u> </u>	+	
calponin 2 (CNN2)	1	D83735	В, Т	+			+		
calponin 2 (CNN2) (low score)	1	D83735	·		+		+	+	
calumenin (CALU)	3	AF013759	В		<u> </u>	<u> </u>	ļ <u> </u>	二	
cAMP response element- binding protein CRE-Bpa (H_GS165L15.1)	4	L05912					<u> </u>		
cAMP-dependent protein kinase type II (Ht31)	1	M90360				<u></u>			
canicular multispecific organic anion transporter (CMOAT2)	1	AF009670				+	+	+	
capping protein (actin filament) muscle Z-line, alpha 1 (CAPZA1)	6	U56637	В, Т	<u> </u>	+			Ĺ	
capping protein (actin filament) muscle Z-line, alpha 2 (CAPZA2)	2	U03269	В	+					
capping protein (actin filament) muscle Z-line, beta (CAPZB)	1	U03271	+	+				+	·

capping protein (actin							_			A.00/00	005
filament), gelsolin-like (CAPG)	8	M94345	+	+		7		+			
carbamoyi-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD)	1	D78586	+	+	+	7		+			
carbonic anhydrase V, mitochondrial (CA5)	1	L19297	-	+	+-	+	+	-			
carboxypeptidase D (CPD)	3	U65090	В		-	4_					
camitine/acylcamitine	1	Y10319	- B	+	<u> </u>				<u> </u>		
translocase (CACT)		110319		+	+		+	1			
Cas-Br-M (munne) ecotropic retroviral	2	X57110		_	+	+	+	+	-		
transforming sequence (cbl)											
casein kinase 1, alpha 1 (CSNK1A1)	1	L37042	+	+	+	+		+			
casein kinase 2. alpha 1 polypeptide (CSNK2A1)	2	M55265	В	+	<b>†</b>	T	+	+			
casein kinase I gamma 3L (CSNK1G3L)	1	AF049090.1				†					<del></del>
casein kinase II alpha subunit(=S72393)	1	X69951			1	1					
CASP8 and FADD-like	4	AF015450	<del> </del>	++	+	+	+	+			
apoptosis regulator (CFLAR)											
caspase 1, apoptosis- related cysteine protease	7	U13697	. +	1		+	1				
(interleukin 1, beta.							1				
convertase) (CASP1) caspase 10, apoptosis-	1	USOSIO					<u>l</u>				
related cysteine proteas (CASP10)	'	U60519	B, T act	ivated, homa	Ŧ		+				
caspase 3, apoptosis- related cysteine protease (CASP3)	3	U13737	B, T	+	+	+	+			, ,	
caspase 4, apoptosis- related cysteine protease (CASP4)	6	U25804	+	+	+	+		+	<u></u> -	į,	
caspase 5, apoptosis- related cysteine protease (CASP5)	1	U28015			+					<del></del>	
caspase 8, apoptosis- related cysteine protease (CASP8)	2	X98173		+		+		+			
caspase 9, apoptosis- related cysteine protease (CASP9)	1	U56390	В			+	+			,	
catalase (CAT)	5	X04076	В	+	+		+	-+			
catechol-O- methyltransferase (COMT)	1	M65213		+	+		+	_		·	
catenin (cadherin- associated protein), alpha	6	D14705		+	+		$\dashv$	$\dashv$	<del></del>		
1 (102kD) (CTNNA1) cathelicidin antimicrobial	<del>- 1</del>	X89658	В			_		$\dashv$			
peptide (CAMP) cathepsin B (CTSB)	4	L16510					$\perp$				
cathepsin C (CTSC)	3	U79415			+		+	+			
cathensin D (Ivsosomal	4	M11233		+	+	+	$\perp$	+			
aspartyl protease) (CTSD) cathepsin E (CTSE)	<del>-</del> 1	J05036		+	+		+				
cathepsin G (CTSG)	<del>-                                    </del>	M16117					+				
cathepsin S (CTSS)	34	M86553	T, W B, Monocyte	e stimu	+ lated		+	+			
cathepsin W (lymphopain) (CTSW)	4	AF013611		phoma		-	$\dashv$	+			
CBF1 interacting corepressor CIR (=U03644	1	AF098297				$\dashv$	$\dashv$	+		<u> </u>	
recepin)											

WO 00/40749									
CCAAT/enhancer binding protein (C/EBP), alpha (CEBPA)	3	X87248		+	+	+		+	
CCAAT/enhancer binding protein (C/EBP), delta (CEBPB)	1	S63168			+		+	+	
CCAAT-box-binding transcription factor (CBF2)	2	M37197	Tlymphoma			+	+		
CCR5 receptor (CCR5) (non-exact?)	1	AF011504							
CD14 antigen (CD14)	11	M86511	+	+	+	+		+	
CD18 (=M95293)	4	X64071							
CD1C antigen, c polypeptide (CD1C)	2	M28827						+	
CD2 antigen (cytoplasmic tail)-binding protein 2 (CD2BP2)	1	AF104222							
CD2 antigen (p50), sheep red blood cell receptor (CD2)	4	M14362	+		+	+		+	
CD2 cytoplasmic tail- binding protein 1 (CD2BP1)	2	AF038602					+		
CD20 antigen (CD20)	1	X12530				<u> </u>	<u> </u>		
CD20 receptor (S7)	1	X07203				ļ			
CD22 antigen (CD22)	1	U62631	В	<u> </u>		<u> </u>			
CD24 signal transducer	1	M58664				<u> </u>			
CD33 antigen (gp67) (CD33)	1	M23197				<u> </u>	+		
CD33 antigen-like 2; OB binding protein-2 (CD33L2) (non-exact, 68%)	1	U71383					-		
CD33L2 (61% aa)	1	D86359							
CD36 antigen (collagen type I receptor, thrombospondin receptor) (CD36)	7	M98398	Tlymphoma		+		+	+	
CD37 antigen (CD37)	5	X14046	+	+		+		+	
CD38 alt	1	D84277				1			
CD39 antigen (CD39)	1	U87967	В	+		1	+	+	
CD3D antigen, delta polypeptide (TiT3 complex) (CD3D)	1	X03934			+	+		+	
CD3E antigen, epsilon polypeptide (TiT3 complex) (CD3E)	1	X03884	+			+			
CD3G antigen, gamma polypeptide (TIT3 complex) (CD3G)	2	X06026	W				+		
CD3Z antigen, zeta polypeptide (TiT3 complex) (CD3Z)	2	J04132	+			+			
CD3-zeta (clone pBS NK1)	1	X55510					<u> </u>		
CD4 (low match)	1	S68043					_	<u> </u>	
CD4 antigen (p55) (CD4)	4	M12807		+	+		+	<u> </u>	
CD44 antigen (homing function and Indian blood group system (CD44)	6	X56794	W				+	+	·
CD48 antigen (B-cell membrane protein) (CD48)	3	X06341	+	+	+	+	1	+	
CD53 antigen (CD53)	10	L11670	+	+	<u> </u>	+	$oldsymbol{\perp}$	+	
CD53 antigen (CD53) (low match)	1	M60871						1	
CD63 antigen (melanoma 1 antigen) (CD63)	3	M59907				_	<u> </u>	<u> </u>	
CD68 antigen (CD68)	2	S57235			+			+	

1. m. 18. .

							•	C1/CA00/00003
72	K01144	+	+	+	+	+	+	high in many libraries
						-		
2	M80462			+				
	MARODEZ		-	↓	<del>-</del>	4		
	MIGBEST							
2	M27161	+ -		$\dagger$	+	+	+	
1	X13445	W			1			
1	M33680		+	+			+	
1	Q01151	В	+	+			+	
1	U82988		+	+			+	
· ·	L25259		+		$\top$			
_	M38690			+	_	+	+	
12	X84700	. +	+		+		1	
1	P48960				T			
1	X94630	+	+		+			
1	AF053977	-	+			+	+	
1	U63131	B	-		—		_	
2	AF104857	В	+	+		+	·	
1	L29219	<del></del>	+	+	+		+	
1	AF023268	В	+	+				
13	X15183	Tactivated	+	+		+		
1	AF011794							
4	S72008	+	+	+	+		+	
1	U05340		+	+	+			
	Z68092	+	+	+	+		+	
1	AF067514							
5	M35543	+	+	+	+		+	· · · · · · · · · · · · · · · · · · ·
1	AF063015					_	_	
1	Q13033							
1	X55039		+		1	+	$\dashv$	
3	AF022655	В	+	$\rightarrow$		+	_	
	2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 M80462 2 M89957 2 M27161 1 X13445 1 M33680 1 Q01151 1 U82988 1 L25259 2 M38690 12 X84700 1 P48960 1 X94630 1 AF053977 1 U63131 2 AF104857 1 L29219 1 AF023268 13 X15183 1 AF011794 4 S72008 1 U05340 6 Z68092 1 AF067514 5 M35543 1 AF063015 1 Q13033	2 M89957 +  2 M89957 +  1 X13445 W  1 M33680  1 Q01151 B  1 U82988 1 L25259 2 M38690 12 X84700 + 1 P48960 1 X94630 + 1 AF053977  1 U63131 B 2 AF104857 B 1 L29219 1 AF023268 B 13 X15183 Tactivated  1 AF011794 4 S72008 +  1 U05340 6 Z68092 + 1 AF067514 5 M35543 +  1 AF063015 1 Q13033	2 M89957 +  2 M27161 +  1 X13445 W  1 M33680 +  1 Q01151 B +  1 U82988 +  1 L25259 +  2 M38690 +  1 P48960 +  1 P48960 +  1 AF053977 +  1 U63131 B +  2 AF104857 B +  1 L29219 +  1 AF023268 B +  13 X15183 T activated +  1 AF011794 +  4 S72008 +  1 U05340 +  6 Z68092 +  1 AF067514 +  1 AF063015 1 Q13033 +  1 X55039 +	2 M89957 +	2 M80462 + +	2 M80462	2 M89957 +

WO 00/40749								PC1/CA00/00005		
		AF017456	<del>- + T</del>	+ 1	+ 1	+ 1	+	+	high in bone	
roid-lipofuscinosis, juronal 2, late infantile ansky-Bielschowsky		AF017450	·							
sease) (CLN2) fgr (=M63877 inreceptor protein-	6	X52206								
osine kinase (fgr)) GI-19 protein	3	AF132953.1				1				
aperonin containing	1	X74801		+	+			+		
CP1, subunit 3 (gamma)			·	+	+	_	+	+		
naperonin containing CP1, subunit 4 (delta) CCT4)	1	AF026291								
naperonin containing CP1, subunit 6A (zeta 1)	4	L27706	В	+	+					
CCT6A) haperonin containing	4	AF026292	В	+				+	*	
CP1, subunit 7 (eta)		U67615	В. Т	+	+		+			
Chediak-Higashi syndrome (CHS1)	1	U67615	lymphoma							
Chediak-Higashi syndrome (CHS1) (low score)	1							<u> </u>		
hemokine (C-C motif) eceptor 2 (CCR2)	4	U03905								
hemokine (C-C motif) ecceptor 4 (CCR4) (low match) (may contain	1	X85740								
epeat) hemokine (C-C motif)	6	L31581								
eceptor 7 (CCR7) chemokine (C-X3-C)	5	U20350		+						
receptor 1 (CX3CR1) chemokine (C-X-C motif),	5 .	M99293	+	+	+	+		+		
receptor 4 (fusin) (CXCR4) chitinase 3-like 1 (cartilage	2	M80927		+		+		+		
glycoprotein-39) (CHI3L1) chitinase 3-like 2 (CHI3L2)	2	U49835		+		+	L	+		
chloride channel 1 , skeletal muscle (CLCN1)	1	G18280						L		
chlonde channel 6	1	D28475		+	+					
(CLCN6) Chlonde intracellular	1	U93205	+	+	+	+		+		
channel 1 (CLIC1)	5	X15998		1	+		T	1		
proteoglycan 2 (versican) (CSPG2)		J02814	<del> </del>	-	+	╀	+	++		
chondroitin sulfate proteoglycan core protein	2	302814					$\perp$			
chromatin assembly factor 1 p48 subunit (CAF-1 P48 subunit) (retinoblastoma binding protein p48) (retinoblastoma-binding protein 4) (MSI1 protein homolog)		Q09028			,					
chromodomain helicase DNA binding protein 1 (CHD1)	2	AF006513						$\perp$		
chromodomain helicase DNA binding protein 1-like (CHD1L)	1	AF054177		-	+			-		
chromodomain helicase DNA binding protein 2 (CHD2)	1	AF006514	В							
chromodomain helicase DNA binding protein 3 (CHD3)	1	AF006515							+	
chromodomain helicase DNA binding protein 4 (CHD4)	5	X86691	+	+	•					

11: 44

							•				•
chromosome 1 open reading frame 7 (C10RF7)	1	AF054176						T			
chromosome 1 specific transcript KIAA0493	1	AB007962					T				-
chromosome 17 open reading frame 1B (C17ORF1B)	1	AJ008112		+							
chromosome 4 open reading frame 1 (C4ORF1)	1	AF006621		+	+	+		+			
chromosome condensation 1-like (CHC1L)	2	AF060219		1 +	+	+		+			
chromosome X open reading frame 5 (CXORF5)	1	Y15164	В	+	+		+				
chromosome-associated polypeptide C(CAP-C)	2	AF092564	В	+	+		+	+			
cig42	1	AF026944			1	+	+-	+	<del>                                     </del>		
cig5	3	AF026941		<del></del>	┼	╁	+-	+	<del> </del>		
citrate synthase (CS)	2	AF047042	В	+	+	+	╁	+			
	L			+	<u> </u>	↓	-	<u> </u>			
class I major histocompatibility antigen (HLA-Cw3)	2	U31372									
class I major histocompatibility antigen (HLA-Cw3) (low match)	1	U31372									
clathrin assembly protein lymphoid myeloid leukemia (CALM)	3	U45976	В	+	+			+			
clathrin heavy chain	1	X55878		+	<del>                                     </del>	┼	-	<del> </del>			
clathrin, heavy polypeptide- like 2 (CLTCL2)	1	D21260		1							
clathrin, light polypeptide (Lca) (CLTA) (low match)	1	M20472								****	
clathrin-	3	D63475		+	+	+	+	+		1 11	
associated/assembly/adapt or protein, medium 1 (CLAPM1)										47. N	
deavage stimulation factor, 3' pre-RNA, subunit 2 64kD (CSTF2) (non-exact 82%)	1	M85085								**	
cleavage stimulation factor, 3' pre-RNA, subunit 3, 77kD (CSTF3)	1	U15782	В	+	+		+				
clk3		L29220	В	+	+		Ì				
clone 23815 (Hs.82845)	1	U90916		+	+			+			
cione 24592 mRNA sequence	1	D88378	+	+	+	+		+			
Clq/MBL/SPA receptor C1qR(p) ()	1	U94333	<del></del>		-						
clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed prostate message 2, apolipoprotein J) (CLU)	1	M64722	+	+	+	+	+	+	1 7 1		
CMP-sialic acid transporter (CMPST)	1	D87969	В	+	+						
CMRF35	3	X66171									
c-myc oncogene containing coxIII	1	X54629						·	<del></del>		
coagulation factor II (thrombin) receptor (F2R)	1	M62424		+	+			+			
coagulation factor V (proaccelerin, labile factor) (F5)	1	M14335		+		+	+				
coagulation factor XIII a subunit	3	M21998									
coagulation factor XIII, A1 polypeptide (F13A1)	6	M14354		+	+.	+		+			
coated vesicle membrane protein (RNP24)	1	X92098	+	+	+	+	+	+			

WO 00/40749								_		/CA00/00005
atomer protein complex.	5	U24105	1	+			+			
hunit alpha (COPA)			<del></del>	+	+	+	+	╁╸	hi	gh in fetal brain
ofilin 1 (non-muscle)	13	X95404		+	<u>.</u>	<del> </del>	-	1,		
old inducible RNA-binding otein (CIRBP)	7	D78134		Ť	+	1_	╀-	╀-	_	
old shock domain protein	3	X95325		T			↓_	1	$\perp$	
(CSDA) oliagen, type IX, aipha 2	3	AF019406	В					$\perp$		
OL9A2) olony stimulating factor 1	3	X03663		+			+	'	+	
eceptor, formerly icDonough feline sarcoma iral (v-fms) oncogene omolog (CSF1R)										
olony stimulating factor 2 eceptor, beta, low-affinity granulocyte-macrophage)	5	M59941							_	
CSF2RB) colony stimulating factor 2 eceptor, beta, low-affinity granulocyte-macrophage) CSF2RB) (low match)	1	M59941							_	
colony stimulating factor 3 eceptor (granulocyte)	16	X55720			ļ 			1	_	
complement component 5 eceptor 1 (C5a ligand)	1	M62505	<u>.</u>	1	+		-	_	+	
conserved gene amplified in osteosarcoma (OS4)	2	AF000152					$\perp$	$\downarrow$	+	
COP9 (constitutive photomorphogenic, Arabidopsis, homolog)	2	AF031647		+	+					
subunit 3 (COPS3) COP9 homolog (HCOP9)	2	U51205	В	+			1	+	+	
COPII protein, homolog of s. cerevisiae SEC23p (SEC23A)	4	X97064		+				+		
copine I (CPNE1)	2	U83246	В	+		+	-	_		
copine I (CPNE1) (low	1	U83246				$\perp$	$\perp$			
score) coproporphyrinogen oxidase (coproporphyria, harderoporphyria) (CPO)	1	D16611				+		+	+	`
core-binding factor, beta subunit (CBFB)	1	L20298		+	$\perp$	+	_	+		
coronin	22	X89109	T, W	+	+		-+	<u> </u>		
coronin (low match)	1	U34690			_		+		├-	
coronin (non-exact, 71%)	1	X89109			4	+	+		+	<del> </del>
cot (cancer Osaka thyroid) oncogene (COT)		D14497	+	+	_	+			·	
cryptochrome 1 (photolyase-like) (CRY1)	1	D84657		+	$\perp$		<u> </u>		+	
idomain, RNA polymerase III, polypeptide A) phosphatase, subunit 1 (CTDP1)	1	AF081287		+		+	Ť	+		
C-terminal binding protein	1	U37408	В			Ţ		+	-	<u> </u>
C-terminal binding protein 2 (CTBP2)	2	AF016507	1		$\perp$	+	+	_	++	
CUG triplet repeat, RNA- binding protein 1 (CUGBP1)	3	U63289			-	+	+	_	<u> </u>	
cullin 1 (CUL1)	3	U58087				+	+	-	+	
cullin 3 (CUL3)	2	U58089			*		<u> </u>	<u> </u>	+	<del> </del>
cut (Drosophila)-like 1 (CCAAT displacement protein) (CUTL1)	1	M74099	34		+					

cyclin D2 (CCND2)	2	D13639	T	+	+	T +	Т	T +	<del></del>
cyclin D3 (CCND3)	5	M92287	В. Т	+-	+	-	+	+	
cyclin G1 (CNNG1)		1570044	lymphoma		<u> </u>		<u></u>	<u> </u>	
cydin I	3	D78341	В	+	-			+	
cyclin T2 (CNNT2)	1 1	D50310	В	+			+		
		AF048732	B. T lymphoma	В					
cyclin-dependent kinase 2 (CDK2)	1	X62071							
cyclin-dependent kinase inhibitor (p27Kip1)	1	S76986							
cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A)	2	S67388	+	+	+	+	+	+	
CYP2D7-CYP2D6 intergenic region (partial)	1	X90926							
cystatin B (stefin B) (CSTB)	1	L03558		$\vdash$	+		+	+	
cysteine and glycine-rich protein 3 (cardiac LIM protein) (CSRP3)	5	L54057			+				
cytidine deaminase (CDA)	2	L27943				$\vdash$	+	_	
cytochrome b	1	AF042500					<del>                                     </del>	<del>                                     </del>	
cytochrome b (CYTB) (isolate Aus5)	1	AF042518							
cytochrome b(-245) beta chain N-terminal region (X- linked granulomatous disease gene)		X05895							
cytochrome b-245, beta polypeptide (chronic granulomatous disease) (CYBB)	2	X04011	+			+		+	***
cytochrome C	1	P00001							
cytochrome c oxidase subunit IV (COX4)	1	U90915	T	+	+		+	+	\$ MP.
cytochrome c oxidase subunit Vb (COX5B)	2	M59250					+		-
cytochrome c oxidase subunit VII-related protein (COX7RP)	6	AB007618	+	+	+	+		+	
cytokine suppressive anti- inflammatory drug binding protein 1 (p38 MAP kinase) (CSBP1)	1	L35263	lymphocyte	+	+		+		
Cytoplasmic antiproteinase=38 kda intracellular serine proteinase inhibitor	1	S69272			+				
cytotoxic granule- associated RNA-binding protein p40-TIA-1	1	570114							
D123 (D123)	1	D14878	+	+		+		+	<del></del>
D2-2	1	AF019226			$\neg \neg$				<del> </del>
D38	1	X74802				<u> </u>			
damage-specific DNA binding protein 1 (127kD) (DDB1)	2	AJ002955	+	+	+	+	+	+	
DCHT (low match)	1	AF017635		-+	$\neg +$	-	$\dashv$	$\dashv$	
DEAD/H (Asp-Glu-Ala- Asp/His) box binding protein 1 (DDXBP1)	1	U78524		.+	+	+	+	+	
DEAD/H (Asp-Glu-Ala- Asp/His) box polypeptide 72KD) (P72)	2	U59321	T	+	+		+	+	
DEAD/H (Asp-Glu-Ala- Asp/His) box polypeptide 1 DDX1)	1	X70649		+	+		1	+	· · · · · · · · · · · · · · · · · · ·

PCT/CA00/00005

								PCT	CA00/00005
WO 00/40749							-		
EAD/H (Asp-Glu-Ala- sp/His) box polypeptide	2	AB001636							
(DDX15) =AD/H (Asp-Glu-Ala- p/His) box polypeptide	2	AB011149	+	+	+	+		+	
(DDX16) EAD/H (Asp-Glu-Ala-	3	U50553	+	+	+	+	$\neg$	+	
sp/His) box polypeptide 3						_	_	+	
EAD/H (Asp-Glu-Ala- sp/His) box polypeptide 5 RNA helicase, 68kD)	37	X15729	+	+	+	†			
DDX5) EAD/H (Asp-Glu-Ala- sp/His) box polypeptide 5 RNA helicase, 68kD)	1	AF015812							
ODX5) (low match)	2	D17532	+	+		$\dashv$	_	$\neg$	
EAD/H (Asp-Glu-Ala- sp/His) box polypeptide 6 RNA helicase, 54kD) DDX6)				+	+	+		+	
EAD/H (Asp-Glu-Ala- sp/His) box polypeptide 8 RNA helicase, 54kD) DDX8)	1	D50487							
DDAO) DEAD/H (Asp-Glu-Ala- Asp/His) box polypeptide 9 RNA helicase A, nuclear DNA helicase II;	3	L13848	+	+	+	+		+	
eukophysin) (DDX9) DEAD/H (Asp-Glu-Ala-	-1	AF000985		+	+		+		
/ chromosome (DBY)	2	X83544	+	+	+	+	+	+	
DAP3)	1	AF083236		+	+	+		+	
containing protein (DEDD) death-associated protein 6	2	AF039136		+	+	+		+	
(DAXX) dedicator of cyto-kinesis 2	4	D86964	+	+		+	Г	+	
(DOCK2) defender against cell death	<del></del>	D15057			+		+	+	
1 (DAD1) Defensin, alpha 1, myeloid-	4	L12690				+	+	+	
related sequence (DEFA1)		X64229	В		+	+	+		
DEK gene (D6S231E) delta sleep inducing peptide, immunoreactor	4	Z50781	+	+	+	+		+	
(DSIPI) dendritic cell protein	3	AF064603	+	+	+	+		+	
(GA17) deoxycytidine kinase	1	M60527							
(DCK) deoxynbonuclease II, lysosomal (DNASE2)	3	AB004574						_	
DGS-I	2	L77566		+	<del> </del>	_	4_	-	
diacylglycerol kinase	3	D16440		<u>L</u> .	1_	$\perp$	-	┼	<u> </u>
diacylglycerol kinase alpha	3	AF064771		+	_	_	$\bot$	_	
diacylglycerol kinase alpha (DAGK1) (clone 24) (low	1	AF064771		+	+	1	+	+	
diaphanous (Drosophila, homolog) 1 (DIAPH1)	1	AF051782	B, monocyte stimulated	+	+				
diaphorase (NADH) (cytochrome b-5 reductase) (DIA1)		Y09501	+	+	1.		+		
differentiated Embryo Chondrocyte expressed gene 1 (DEC1)	1	AB004066							

differentiated Embryo	1	AB004066	<del></del>	<del></del>			<del></del>		PCT/CA00/00005
Chondrocyte expressed gene 1 (DEC1) (low match)		A5004000							
differentiation antigen CD20	1	L23415		-	+	+	+	<del>-  </del>	
DiGeorge syndrome critical region gene 2 (DGCR2)	1	X84076		+	+	+	+	+	+
dihydrolipoamide	2	J03620	<del> </del>	+	+		+	+	+
dehydrogenase (E3 component of pyruvate dehydrogenase complex, 2-oxo-glutarate complex, branched chain keto acid dehydrogenase complex) (DLD)									
dihydrolipoamide S- acetyltransferase (E2 component of pyruvate dehydrogenase complex) (DLAT)		Y00978	В	+			+		
dihydropyrimidinase-like 2 (DPYSL2)	1	D78013		+	+	$\dagger$	+	+	
dinG gene	1	Y10571		_	+-	+-	+-	+-	
dipthena toxin resistance protein required for diphthamide biosynthesis (Saccharomyces)-like 2 (DPH2L2)	3	AF053003	В	+	+	0	+	+	
disintegrin-protease (non- exact 72%)	1"	Y13323			1	T	<del>                                     </del>	+	
DJ-1 protein	2	AF021819	+	+	+	+	┼	+	
Dmx-like 1 (DMXL1)	1	AJ005821	+		+	+	┼—	+-	
DNA (cytosine-5-)- methyltransferase 1 (DNMT1)	3	X63692	Tactivated, lymphoma	+			+	+	
DNA fragmentation factor, 40 kD, beta subunit (DFFB)	1	AF064019				1-		+	
DNA fragmentation factor, 45 kD, alpha subunit (DFFA)	2	U91985	T	+	+			+	
DNA mismatch repair protein (hMLH1)	1	U17840				<del> </del>	-	╁	
DNA segment on chromosome X (unique) 548 expressed seguence	3	M64241	+	+	+	+	+	+	high in many librari
DNA segment, single copy probe LNS-CAI/LNS-CAII deleted in polyposis D5S346)	3	M73547		+	+	+		+	
DNA-damage-inducible ranscript 1 (DDIT1) (low natch)	1	L24498							
OnaJ protein	1	AJ001309				-			
onal protein	1	AJ001309							<del>                                     </del>
locking protein 2, 56kD DOK2)	1	AF034970							
olichyl- iphosphooligosaccharide- rotein glycosyltransferase DDOST)	1	D89060	+	+	+	+	+	+	activated T cell
olichyl-phosphate nannosyttransferase olypeptide 1, catalytic ubunit (DPM1)	1	D86198	Tactivated	+	+		+		
own-regulated by ctivation (immunoglobulin uperfamily) (DORA)	1	AJ223183					+		
OWO COOLINGS	4	DANGTO							
own-regulated in denoma DRA (low match) -type cyclin-interacting	1	P40879 AF082569	1		- 1	- 1	- 1		

PCT/CA00/00005 WO 00/40749

			•					PC	T/CA00/00005
WO 00/40749		X68277	+	+ 1	+	+	+	+	
ial specificity nosphatase 1 (DUSP1)	4		<del></del>	+	+	+	-	+	
ial specificity cosphatase 11 (RNA/RNP complex 1-interacting)	1	AF023917					+	+	
usp11)	1	L05147		+	+		1	1	
nosphatase 3 (vaccinia rus phosphatase VH1- lated) (DUSP3)				+	-	-	+	+	
ial specificity	6	X93920	*						
nosphatase 6 (DUSP6) nactin 1 (p150, Glued	3	X98801							
Orosophila) homolog)			В	+-	+	┼-	├-		
ynactin 1 (p150, Glued Orosophila) homolog) OYTN1) (low match)	1	X98801				-	-	ļ	
ynamin 2 (DNM2)	1	L36983		-	┼	+	+	+-	
ynamitin (dynactin omplex 50 kD subunit) DCTN-50) (non-exact	1	U50733 X99947			_	-	-	_	
lynein, axonemal, heavy polypeptide 17-like (non-	1	X99947						_	
exact, 57%aa)  dynein, cytoplasmic, light ntermediate polypeptide 2		AF035812	В .	+	+			+	
DNCLI2)	1	AF035812		+-	+-	1	1		
intermediate polypeptide 2 (DNCLI2) (non-exact, 69%)		U59151	В	++	-	+	+	+	
dyskeratosis congenita 1, dyskerin (DKC1)	1			+	+-	+	+	++	
dystonia 1, torsion (autosomal dominant)	1	AF007871							
(DYT1) dystrobrevin, beta (DTNB)	1	AF022728		+			+-	+-	·
dystrophia myotonica- containing WD repeat motif	1	L19267		+					
(DMWD)	1	L08835	+	7					·
protein kinase (DMPK) dystrophin (muscular		X14298			_	$\top$		T	
dystrophin (muscular dystrophy, Duchenne and Becker types) (DMD) (low match, 59%aa)						+		1	+
E1B-55kDa-associated protein	1	AJ007509	W			+			+
E2F transcription factor 3	2	D38550						+	
(E2F3) E2F transcription factor 4, p107/p130-binding (E2F4)	1	X86096	В					_	+
E2F transcription factor 5, p130-binding (E2F5)	2	U15642	+		+	_	+	+	+
E74-like factor 1 (ets domain transcription factor) (ELF1)		M82882	В		+	+			+
E74-like factor 4 (ets domain transcription factor (ELF4)	l	U32645					_	$\dashv$	
E74-like factor 4 (ets domain transcription factor (FLF4) (non-exact, 71%)		U32645			+	+	+		+
early development regulator 2 (homolog of nolyhomeotic 2) (EDR2)	4	U89278	T +						
EBV induced G-protein	1	L08177.			+		+		
ecotropic viral integration site 2B (EVI2B)	3	M60830							

								r	C1/CA00/0	0005
ectin, galactoside-binding, soluble, 1 (galectin 1) (LGALS1)		J04456						+		
EGF-like-domain, multiple 4 (EGFL4)	1	AB011541				T		$\top$		
elF-2-associated p67 homolog	3	U13261	В	+			1	+		
elastin (supravalvular aortic stenosis, Williams-Beuren syndrome) (ELN) (low match)		M24782		+	+					
elav-type RNA-binding protein (ETR-3)	3	U69546		1			+	+	1	
electron-transfer- flavoprotein, alpha polypeptide (glutaric aciduria II) (ETFA)	2	J04058		+						
ELK3, ETS-domain protein (SRF accessory protein 2) (ELK3)	2	Z36715			+			+		
elongation factor 1-beta	1	L26404					1	+-	-	
elongation factor Ts (mitochondrial protein)	1	AF110399		1						
elongation factor Tu- nuclear encoded mitochondrial	1	X84694								
eMDC II protein	1	AJ242015.1					<del> </del>	<del>                                     </del>		· · · · · · · ·
ems1 sequence (mammary tumor and squamous cell carcinoma-associated (p80/85 src substrate) (EMS1)	1	M98343		+	+		+	+	•	
endogenous retroviral element HC2	1	270664		1					4.54	
endosulfine alpha (ENSA)	1	X99906		+	<del></del>	-		├─┤		
endothelial differentiation, sphingolipid G-protein- coupled receptor, 1 (EDG1)	2	M31210		+	+	+		+		
endothelial differentiation, sphingolipid G-protein- coupled receptor, 1 (EDG1) (low match 66%)	1	M31210								
endothelial monocyte- activating polypeptide (EMAPII)	1	U10117	+	+	+	+		+		
enolase 1, (alpha) (ENO1) enolase 2, (gamma,	12	M14328	+	+	+	+	+	+		
neuronal) (ENO2)	1	X51956		+						
enolase-alpha	1	D28437						$\neg$		
enoyl Coenzyme A hydratase 1, peroxisomal (ECH1)	2	U16660								
enoyl Coenzyme A hydratase, short chain, 1, mitochondrial (ECHS1)	1	D13900	+	+	+	+	+	+		
ENOYL-COA HYDRATASE, MITOCHONDRIAL PRECURSOR (SHORT CHAIN ENOYL-COA HYDRATASE) (SCEH) (ENOYL-COA HYDRATASE 1) (low match, non-exact 56%)	1	P30084								
epidermal growth factor receptor pathway substrate 15 (EPS15)	2	U07707		+		+		+		

WO 00/40749										CA00/00005
	2	015668				I				ļ
PIDIDYMAL ECRETORY PROTEIN PRECURSOR (EPI-1) E1) (EPIDIDYMAL ECRETORY PROTEIN	2	213000								
(6) (ESP14.6) orthelial membrane		U87947	+	+	+	+		+		
ntein 3 (FMIP3)		29766		-		+-	1			+ only
poxide hydrolase 1, icrosomal (xenobiotic)							_	-	—	
PHX1) RCC2 (=L47234)	-1	X52221				++	↓	++	hic	gh in gall bladder
RF-2	3	U07802	+	+	+	1	↓_	+		911 117 9-11-1
		X94910	+	+	+	+	┷	1	4	
Rp28 protein rythrocyte membrane	2	M81635						_	$\perp$	
rotein	2	L25343					<u> </u>			
rythroleukemic cells K562		U24166						1_		
ST (Hs.189509)		L38487		+			$\top$	$\top$		
estrogen receptor-related protein (hERRa1)	1	X66503	В. Т	++	+		+-	+	+	
STS, Highly similar to ADENYLOSUCCINATE SYNTHETASE	1				-	+	$\perp$	<del> </del>	-	
STs, Moderately similar to	1	U28811	+	+						
nrowth factor receptor		U93181	. +	+		1	7	T	•	
ET binding factor 1 (SBF1)	· · · · · · · · · · · · · · · · · · ·	U15655	+	+	1 -	- 1-	- 1		+	
ets domain protein ERF	1			<del>-                                    </del>	+-	-	+	+	+	
eukaryotic translation elongation factor 1 alpha 1	. 326	X03558							_	
(EEF1A1) eukaryotic translation elongation factor 1 alpha 1	1	X03558					-			
(EEF1A1) (low match)	1	X03558		1	+	+		十	1	
elongation factor 1 alpha 1 (FEF1A1) (low match)		X60489	+	+	+	+	+	$\dashv$	+	
eukaryotic translation elongation factor 1 beta 2 (EEF1B2)	5					+	+	+	+	
eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein) (EEF1D)	-1	221507	+			Ð				
eukaryotic translation elongation factor 1 gamma	31	Z11531							+	
(EEF1G) eukaryotic translation elongation factor 2 (EEF2)	2	X51466					$\dashv$	_		
eukaryotic translation initiation factor 2, subunit 1 (alpha, 35kD) (EIF2S1)	1	J02645								
eukaryotic translation initiation factor 2, subunit 2 (beta, 38kD) (EIF2S2)	1	M29536			+	+				
eukaryotic translation initiation factor 2, subunit 3 (gamma, 52kD) (EIF2S3)		L19161								
eukaryotic translation initiation factor 3, subunit 10 (theta, 150/170kD)	2	U78311					+	+	-	high in white blood
(EIF3S10) eukaryotic translation initiation factor 3, subunit 2 (beta, 36kD) (EIF3S2)		U36764	+		+	+	+	_	+	cells
eukaryotic translation initiation factor 3, subunit 3 (gamma, 40kD) (EIF3S3)		U54559	+			+	-		+	
eukaryotic translation initiation factor 3, subunit 4 (delta, 44kD) (EIF3S4)	9	AF020833			•					

77.000,40743								r	C1/CA00/00005
eukaryotic translation initiation factor 3, subunit 6 (48kD) (EIF3S6)	4	U94175	+	+	+	+		T +	high in bladder
eukaryotic translation initiation factor 3, subunit 6 (EIF3S6)	1	U62962		+	+	+		+	Highly represented (1.4833 pct) in library 36 human gall bladder
eukaryotic translation initiation factor 3, subunit 7 (zeta, 66/67kD) (EIF3S7)	3	U54558	+	+	+	+		+	
eukaryotic translation initiation factor 3, subunit 8, 110KD (EIF3S8)	5	U46025	+	+	+	+	+	+	high in testis
eukaryotic translation initiation factor 4 gamma, 1 (EIF4G)	1	AF012088							
eukaryotic translation initiation factor 4 gamma, 1 (EIF4G) (low match)	1	AF012088							
eukaryotic translation initiation factor 4 gamma, 1 (EIF4G1)	2	D12686	-						
eukaryotic translation initiation factor 4 gamma, 2 (EIF4G2)	6	U73824	+	+	+	+	+	+	
eukaryotic translation initiation factor 4 gamma, 2 (EIFG2)	2	U76111	+	+	+	+	+	+	
eukaryotic translation initiation factor 4A, isoform 1 (EIF4A1)	29	D13748	•						
eukaryotic translation initiation factor 4A, isoform 2 (EIF4A2)	11	D30655	+	+	+	+	+	+	
eukaryotic translation initiation factor 4B (EIF4B)	18	X55733	+	+	+	+		+	
eukaryotic translation initiation factor 4E (EIF4E)	1	P06730							
Eukaryotic translation initiation factor 4E binding protein 2 (EIF4EBP2)	3	L36056	Т, В	+			+	+	
eukaryotic translation initiation factor 4H (EIF4H)	2	Q15056							
eukaryotic translation initiation factor 5 (EIF5)	2	U49436	+	+	+	+	+	+	
eukaryotic translation termination factor 1 (ETF1)	2	U90176	+	+	+	+		+	·
EV12 protein	1	M55266		+ +			Ť		· · · · · · · · · · · · · · · · · · ·
Ewing sarcoma breakpoint region 1 (EWSR1)	1	X66899	+	+	+	+	$\neg$	+	
EWS/FLI1 activated transcript 2 homolog (EAT-2)	2	AF020264							
EWS-E1A-F chimeric protein	1	U35622			1	_	_	$\dashv$	
excision repair cross- complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence) (ERCC1)	1	M28650	+	+	+	+		+	
excision repair cross- complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome)) (ERCC5)	1	X69978		+	+	+		+	·
exostoses (multiple)-like 3 (EXTL3)	1	AF001690		+	+	+	+	+	
F11	1	X77744		<del>                                     </del>	$\dashv$	+	-	-	
· · · · · · · · · · · · · · · · · · ·		·							

WO 00/40749			-					rc.	1/CA00/00003
I-ATPase beta subunit	2	X03559							
-1 beta) anconi anaemia group A	-2-+	Z83095							
anconi anaemia,	-1	X99226	+	+	+	+			
omplementation group A					+			+	
r upstream element FUSE) binding protein 1 FUBP1)	2	U05040	+					+	
arnesyl diphosphate ynthase (farnesyl yrophosphate ynthetase,dimethylallyltra stransferase, leranyltranstransferase)	1	J05262	+	+	+	+			
FDPS) arnesyl-diphosphate arnesyltransferase 1	2	X69141	+	+	+	+	+	+	
FDFT1) arnesyltransferase, CAAX	2	L00635		+	+				
oox, beta (FNTB) -as ligand (gene and		AF044583		1 1			寸		
romoter region)		U70667		+			$\dashv$	-+	
as-ligand associated				<del>  -  </del>	+	+	+	+	
atty-acid-Coenzyme A igase, long-chain 1 (FACL1)	4	D10040	+	Ť		Ť			
Fc fragment of IgA,	1	X54150							
receptor for (FCAR) Fc fragment of IgE, high affinity I, receptor for: gamma polypeptide	1	м33195	+	+	+	+		+	
(FCER1G) Fc fragment of IgE, low affinity II, receptor for (CD23A) (FCER2)	2	X04772	+	+					
Fc fragment of IgG, low affinity IIa, receptor for	6	M31932	+	+	+	+	+	+	
(CD32) Fc fragment of IgG, low affinity IIa, receptor for (CD32) (FCGR2A)	1	X62572	+	+	+	+	+	+	
Fc fragment of IgG, low affinity Illa, receptor for (CD16) (FCGR3A)	34	X07934	+	+	+	+		+	high in many librane
Fc fragment of IgG, receptor, transporter, alpha (FCGRT)	3	U12255		+	+	+	+		mgn in many librarie
fc-fgr	1	Z13983				┷	<b>↓</b>		
Fc-gamma-receptorIIIB (FCGR3B)	2	M90746							
feline sarcoma (Snyder- Theilen) viral (v- fes)/Fujinami avian sarcoma (PRCII) viral (v- fps) oncogene homolog(FES) c-fes/fps)	3	X06292							
female sterile homeotic- related gene 1 (mouse homolog) (FSRG1)	2	X96670	+	+		+	_	+	
ferritin L-chain	9	Y09188			+	++	+	┿	
ferritin, heavy polypeptide 1 (FTH1)		M11146	+	+	<b> </b>	+	$\perp$	<u> </u>	
fertilin alpha pseudogene	1 2	Y09232 U05237	-	+	+-	+	+-	+	-
fetal Alzheimer antigen (FALZ)	1	M34024			+	+	+	+	
fetal ig heavy chain variable region			ļ	+	+-	+	$\downarrow_{\pm}$	+	<del> </del>
fibrillarin (FBL)	1.	X56597 Z36531	+	<del>-   -</del>	+	+		+	<del>                                     </del>
fibrinogen-like protein 2 (T49)	3	230331	1	1			1		

## This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)